1 00:00:05,520 --> 00:00:09,280 >> I'M KEN FREEDBERG, CHAIR OF 2 00:00:09,280 --> 00:00:10,720 THE AIDS RESEARCH ADVISORY 3 00:00:10,720 --> 00:00:11,560 COMMITTEE, I WANT TO WELCOME 4 00:00:11,560 --> 00:00:14,720 EVERYONE TO THE JUNE 6 VIRTUAL 5 00:00:14,720 --> 00:00:19,200 MEETING OF ARAC. WE HAVE A FULL 6 00:00:19,200 --> 00:00:20,200 INTERESTING AGENDA. 7 00:00:20,200 --> 00:00:23,000 WE WILL START OFF WITH APPROVAL 8 00:00:23,000 --> 00:00:24,760 OF THE MINUTES OF OUR JANUARY 9 00:00:24,760 --> 00:00:28,360 31ST MEETING AND CAN I HAVE A 10 00:00:28,360 --> 00:00:29,880 MOTION TO APPROVE THOSE MINUTES? 11 00:00:29,880 --> 00:00:31,680 >> SO MOVED. 12 00:00:31,680 --> 00:00:33,080 >> SECOND ANYONE? 13 00:00:33,080 --> 00:00:33,880 >> SECOND. 14 00:00:33,880 --> 00:00:34,560 >> SECOND. 15 00:00:34,560 --> 00:00:37,600 >> GREAT SO THIS IS A MOTION TO 16 00:00:37,600 --> 00:00:41,120 APPROVE MINUTES OF JANUARY 31ST, 17 00:00:41,120 --> 00:00:43,440 ANY DEBATE ON THAT? 18 00:00:43,440 --> 00:00:44,920 NO DEBATE. 19 00:00:44,920 --> 00:00:46,960 WHY DON'T WE HAVE A VOTE THEN. 20 00:00:46,960 --> 00:00:48,720 EVERYONE IN FAVOR OF APPROVING 21 00:00:48,720 --> 00:00:49,200 THE MINUTES? 22 00:00:49,200 --> 00:00:49,960 >> AYE. 23 00:00:49,960 --> 00:00:51,280 >> AYE. 24 00:00:51,280 --> 00:00:56,760 >> ANYONE OPPOSED? 25 00:00:56,760 --> 00:00:59,480 HEARING NONE THE MOTION IS 26 00:00:59,480 --> 00:01:01,840 PASSED TO APPROVE THE MINUTES. 27 00:01:01,840 --> 00:01:03,280 IT WAS A GREAT MEETING. 28 00:01:03,280 --> 00:01:05,600 ANYONE WHO WANTS TO REREAD THEM, 29 00:01:05,600 --> 00:01:06,840 FANTASTIC MEETING. 30 00:01:06,840 --> 00:01:11,880 LET ME TURN THIS OVER NOW TO DR. 31 00:01:11,880 --> 00:01:15,120 CARL DIEFFENBACH, DIRECTER OF 32 00:01:15,120 --> 00:01:16,320 THE DIVISION OF AIDS, LOOK 33 00:01:16,320 --> 00:01:17,400 FORWARD TO HEARING FROM YOU. 34 00:01:17,400 --> 00:01:19,960 >> THANK YOU, KEN A PLEASURE. 35 00:01:19,960 --> 00:01:21,560 CAN SOMEBODY PLEASE CALL UP MY 36 00:01:21,560 --> 00:01:21,880 SLIDES? 37 00:01:21,880 --> 00:01:27,600 NEXT SLIDE PLEASE. 38 00:01:27,600 --> 00:01:29,040 GOOD AFTERNOON, EVERYONE. 39 00:01:29,040 --> 00:01:30,600 WELCOME TO JUNE MEETING OF THE 40 00:01:30,600 --> 00:01:31,480 AIDS RESEARCH ADVISERY 41 00:01:31,480 --> 00:01:33,920 COMMITTEE. 42 00:01:33,920 --> 00:01:38,880 WELCOMING TO JONAH SASCHA NEW 43 00:01:38,880 --> 00:01:40,560 OFFICE OF COUNCIL LIAISON TO 44 00:01:40,560 --> 00:01:42,920 ARAC. 45 00:01:42,920 --> 00:01:45,480 AND JONAH RECEIVED HIS Ph.D. 46 00:01:45,480 --> 00:01:47,880 FROM THE UNIVERSITY OF WISCONSIN 47 00:01:47,880 --> 00:01:51,640 MADISON AND THE LAB OF ANOTHER 48 00:01:51,640 --> 00:01:53,360 PROMINENT PRIME TOLL GIST, DR. 49 00:01:53,360 --> 00:01:55,480 DAVID WATKINS AFTER HE JOINED 50 00:01:55,480 --> 00:01:59,480 THE FACULTY AT UDUB MEDICINE 51 00:01:59,480 --> 00:02:01,600 AFFECTING RETRO VIRUS SPECIFIC 52 00:02:01,600 --> 00:02:04,160 CD4 CD8 CELLS. 53 00:02:04,160 --> 00:02:06,440 IN 2011 HE JOINED THE OREGON 54 00:02:06,440 --> 00:02:07,920 HEALTH AND SCIENCE UNIVERSITY 55 00:02:07,920 --> 00:02:09,600 WITH APPOINTMENTS IN VACCINE AND 56 00:02:09,600 --> 00:02:12,080 GENE THERAPY INSTITUTE AND THE 57 00:02:12,080 --> 00:02:13,680 OREGON NATIONAL PRIMATE RESEARCH 58 00:02:13,680 --> 00:02:14,320 CENTER. 59 00:02:14,320 --> 00:02:15,960 HIS RESEARCH INTERESTS INCLUDE 60 00:02:15,960 --> 00:02:18,880 T-CELL BIOLOGY, RETRO VIRUSES 61 00:02:18,880 --> 00:02:19,920 VACCINE DEVELOPMENT. 62 00:02:19,920 --> 00:02:24,560 PLEASE JOIN ME IN WELCOMING 63 00:02:24,560 --> 00:02:24,760 JONAH. 64 00:02:24,760 --> 00:02:26,840 THANK YOU FOR JOINING AS OARAC 65 00:02:26,840 --> 00:02:28,720 LIAISON. 66 00:02:28,720 --> 00:02:29,840 I THINK IT IS IMPORTANT I WANT 67 00:02:29,840 --> 00:02:32,040 TO SPEND A LITTLE TIME ON THE 68 00:02:32,040 --> 00:02:35,200 BUDGET, IT IS KIND OF COMPLI 69 00:02:35,200 --> 00:02:36,120 COMPLICATED, SO I LIKE TO WALK 70 00:02:36,120 --> 00:02:38,400 YOU THROUGH IT. 71 00:02:38,400 --> 00:02:42,840 YOU SEE THE NIAID RECEIVED ABOUT 72 00:02:42,840 --> 00:02:45,720 A 4.2 INCREASE IN FISCAL YEAR 22 73 00:02:45,720 --> 00:02:46,480 AS ENACTED. 74 00:02:46,480 --> 00:02:52,200 WHICH WAS A VERY NICE AMOUNT. 75 00:02:52,200 --> 00:02:55,520 THEN AS WE LOOK AT THE REQUEST 76 00:02:55,520 --> 00:03:01,440 FOR THE PRESIDENT'S BUDGET FOR 77 00:03:01,440 --> 00:03:05,600 '23, WE SEE A LITTLE BIT OF 78 00:03:05,600 --> 00:03:07,200 ANOMALY THAT IT IS PROPOSED TO 79 00:03:07,200 --> 00:03:08,120 GO DOWN A LITTLE BIT. 80 00:03:08,120 --> 00:03:10,720 AS DR. FAUCI EXPLAINED EARLIER 81 00:03:10,720 --> 00:03:12,840 TODAY, THIS IS LARGELY DUE TO 82 00:03:12,840 --> 00:03:15,840 THE FACT THAT THE BUDGET WAS 83 00:03:15,840 --> 00:03:18,600 BUILT PRIOR TO THE APPROVAL OF 84 00:03:18,600 --> 00:03:22,400 THE FINAL FY 22 BUDGET. 85 00:03:22,400 --> 00:03:24,360 NEXT SLIDE PLEASE. 86 00:03:24,360 --> 00:03:29,120 SO FOR FISCAL YEAR 22 WE HAVE 87 00:03:29,120 --> 00:03:31,200 DECIDED TO MAINTAIN THE 88 00:03:31,200 --> 00:03:33,960 ESTABLISHED PI PAY LINE AT THE 89 00:03:33,960 --> 00:03:34,680 12TH PERCENTILE. 90 00:03:34,680 --> 00:03:38,440 THE NEW PI PAY LINE AT THE 16TH 91 00:03:38,440 --> 00:03:39,000 PERCENTILE. 92 00:03:39,000 --> 00:03:42,400 NO COMPETING OR NON-COMPETING 93 00:03:42,400 --> 00:03:44,880 ADJUSTMENTS, RESEARCH PRIORITIES 94 00:03:44,880 --> 00:03:47,960 WILL CONTINUE TO RECEIVE 95 00:03:47,960 --> 00:03:49,280 ATTENTION AND THE ESTIMATED 96 00:03:49,280 --> 00:03:51,960 SUCCESS RATE WE ARE STILL HOPING 97 00:03:51,960 --> 00:03:55,480 TO RECEIVE TO MAKE IT AT ABOUT 98 00:03:55,480 --> 00:04:00,520 18 TO 22ND PERCENTILE. 99 00:04:00,520 --> 00:04:01,720 I THINK IT IS IMPORTANT TO THINK 100 00:04:01,720 --> 00:04:04,960 ABOUT WHERE WE GOT A 4.2% 101 00:04:04,960 --> 00:04:06,640 INCREASE BUT WHERE DID THAT 102 00:04:06,640 --> 00:04:06,920 MONEY GO? 103 00:04:06,920 --> 00:04:08,840 IT IS IMPORTANT TO GO BACK AND 104 00:04:08,840 --> 00:04:13,200 REVISIT THIS QUESTION OF EAR 105 00:04:13,200 --> 00:04:13,400 MARKS. 106 00:04:13,400 --> 00:04:15,680 YOU CAN SEE THE AMOUNT THAT WE 107 00:04:15,680 --> 00:04:17,800 -- THERE WAS A FAIR AMOUNT OF 108 00:04:17,800 --> 00:04:22,840 INCREASE IN EAR MARKS THIS CYCLE 109 00:04:22,840 --> 00:04:26,120 FROM 10 MILLION FOR CFARS TO 110 00:04:26,120 --> 00:04:28,560 ADDITIONAL INCREASES IN A NUMBER 111 00:04:28,560 --> 00:04:31,640 OF OTHER EARMARKS AS YOU CAN SEE 112 00:04:31,640 --> 00:04:34,520 AMR WENT UP BY 15 MILLION, ONE 113 00:04:34,520 --> 00:04:38,480 OF THE BIGGER ISSUES WAS THIS 114 00:04:38,480 --> 00:04:42,840 $52 MILLION IMPACT OF THE RBLs 115 00:04:42,840 --> 00:04:44,120 OVERALL ON THE BUDGET. 116 00:04:44,120 --> 00:04:46,080 SO WHILE THE BUDGET WENT UP SO 117 00:04:46,080 --> 00:04:48,000 DID THE EARMARKS AND THAT MAKES 118 00:04:48,000 --> 00:04:55,360 FOR A RELATIVELY TIGHT PAY LINE. 119 00:04:55,360 --> 00:04:56,640 I WILL PAUSE THERE AND SEE IF 120 00:04:56,640 --> 00:04:57,800 PEOPLE HAVE ANY SPECIFIC 121 00:04:57,800 --> 00:05:06,560 QUESTIONS ON THE BUDGET. 122 00:05:06,560 --> 00:05:07,760 HEARING NONE WE CAN BRING THESE 123 00:05:07,760 --> 00:05:08,600 UP AT END. 124 00:05:08,600 --> 00:05:10,560 I WANT TO SPEND SOME TIME 125 00:05:10,560 --> 00:05:11,280 TALKING ABOUT SCIENTIFIC 126 00:05:11,280 --> 00:05:13,240 PROGRAMMATIC UPDATES. 127 00:05:13,240 --> 00:05:14,920 THIS CYCLE I'M GOING TO SPEND A 128 00:05:14,920 --> 00:05:17,880 LITTLE BIT MORE TIME ON 129 00:05:17,880 --> 00:05:20,760 PROGRAMMATIC UPDATES RELATED TO 130 00:05:20,760 --> 00:05:24,400 DIVERSITY EQUITY INCLUSION AND 131 00:05:24,400 --> 00:05:27,480 ACCESSIBILITY. 132 00:05:27,480 --> 00:05:28,800 THIS REPRESENT IT IS WHOLE OF 133 00:05:28,800 --> 00:05:30,560 NIH AND OVERARCHING RESEARCH 134 00:05:30,560 --> 00:05:30,920 PRIORITIES. 135 00:05:30,920 --> 00:05:32,600 THIS IS THE SLIDE THE OFFICE OF 136 00:05:32,600 --> 00:05:34,200 AIDS RESEARCH USES TO REALLY 137 00:05:34,200 --> 00:05:36,280 FOCUS IN ON THE TOP PRIORITIES 138 00:05:36,280 --> 00:05:41,360 OF REDUCING INCIDENTS RESEARCH 139 00:05:41,360 --> 00:05:45,440 TOWARDS A CURE, NEXT GENERATION 140 00:05:45,440 --> 00:05:47,960 THERAPIES CO-MORBIDITIES AND THE 141 00:05:47,960 --> 00:05:49,200 CROSS CUTTING AREAS. 142 00:05:49,200 --> 00:05:52,120 AS WE LOOK AT NIAID IN OUR 143 00:05:52,120 --> 00:05:54,920 STRATEGIC GOALS WE SEE OUR 144 00:05:54,920 --> 00:05:55,680 STRATEGIC GOALS ROLL ALIGNED 145 00:05:55,680 --> 00:05:57,640 WITH NATIONAL HIV AIDS STRATEGY 146 00:05:57,640 --> 00:06:02,320 AND ARE FOCUSED ON ENDING THE 147 00:06:02,320 --> 00:06:04,880 HIV EPIDEMIC. 148 00:06:04,880 --> 00:06:06,760 WHEN ADVANTAGEOUS WE AS AN 149 00:06:06,760 --> 00:06:09,280 ORGANIZATION SEEK TO ACHIEVE OUR 150 00:06:09,280 --> 00:06:10,120 GOALS TO ESTABLISHMENT OF 151 00:06:10,120 --> 00:06:12,920 STRATEGIC PARTNERSHIPS, WITHIN 152 00:06:12,920 --> 00:06:16,080 THE NIH WITHIN HHS WITHIN THE US 153 00:06:16,080 --> 00:06:17,760 GOVERNMENT OVERALL WITH OTHER 154 00:06:17,760 --> 00:06:18,960 GOVERNMENTS AND OUTSIDE GROUPS 155 00:06:18,960 --> 00:06:20,960 SUCH AS PHARMA, THE GATES 156 00:06:20,960 --> 00:06:22,560 FOUNDATION AND INTERNATIONAL 157 00:06:22,560 --> 00:06:26,680 AIDS VACCINE INITIATIVE. 158 00:06:26,680 --> 00:06:29,000 PRINCIPLE THAT WE COMPLETELY 159 00:06:29,000 --> 00:06:30,400 BELIEVE IN AND PRACTICE IS 160 00:06:30,400 --> 00:06:32,760 CONSULTATION WITH COMMUNITY AS 161 00:06:32,760 --> 00:06:33,880 AN ESSENTIAL ELEMENT OF OUR 162 00:06:33,880 --> 00:06:35,360 PROCESSES. 163 00:06:35,360 --> 00:06:37,600 AND WE EVALUATE OUR ACTIVITIES 164 00:06:37,600 --> 00:06:39,080 THROUGH THE LENS OF DIVERSITY 165 00:06:39,080 --> 00:06:44,920 EQUITY AND INCLUSION AND ACCESS. 166 00:06:44,920 --> 00:06:46,120 SO I WANT TO SPEND TIME TALKING 167 00:06:46,120 --> 00:06:47,600 WITH YOU AS THE COUNCIL ON WHAT 168 00:06:47,600 --> 00:06:50,120 WE ARE SPECIFICALLY DOING BOTH 169 00:06:50,120 --> 00:06:52,120 INTERNALLY AND EXTERNALLY IN 170 00:06:52,120 --> 00:06:57,920 THIS AREA OF CIVILITY AND 171 00:06:57,920 --> 00:07:01,200 DIVERSITY AND WE HAVE BEEN 172 00:07:01,200 --> 00:07:03,320 INTERESTED PUSHING ON MANY OF 173 00:07:03,320 --> 00:07:06,080 THESE QUESTIONS FOR A VERY LONG 174 00:07:06,080 --> 00:07:06,840 TIME. 175 00:07:06,840 --> 00:07:09,680 MANY OF THE THINGS WE HAVE DONE, 176 00:07:09,680 --> 00:07:10,960 MANY ACCOMPLISHMENTS HAVE BEEN 177 00:07:10,960 --> 00:07:14,720 DONE QUIETLY. 178 00:07:14,720 --> 00:07:16,400 YOU CAN IMAGINE WHY THAT WOULD 179 00:07:16,400 --> 00:07:18,520 BE IF YOU THINK BACK TO 2016, 180 00:07:18,520 --> 00:07:21,760 AND WE ARE PLEASED WITH THE 181 00:07:21,760 --> 00:07:24,960 PROGRESS WE HAVE MADE MAINLY 182 00:07:24,960 --> 00:07:25,880 THROUGH DIVERSITY ACTIVITIES 183 00:07:25,880 --> 00:07:30,080 THROUGH NETWORKS AND OTHER LARGE 184 00:07:30,080 --> 00:07:31,520 MULTI-DISCIPLINARY FUNDING 185 00:07:31,520 --> 00:07:34,000 ACTIVITIES SUCH AS CFAR AND THE 186 00:07:34,000 --> 00:07:34,400 NETWORKS. 187 00:07:34,400 --> 00:07:38,000 SO NIAID IS ESTABLISHED A 188 00:07:38,000 --> 00:07:40,560 WORKPLACE CIVILITY TASK FORCE TO 189 00:07:40,560 --> 00:07:43,800 PROVIDE EPIPUT ON AND CHAMPION 190 00:07:43,800 --> 00:07:44,920 WORKPLACEVILLETY AND 191 00:07:44,920 --> 00:07:47,360 ANTI-HARASSMENT EFFORTS ACROSS 192 00:07:47,360 --> 00:07:49,680 THE INSTITUTE. 193 00:07:49,680 --> 00:07:52,120 WE ESTABLISHED A DEIA COUNCIL TO 194 00:07:52,120 --> 00:07:55,480 HELP NIAID PLAN TO ADDRESS DEIA 195 00:07:55,480 --> 00:07:57,760 INCLUDING OUR INTERNAL WORK 196 00:07:57,760 --> 00:08:00,320 FORCE, THE EXTRAMURAL WORK FORCE 197 00:08:00,320 --> 00:08:03,520 AND IN RESEARCH TO PROMOTE 198 00:08:03,520 --> 00:08:05,640 ADDRESS HEALTH DISPARITIES. 199 00:08:05,640 --> 00:08:08,520 ONE OF THE THINGS YOU WILL HEAR 200 00:08:08,520 --> 00:08:12,280 ABOUT TODAY IS A FUNDING 201 00:08:12,280 --> 00:08:12,960 ANNOUNCEMENT BEING BROUGHT 202 00:08:12,960 --> 00:08:15,040 FORWARD AS A CROSS NIAID 203 00:08:15,040 --> 00:08:16,480 ACTIVITY THAT I THINK IS 204 00:08:16,480 --> 00:08:17,040 IMPORTANT. 205 00:08:17,040 --> 00:08:20,400 THAT IS ONE OF THE REASONS I'M 206 00:08:20,400 --> 00:08:21,640 SPENDING TIME ON A LITTLE 207 00:08:21,640 --> 00:08:23,320 BACKGROUND ON THIS TOPIC. 208 00:08:23,320 --> 00:08:26,320 NEXT SLIDE PLEASE. 209 00:08:26,320 --> 00:08:28,720 SO A WORD OR TWO ABOUT WORK 210 00:08:28,720 --> 00:08:31,160 FORCE CIVILITY TASK FORCE. 211 00:08:31,160 --> 00:08:37,800 WE DEFINE CIVILITY AS AN 212 00:08:37,800 --> 00:08:39,440 EXPECTATION STATEMENT TO CREATE 213 00:08:39,440 --> 00:08:42,600 A CIVIL WORKPLACE NIAID EXPECTS 214 00:08:42,600 --> 00:08:44,440 ALL STAFF REGARDLESS OF 215 00:08:44,440 --> 00:08:45,440 BACKGROUND OR POSITION TO ACT 216 00:08:45,440 --> 00:08:48,160 WITH PROFESSIONALISM AND 217 00:08:48,160 --> 00:08:49,640 RESPECT, LISTEN WITH AN OPEN 218 00:08:49,640 --> 00:08:52,080 MIND, COMMUNICATE CONSTRUCTIVELY 219 00:08:52,080 --> 00:08:53,480 AND WORK COLLABORATIVELY IN 220 00:08:53,480 --> 00:08:57,520 SUPPORT OF THE NIAID MISSION. 221 00:08:57,520 --> 00:09:03,000 THIS WAS THE CIVILITY WORKPLACE, 222 00:09:03,000 --> 00:09:04,440 CIVILITY PLEDGE WAS DEVELOPED 223 00:09:04,440 --> 00:09:09,280 FOR EMPLOYEES BY EMPLOYEES. 224 00:09:09,280 --> 00:09:10,640 NEXT SLIDE PLEASE. 225 00:09:10,640 --> 00:09:14,080 THERE'S A GRAPHIC WE PREPARED 226 00:09:14,080 --> 00:09:16,040 THAT IS PRINCIPLE PEOPLE CAN PUT 227 00:09:16,040 --> 00:09:18,280 UP IN THEIR OFFICE. 228 00:09:18,280 --> 00:09:19,600 YOU CAN SEE IT HERE. 229 00:09:19,600 --> 00:09:21,240 BASICALLY IT HIGHLIGHTS EACH OF 230 00:09:21,240 --> 00:09:24,800 THE TOPICS THAT I MENTIONED 231 00:09:24,800 --> 00:09:25,680 INCLUDING THINGS LIKE LISTEN 232 00:09:25,680 --> 00:09:26,320 ACTIVELY. 233 00:09:26,320 --> 00:09:31,320 NEXT SLIDE PLEASE. 234 00:09:31,320 --> 00:09:33,760 FOR DIVERSITY EQUITY INCLUSION 235 00:09:33,760 --> 00:09:39,280 AND ACCESS CIVILITY COUNCIL, 236 00:09:39,280 --> 00:09:42,960 HERE IS A STATEMENT ABOUT IT IN 237 00:09:42,960 --> 00:09:44,400 ACHIEVING ITS MISSION TO BETTER 238 00:09:44,400 --> 00:09:46,800 UNDERSTAND TREAT AND PREVENT 239 00:09:46,800 --> 00:09:48,920 INFECTIOUS IMMUNOLOGIC ALLERGIC 240 00:09:48,920 --> 00:09:51,360 DISEASES NIAID IS COMMITTED TO 241 00:09:51,360 --> 00:09:53,320 DIVERSITY EQUITY INCLUSION 242 00:09:53,320 --> 00:09:54,440 ACCESSIBILITY THROUGH FOSTERING 243 00:09:54,440 --> 00:09:57,240 A DIVERSE INCLUSIVE WORK FORCE 244 00:09:57,240 --> 00:10:00,480 AND WORKPLACE FOR ALL STAFF 245 00:10:00,480 --> 00:10:02,160 FUNDING EXTRAMURAL RESEARCH 246 00:10:02,160 --> 00:10:03,680 PORTFOLIO THAT IS REPRESENTATIVE 247 00:10:03,680 --> 00:10:06,160 OF THE DIVERSE POPULATION ITS 248 00:10:06,160 --> 00:10:08,920 SERVES AND PRIORITIZING HEALTH 249 00:10:08,920 --> 00:10:10,720 EQUITY IN ALL RESEARCH NIAID 250 00:10:10,720 --> 00:10:14,760 CONDUCTS AND SUPPORTS. 251 00:10:14,760 --> 00:10:20,080 AS WAY OF HELPING THE DEIA 252 00:10:20,080 --> 00:10:21,000 COUNCIL BECOME ACTIONABLE AND 253 00:10:21,000 --> 00:10:24,000 MOVE FORWARD TO WORK GROUPS WHO 254 00:10:24,000 --> 00:10:25,240 ESTABLISH ONE LOOKING AT THE 255 00:10:25,240 --> 00:10:26,840 INTERNAL WORK FORCE AND THE 256 00:10:26,840 --> 00:10:30,200 SECOND WAS EXTRAMURAL WORK GROUP 257 00:10:30,200 --> 00:10:34,080 LOOKING AT EXTRAMURAL COMMUNITY. 258 00:10:34,080 --> 00:10:36,400 WE ARE NOT THE ONLY ONES AT NIH 259 00:10:36,400 --> 00:10:40,080 WHO HAVE BEEN WORKING ON THIS. 260 00:10:40,080 --> 00:10:43,920 WE ARE BIG ON WE SEE BEST 261 00:10:43,920 --> 00:10:45,680 PRACTICES TAKING THEM AND 262 00:10:45,680 --> 00:10:49,560 ADAPTING THEM FOR OWN NEEDS, 263 00:10:49,560 --> 00:10:52,760 THERE WAS A PLAN DEVELOPED BY 264 00:10:52,760 --> 00:10:53,840 THE BRAIN DIVERSITY INITIATIVE 265 00:10:53,840 --> 00:10:55,760 CALLED THE PLAN FOR ENHANCING 266 00:10:55,760 --> 00:10:57,840 DIVERSE PERSPECTIVES. 267 00:10:57,840 --> 00:10:59,760 THIS WAS TO PUT IN A NEW 268 00:10:59,760 --> 00:11:02,040 COMPONENT INTO FUNDING 269 00:11:02,040 --> 00:11:03,440 OPPORTUNITY ANNOUNCEMENTS THAT 270 00:11:03,440 --> 00:11:05,960 WOULD BE PART OF THE BRAIN 271 00:11:05,960 --> 00:11:08,040 INITIATIVE FOR PIs AND 272 00:11:08,040 --> 00:11:09,680 RESEARCH INSTITUTIONS TO TALK 273 00:11:09,680 --> 00:11:11,800 ABOUT AND BRING FORWARD DIVERSE 274 00:11:11,800 --> 00:11:13,920 PERSPECTIVES AND BRING ALONG THE 275 00:11:13,920 --> 00:11:15,040 CULTURE CHANGE NECESSARY TO 276 00:11:15,040 --> 00:11:17,120 ADDRESS THE INEQUITIES AND 277 00:11:17,120 --> 00:11:20,120 SYSTEMATIC BIASES IN BIOMEDICAL 278 00:11:20,120 --> 00:11:21,680 RESEARCH WHILE ADVANCING 279 00:11:21,680 --> 00:11:22,840 SCIENTIFIC INNOVATION AND 280 00:11:22,840 --> 00:11:24,360 EXCELLENT THROUGH THE INCLUSION 281 00:11:24,360 --> 00:11:28,320 OF ALL VOICES. 282 00:11:28,320 --> 00:11:31,760 THE IDEA OF THIS ADDITION TO THE 283 00:11:31,760 --> 00:11:35,680 FOA IS IT WOULD BENEFIT DIVERSE 284 00:11:35,680 --> 00:11:38,360 SCIENTIFIC WORK FORCE TO INCLUDE 285 00:11:38,360 --> 00:11:40,840 FOSTERING SCIENTIFIC INNOVATION 286 00:11:40,840 --> 00:11:45,000 ENHANCING GLOBAL COMPETITIVENESS 287 00:11:45,000 --> 00:11:46,800 CONTRIBUTING TO ROBUST LEARNING 288 00:11:46,800 --> 00:11:48,320 ENVIRONMENTS, IMPROVING THE 289 00:11:48,320 --> 00:11:50,120 QUALITY OF RESEARCH, ADVANCING 290 00:11:50,120 --> 00:11:52,680 THE LIKELIHOOD THAT UNDERSERVED 291 00:11:52,680 --> 00:11:54,240 POPULATIONS PARTICIPATE IN AND 292 00:11:54,240 --> 00:11:56,760 BENEFIT FROM RESEARCH. 293 00:11:56,760 --> 00:11:57,960 THEREFORE ENHANCING PUBLIC 294 00:11:57,960 --> 00:11:58,360 TRUST. 295 00:11:58,360 --> 00:12:00,800 THIS WAS TO BE SUBMITTED AS A 296 00:12:00,800 --> 00:12:03,240 ONE PAGE OTHER ATTACHMENT TO BE 297 00:12:03,240 --> 00:12:04,920 INCLUDED IN GRANT APPLICATIONS 298 00:12:04,920 --> 00:12:06,440 SUBMITTED IN RESPONSE TO 299 00:12:06,440 --> 00:12:08,440 SPECIFIC FOAs. 300 00:12:08,440 --> 00:12:12,280 NIAID IS GOING TO PILOT THIS 301 00:12:12,280 --> 00:12:14,520 TYPE OF AN APPROACH FOR 302 00:12:14,520 --> 00:12:15,480 MULTI-SPECIFIC FOAs. 303 00:12:15,480 --> 00:12:17,040 YOU WILL HEAR FROM ERIC TODAY 304 00:12:17,040 --> 00:12:19,920 ABOUT HOW THIS IS BEING 305 00:12:19,920 --> 00:12:22,520 INCORPORATED INTO THE CFAR AS WE 306 00:12:22,520 --> 00:12:27,560 GET READY TO RENEW THAT 307 00:12:27,560 --> 00:12:29,160 MULTI-DISCIPLINARY, 308 00:12:29,160 --> 00:12:30,640 MULTI-PROJECT FUNDING ACTIVITY. 309 00:12:30,640 --> 00:12:34,040 NEXT SLIDE PLEASE. 310 00:12:34,040 --> 00:12:38,840 SO THE GOALS TO BE DESCRIBED IN 311 00:12:38,840 --> 00:12:40,760 THE PLAN IS TO MAXIMIZE 312 00:12:40,760 --> 00:12:42,000 PARTICIPATION OF INVESTIGATORS 313 00:12:42,000 --> 00:12:44,560 FROM DIVERSE BACKGROUNDS 314 00:12:44,560 --> 00:12:47,240 INCLUDING GROUPS TRADITIONALLY 315 00:12:47,240 --> 00:12:49,080 UNDER-REPRESENTED IN BIOMEDICAL 316 00:12:49,080 --> 00:12:50,400 BEHAVIORAL AND CLINICAL RESEARCH 317 00:12:50,400 --> 00:12:52,320 WORK FORCE SUCH AS 318 00:12:52,320 --> 00:12:56,720 UNDER-REPRESENTED RACIAL ETHNIC 319 00:12:56,720 --> 00:12:58,360 GROUPS THOSE WITH DISABILITIES 320 00:12:58,360 --> 00:12:59,320 DISADVANTAGED BACKGROUNDS IN 321 00:12:59,320 --> 00:13:00,520 WOMEN, ENHANCE DIFFERENT TYPES 322 00:13:00,520 --> 00:13:05,360 OF INSTITUTIONS AND 323 00:13:05,360 --> 00:13:07,720 ORGANIZATIONS, THAT ARE INVOLVED 324 00:13:07,720 --> 00:13:09,040 INCLUDING RESEARCH INTENSIVE 325 00:13:09,040 --> 00:13:10,600 RESEARCH ACTIVE UNDERGRADUATE 326 00:13:10,600 --> 00:13:13,640 FOCUSED MINORITY SERVING AND 327 00:13:13,640 --> 00:13:17,640 COMMUNITY BASED USE OF THE 328 00:13:17,640 --> 00:13:18,320 PROJECT INFRASTRUCTURE TO 329 00:13:18,320 --> 00:13:20,560 SUPPORT CAREER ENHANCING 330 00:13:20,560 --> 00:13:22,120 RESEARCH OPPORTUNITIES. 331 00:13:22,120 --> 00:13:25,040 FOR DIVERSE EARLY MID CAREER 332 00:13:25,040 --> 00:13:27,040 RESEARCHERS CREATE TRAINING AND 333 00:13:27,040 --> 00:13:28,280 MENTORING OPPORTUNITIES 334 00:13:28,280 --> 00:13:31,760 ENCOURAGING PARTICIPATION OF 335 00:13:31,760 --> 00:13:32,560 STUDENTS POST DOCTORAL 336 00:13:32,560 --> 00:13:33,720 RESEARCHERS AND CO-INVESTIGATORS 337 00:13:33,720 --> 00:13:34,960 FROM DIVERSE BACKGROUNDS AND 338 00:13:34,960 --> 00:13:35,720 WHERE APPROPRIATE INCLUDE 339 00:13:35,720 --> 00:13:38,880 COMMUNITY BASED PARTNERS TO 340 00:13:38,880 --> 00:13:40,400 ENSURE ALIGNMENT OF VERGE GOALS 341 00:13:40,400 --> 00:13:41,600 AND ACTIVITIES WITH COMMUNITY 342 00:13:41,600 --> 00:13:50,520 VALUES. 343 00:13:50,520 --> 00:13:52,440 THAT IS A LOT TO THROW AT YOU 344 00:13:52,440 --> 00:13:55,600 BUT IT WAS IMPORTANT TO HAVE 345 00:13:55,600 --> 00:13:58,960 THIS AS A BIG PART OF THE 346 00:13:58,960 --> 00:13:59,880 DIRECTORS REPORT. 347 00:13:59,880 --> 00:14:01,760 MY PLEDGE TO YOU IS THAT AS PART 348 00:14:01,760 --> 00:14:03,680 OF THE DIRECTOR'S REPORT FROM 349 00:14:03,680 --> 00:14:06,440 HERE ON OUT, I WILL HAVE A 350 00:14:06,440 --> 00:14:10,600 SECTION ON DEIA AS PART OF EVERY 351 00:14:10,600 --> 00:14:13,040 DIRECTOR'S REPORT SO IT STAYS ON 352 00:14:13,040 --> 00:14:15,200 OUR RADAR. 353 00:14:15,200 --> 00:14:16,760 AND IT IS BECOMES PARTS OF JUST 354 00:14:16,760 --> 00:14:18,640 WHO WE ARE AND WHAT WE DO AS 355 00:14:18,640 --> 00:14:24,040 PART OF OUR DAILY RESPONSIBILITY 356 00:14:24,040 --> 00:14:26,880 TO ENHANCE AND SUPPORT HIV AND 357 00:14:26,880 --> 00:14:30,120 HIV RELATED RESEARCH. 358 00:14:30,120 --> 00:14:36,480 SO THAT IS THE PLEDGE TO YOU AS 359 00:14:36,480 --> 00:14:40,240 WE MOVE ALONG. 360 00:14:40,240 --> 00:14:41,880 YOU WILL HEAR ABOUT TWO SPECIFIC 361 00:14:41,880 --> 00:14:44,600 ACTIVITIES LATER IN THE TODAY'S 362 00:14:44,600 --> 00:14:47,600 AGENDA AS I SAID BEFORE. 363 00:14:47,600 --> 00:14:48,600 SWITCHING GEARS I WOULD LIKE TO 364 00:14:48,600 --> 00:14:53,800 UPDATE WHERE WE ARE ON COVID 365 00:14:53,800 --> 00:14:54,560 STUDIES. 366 00:14:54,560 --> 00:14:58,080 ACTIVE TOO IN LONG TERM 367 00:14:58,080 --> 00:15:00,160 FOLLOW-UP SAFETY AND EFFICACY 368 00:15:00,160 --> 00:15:03,440 KNOWN TO AGENTS HAVE COME IN, 369 00:15:03,440 --> 00:15:05,720 ACTIV 2D IS AWAITING FDA SIGN 370 00:15:05,720 --> 00:15:07,680 OFF ON A NEW STUDY DESIGN, 371 00:15:07,680 --> 00:15:08,720 HOPEFULLY IT WILL HAVE FIRST 372 00:15:08,720 --> 00:15:15,560 PATIENT IN IN JULY. 373 00:15:15,560 --> 00:15:17,720 ALL US GOVERNMENT SUPPORTED 374 00:15:17,720 --> 00:15:19,800 PHASE 3 SPONSORED STUDIES AND 375 00:15:19,800 --> 00:15:23,480 SAFETY FOLLOW-UP STAGES, FADS 376 00:15:23,480 --> 00:15:27,600 HAD RECOMMENDED A 24 MONTH 377 00:15:27,600 --> 00:15:28,280 SAFETY POSSIBILITY. 378 00:15:28,280 --> 00:15:31,400 THE MODERNA mRNA 1273 VACCINE 379 00:15:31,400 --> 00:15:34,480 HAS BEEN LICENSE FOR 18 AND OVER 380 00:15:34,480 --> 00:15:37,680 AND THE FDA WILL CONVENE -- 381 00:15:37,680 --> 00:15:42,240 CONFER A VRBPAC WITHIN THE NEXT 382 00:15:42,240 --> 00:15:44,680 -- BASICALLY WITHIN THE NEXT 383 00:15:44,680 --> 00:15:46,800 NINE DAYS OR SO. 384 00:15:46,800 --> 00:15:51,000 TO LOOK AT THE QUESTION OF EUA 385 00:15:51,000 --> 00:15:53,600 FOR AGES 6 TO 17 AND SIX YEARS 386 00:15:53,600 --> 00:15:56,680 TO SIX YEARS OF AGE DAY LATER. 387 00:15:56,680 --> 00:15:59,440 THE NOVAVAX PROTEIN BASED 388 00:15:59,440 --> 00:16:02,200 VACCINE WILL ALSO BE REVIEWED AT 389 00:16:02,200 --> 00:16:06,680 A VRBPAC TOMORROW. 390 00:16:06,680 --> 00:16:09,280 AS THEY SEEK EUA AUTHORIZATION. 391 00:16:09,280 --> 00:16:14,040 THE SANOFI EUA IS PLANNED FOR 392 00:16:14,040 --> 00:16:14,400 JUNE. 393 00:16:14,400 --> 00:16:16,280 THAT IS WHERE WE ARE WITH MAJOR 394 00:16:16,280 --> 00:16:17,440 ACTIVITIES ON COVID OF THE 395 00:16:17,440 --> 00:16:20,600 DIVISION. 396 00:16:20,600 --> 00:16:22,520 I WOULD LIKE TO CLOSE BY 397 00:16:22,520 --> 00:16:25,800 SPENDING TIME ON OUR ACTIVITIES 398 00:16:25,800 --> 00:16:26,360 RELATED TO ENDING THE HIV 399 00:16:26,360 --> 00:16:31,080 EPIDEMIC WHICH IS A CROSS ALL 400 00:16:31,080 --> 00:16:34,960 PARTS OF HHS ACTIVITY THAT WE 401 00:16:34,960 --> 00:16:36,440 PLAY A ROLE IN THROUGH CURRENTLY 402 00:16:36,440 --> 00:16:41,800 THE CFAR PROGRAM. 403 00:16:41,800 --> 00:16:45,000 YOU WILL RECALL THE GOAL OF THE 404 00:16:45,000 --> 00:16:47,440 THE ENDING THE HIV PANDEMIC IS 405 00:16:47,440 --> 00:16:51,160 TO REDUCE NEW HIV INFECTIONS BY 406 00:16:51,160 --> 00:16:56,120 75% IN FIVE YEARS AND 90% IN IN 407 00:16:56,120 --> 00:16:56,480 TEN YEARS. 408 00:16:56,480 --> 00:16:59,720 IT STARTED WITH A NUMBER OF 409 00:16:59,720 --> 00:17:02,760 TARGETED HIGH BURDEN COUNTIES 410 00:17:02,760 --> 00:17:05,960 AND STATES WITH SUBSTANTIAL 411 00:17:05,960 --> 00:17:07,240 BURDEN YOU CAN SEE BASED ON 412 00:17:07,240 --> 00:17:12,480 WHERE THE STARS AND RED RIBBONS 413 00:17:12,480 --> 00:17:17,120 ARE THAT NIMH AND NIH CENTERS 414 00:17:17,120 --> 00:17:20,960 FOR FUNDED AIDS RESEARCH ARE 415 00:17:20,960 --> 00:17:23,360 WELL-POSITIONED TO BE PLACES 416 00:17:23,360 --> 00:17:27,200 WHERE THERE ARE ONGOING EHE 417 00:17:27,200 --> 00:17:30,760 ACTIVITIES IN PRIORITY 418 00:17:30,760 --> 00:17:32,000 JURISDICTIONS. 419 00:17:32,000 --> 00:17:36,840 SO THE APPROACH WE HAVE TAKEN IS 420 00:17:36,840 --> 00:17:39,040 USING AN INNER AGENCY PROCESS TO 421 00:17:39,040 --> 00:17:40,840 ACCELERATE AND OPTIMIZE THE 422 00:17:40,840 --> 00:17:45,320 EFFECT OF THE IMPLEMENTATION. 423 00:17:45,320 --> 00:17:49,280 SO IT IS FINE FOR NIH TO DESIGN 424 00:17:49,280 --> 00:17:50,520 STUDIES AND BRING THINGS FORWARD 425 00:17:50,520 --> 00:17:55,000 BUT WHAT MAKES OUR SCIENCE 426 00:17:55,000 --> 00:17:56,600 BETTER IS WHEN THIS IS COMMUNITY 427 00:17:56,600 --> 00:17:58,440 ENGAGEMENT AND PARTNERSHIP. 428 00:17:58,440 --> 00:18:02,160 SO TO COLLABORATE WITH CDC AND 429 00:18:02,160 --> 00:18:06,240 HRSA ON IMPLEMENTATION 430 00:18:06,240 --> 00:18:11,120 QUESTIONS, WE CAN GET INNOVATIVE 431 00:18:11,120 --> 00:18:17,040 STRATEGIES BASED ON -- THAT 432 00:18:17,040 --> 00:18:18,480 ADDRESS THE REAL WORLD 433 00:18:18,480 --> 00:18:21,120 CONSTRAINTS AND FACILITATE 434 00:18:21,120 --> 00:18:22,280 ADAPTATIONS FOR THE SPECIFIC 435 00:18:22,280 --> 00:18:25,000 CONTEXT OF MANY OF THE 436 00:18:25,000 --> 00:18:27,120 JURISDICTIONS THAT WHETHER IT IS 437 00:18:27,120 --> 00:18:29,200 A STATE OR LOCAL HEALTH 438 00:18:29,200 --> 00:18:31,120 DEPARTMENT IN COLLABORATION WITH 439 00:18:31,120 --> 00:18:32,320 CDC OR HRSA. 440 00:18:32,320 --> 00:18:35,960 THIS ALLOWS US TO ENHANCE 441 00:18:35,960 --> 00:18:36,880 IMPLEMENTATION RESEARCH 442 00:18:36,880 --> 00:18:38,400 KNOWLEDGE TO CREATE A RESEARCH 443 00:18:38,400 --> 00:18:40,280 BASE AND TO INTEGRATE THESE 444 00:18:40,280 --> 00:18:42,160 RESEARCH ADVANCES INTO CLINICAL 445 00:18:42,160 --> 00:18:42,560 SETTINGS. 446 00:18:42,560 --> 00:18:45,320 THIS ALLOWS US TO SHARE THE 447 00:18:45,320 --> 00:18:47,080 INTERVENTIONS AND STRATEGIES 448 00:18:47,080 --> 00:18:48,640 WITH HIV CARE AND PREVENTION 449 00:18:48,640 --> 00:18:49,560 PROVIDERS. 450 00:18:49,560 --> 00:18:51,280 AND IMPROVE PATIENT OUTCOMES 451 00:18:51,280 --> 00:18:52,160 THROUGH THIS IMPLEMENTATION 452 00:18:52,160 --> 00:18:53,520 PROCESS. 453 00:18:53,520 --> 00:18:57,600 SO IT IS A CYCLE OF DISCUSSION 454 00:18:57,600 --> 00:19:02,360 WITH CDC AND HRSA BRINGING 455 00:19:02,360 --> 00:19:05,760 THINGS FORWARD THAT ARE MUTUALLY 456 00:19:05,760 --> 00:19:08,880 WHEN IMPLEMENTED HELPFUL THROUGH 457 00:19:08,880 --> 00:19:10,560 THE THREE ORGANIZATIONS. 458 00:19:10,560 --> 00:19:15,400 ALSO WORKING WITH COMMUNITY TO 459 00:19:15,400 --> 00:19:16,400 IDENTIFY QUESTIONS OF GENERAL 460 00:19:16,400 --> 00:19:17,320 INTEREST TO THEM. 461 00:19:17,320 --> 00:19:21,600 NEXT SLIDE PLEASE. 462 00:19:21,600 --> 00:19:24,840 IN TERMS OF WHERE THIS THIS IS 463 00:19:24,840 --> 00:19:25,640 IMPLEMENTED, IT IS INTERESTING 464 00:19:25,640 --> 00:19:29,880 TO LOOK AT THE 135 PROJECTS THAT 465 00:19:29,880 --> 00:19:34,080 WE FUNDED THROUGH EHE TODAY, 466 00:19:34,080 --> 00:19:35,520 WHERE THE VAST MAJORITY OF THESE 467 00:19:35,520 --> 00:19:37,120 HAVE BEEN IMPLEMENTED THROUGH A 468 00:19:37,120 --> 00:19:38,680 A COMMUNITY BASED ORGANIZATION, 469 00:19:38,680 --> 00:19:41,400 THE HEALTH DEPARTMENT, MUCH 470 00:19:41,400 --> 00:19:43,840 SMALLER AMOUNTS WITHIN THE 471 00:19:43,840 --> 00:19:45,080 COLLEGE OR UNIVERSITIES, WE HAVE 472 00:19:45,080 --> 00:19:48,920 BEEN ABLE TO ENGAGE FAITH BASED 473 00:19:48,920 --> 00:19:53,000 SPIRITUAL ORGANIZATIONS AND VERY 474 00:19:53,000 --> 00:19:55,520 FEW PRIVATE SECTOR PARTNERS. 475 00:19:55,520 --> 00:19:56,440 PUBLIC PROGRAMS HAVE BEEN PART 476 00:19:56,440 --> 00:19:58,000 OF THIS TOO BUT REALLY HAS BEEN 477 00:19:58,000 --> 00:20:00,000 FOCUSED AT THE COMMUNITY LEVEL 478 00:20:00,000 --> 00:20:03,200 THROUGH CBOs, HEALTH 479 00:20:03,200 --> 00:20:05,440 DEPARTMENTS, FQHCs AND OTHER 480 00:20:05,440 --> 00:20:08,720 COMMUNITY BASED CLINICS. 481 00:20:08,720 --> 00:20:11,200 AND ELIMINATE FROM SCHOOL 482 00:20:11,200 --> 00:20:11,560 SYSTEMS. 483 00:20:11,560 --> 00:20:12,520 NEXT SLIDE PLEASE. 484 00:20:12,520 --> 00:20:14,120 SO HERE ARE THE THEMES THAT WE 485 00:20:14,120 --> 00:20:16,160 HAVE BEEN WORKING ON AND THE 486 00:20:16,160 --> 00:20:19,680 NUMBERS OF PROJECTS PER YEAR YOU 487 00:20:19,680 --> 00:20:21,920 CAN SEE THAT IN FISCAL YEAR 19 488 00:20:21,920 --> 00:20:25,760 WE HAD 65, ONE YEAR PROJECTS 489 00:20:25,760 --> 00:20:27,160 LOOKING AT STRATEGIC 490 00:20:27,160 --> 00:20:28,120 PARTNERSHIPS WORKING WITH 491 00:20:28,120 --> 00:20:29,640 RACIALETH IN MIC MINORITY 492 00:20:29,640 --> 00:20:34,880 POPULATIONS IN 2020 LOOKED AT 493 00:20:34,880 --> 00:20:38,240 SPECIFICALLY TARGETING SIS 494 00:20:38,240 --> 00:20:39,720 GENDER HETEROSEXUAL WOMEN 495 00:20:39,720 --> 00:20:43,160 RELATED TO PREP UPTAKE. 496 00:20:43,160 --> 00:20:44,120 DEVELOPING DATA DRIVEN 497 00:20:44,120 --> 00:20:45,800 COMMUNATION STRATEGIES IN FISCAL 498 00:20:45,800 --> 00:20:47,880 YEAR 21 WE LOOK AT SOCIAL 499 00:20:47,880 --> 00:20:49,760 DETERMINANTS OF HEALTH OF HIV 500 00:20:49,760 --> 00:20:50,800 USING INTERSECTIONAL FRAMEWORK 501 00:20:50,800 --> 00:20:51,800 YOU CAN SEE THE NUMBERS OF 502 00:20:51,800 --> 00:20:59,920 PROJECTS EACH YEAR, HERE IS A 503 00:20:59,920 --> 00:21:01,720 LISTING OF THE EHE ACTIVITIES 504 00:21:01,720 --> 00:21:07,720 THAT WE HAVE SOUGHT TO DEVELOP 505 00:21:07,720 --> 00:21:08,160 PROJECT PROJECTS IN. 506 00:21:08,160 --> 00:21:10,040 WE ARE IN THE PROCESS OF VERY 507 00:21:10,040 --> 00:21:11,360 VIEWING WE WILL ANNOUNCE FUNDING 508 00:21:11,360 --> 00:21:16,240 FOR SUPPLEMENTS SHORTLY BASED IN 509 00:21:16,240 --> 00:21:21,280 THESE FIVE TARGETED AREAS. 510 00:21:21,280 --> 00:21:24,040 FOR 23 AND BEYOND, CONSULTATIONS 511 00:21:24,040 --> 00:21:30,080 WITH CDC AND HRSA IS HOW CAN WE 512 00:21:30,080 --> 00:21:32,800 EXPAND STATUS NEUTRAL APPROACH? 513 00:21:32,800 --> 00:21:34,400 HOW CAN WE DETERMINE HOW BEST 514 00:21:34,400 --> 00:21:38,520 THIS COULD BE IMPLEMENTED SO 515 00:21:38,520 --> 00:21:39,560 DOESN'T MATTER WHETHER LIVING 516 00:21:39,560 --> 00:21:42,480 WITH HIV UNDIAGNOSED OR AT RISK 517 00:21:42,480 --> 00:21:44,680 OF HIV YOU COME INTO A CLINIC, 518 00:21:44,680 --> 00:21:49,120 YOU ARE EVALUATED, YOU RECEIVE 519 00:21:49,120 --> 00:21:51,960 TREATMENT, THE GOAL IS REALLY 520 00:21:51,960 --> 00:21:54,880 USING STATUS NEUTRAL AS WAY OF 521 00:21:54,880 --> 00:21:55,560 BATTLING STIGMA. 522 00:21:55,560 --> 00:21:57,440 WE WANT TO CONTINUE TO MITIGATE 523 00:21:57,440 --> 00:22:04,080 HEALTH RELATED DISPARITIES AND 524 00:22:04,080 --> 00:22:05,440 SPEND TIME AND ENERGY FOCUSING 525 00:22:05,440 --> 00:22:07,600 ON AGING, HIV AND AGING 526 00:22:07,600 --> 00:22:09,880 IMPROVING THE HEALTH OUTCOMES, 527 00:22:09,880 --> 00:22:14,160 AND THE QUALITY OF LIFE OF 528 00:22:14,160 --> 00:22:15,480 PEOPLE AGING WITH HIV. 529 00:22:15,480 --> 00:22:17,800 SO MANY PEOPLE LIVING WITH HIV 530 00:22:17,800 --> 00:22:21,320 ARE OVER 50. 531 00:22:21,320 --> 00:22:27,120 AND AS YEARS PASSED WE HAVE A 532 00:22:27,120 --> 00:22:28,920 GRAYING OF THE HIV PANDEMIC IN 533 00:22:28,920 --> 00:22:30,320 THE UNITED STATES AND WE WANT TO 534 00:22:30,320 --> 00:22:31,960 MAKE SURE THAT PEOPLE CAN LIVE 535 00:22:31,960 --> 00:22:36,920 THEIR BEST LIVES THROUGH PATIENT 536 00:22:36,920 --> 00:22:40,160 CENTERED PERSON CENTERED CARE 537 00:22:40,160 --> 00:22:41,360 BEING IMPLEMENTED THROUGH 538 00:22:41,360 --> 00:22:43,200 CLINICS SO THIS GETS BACK TO THE 539 00:22:43,200 --> 00:22:44,800 HEALTH RELATED QUALITY OF LIFE 540 00:22:44,800 --> 00:22:50,480 QUESTIONS. 541 00:22:50,480 --> 00:22:54,080 SO WE HAVE HAD JOURNAL 542 00:22:54,080 --> 00:22:55,400 SUPPLEMENTS IN SPRING SUMMER 543 00:22:55,400 --> 00:22:57,680 THIS YEAR, WE ARE GOING TO HAVE 544 00:22:57,680 --> 00:22:58,680 ONE WITH 30 ARTICLES REPORTING 545 00:22:58,680 --> 00:23:05,200 FINDINGS FROM EHE PROJECTS. 546 00:23:05,200 --> 00:23:07,080 THERE IS A MEETING SCHEDULED FOR 547 00:23:07,080 --> 00:23:09,640 BIRMINGHAM ALABAMA IN SENT TO 548 00:23:09,640 --> 00:23:12,800 LOOK AT COMMUNITY COLLABORATION 549 00:23:12,800 --> 00:23:16,520 TOWARDS ENDING HIV EPIDEMIC. 550 00:23:16,520 --> 00:23:18,240 THE MEETING OBJECTIVES WHICH ARE 551 00:23:18,240 --> 00:23:20,240 SHARED BEST PRACTICES AND 552 00:23:20,240 --> 00:23:25,200 LESSONS LEARNED. SO THAT WAS 553 00:23:25,200 --> 00:23:27,320 ALL I WAS GOING TO SAY ABOUT 554 00:23:27,320 --> 00:23:27,920 EHE. 555 00:23:27,920 --> 00:23:29,480 SO ONE OF THE THINGS YOU ARE 556 00:23:29,480 --> 00:23:33,560 PROBABLY VERY AWARE OF THAT IS 557 00:23:33,560 --> 00:23:36,640 THAT WE RECEIVE REQUEST AND 558 00:23:36,640 --> 00:23:39,640 RECEIVE PUBLIC COMMENTS AND THIS 559 00:23:39,640 --> 00:23:42,760 CYCLE WE HAVE RECEIVED A NUMBER 560 00:23:42,760 --> 00:23:45,720 OF COMMENTS FROM THE 561 00:23:45,720 --> 00:23:50,240 ORGANIZATION FOR HERPES CURE 562 00:23:50,240 --> 00:23:51,960 ADVOCACY GROUP. 563 00:23:51,960 --> 00:23:54,960 AND THERE ARE PLANS UNDERWAY 564 00:23:54,960 --> 00:23:57,200 BETWEEN NIAID AND CDC TO HOLD A 565 00:23:57,200 --> 00:24:01,920 WORKSHOP IN THE FALL OF 2022 TO 566 00:24:01,920 --> 00:24:06,440 LOOK AT THE STATUS OF THE 567 00:24:06,440 --> 00:24:07,880 RESEARCH CONTROL AND PREVENTION 568 00:24:07,880 --> 00:24:09,360 STRATEGIES, IDENTIFY CHALLENGES 569 00:24:09,360 --> 00:24:10,760 GAPS AND OPPORTUNITIES FOR 570 00:24:10,760 --> 00:24:13,320 FUTURE WORK FOCUSED ON HSV 571 00:24:13,320 --> 00:24:14,720 INFECTION AND DISEASE. 572 00:24:14,720 --> 00:24:19,080 IT IS THE INTENTION OF CDC AND 573 00:24:19,080 --> 00:24:21,400 NIH TO ENGAGE COMMUNITY GROUPS 574 00:24:21,400 --> 00:24:23,720 TO BE PART OF THE MEETING. 575 00:24:23,720 --> 00:24:27,680 AND TO HAVE SECTIONS DEVOTED TO 576 00:24:27,680 --> 00:24:28,400 THEIR QUESTIONS AND NEEDS. 577 00:24:28,400 --> 00:24:32,080 WE ALSO RECEIVED A COMMENT, 578 00:24:32,080 --> 00:24:39,240 AGAIN JUST TO BE CLEAR, THE 579 00:24:39,240 --> 00:24:40,800 CENTER OF GRAVITY ON HERPES 580 00:24:40,800 --> 00:24:43,560 QUESTIONS ARE ON DMID DAIDS IS 581 00:24:43,560 --> 00:24:45,560 AWARE AND WILL PARTICIPATE AS 582 00:24:45,560 --> 00:24:47,400 NEEDED. 583 00:24:47,400 --> 00:24:49,640 BUT THE MEETING IS LARGELY BEING 584 00:24:49,640 --> 00:24:53,800 PLANNED BY COLLEAGUES IN KMID. 585 00:24:53,800 --> 00:24:56,920 WE ALSO RECEIVED A REQUEST TO 586 00:24:56,920 --> 00:24:59,640 MAKE COMPLAINING THAT THE ARAC 587 00:24:59,640 --> 00:25:02,840 MEETING WAS NOT AN OPEN MEETING 588 00:25:02,840 --> 00:25:04,680 WHICH IT IS IN FACT AND THERE 589 00:25:04,680 --> 00:25:07,560 CONTINUES TO BE ONGOING 590 00:25:07,560 --> 00:25:10,480 DISCUSSIONS ABOUT HOW ANIMAL 591 00:25:10,480 --> 00:25:12,280 RESEARCH IS BEINGS CONDUCTED SO 592 00:25:12,280 --> 00:25:14,480 THAT IS THE EXTENT OF THE PUBLIC 593 00:25:14,480 --> 00:25:18,920 COMMENTS FOR THIS CYCLE TO GIVE 594 00:25:18,920 --> 00:25:22,000 A SENSE OF UPCOMING MEETINGS, WE 595 00:25:22,000 --> 00:25:26,480 ARE LOOK AT POTENTIALLY 596 00:25:26,480 --> 00:25:27,360 SEPTEMBER BEING HYBRID. 597 00:25:27,360 --> 00:25:30,560 JANUARY IS VIRTUAL EVEN IF WE 598 00:25:30,560 --> 00:25:34,840 WERE IN FULL OPPORTUNITY WE ARE 599 00:25:34,840 --> 00:25:37,920 CONSIDERING AVRSWG MEETING FOR 600 00:25:37,920 --> 00:25:39,000 THE JANUARY MEETING. 601 00:25:39,000 --> 00:25:40,720 TESTIFY REST OF THE DATES ARE 602 00:25:40,720 --> 00:25:43,240 LISTED THERE FOR YOUR CALENDARS. 603 00:25:43,240 --> 00:25:51,920 I THINK THAT IS IT FOR ME. 604 00:25:51,920 --> 00:25:56,520 I AM AVAILABLE FOR QUESTIONS. 605 00:25:56,520 --> 00:25:57,560 ANY QUESTIONS FOR DR. 606 00:25:57,560 --> 00:26:02,360 DIEFFENBACH. 607 00:26:02,360 --> 00:26:03,880 >> IT WAS GOING TO BE SOMEWHERE 608 00:26:03,880 --> 00:26:05,520 BETWEEN A QUESTION AND COMMENT, 609 00:26:05,520 --> 00:26:09,160 HAPPY TO SEE THE HSV WORK 610 00:26:09,160 --> 00:26:11,080 GETTING SOME ATTENTION. 611 00:26:11,080 --> 00:26:13,120 WITHIN THE INSTITUTE. 612 00:26:13,120 --> 00:26:18,080 THERE IS A RECOGNITION AMONG 613 00:26:18,080 --> 00:26:19,720 WITHIN THIS GROUP HOPEFULLY 614 00:26:19,720 --> 00:26:21,960 SUBSTANTIAL ATTRIBUTABLE RISK 615 00:26:21,960 --> 00:26:23,640 FOR HIV ACQUISITION DUE TO 616 00:26:23,640 --> 00:26:25,040 PRE-EXISTING GENITAL DISEASE FOR 617 00:26:25,040 --> 00:26:26,200 HSV. 618 00:26:26,200 --> 00:26:28,280 THAT IS MORE COMMENT THAN 619 00:26:28,280 --> 00:26:29,320 QUESTION IF THERE IS THAT 620 00:26:29,320 --> 00:26:30,680 RECOGNITION BECAUSE THAT IS AN 621 00:26:30,680 --> 00:26:31,960 IMPORTANT PART OF OUR MISSION AS 622 00:26:31,960 --> 00:26:34,760 WELL. 623 00:26:34,760 --> 00:26:35,560 >> THANK YOU AGAIN. 624 00:26:35,560 --> 00:26:38,920 WE WILL CONTINUE TO WORK CLOSELY 625 00:26:38,920 --> 00:26:42,120 WITH DMID AND THE SDI GROUP 626 00:26:42,120 --> 00:26:44,480 THERE TO ADDRESS THESE 627 00:26:44,480 --> 00:26:48,920 OVERLAPPING AREAS OF INTEREST. 628 00:26:48,920 --> 00:26:52,400 DR. WALLACE, QUESTION. 629 00:26:52,400 --> 00:26:56,200 >> HI CARL. 630 00:26:56,200 --> 00:26:57,960 CURIOUS IF WHAT THE 631 00:26:57,960 --> 00:26:58,760 CONVERSATIONS HAVE BEEN OR IF 632 00:26:58,760 --> 00:27:00,840 THERE IS ANY PROGRESS IN 633 00:27:00,840 --> 00:27:03,080 CONVERSATIONS TO ENGAGE 634 00:27:03,080 --> 00:27:04,800 HISTORICALLY BLACK COLLEGES, 635 00:27:04,800 --> 00:27:06,200 HISTORICALLY BLACK MEDICAL 636 00:27:06,200 --> 00:27:07,800 SCHOOLS AND OTHER MINORITY 637 00:27:07,800 --> 00:27:09,880 SERVING ORGANIZATIONS BASED TON 638 00:27:09,880 --> 00:27:11,720 SLIDE YOU PUT UP ABOUT ENGAGING 639 00:27:11,720 --> 00:27:12,760 DIVERSE GROUPS AND RESEARCH AND 640 00:27:12,760 --> 00:27:14,680 BUILDING OUT THAT CAPACITY. 641 00:27:14,680 --> 00:27:19,360 >> SO WITHIN THE INSTITUTE THERE 642 00:27:19,360 --> 00:27:24,320 ABSOLUTELY HAS BEEN WE HAVE 643 00:27:24,320 --> 00:27:28,280 BROUGHT IN SEVERAL MEDICAL 644 00:27:28,280 --> 00:27:32,360 SCHOOLS TO BE PART OF CO-VPN AND 645 00:27:32,360 --> 00:27:35,520 THOSE ACTIVITIES HAVE CONTINUED 646 00:27:35,520 --> 00:27:39,240 LARGELY THROUGH DMID GROUP THE 647 00:27:39,240 --> 00:27:44,080 IDCRC CONTINUES TO MAINTAIN 648 00:27:44,080 --> 00:27:45,480 LINKAGES TO BRING THOSE GROUPS 649 00:27:45,480 --> 00:27:47,040 WITHIN A LARGER CLINICAL TRIALS 650 00:27:47,040 --> 00:27:51,800 FRAMEWORK THAN IS AVAILABLE FOR 651 00:27:51,800 --> 00:27:53,000 WHERE WHAT CURRENTLY DOING 652 00:27:53,000 --> 00:27:54,080 WITHIN THE DIVISION OF AIDS SO 653 00:27:54,080 --> 00:27:55,120 THERE IS SHARING ACROSS THE 654 00:27:55,120 --> 00:27:58,560 INSTITUTION AND MAKING SURE THAT 655 00:27:58,560 --> 00:28:01,760 WHICH ARE GIVING ORGANIZATIONS 656 00:28:01,760 --> 00:28:04,440 OPPORTUNITIES COMMENSURATE WITH 657 00:28:04,440 --> 00:28:11,800 AND CAN GROW WITH THEIR 658 00:28:11,800 --> 00:28:12,240 POTENTIAL. 659 00:28:12,240 --> 00:28:14,240 >> THANK YOU, DR. DIEFFENBACH. 660 00:28:14,240 --> 00:28:17,080 WE WILL KEEP MOVING, VERY NICE 661 00:28:17,080 --> 00:28:17,320 REPORT. 662 00:28:17,320 --> 00:28:20,440 IT IS A PLEASURE NOW FOR ME TO 663 00:28:20,440 --> 00:28:21,960 INTRODUCE WELCOME DR. MAUREEN 664 00:28:21,960 --> 00:28:23,800 GOODENOW WHO AS YOU KNOW IS THE 665 00:28:23,800 --> 00:28:24,920 DIRECTOR OF OFFICE OF AIDS 666 00:28:24,920 --> 00:28:26,600 RESEARCH. 667 00:28:26,600 --> 00:28:27,960 WHO WILL BE GIVING US AN UPDATE. 668 00:28:27,960 --> 00:28:32,160 THANK YOU, DR. GOODENOW. 669 00:28:32,160 --> 00:28:39,840 >> THANK YOU VERY MUCH FO FOR TE 670 00:28:39,840 --> 00:28:41,200 OPPORTUNITY TO PROVIDE RESEARCH 671 00:28:41,200 --> 00:28:48,160 AND UPDATES ON OFFICE OF OHOR. 672 00:28:48,160 --> 00:28:49,920 PARTICULARLY WITH EXPANSION OF 673 00:28:49,920 --> 00:28:51,760 THE WORK FORCE. 674 00:28:51,760 --> 00:28:52,960 I UNDERSTAND CENTRALLY IS 675 00:28:52,960 --> 00:28:55,880 WORKING THE SLIDES. 676 00:28:55,880 --> 00:28:57,240 I WILL LET YOU FOE WHEN I NEED 677 00:28:57,240 --> 00:28:58,280 TO CHANGE. 678 00:28:58,280 --> 00:29:01,360 AS AN EXOFFICIO MEMBER OF ARAC, 679 00:29:01,360 --> 00:29:03,920 HAPPY TO DISCUSS THE ROLE OF OAR 680 00:29:03,920 --> 00:29:04,720 WITH YOU. 681 00:29:04,720 --> 00:29:06,560 IN FACT THIS PRESENTATION IS 682 00:29:06,560 --> 00:29:12,960 PART OF THE ONGOING STRATEGY TO 683 00:29:12,960 --> 00:29:14,000 SHARE OAR PERSPECTIVES WITHIN 684 00:29:14,000 --> 00:29:14,960 NIH INSTITUTES CENTERS AND 685 00:29:14,960 --> 00:29:19,120 OFFICES AND THEIR COUNCILS MORE 686 00:29:19,120 --> 00:29:19,480 BROADLY. 687 00:29:19,480 --> 00:29:21,440 MY REMARKS WILL FOCUS ON TWO 688 00:29:21,440 --> 00:29:24,200 AREAS WHICH THE NIH OAR 689 00:29:24,200 --> 00:29:26,760 INFLUENCES THE HIV RESEARCH WORK 690 00:29:26,760 --> 00:29:29,200 FORCE, FIRST THE OAR LISTENING 691 00:29:29,200 --> 00:29:30,880 SESSIONS AND THE SECOND OAR 692 00:29:30,880 --> 00:29:31,720 INITIATIVES THAT SUPPORT EARLY 693 00:29:31,720 --> 00:29:34,120 CAREER INVESTIGATORS WITH A 694 00:29:34,120 --> 00:29:39,920 FOCUS ON DIVERSITY THE OAR IS 695 00:29:39,920 --> 00:29:41,360 EMBEDDED WITHIN OFFICE OF THE 696 00:29:41,360 --> 00:29:42,960 NIH DIRECTOR. 697 00:29:42,960 --> 00:29:45,800 WAS ESTABLISHED BY CONGRESS 698 00:29:45,800 --> 00:29:46,840 NEARLY 35 YEARS AGO. 699 00:29:46,840 --> 00:29:50,600 BY LEGISLATION THAT DEFINE THE 700 00:29:50,600 --> 00:29:51,960 ACTIVITY ROLES AND 701 00:29:51,960 --> 00:29:53,640 RESPONSIBILITIES FOR THE OFFICE. 702 00:29:53,640 --> 00:29:58,120 THE OAR DIRECTOR IS APPOINTED BY 703 00:29:58,120 --> 00:29:59,680 THE HHS SECRETARY AND REPORTS AS 704 00:29:59,680 --> 00:30:02,080 THE ASSOCIATE DIRECTOR FOR AIDS 705 00:30:02,080 --> 00:30:05,720 RESEARCH TO THE NIH DIRECTOR. 706 00:30:05,720 --> 00:30:08,720 HIV RESEARCH FUNDING COMPRISES 707 00:30:08,720 --> 00:30:11,920 7% OVERALL HIV BUDGET AND 708 00:30:11,920 --> 00:30:14,840 CURRENTLY TOTALS CLOSE TO 709 00:30:14,840 --> 00:30:16,920 $3.2 BILLION ANNUALLY. 710 00:30:16,920 --> 00:30:20,000 OAR'S RESPONSIBLE FOR THE 711 00:30:20,000 --> 00:30:21,600 ALLOCATION TRACKING AND 712 00:30:21,600 --> 00:30:24,200 REPORTING OF THE NIH HIV FUNDING 713 00:30:24,200 --> 00:30:27,200 ACROSS INSTITUTE CENTERS AND 714 00:30:27,200 --> 00:30:29,480 OFFICES OR ICOs AND DEFINING 715 00:30:29,480 --> 00:30:33,440 THE NIH STRATEGIC PLAN FOR HIV 716 00:30:33,440 --> 00:30:39,520 AND HIV RELATED RESEARCH. 717 00:30:39,520 --> 00:30:41,600 OAR PRIORITY ACTIVITIES ARE 718 00:30:41,600 --> 00:30:45,240 ORGANIZED BY FOUR KEY FUNCTIONS. 719 00:30:45,240 --> 00:30:47,120 TO CONVENE CATALYZE COORDINATE 720 00:30:47,120 --> 00:30:51,640 AND COMMUNICATE HIV RELATED 721 00:30:51,640 --> 00:30:52,720 RESEARCH ACROSS THE NIH. 722 00:30:52,720 --> 00:30:54,920 CENTRAL TO ALL THESE ACTIVITIES 723 00:30:54,920 --> 00:30:57,920 IS THE NEED TO ENSURE DIVERSITY 724 00:30:57,920 --> 00:31:00,040 AND INCLUSIVITY AND COMBAT 725 00:31:00,040 --> 00:31:02,480 RACISM IN ALL ITS FORMS TO 726 00:31:02,480 --> 00:31:04,600 ENSURE THE SUSTAINED SUCCESS OF 727 00:31:04,600 --> 00:31:09,880 THE NIH HIV RESEARCH ENTERPRISE 728 00:31:09,880 --> 00:31:11,680 THE NIH UNITE INITIATIVE IS 729 00:31:11,680 --> 00:31:13,520 AGENCY WIDE EFFORT TO IDENTIFY 730 00:31:13,520 --> 00:31:18,680 AND ADDRESS STRUCTURAL RACISM 731 00:31:18,680 --> 00:31:20,560 WITHIN BIOMEDICAL RESEARCH AND 732 00:31:20,560 --> 00:31:21,960 BOLSTER EFFORTS OF HIV OFFICES 733 00:31:21,960 --> 00:31:23,080 INVOLVED IN DIVERSITY EQUITY 734 00:31:23,080 --> 00:31:32,040 INCLUSION AND ACCESSIBILITY. 735 00:31:32,040 --> 00:31:33,720 IMPORTANTLY NIH OAR WORKS 736 00:31:33,720 --> 00:31:35,040 CLOSELY WITH OTHER HHS AGENCIES 737 00:31:35,040 --> 00:31:37,600 TO CARRY OUT THE MISSION WITH 738 00:31:37,600 --> 00:31:39,920 INPUT AND GUIDANCE FROM THE OAR 739 00:31:39,920 --> 00:31:41,960 ADVISORY COUNCIL OR OARAC AND 740 00:31:41,960 --> 00:31:46,560 YOU HAVE BEEN INTRODUCED TO DR. 741 00:31:46,560 --> 00:31:49,880 JONAS SASHA HERE AS INCOMING 742 00:31:49,880 --> 00:31:55,960 REPRESENTATIVE FROM OARAC T TO 743 00:31:55,960 --> 00:31:58,840 ARAC. 744 00:31:58,840 --> 00:32:01,080 THE OARAC AND OTHER HIV 745 00:32:01,080 --> 00:32:01,720 ACTIVITIES CONDUCTED OR 746 00:32:01,720 --> 00:32:12,080 SUPPORTED BY THE NIH. 747 00:32:13,560 --> 00:32:18,720 O OARAC'S HINNIES NIH OFFICE OF 748 00:32:18,720 --> 00:32:20,640 DIRECTOR CDC VETERANS 749 00:32:20,640 --> 00:32:21,920 ADMINISTRATION AND DEPARTMENT OF 750 00:32:21,920 --> 00:32:22,520 DEFENSE. 751 00:32:22,520 --> 00:32:25,640 WHILE OTHER EXOFFICIOS REPRESENT 752 00:32:25,640 --> 00:32:27,760 COUNSELS OF NIH ICs, WITH 753 00:32:27,760 --> 00:32:29,360 LARGEST PROPORTION OF HIV 754 00:32:29,360 --> 00:32:32,600 FUNDING AND THAT INCLUDES NIAID 755 00:32:32,600 --> 00:32:36,840 WITH DR. CARL DIEFFENBACH, NIDA, 756 00:32:36,840 --> 00:32:39,840 NCI NIMH AND NICHD. 757 00:32:39,840 --> 00:32:45,480 THESE EXOFFICIO MEMBERS INFORM 758 00:32:45,480 --> 00:32:46,400 INFORM AND FACILITATE ACTIVITIES 759 00:32:46,400 --> 00:32:48,040 WITHIN THE NIH AND ACROSS OTHER 760 00:32:48,040 --> 00:32:50,680 US GOVERNMENT AGENCIES AND THE 761 00:32:50,680 --> 00:32:52,680 REPRESENTATION HELPS ENSURE THE 762 00:32:52,680 --> 00:32:54,840 APPROPRIATE BREADTH AND DEPTH OF 763 00:32:54,840 --> 00:33:00,360 NIH HIV RESEARCH PORTFOLIO. IN 764 00:33:00,360 --> 00:33:01,680 THE NEXT SLIDES THE OFFICE OF 765 00:33:01,680 --> 00:33:03,240 AIDS RESEARCH WORKS ACROSS THE 766 00:33:03,240 --> 00:33:06,000 NIH ICOs TO ADVANCE RESEARCH 767 00:33:06,000 --> 00:33:08,840 TO ENDS THE HIV EPIDEMIC IMPROVE 768 00:33:08,840 --> 00:33:10,760 HEALTH OUTCOMES FOR PEOPLE WITH 769 00:33:10,760 --> 00:33:12,520 HIV AND ENSURE RESEARCH FUNDING 770 00:33:12,520 --> 00:33:16,800 IS DIRECTED AT HIGHEST PRIORITY 771 00:33:16,800 --> 00:33:19,440 AREAS TO DO THIS EACH ICO WITH 772 00:33:19,440 --> 00:33:21,880 HIV PORTFOLIO HAS A COORDINATOR. 773 00:33:21,880 --> 00:33:24,200 APPOINTED BY THE RESPECTIVE 774 00:33:24,200 --> 00:33:25,960 INSTITUTE CENTER OFFICE 775 00:33:25,960 --> 00:33:26,360 DIRECTOR. 776 00:33:26,360 --> 00:33:29,920 AND THE COORDINATOR SERVES ON 777 00:33:29,920 --> 00:33:34,760 THE NIH HIV AIDS EXECUTIVE 778 00:33:34,760 --> 00:33:35,800 COMMITTEE. 779 00:33:35,800 --> 00:33:39,880 THE NAC PROVIDES A FORUM FOR OAR 780 00:33:39,880 --> 00:33:41,360 AND OTHER CONSTITUENTS TO WORK 781 00:33:41,360 --> 00:33:42,800 TOGETHER TO SYNERGIZE HIV 782 00:33:42,800 --> 00:33:44,040 RESEARCH ACROSS THE AGENCY. 783 00:33:44,040 --> 00:33:48,040 AND I WOULD LIKE TO TAKE THIS 784 00:33:48,040 --> 00:33:49,840 OPPORTUNITY TO THANK ROB PALMER 785 00:33:49,840 --> 00:33:52,760 AND THE REST OF THE NIAID DAIDS 786 00:33:52,760 --> 00:33:57,600 TEAM FOR THEIR WORK WITH US ON 787 00:33:57,600 --> 00:33:58,520 THE NAC. 788 00:33:58,520 --> 00:34:00,920 THE NAC INCLUDES SEVERAL WORKING 789 00:34:00,920 --> 00:34:02,120 GROUPS THAT FACILITATE 790 00:34:02,120 --> 00:34:04,120 COLLABORATION SUCH AS ENDI EN EE 791 00:34:04,120 --> 00:34:05,400 HIV EPIDEMIC THAT CARL MENTIONED 792 00:34:05,400 --> 00:34:07,160 AND THE, WHOING GROUP TO SUPPORT 793 00:34:07,160 --> 00:34:09,120 EARLY CAREER INVESTIGATORS IN 794 00:34:09,120 --> 00:34:13,080 HIV. 795 00:34:13,080 --> 00:34:15,200 SIMILAR NIH WIDE COORDINATION 796 00:34:15,200 --> 00:34:16,760 EFFORTS ORIGIN GNAT MULTIPLE 797 00:34:16,760 --> 00:34:19,080 EFFORTS AND WAYS ACROSS THE NIH 798 00:34:19,080 --> 00:34:22,240 AND ONE OF THESE EXAMPLES IS THE 799 00:34:22,240 --> 00:34:23,400 NIH CFAR STEERING COMMITTEE 800 00:34:23,400 --> 00:34:27,160 WHICH INVOLVES ALL ICOs THAT 801 00:34:27,160 --> 00:34:29,520 SUPPORT THE CFAR PROGRAM. 802 00:34:29,520 --> 00:34:33,600 IN THE NEXT SLIDE, IS SHOWN THE 803 00:34:33,600 --> 00:34:36,360 DISTRIBUTION OF FISCAL YEAR 2021 804 00:34:36,360 --> 00:34:39,560 HIV FUNDING ACROSS THE NIH 805 00:34:39,560 --> 00:34:43,440 INSTITUTES AND CENTERS. 806 00:34:43,440 --> 00:34:45,200 THERE IS A CLEAR RANGE IN TERMS 807 00:34:45,200 --> 00:34:48,760 OF TOTAL FUNDING LEVELS FROM 808 00:34:48,760 --> 00:34:51,320 ACROSS THE TOP MORE THAN 809 00:34:51,320 --> 00:34:55,280 1.6 BILLION OF 3.2 BILLION FOR 810 00:34:55,280 --> 00:34:57,280 NIAID RANGING DOWN TO A FEW 811 00:34:57,280 --> 00:34:58,640 MILLION FOR SOME OF THE OTHER 812 00:34:58,640 --> 00:35:01,520 ICs. 813 00:35:01,520 --> 00:35:03,440 THERE ARE ALSO DIFFERENCES IN 814 00:35:03,440 --> 00:35:04,440 MAG INSTITUTES OF HIV FUNDING 815 00:35:04,440 --> 00:35:08,200 RELATIVE TO ICOs TOTAL FUNDING 816 00:35:08,200 --> 00:35:11,960 SO THE DARKER SHADES REPRESENT 817 00:35:11,960 --> 00:35:13,760 ICs WITH LARGER PROPORTIONAL 818 00:35:13,760 --> 00:35:15,800 HIV RESEARCH FUNDING. 819 00:35:15,800 --> 00:35:21,520 SO NIAID, THEIR HIV RESEARCH 820 00:35:21,520 --> 00:35:22,840 FUNDING REPRESENTS AT LEAST A 821 00:35:22,840 --> 00:35:24,120 THIRD OF THEIR TOTAL NIH 822 00:35:24,120 --> 00:35:29,080 FUNDING. 823 00:35:29,080 --> 00:35:30,840 FOR OTHER ICs HIV FUNDING 824 00:35:30,840 --> 00:35:32,640 REPRESENTS GENERALLY SOMEWHERE 825 00:35:32,640 --> 00:35:35,920 BETWEEN 2 TO 20% OF THEIR 826 00:35:35,920 --> 00:35:39,960 OVERALL NIH RESEARCH ALLOCATION 827 00:35:39,960 --> 00:35:41,920 IN THE NEXT SLIDE WHICH CARL HAS 828 00:35:41,920 --> 00:35:45,800 SHOWN YOU, THE NIH RESEARCH 829 00:35:45,800 --> 00:35:47,160 PRIORITIES REQUIRE A 830 00:35:47,160 --> 00:35:48,880 MULTI-INSTITUTE 831 00:35:48,880 --> 00:35:50,520 MULTI-DISCIPLINARY APPROACH THAT 832 00:35:50,520 --> 00:35:53,240 ALIGNS WITH NIH HIV RESEARCH 833 00:35:53,240 --> 00:35:54,720 PRIORITIES AND IN PARTICULAR, 834 00:35:54,720 --> 00:35:55,880 THE CROSS CUTTING AREAS OF 835 00:35:55,880 --> 00:35:56,960 RESEARCH REPRESENTED BY THE 836 00:35:56,960 --> 00:36:00,360 WHITE CIRCLES, INCLUDE RESEARCH 837 00:36:00,360 --> 00:36:01,600 TRAINING, INFRASTRUCTURE, AND 838 00:36:01,600 --> 00:36:03,400 WORK FORCE CAPACITY BUILDING. 839 00:36:03,400 --> 00:36:05,040 WHICH I WILL TALK MORE ABOUT 840 00:36:05,040 --> 00:36:09,000 NOW. 841 00:36:09,000 --> 00:36:11,360 IN THE NEXT SLIDE OAR CONTINUES 842 00:36:11,360 --> 00:36:12,320 TO ORGANIZE FORMAL LISTENING 843 00:36:12,320 --> 00:36:14,280 SESSIONS TO HEAR DIRECTLY FROM 844 00:36:14,280 --> 00:36:20,000 DIVERSE STAKEHOLDERS. 845 00:36:20,000 --> 00:36:21,800 SINCE 2018 OAR HELD MORE THAN 60 846 00:36:21,800 --> 00:36:23,000 COMETSIC LISTENING SESSIONS AND 847 00:36:23,000 --> 00:36:24,240 COMMUNITY ENGAGEMENTS AT THE 848 00:36:24,240 --> 00:36:26,000 LOCATIONS INDICATED BY THE RED 849 00:36:26,000 --> 00:36:28,080 CIRCLES IN THIS MAP. 850 00:36:28,080 --> 00:36:29,000 AND YOU HAVE ALREADY SEEN 851 00:36:29,000 --> 00:36:30,600 ANOTHER VERSION OF THIS MAP FROM 852 00:36:30,600 --> 00:36:35,520 CARL WHICH INDICATED THE 853 00:36:35,520 --> 00:36:39,360 JURISDICTIONS FOR EHE AS WELL AS 854 00:36:39,360 --> 00:36:41,000 LOCALIZATION OF CENTER FOR AIDS 855 00:36:41,000 --> 00:36:46,080 RESEARCH AND THE NIMH AIDS 856 00:36:46,080 --> 00:36:46,320 RESEARCH. 857 00:36:46,320 --> 00:36:47,960 MANY LOCATIONS IN THE WILL BEING 858 00:36:47,960 --> 00:36:51,160 SESSIONS OVERLAPPED WITH THE EHE 859 00:36:51,160 --> 00:36:53,440 JURISDICTIONS, WITH RURAL 860 00:36:53,440 --> 00:36:55,280 COMMUNITIES WITH HIGH HIV BURDEN 861 00:36:55,280 --> 00:36:56,920 OR WITH KEY HIV STAKEHOLDER 862 00:36:56,920 --> 00:36:59,920 ORGANIZATIONS. 863 00:36:59,920 --> 00:37:02,280 OAR DEVELOPED A STAKEHOLDER 864 00:37:02,280 --> 00:37:03,360 OUTREACH AND ENGAGEMENT REPORT 865 00:37:03,360 --> 00:37:04,800 THAT IS AVAILABLE ON OUR 866 00:37:04,800 --> 00:37:07,920 WORKSHOP ON OUR WEBSITE. AND 867 00:37:07,920 --> 00:37:09,960 THIS REPORT DETAILS KEY THEMES 868 00:37:09,960 --> 00:37:11,480 FROM IN PERSON LISTENING 869 00:37:11,480 --> 00:37:13,320 SESSIONS HELD BETWEEN 2018 870 00:37:13,320 --> 00:37:17,200 THROUGH EARLY 2020. 871 00:37:17,200 --> 00:37:19,080 LISTENING SESSIONS SHIFTED TO A 872 00:37:19,080 --> 00:37:22,320 VIRTUAL PLATFORM IN 2022, AS A 873 00:37:22,320 --> 00:37:23,320 RESULT OF COVID. 874 00:37:23,320 --> 00:37:25,680 AND A SUMMARY OF THESE VIRTUAL 875 00:37:25,680 --> 00:37:27,040 SESSIONS HAS JUST BEEN CLEARED 876 00:37:27,040 --> 00:37:29,640 AND WILL BE AVAILABLE ON THE OAR 877 00:37:29,640 --> 00:37:32,600 WEBSITE IN THE NEXT TWO WEEKS. 878 00:37:32,600 --> 00:37:34,120 IMPORTANTLY, IN EVERY LISTENING 879 00:37:34,120 --> 00:37:36,440 SESSION WITH ACADEMIC PARTNERS 880 00:37:36,440 --> 00:37:37,880 PARTICIPANTS UNDERSCORED THE 881 00:37:37,880 --> 00:37:40,000 NEED TO ENHANCE THE PIPELINE OF 882 00:37:40,000 --> 00:37:43,040 EARLY AND MID CAREER HIV 883 00:37:43,040 --> 00:37:45,760 INVESTIGATORS AND ENSURE DIVERSE 884 00:37:45,760 --> 00:37:47,920 -- DIVERSITY AND INSTITUTIONAL 885 00:37:47,920 --> 00:37:50,680 CAPACITY TO CONDUCT CUTTING EDGE 886 00:37:50,680 --> 00:37:55,680 RIGOROUS SCIENTIFIC RESEARCH. 887 00:37:55,680 --> 00:37:59,320 IN THE NEXT SLIDE AS NOTED THE 888 00:37:59,320 --> 00:38:00,440 OAR DEVELOPS THE NIH STRATEGIC 889 00:38:00,440 --> 00:38:02,600 PLAN FOR HIV AND HIV RELATED 890 00:38:02,600 --> 00:38:04,320 RESEARCH. 891 00:38:04,320 --> 00:38:07,400 THE CURRENT PLAN COVERS FISCAL 892 00:38:07,400 --> 00:38:11,360 YEARS 2021 THROUGH 2025 AND 893 00:38:11,360 --> 00:38:13,680 FEATURES FOUR STRATEGIC GOALS. 894 00:38:13,680 --> 00:38:16,200 IN IN PARTICULAR STRATEGIC FOUR 895 00:38:16,200 --> 00:38:18,840 GOAL STATES BUILD HUMAN RESOURCE 896 00:38:18,840 --> 00:38:20,320 AND INFRASTRUCTURE CAPACITY TO 897 00:38:20,320 --> 00:38:23,400 ENHANCE SUSTAINABILITY OF HIV 898 00:38:23,400 --> 00:38:25,160 RESEARCH DISCOVERY AND THE 899 00:38:25,160 --> 00:38:26,920 IMPLEMENTATION OF FINDINGS BY 900 00:38:26,920 --> 00:38:28,560 DIVERSE AND MULTI-DISCIPLINARY 901 00:38:28,560 --> 00:38:31,920 WORK FORCE. 902 00:38:31,920 --> 00:38:33,960 TO IMPLEMENT STRATEGIC GOAL 4 903 00:38:33,960 --> 00:38:35,160 OAR LAUNCHED A NUMBER OF 904 00:38:35,160 --> 00:38:37,520 ACTIVITIES TO SUPPORT THE HIV 905 00:38:37,520 --> 00:38:38,440 RESEARCH WORK FORCE. 906 00:38:38,440 --> 00:38:41,080 FOR EXAMPLE IN FY 21 WE 907 00:38:41,080 --> 00:38:43,040 FACILITATED A SERIES OF 908 00:38:43,040 --> 00:38:44,520 ADMINISTRATIVE SUPPLEMENTS TO 909 00:38:44,520 --> 00:38:46,520 SUPPORT COLLABORATIVE HIV 910 00:38:46,520 --> 00:38:48,400 RESEARCH AT NATIONAL INSTITUTES 911 00:38:48,400 --> 00:38:50,400 OF MINORITY HEALTH AND HEALTH 912 00:38:50,400 --> 00:38:53,160 DISPARITY RESEARCH CENTERS IN 913 00:38:53,160 --> 00:38:54,840 MINORITY INSTITUTES AND WE JUST 914 00:38:54,840 --> 00:38:56,880 TALKED A LITTLE BIT ABOUT THE 915 00:38:56,880 --> 00:38:58,240 RCMIs. 916 00:38:58,240 --> 00:39:01,840 THIS INITIATIVE WAS CO-FUNDED BY 917 00:39:01,840 --> 00:39:04,800 NIMHD AND THE HHS MINORITY HIV 918 00:39:04,800 --> 00:39:08,160 AIDS FUND. 919 00:39:08,160 --> 00:39:09,360 OTHER EFFORTS TO SUPPORT 920 00:39:09,360 --> 00:39:11,160 DIVERSITY AND INCLUSION STEM 921 00:39:11,160 --> 00:39:14,440 FROM PROGRAMS SUCH AS THE 922 00:39:14,440 --> 00:39:16,040 MENTORING PROGRAM FOR NEW HIV 923 00:39:16,040 --> 00:39:19,160 AIDS INVESTIGATORS TO MEET THE 924 00:39:19,160 --> 00:39:20,480 NEEDS OF HISPANIC LATINO 925 00:39:20,480 --> 00:39:22,840 COMMUNITIES AS WELL AS THE C FAR 926 00:39:22,840 --> 00:39:27,440 DIVERSITY EQUITY AND INCLUSION 927 00:39:27,440 --> 00:39:28,680 PIPELINE INITIATIVE THAT AIMS TO 928 00:39:28,680 --> 00:39:29,680 INCREASE NUMBER OF UNDERSTOOD 929 00:39:29,680 --> 00:39:33,280 REPRESENTED MINORITIES AND 930 00:39:33,280 --> 00:39:36,240 TRAINEES ENGAGED IN HIV SCIENCE 931 00:39:36,240 --> 00:39:37,120 FROM HIGH SCHOOL TO 932 00:39:37,120 --> 00:39:38,360 POST-DOCTORAL LEVELS. 933 00:39:38,360 --> 00:39:41,160 OAR CONVENED INPUT ACROSS NIH 934 00:39:41,160 --> 00:39:44,960 ICOs TO UPDATE OBJECTIVES AND 935 00:39:44,960 --> 00:39:46,200 IMPLEMENTATION PLANS TO THE 936 00:39:46,200 --> 00:39:49,400 WHITE HOUSE NATIONAL HIV AIDS 937 00:39:49,400 --> 00:39:51,880 STRATEGY. 938 00:39:51,880 --> 00:39:53,960 THIS INCLUDED ADDING EXPANSION 939 00:39:53,960 --> 00:39:55,320 AND DIVERSIFICATION OF THE 940 00:39:55,320 --> 00:39:57,080 RESEARCH WORK FORCE AS WELL AS 941 00:39:57,080 --> 00:40:00,720 THE TOPICAL RESEARCH AREAS OF 942 00:40:00,720 --> 00:40:04,160 HIV CURE, INTERVENTION 943 00:40:04,160 --> 00:40:05,480 DEVELOPMENT, IMPLEMENTATION 944 00:40:05,480 --> 00:40:12,040 STIGMA AND DISPARITIES. 945 00:40:12,040 --> 00:40:13,560 IN THE PAST TWO YEARS NIH OAR 946 00:40:13,560 --> 00:40:16,640 CONDUCT SYSTEMATIC STEP WISE 947 00:40:16,640 --> 00:40:18,200 APPROACH EFFORT TO SUPPORT HIV 948 00:40:18,200 --> 00:40:21,640 EARLY CAREER INVESTIGATORS WITH 949 00:40:21,640 --> 00:40:22,800 A FOCUS ON DIVERSITY, ACTIVITIES 950 00:40:22,800 --> 00:40:24,720 I INCLUDE PORTFOLIO ANALYSIS I 951 00:40:24,720 --> 00:40:26,160 WILL DESCRIBE SHORTLY AND FOUR 952 00:40:26,160 --> 00:40:29,360 LISTENING SESSIONS TO UNDERSTAND 953 00:40:29,360 --> 00:40:31,120 ISSUES AFFECTING HIV 954 00:40:31,120 --> 00:40:31,480 RESEARCHERS. 955 00:40:31,480 --> 00:40:33,720 SOME OF THE THEMES THAT EMERGED 956 00:40:33,720 --> 00:40:35,280 INCLUDED DIVERSITY MENTORING 957 00:40:35,280 --> 00:40:40,840 PEER REVIEW, FUNDING MECHANISMS 958 00:40:40,840 --> 00:40:42,120 NETWORKS, AND COVID-19. 959 00:40:42,120 --> 00:40:44,080 OAR CONVENED A PANEL OF 19 960 00:40:44,080 --> 00:40:45,960 SENIOR HIV INVESTIGATORS AND 961 00:40:45,960 --> 00:40:48,480 EXPERIENCED MENTORS FROM DIVERSE 962 00:40:48,480 --> 00:40:50,080 ACADEMIC INSTITUTIONS, TO 963 00:40:50,080 --> 00:40:52,720 PARTICIPATE IN AN EXPERT 964 00:40:52,720 --> 00:40:55,440 CONSULTATION PATTERN EXPERT 965 00:40:55,440 --> 00:40:56,400 CONSULTATION PANEL. 966 00:40:56,400 --> 00:41:00,880 AND REPORT SUMMARIZES IS IN 967 00:41:00,880 --> 00:41:03,240 CLEARANCE AND WILL BE POSTED TO 968 00:41:03,240 --> 00:41:05,800 OUR WEBSITE. 969 00:41:05,800 --> 00:41:07,600 NO RESPONSE TO INPUT RECEIVED 970 00:41:07,600 --> 00:41:10,600 THE NIH OAR DEVELOPED EARLY 971 00:41:10,600 --> 00:41:11,720 CAREER INVESTIGATOR YOU CAN SEE 972 00:41:11,720 --> 00:41:12,920 A SCREEN SHOT ON THE RIGHT SIDE 973 00:41:12,920 --> 00:41:13,920 OF THE SLIDE. 974 00:41:13,920 --> 00:41:15,680 TO CENTRALIZE RELEVANT 975 00:41:15,680 --> 00:41:18,400 INFORMATION FOR INVESTIGATORS 976 00:41:18,400 --> 00:41:22,720 AND PROVIDE EASY ACCESS TO ONE 977 00:41:22,720 --> 00:41:23,720 PLACE TO GRANT OPPORTUNITIES AND 978 00:41:23,720 --> 00:41:29,840 OTHER RESOURCES. THE NEXT SLIDE 979 00:41:29,840 --> 00:41:33,720 IS THREE OF THESE KEY STEPS. 980 00:41:33,720 --> 00:41:36,160 IT SHOULD BE THE ESI AWARDEES 981 00:41:36,160 --> 00:41:39,880 NIH OVERALL VERSUS NIH HIV. 982 00:41:39,880 --> 00:41:42,720 IN 2020 AND 2021, OAR CONDUCTED 983 00:41:42,720 --> 00:41:44,640 A PORTFOLIO ANALYSIS OF EARLY 984 00:41:44,640 --> 00:41:46,840 STAGE INVESTIGATORS. 985 00:41:46,840 --> 00:41:48,680 ACROSS THE NIH ENTERPRISE THERE 986 00:41:48,680 --> 00:41:51,760 WAS A 50 PERCENT INCREASE IN 987 00:41:51,760 --> 00:41:53,640 NUMBER OF NEW RESEARCHERS FROM 988 00:41:53,640 --> 00:41:56,600 900 IN 2017 TO ALMOST 1400 IN 989 00:41:56,600 --> 00:42:00,840 2020. 990 00:42:00,840 --> 00:42:01,920 SINCE INCEPTION OF NEXT 991 00:42:01,920 --> 00:42:02,840 GENERATION RESEARCH INITIATIVE. 992 00:42:02,840 --> 00:42:03,880 THIS IS THE TOP BLUE LINE ON 993 00:42:03,880 --> 00:42:06,200 THIS. 994 00:42:06,200 --> 00:42:08,000 ON THE LEFT-HAND SIDE OF THE 995 00:42:08,000 --> 00:42:11,840 GRAFT IN GRAY SHADING ARE LEVELS 996 00:42:11,840 --> 00:42:13,840 OF EARLY STAGE INVESTIGATOR 997 00:42:13,840 --> 00:42:20,800 AWARDEES PRE AND NGRI AND THEN 998 00:42:20,800 --> 00:42:22,120 STARTING ON RIGHT HAND SIDE POST 999 00:42:22,120 --> 00:42:23,080 NGRI. 1000 00:42:23,080 --> 00:42:27,640 THE 2020 ESI AWARDS ACROSS THE 1001 00:42:27,640 --> 00:42:29,560 NIH REPRESENT ABOUT 5% OF THE 1002 00:42:29,560 --> 00:42:35,360 TOTAL RO1 FUNDING AT THE NIH. 1003 00:42:35,360 --> 00:42:37,400 IN CONTRAST RED LINE ACROSS 1004 00:42:37,400 --> 00:42:40,280 BOTTOM FROM 2017 TO 2019 NUMBER 1005 00:42:40,280 --> 00:42:43,040 OF HIV FOCUSED ESI RECEIVING 1006 00:42:43,040 --> 00:42:47,480 FIRST GRANTS WAS STABLE AT 45. 1007 00:42:47,480 --> 00:42:49,680 THIS REPRESENTS APPROXIMATELY 3 1008 00:42:49,680 --> 00:42:53,800 PERCENT OF TOTAL HIV RO1 AWARDS. 1009 00:42:53,800 --> 00:42:56,040 IN 2020, OAR INCREASED THE 1010 00:42:56,040 --> 00:42:57,680 NUMBER OF HIV ESI AWARDEES BY 1011 00:42:57,680 --> 00:42:58,960 NINE. 1012 00:42:58,960 --> 00:43:00,720 THAT IS SHOWN IN THE CIRCLE AT 1013 00:43:00,720 --> 00:43:02,520 THE FAR RIGHT OF THE GRAPH. 1014 00:43:02,520 --> 00:43:04,400 TO MAINTAIN THE AVERAGE OF 45 1015 00:43:04,400 --> 00:43:09,920 AWARDEES. WITHOUT OAR ACTION 1016 00:43:09,920 --> 00:43:10,800 THAT NUMBER WOULD HAVE BEEN 36 1017 00:43:10,800 --> 00:43:13,160 AS SHOWN ON THE SLIDE. 1018 00:43:13,160 --> 00:43:14,040 CURRENT EFFORTS ARE AN 1019 00:43:14,040 --> 00:43:15,280 IMPROVEMENT A SUSTAINABILITY 1020 00:43:15,280 --> 00:43:17,840 PLAN IS NEEDED TO MAINTAIN AND 1021 00:43:17,840 --> 00:43:19,320 INCREASE NEXT GENERATION OF HIV 1022 00:43:19,320 --> 00:43:22,200 INVESTIGATORS. 1023 00:43:22,200 --> 00:43:25,720 IN THE NEXT SLIDE, ON APRIL OF 1024 00:43:25,720 --> 00:43:27,400 THIS YEAR OAR CONVENED THE FIRST 1025 00:43:27,400 --> 00:43:29,480 WORKSHOP FOR EARLY CAREER 1026 00:43:29,480 --> 00:43:32,720 INVESTIGATORS IN HIV AIDS. 1027 00:43:32,720 --> 00:43:35,760 THE WORKSHOP AIMED TO STIMULATE 1028 00:43:35,760 --> 00:43:37,240 SCIENTIFIC EXCHANGE NETWORKING 1029 00:43:37,240 --> 00:43:38,040 COLLABORATION, FACILITATE 1030 00:43:38,040 --> 00:43:39,720 INTERACTIONS AND INCREASE 1031 00:43:39,720 --> 00:43:41,080 FAMILIARITY ABOUT THE NIH REVIEW 1032 00:43:41,080 --> 00:43:45,160 AND FUNDING PROCE PROCESSES. 1033 00:43:45,160 --> 00:43:51,840 IN THE NEXT SLIDE, THE NIH OAR 1034 00:43:51,840 --> 00:43:53,840 WILL PRIORITIZE AND SUPPORT 1035 00:43:53,840 --> 00:43:56,280 DIVERSE HIV RESEARCH WORK FORCE. 1036 00:43:56,280 --> 00:43:58,320 BASED ON THE TREMENDOUS INTEREST 1037 00:43:58,320 --> 00:44:00,440 IN THE FIRST HIV ECI WORKSHOP WE 1038 00:44:00,440 --> 00:44:04,160 PLAN TO COORDINATE WITH THE NAC, 1039 00:44:04,160 --> 00:44:05,280 ADDITIONAL EVENTS EARLY CAREER 1040 00:44:05,280 --> 00:44:08,000 HIV INVESTIGATORS. 1041 00:44:08,000 --> 00:44:09,560 AND CONTINUE TO UPDATE THE 1042 00:44:09,560 --> 00:44:11,560 WEBSITE WITH TIMELY RELEVANT 1043 00:44:11,560 --> 00:44:12,160 RESOURCES. 1044 00:44:12,160 --> 00:44:14,560 WE WILL CONTINUE TO MONITOR AND 1045 00:44:14,560 --> 00:44:15,800 SUPPORT IMPLEMENTATION OF 1046 00:44:15,800 --> 00:44:17,680 RESEARCH WORK FORCE OBJECTIVES 1047 00:44:17,680 --> 00:44:20,600 OF THE NHAS AS WELL AS NIH UNITE 1048 00:44:20,600 --> 00:44:27,680 INITIATIVEMENT IN THE NEXT SLIDE 1049 00:44:27,680 --> 00:44:30,240 NEXT OARAC MEETING WILL BE HELD 1050 00:44:30,240 --> 00:44:33,240 IN A FEW WEEKS JUNE 23, NOON TO 1051 00:44:33,240 --> 00:44:33,600 4:30. 1052 00:44:33,600 --> 00:44:35,160 IT IS A LIVE OPEN VIDEO CAST 1053 00:44:35,160 --> 00:44:35,720 MEETING. 1054 00:44:35,720 --> 00:44:39,120 AND THE AGENDA WILL FEATURE 1055 00:44:39,120 --> 00:44:40,080 UPDATES FROM NUMBER OF 1056 00:44:40,080 --> 00:44:46,200 INTERAGENCY PARTNERS. 1057 00:44:46,200 --> 00:44:48,200 IN THE FINAL SLIDE I WOULD LIKE 1058 00:44:48,200 --> 00:44:49,680 TO THANK THE OAR TEAM FOR 1059 00:44:49,680 --> 00:44:51,040 LEADING THE EFFORTS THROUGH THE 1060 00:44:51,040 --> 00:44:53,040 NEXT GENERATION HIV 1061 00:44:53,040 --> 00:44:53,880 INVESTIGATORS, PARTICULARLY DR. 1062 00:44:53,880 --> 00:45:02,040 LIZ TAYLOR AND MELISSA OMARA. 1063 00:45:02,040 --> 00:45:03,960 THANK YOU VERY MUCH, HAPPY TO 1064 00:45:03,960 --> 00:45:05,040 ANSWER ANY QUESTIONS. 1065 00:45:05,040 --> 00:45:06,520 >> THANK YOU, DR. GOODENOW FOR 1066 00:45:06,520 --> 00:45:10,320 THE OVERVIEW AND GREAT 1067 00:45:10,320 --> 00:45:13,240 COMMITMENT TO NGRI TO ENHANCING 1068 00:45:13,240 --> 00:45:16,160 DIVERSITY IN THE WORK FORCE. 1069 00:45:16,160 --> 00:45:17,640 LET'S TAKE TIME FOR A QUESTION 1070 00:45:17,640 --> 00:45:19,920 OR TWO. 1071 00:45:19,920 --> 00:45:24,840 >> MAYBE WE CAN TURN THE SLIDES 1072 00:45:24,840 --> 00:45:33,440 OFF 1073 00:45:33,440 --> 00:45:35,480 >> THANK YOU SO MUCH. 1074 00:45:35,480 --> 00:45:37,000 THOSE ARE SO GREAT. 1075 00:45:37,000 --> 00:45:42,600 REALLY FASCINATED BY THE 1076 00:45:42,600 --> 00:45:43,640 CIVILITY PLEDGE BECAUSE I THINK 1077 00:45:43,640 --> 00:45:45,600 EVERYONE NEEDS TO BECOME SO 1078 00:45:45,600 --> 00:45:46,600 CIVIL, EVERYONE IS SUCH A MESS 1079 00:45:46,600 --> 00:45:47,000 WITH THE PANDEMIC. 1080 00:45:47,000 --> 00:45:48,680 SO I THINK THAT IS A REALLY 1081 00:45:48,680 --> 00:45:52,040 INTERESTING THING TO SEE AND 1082 00:45:52,040 --> 00:45:54,520 TAKE FROM NIH WHO RECEIVES NIH 1083 00:45:54,520 --> 00:45:55,680 FUNDING IT FEELS STRONGLY WE 1084 00:45:55,680 --> 00:45:58,840 SHOULD BE TAKING A PROFESSIONAL 1085 00:45:58,840 --> 00:45:59,200 PLEDGE. 1086 00:45:59,200 --> 00:46:01,120 THE ONE THING I WANT TO ASK 1087 00:46:01,120 --> 00:46:04,240 ABOUT THE DIVERSITY IS I AM 1088 00:46:04,240 --> 00:46:05,880 SEEING A REAL COMMITMENT FROM 1089 00:46:05,880 --> 00:46:08,840 THE NIH AND OFFICE OF AIDS 1090 00:46:08,840 --> 00:46:11,120 RESEARCH ABOUT THIS ENCOURAGING 1091 00:46:11,120 --> 00:46:12,680 DIVERSE PARTICIPANTS IN 1092 00:46:12,680 --> 00:46:13,600 RESEARCH. 1093 00:46:13,600 --> 00:46:15,160 BUT I HAVE ALSO SEEN, THIS IS 1094 00:46:15,160 --> 00:46:18,720 SPECIFIC FROM INFECTIOUS 1095 00:46:18,720 --> 00:46:25,400 DISEASE, THAT BIOMEDICAL 1096 00:46:25,400 --> 00:46:27,080 DEPLETED, PEOPLE ARE FEELING 1097 00:46:27,080 --> 00:46:27,760 DISILLUSIONED AFTER THE PANDEMIC 1098 00:46:27,760 --> 00:46:30,840 AND THE PANDEMIC AND I DON'T SEE 1099 00:46:30,840 --> 00:46:33,400 OUR PIPELINE FOR INFECTIOUS 1100 00:46:33,400 --> 00:46:35,080 DISEASE FELLOWS GOING DOWN AND 1101 00:46:35,080 --> 00:46:37,600 THE DERAILMENT OF THEIR OWN 1102 00:46:37,600 --> 00:46:38,400 RESEARCH DURING THE COVID 1103 00:46:38,400 --> 00:46:39,560 PANDEMIC. 1104 00:46:39,560 --> 00:46:44,600 PEOPLE ON Ts AND Ks. 1105 00:46:44,600 --> 00:46:45,960 SO WE HAVE MADE GREAT EFFORTS 1106 00:46:45,960 --> 00:46:47,960 LIKE INCREASING THE PAY LINE FOR 1107 00:46:47,960 --> 00:46:50,120 K 23 AT NIAID AND KO 8 WHICH IS 1108 00:46:50,120 --> 00:46:53,320 AMAZING. 1109 00:46:53,320 --> 00:46:57,400 BUT I THINK STRESSING OF THE 1110 00:46:57,400 --> 00:46:59,600 INCREASING SUPPORT FOR CFARS 1111 00:46:59,600 --> 00:47:00,760 WHICH DEVELOP EARLY STAGE 1112 00:47:00,760 --> 00:47:02,200 INVESTIGATORS BUT THE DIVERSITY 1113 00:47:02,200 --> 00:47:04,600 ASPECT IS PUTTING MONEY LIKE 1114 00:47:04,600 --> 00:47:05,520 DESIGNATED MONEY TO PEOPLE WHO 1115 00:47:05,520 --> 00:47:06,200 ARE DIVERSE. 1116 00:47:06,200 --> 00:47:08,000 AND I KNOW WE WILL TALK ABOUT 1117 00:47:08,000 --> 00:47:08,400 THAT. 1118 00:47:08,400 --> 00:47:10,480 BUT LITERALLY DESIGNATED GRANTS 1119 00:47:10,480 --> 00:47:12,040 AS MUCH AS YOU CAN WITHIN THE 1120 00:47:12,040 --> 00:47:16,640 PARAMETERS OF THE LAW THAT ARE 1121 00:47:16,640 --> 00:47:21,120 SPECIFICALLY FOR URMs. 1122 00:47:21,120 --> 00:47:22,360 >> I WILL SAY SOMETHING ABOUT 1123 00:47:22,360 --> 00:47:24,920 THAT, MONICA, WE AGREE. 1124 00:47:24,920 --> 00:47:27,120 AND THE NEXT INITIATIVE ON THE 1125 00:47:27,120 --> 00:47:32,040 BOOKS THAT WE WILL HEAR ABOUT 1126 00:47:32,040 --> 00:47:34,920 TODAY REPRESENTS NIAID WIDE 1127 00:47:34,920 --> 00:47:36,080 EFFORT TO SPECIFICALLY ADDRESS 1128 00:47:36,080 --> 00:47:38,960 THIS POINT. 1129 00:47:38,960 --> 00:47:42,160 WE HAVE BEEN TALKING AS JUST THE 1130 00:47:42,160 --> 00:47:44,520 DAIDS INITIATIVE BUT WE FELT IT 1131 00:47:44,520 --> 00:47:46,520 WAS EXTREMELY IMPORTANT WE MAKE 1132 00:47:46,520 --> 00:47:50,080 THIS NIAID WIDE ACTIVITY. 1133 00:47:50,080 --> 00:47:52,760 BECAUSE IT IS NIAID WIDE THAT IS 1134 00:47:52,760 --> 00:47:54,720 WHY LESHAWNDRA WILL TALK ABOUT 1135 00:47:54,720 --> 00:47:56,120 THIS FROM THE STANDPOINT OF THE 1136 00:47:56,120 --> 00:47:56,520 INSTITUTE. 1137 00:47:56,520 --> 00:47:58,800 THE KEY WORDS YOU SAID THERE 1138 00:47:58,800 --> 00:48:02,320 WITHIN THE LIMITS OF THE LAW. 1139 00:48:02,320 --> 00:48:05,960 WE HAVE -- WE ALL DO THE BEST WE 1140 00:48:05,960 --> 00:48:08,520 CAN AND THERE ARE THINGS THAT 1141 00:48:08,520 --> 00:48:11,280 ARE LAW AND THAT ARE GUIDELINES 1142 00:48:11,280 --> 00:48:13,560 AND GUIDELINES ARE MEANT TO BE 1143 00:48:13,560 --> 00:48:15,880 NOT BROKEN BUT BENT. 1144 00:48:15,880 --> 00:48:18,840 WE WILL FIND WAY. 1145 00:48:18,840 --> 00:48:20,240 CFARS CONTINUES TO BE MASSIVE 1146 00:48:20,240 --> 00:48:21,280 SOURCE OF INNOVATION, YOU WILL 1147 00:48:21,280 --> 00:48:23,000 HEAR ABOUT THAT FROM ERIC AND 1148 00:48:23,000 --> 00:48:26,280 NETWORKS HAVE CONTINUED TO BE 1149 00:48:26,280 --> 00:48:27,560 SOURCE OF TRAINING MINORITY 1150 00:48:27,560 --> 00:48:29,120 INVESTIGATORS. 1151 00:48:29,120 --> 00:48:32,800 THE BIGGEST PROBLEM WE HAVE THIS 1152 00:48:32,800 --> 00:48:36,040 IS MY SPEECH, WE ARE LATE IN THE 1153 00:48:36,040 --> 00:48:36,440 PIPELINE. 1154 00:48:36,440 --> 00:48:40,200 WE ARE AT THE END. 1155 00:48:40,200 --> 00:48:42,120 WITH C FARES STARTED TO DO IS 1156 00:48:42,120 --> 00:48:43,440 MOVE HIGH SCHOOLS AND THAT IS 1157 00:48:43,440 --> 00:48:47,480 CRITICAL FOR US FOR THE FUTURE. 1158 00:48:47,480 --> 00:48:49,440 >> DR. AGARWAL. 1159 00:48:49,440 --> 00:48:52,560 >> I WANTED TO FOLLOW-UP ON THAT 1160 00:48:52,560 --> 00:48:54,080 I HAD MADE IN THE CHAT, YOU MAY 1161 00:48:54,080 --> 00:48:55,720 ALREADY BE AWARE OF THE PROGRAM 1162 00:48:55,720 --> 00:48:58,440 THE OFFICE OF DATA SCIENCE 1163 00:48:58,440 --> 00:49:01,200 LAUNCHED ON ENHANCING RESEARCH 1164 00:49:01,200 --> 00:49:05,960 DIVERSITY AND PARTICIPATION IN 1165 00:49:05,960 --> 00:49:08,040 THE AI WORK FORCE M. WONDERING 1166 00:49:08,040 --> 00:49:09,400 IF THAT MODEL IS SOMETHING TO 1167 00:49:09,400 --> 00:49:12,160 CONSIDER, PERHAPS VARIANT TO THE 1168 00:49:12,160 --> 00:49:14,160 POINT MADE EARLIER ABOUT THE 1169 00:49:14,160 --> 00:49:18,040 INVOLVEMENT OF HBCUs, STEPHAN 1170 00:49:18,040 --> 00:49:19,840 SAID THAT DR. DIEFFENBACH'S 1171 00:49:19,840 --> 00:49:21,560 POINT REACHING OUT TO PEOPLE 1172 00:49:21,560 --> 00:49:24,360 VERY EARLY IN THEIR CAREERS, THE 1173 00:49:24,360 --> 00:49:25,240 SAME INITIATIVE IS TARGETED 1174 00:49:25,240 --> 00:49:28,920 DOING EXACTLY THAT, SOMETHING TO 1175 00:49:28,920 --> 00:49:31,840 EXPLORE. 1176 00:49:31,840 --> 00:49:34,280 >> NO DOUBT. 1177 00:49:34,280 --> 00:49:37,160 >> GREAT. 1178 00:49:37,160 --> 00:49:38,760 LAST QUESTION, DR. (INAUDIBLE). 1179 00:49:38,760 --> 00:49:39,640 >> HI, THERE. 1180 00:49:39,640 --> 00:49:44,560 SO THIS IS MORE A GREEDY 1181 00:49:44,560 --> 00:49:45,240 QUESTION. 1182 00:49:45,240 --> 00:49:47,160 THINKING ABOUT CDC BUT ARE YOU 1183 00:49:47,160 --> 00:49:49,600 USING ANY TOOLS TO LOOK AT 1184 00:49:49,600 --> 00:49:50,920 FUNDING OPPORTUNITIES LIKE 1185 00:49:50,920 --> 00:49:53,200 EQUITY OR DIVERSITY -- THIS 1186 00:49:53,200 --> 00:49:53,960 ASSESSMENT OF WHAT GOES OUT THE 1187 00:49:53,960 --> 00:49:54,640 DOOR? 1188 00:49:54,640 --> 00:49:59,000 >> WE HAVE DONE THAT. 1189 00:49:59,000 --> 00:50:00,080 AND IT IS ABYSMAL. 1190 00:50:00,080 --> 00:50:00,960 >> THANK YOU. 1191 00:50:00,960 --> 00:50:04,480 >> IN A WORD, HENCE THE REASON 1192 00:50:04,480 --> 00:50:07,800 WHY WE WANT TO DO SOME THINGS 1193 00:50:07,800 --> 00:50:10,040 THAT ARE REALLY FOCUSED AND 1194 00:50:10,040 --> 00:50:10,640 TARGETED. 1195 00:50:10,640 --> 00:50:13,160 AND CONTINUE TO DO WHAT WE CAN 1196 00:50:13,160 --> 00:50:20,840 TO FIX THE REST OF IT. 1197 00:50:20,840 --> 00:50:21,560 >> THANK YOU VERY MUCH. 1198 00:50:21,560 --> 00:50:22,680 I WANT TO POINT OUT THAT PEOPLE 1199 00:50:22,680 --> 00:50:26,320 WHO ARE INTERESTED IN MORE 1200 00:50:26,320 --> 00:50:28,920 INFORMATION, I SEE DR. AGARWAL 1201 00:50:28,920 --> 00:50:33,000 PUT IN THE CHAT ABOUT OFFICE OF 1202 00:50:33,000 --> 00:50:38,840 DIVERSITY -- STRATEGIC SCIENCE, 1203 00:50:38,840 --> 00:50:40,680 AND THE ADVISORY COUNCIL FOR THE 1204 00:50:40,680 --> 00:50:43,120 NIH DIRECTOR IS MEETING THIS 1205 00:50:43,120 --> 00:50:45,800 WEEK THURSDAY AND FRIDAY AND 1206 00:50:45,800 --> 00:50:49,120 THERE WILL BE DISCUSSION ABOUT 1207 00:50:49,120 --> 00:50:50,760 UNITE PROGRAM AS WELL AS REPORT 1208 00:50:50,760 --> 00:50:53,080 OUT AS FAR AS I KNOW FROM THE 1209 00:50:53,080 --> 00:50:57,680 OFFICE OF DATA SCIENCE STRATEGY. 1210 00:50:57,680 --> 00:50:58,920 IN AUCTION AT THE OARAC MEETING 1211 00:50:58,920 --> 00:51:02,240 LATER IN THE MONTH THE DIRECTOR 1212 00:51:02,240 --> 00:51:07,880 OF ODSS SUSAN GREGARICK WILL BE 1213 00:51:07,880 --> 00:51:09,960 PRESENTING AT THE OARAC MEETING. 1214 00:51:09,960 --> 00:51:11,080 >> THANK YOU VERY MUCH, DR. 1215 00:51:11,080 --> 00:51:11,560 GOODENOW. 1216 00:51:11,560 --> 00:51:13,320 APPRECIATE IT. 1217 00:51:13,320 --> 00:51:14,400 DR. DIEFFENBACH, YOU WANT TO 1218 00:51:14,400 --> 00:51:17,240 INTRODUCE DR. PRICE? 1219 00:51:17,240 --> 00:51:21,360 >> I WOULD LIKE Y'ALL TO WELCOME 1220 00:51:21,360 --> 00:51:23,760 A GUEST PRESENTER TODAY, DR. 1221 00:51:23,760 --> 00:51:25,000 LESHAWNDRA PRICE, DIRECTOR OF 1222 00:51:25,000 --> 00:51:27,640 THE NIAID OFFICE OF RESEARCH 1223 00:51:27,640 --> 00:51:29,240 TRAINING SPECIAL PROGRAMS WITHIN 1224 00:51:29,240 --> 00:51:29,600 DEA. 1225 00:51:29,600 --> 00:51:32,800 OR DIVISION OF EXTRAMURAL 1226 00:51:32,800 --> 00:51:36,440 ACTIVITIES. 1227 00:51:36,440 --> 00:51:37,040 AGAIN, THRILLY SHAN DRAW'S 1228 00:51:37,040 --> 00:51:38,000 EFFORTS WORKING WITH ERIC AND 1229 00:51:38,000 --> 00:51:40,320 TEAM AND WORKING WITH US AND THE 1230 00:51:40,320 --> 00:51:41,200 OTHER DIVISIONS IS PRESENTING 1231 00:51:41,200 --> 00:51:45,200 THIS FOR THE WHOLE OF NIAID. 1232 00:51:45,200 --> 00:51:49,360 OUR DIVISION WAS CHOSEN TO HAVE 1233 00:51:49,360 --> 00:51:50,920 THIS CLEAR THIS COUNCIL BECAUSE 1234 00:51:50,920 --> 00:51:54,200 WE FELT IT WAS A REALLY GOOD 1235 00:51:54,200 --> 00:51:55,560 OPPORTUNITY FOR US IN DIVISION 1236 00:51:55,560 --> 00:51:57,560 OF AIDS TO HIGHLIGHT KINDS OF 1237 00:51:57,560 --> 00:51:58,080 THINGS WE CAN DO AS AN 1238 00:51:58,080 --> 00:51:59,960 INSTITUTE. 1239 00:51:59,960 --> 00:52:02,080 SO I WILL TURN IT OVER TO 1240 00:52:02,080 --> 00:52:03,480 LESHAWNDRA TO PRESENT THE 1241 00:52:03,480 --> 00:52:05,320 INITIATIVE. 1242 00:52:05,320 --> 00:52:07,040 >> THANKS VERY MUCH, THANKS FOR 1243 00:52:07,040 --> 00:52:09,800 THIS OPPORTUNITY TO SHARE A NEW 1244 00:52:09,800 --> 00:52:12,280 NIAID WIDE CONCEPT FOR APPROVAL 1245 00:52:12,280 --> 00:52:15,280 TO ENHANCE WORK FORCE DIVERSITY 1246 00:52:15,280 --> 00:52:16,960 THROUGH SUPPORT OF NEW AT RISK 1247 00:52:16,960 --> 00:52:17,800 INVESTIGATORS. 1248 00:52:17,800 --> 00:52:19,640 I WANT TO THANK COLLEAGUES FROM 1249 00:52:19,640 --> 00:52:25,560 DAIDS INCLUDING ERIC FOR 1250 00:52:25,560 --> 00:52:27,240 DEFINING THE CONCEPT AND 1251 00:52:27,240 --> 00:52:29,160 ASSISTING WITH THE PRESENTATION. 1252 00:52:29,160 --> 00:52:30,840 THE GOAL OF THE PROPOSED 1253 00:52:30,840 --> 00:52:33,600 INITIATIVE IS TO PROVIDE 1254 00:52:33,600 --> 00:52:35,280 INDEPENDENT RESEARCH SUPPORT IN 1255 00:52:35,280 --> 00:52:37,960 ALL NIAID MISSION AREAS TO 1256 00:52:37,960 --> 00:52:39,720 SUPPORT NEW INVESTIGATORS, EARLY 1257 00:52:39,720 --> 00:52:43,160 STAGE INVESTIGATORS, AND AT RISK 1258 00:52:43,160 --> 00:52:44,240 INVESTIGATORS FROM DIVERSE 1259 00:52:44,240 --> 00:52:44,920 BACKGROUNDS. 1260 00:52:44,920 --> 00:52:48,680 AS DEFINED BY THE NIH INTEREST 1261 00:52:48,680 --> 00:52:49,840 IN DIVERSITY. 1262 00:52:49,840 --> 00:52:50,720 YOU WILL RECALL NEW 1263 00:52:50,720 --> 00:52:52,080 INVESTIGATORS ARE DEFINED THOSE 1264 00:52:52,080 --> 00:52:54,520 WHO NOT COMPETED SUCCESSFULLY 1265 00:52:54,520 --> 00:52:56,520 FOR SUBSTANTIAL NIH INDEPENDENT 1266 00:52:56,520 --> 00:52:58,920 FUNDING AND ESIs SUB SETS OF 1267 00:52:58,920 --> 00:53:01,160 NEW INVESTIGATORS, ARE THOSE WHO 1268 00:53:01,160 --> 00:53:03,840 ARE WITHIN TEN YEARS OF TERMINAL 1269 00:53:03,840 --> 00:53:05,920 RESEARCH DEGREE OR ENDS OF POST 1270 00:53:05,920 --> 00:53:08,200 GRADUATE CLINICAL TRAINING. 1271 00:53:08,200 --> 00:53:10,280 YOU MAY BE LESS FAMILIAR WITH AT 1272 00:53:10,280 --> 00:53:11,320 RISK INVESTIGATORS. 1273 00:53:11,320 --> 00:53:14,560 AT RISK INVESTIGATORS HAD PRIOR 1274 00:53:14,560 --> 00:53:16,960 SUPPORT AS PIs ON A 1275 00:53:16,960 --> 00:53:18,520 SUBSTANTIAL RESEARCH AWARD AND 1276 00:53:18,520 --> 00:53:22,040 UNLESS SUCCESSFUL AND SECURING A 1277 00:53:22,040 --> 00:53:24,080 SUBSTANTIAL RESEARCH GRANT AWARD 1278 00:53:24,080 --> 00:53:25,680 IN THE CURRENT FISCAL YEAR WILL 1279 00:53:25,680 --> 00:53:27,720 HAVE NO SUBSTANTIAL RESEARCH 1280 00:53:27,720 --> 00:53:28,840 FUNDING AND THE FOLLOWING FISCAL 1281 00:53:28,840 --> 00:53:29,920 YEAR. 1282 00:53:29,920 --> 00:53:32,040 THE PROPOSED INITIATIVE WILL USE 1283 00:53:32,040 --> 00:53:36,880 THE RO1 MECHANISM AND APPLICANTS 1284 00:53:36,880 --> 00:53:37,840 REQUEST AWARDS UP TO FIVE YEARS 1285 00:53:37,840 --> 00:53:39,160 OF THE SUPPORT. 1286 00:53:39,160 --> 00:53:41,720 WE ANTICIPATE 20 TO 50 1287 00:53:41,720 --> 00:53:43,640 APPLICATIONS EACH YEAR AND 1288 00:53:43,640 --> 00:53:46,120 EXPECT TO MAKE 12 TO 18 AWARDS 1289 00:53:46,120 --> 00:53:46,720 ANNUALLY. 1290 00:53:46,720 --> 00:53:48,440 FIRST YEAR COSTS FOR THE 1291 00:53:48,440 --> 00:53:52,040 INITIATIVE ARE EXPECTED TO BE 1292 00:53:52,040 --> 00:53:53,840 APPROXIMATELY $9 MILLION AND OF 1293 00:53:53,840 --> 00:53:55,560 THAT 9 MILLION, 4 MILLION WILL 1294 00:53:55,560 --> 00:53:59,480 BE FOR AIDS RESEARCH. 1295 00:53:59,480 --> 00:54:00,600 THE LAST SEVERAL YEARS HAVE 1296 00:54:00,600 --> 00:54:02,360 BROUGHT MORE ATTENTION TO WHY 1297 00:54:02,360 --> 00:54:04,040 DIVERSITY MATTERS IN BIOMEDICAL 1298 00:54:04,040 --> 00:54:05,120 RESEARCH. 1299 00:54:05,120 --> 00:54:06,920 STUDIES HAVE NOT ONLY SHOWN THE 1300 00:54:06,920 --> 00:54:08,560 QUALITY OF RESEARCH INCREASES 1301 00:54:08,560 --> 00:54:10,920 WHEN PERFORMED BY DIVERSE GROUPS 1302 00:54:10,920 --> 00:54:12,560 AND DIFFERENT LIFE EXPERIENCES 1303 00:54:12,560 --> 00:54:15,120 ADD VALUABLE PERSPECTIVES TO 1304 00:54:15,120 --> 00:54:17,480 RESEARCH PROJECTS BUT ALSO SUCH 1305 00:54:17,480 --> 00:54:19,400 TEAMS TEND MORE CREATIVE AND 1306 00:54:19,400 --> 00:54:20,000 INNOVATIVE. 1307 00:54:20,000 --> 00:54:21,880 WE ASK ALL KINDS OF DIFFERENT 1308 00:54:21,880 --> 00:54:23,040 RESEARCH QUESTIONS IN SCIENCE 1309 00:54:23,040 --> 00:54:25,440 AND ESPECIALLY IN THE RESEARCH 1310 00:54:25,440 --> 00:54:29,320 SUPPORTED BY NIAID. 1311 00:54:29,320 --> 00:54:30,520 ASKING QUESTIONS DRIVE SCIENCE 1312 00:54:30,520 --> 00:54:34,760 FORWARD AND RESEARCHERS WITH 1313 00:54:34,760 --> 00:54:36,880 DIFFERENT PERSPECTIVES ASK 1314 00:54:36,880 --> 00:54:38,320 DIFFERENT QUESTIONS PROPELLING 1315 00:54:38,320 --> 00:54:39,800 US IN DIRECTION OF BOLD ADVANCES 1316 00:54:39,800 --> 00:54:40,520 IN SCIENCE. 1317 00:54:40,520 --> 00:54:42,320 IT IS ALSO IMPORTANT TO REMEMBER 1318 00:54:42,320 --> 00:54:45,560 THAT WE THE NIH SERVE THE PEOPLE 1319 00:54:45,560 --> 00:54:48,400 OF THE U.S. WE ASPIRE TO SUPPORT 1320 00:54:48,400 --> 00:54:49,480 A RESEARCH WORK FORCE THAT 1321 00:54:49,480 --> 00:54:51,280 REFLECTS SOCIETY AND IS NOT 1322 00:54:51,280 --> 00:54:52,160 DISPROPORTIONATELY WEIGHTED TO 1323 00:54:52,160 --> 00:54:55,440 ONE GROUP OR ANOTHER. 1324 00:54:55,440 --> 00:54:57,240 IN RECENT YEARS TOPIC OF 1325 00:54:57,240 --> 00:54:58,360 DIVERSIFYING THE, WHO FORCE 1326 00:54:58,360 --> 00:55:00,440 BECOME A MORE CENTRAL PRIORITY. 1327 00:55:00,440 --> 00:55:03,400 IT DOESN'T MEAN WE ARE YET 1328 00:55:03,400 --> 00:55:04,880 SUCCEEDING, LONG TERM COMMITMENT 1329 00:55:04,880 --> 00:55:07,200 IS NEEDED TO ACHIEVE AND SUSTAIN 1330 00:55:07,200 --> 00:55:10,080 DIVERSITY AND EQUITY, IN THE 1331 00:55:10,080 --> 00:55:11,000 BIOMEDICAL WORK FORCE. 1332 00:55:11,000 --> 00:55:13,320 NEXT SLIDE PLEASE. 1333 00:55:13,320 --> 00:55:16,120 ALIGNED WITH THE NIH, NIAID 1334 00:55:16,120 --> 00:55:17,760 RECOGNIZES THE IMPORTANCE OF 1335 00:55:17,760 --> 00:55:19,760 ADDRESSING SCIENTIFIC WORK FORCE 1336 00:55:19,760 --> 00:55:21,520 DIVERSITY TO ENSURE WE HAVE A 1337 00:55:21,520 --> 00:55:23,400 POOL OF HIGHLY TALENTED 1338 00:55:23,400 --> 00:55:25,160 SCIENTISTS FROM DIVERSE 1339 00:55:25,160 --> 00:55:26,240 BACKGROUNDS CAPABLE OF 1340 00:55:26,240 --> 00:55:29,000 FURTHERING ARE OUR MISSION. 1341 00:55:29,000 --> 00:55:30,360 THIS PROPOSED INITIATIVE IS 1342 00:55:30,360 --> 00:55:32,840 ALIGNED WITH THE NEXT GENERATION 1343 00:55:32,840 --> 00:55:34,360 RESEARCHERS INITIATIVE ENACTED 1344 00:55:34,360 --> 00:55:36,000 THROUGH THE 21ST CENTURY CURES 1345 00:55:36,000 --> 00:55:36,720 ACT. 1346 00:55:36,720 --> 00:55:38,360 WHICH IS AN INTENDED TO PROMOTE 1347 00:55:38,360 --> 00:55:39,880 AND PROVIDE OPPORTUNITIES FOR 1348 00:55:39,880 --> 00:55:43,120 NEW RESEARCHERS AND EARLY 1349 00:55:43,120 --> 00:55:44,400 RESEARCH INDEPENDENCE AND 1350 00:55:44,400 --> 00:55:46,160 ENHANCE WORK FORCE DIVERSITY. 1351 00:55:46,160 --> 00:55:48,080 SIMILARLY, THE INITIATIVE IS 1352 00:55:48,080 --> 00:55:50,080 CONSISTENT WITH THE NIH INTEREST 1353 00:55:50,080 --> 00:55:51,880 IN DIVERSITY IN THAT INDIVIDUALS 1354 00:55:51,880 --> 00:55:53,600 FROM UNDER-REPRESENTED GROUPS 1355 00:55:53,600 --> 00:55:55,240 WILL BE STRONGLY ENCOURAGED TO 1356 00:55:55,240 --> 00:55:57,600 WORK WITH THEIR ORGANIZATIONS TO 1357 00:55:57,600 --> 00:55:59,600 APPLY FOR NIH SUPPORT. 1358 00:55:59,600 --> 00:56:01,280 THESE POPULATIONS INCLUDE 1359 00:56:01,280 --> 00:56:03,280 INDIVIDUALS FROM RACIAL ETHNIC 1360 00:56:03,280 --> 00:56:04,480 GROUPS THAT HAVE BEEN SHOWN TO 1361 00:56:04,480 --> 00:56:07,160 BE UNDER-REPRESENTED IN HEALTH 1362 00:56:07,160 --> 00:56:08,880 RELATED SCIENCES ON A NATIONAL 1363 00:56:08,880 --> 00:56:11,080 BASIS AND UNDER-REPRESENTED AND 1364 00:56:11,080 --> 00:56:12,280 BIOMEDICAL RESEARCH, INDIVIDUALS 1365 00:56:12,280 --> 00:56:14,440 WITH DISABILITIES, INDIVIDUALS 1366 00:56:14,440 --> 00:56:16,200 FROM DISADVANTAGED BACKGROUNDS 1367 00:56:16,200 --> 00:56:17,920 MEETING CERTAIN CRITERIA. 1368 00:56:17,920 --> 00:56:20,760 AND WOMEN AS OUTLINED IN THE NIH 1369 00:56:20,760 --> 00:56:21,560 INTEREST IN DIVERSITY. 1370 00:56:21,560 --> 00:56:25,240 THE INITIATIVE ALSO IS THE NIH 1371 00:56:25,240 --> 00:56:27,320 STRATEGIC PLAN FOR HIV AND HIV 1372 00:56:27,320 --> 00:56:30,120 RELATED RESEARCH AS DR. GOODENOW 1373 00:56:30,120 --> 00:56:32,080 PREVIOUSLY MENTIONED AND THE 1374 00:56:32,080 --> 00:56:34,280 NATIONAL HIV AIDS STRATEGY WHICH 1375 00:56:34,280 --> 00:56:36,440 SPECIFICALLY ENCOURAGES TRAINING 1376 00:56:36,440 --> 00:56:39,200 AND EXPANSION OF DIVERSE HIV 1377 00:56:39,200 --> 00:56:40,920 WORK FORCE BY FURTHER DEVELOPING 1378 00:56:40,920 --> 00:56:43,080 AND PROMOTING OPPORTUNITIES TO 1379 00:56:43,080 --> 00:56:44,720 SUPPORT THE NEXT GENERATION OF 1380 00:56:44,720 --> 00:56:47,600 HIV PROVIDERS INCLUDING 1381 00:56:47,600 --> 00:56:48,680 RESEARCHERS AND OTHERS FROM 1382 00:56:48,680 --> 00:56:50,920 UNDER-REPRESENTED POPULATIONS. 1383 00:56:50,920 --> 00:56:51,720 AND DR. DIEFFENBACH MENTIONED 1384 00:56:51,720 --> 00:56:53,200 THIS EARLIER AS WELL. 1385 00:56:53,200 --> 00:56:56,360 NEXT SLIDE PLEASE. 1386 00:56:56,360 --> 00:56:58,920 THE NIH HAS A LONG HISTORY OF 1387 00:56:58,920 --> 00:57:01,240 FUNDING PROGRAMS TO ENHANCE 1388 00:57:01,240 --> 00:57:02,520 DIVERSITY PARTICULARLY AT THE 1389 00:57:02,520 --> 00:57:05,000 LEVEL OF INDEPENDENT SCIENTISTS 1390 00:57:05,000 --> 00:57:08,240 AND WITHIN SCIENTIFIC LEADER 1391 00:57:08,240 --> 00:57:09,200 LEADERSHIP. 1392 00:57:09,200 --> 00:57:11,200 SINCE THE GINTHER REPORT TEN 1393 00:57:11,200 --> 00:57:12,760 YEARS AGO THE NIH IS WORKING TO 1394 00:57:12,760 --> 00:57:14,280 NARROW DISPARITIES IN FUNDING. 1395 00:57:14,280 --> 00:57:15,560 IN RECENT YEARS THERE'S BEEN 1396 00:57:15,560 --> 00:57:18,440 SOME ENCOURAGING TRENDS 1397 00:57:18,440 --> 00:57:19,520 INCLUDING AN INCREASE IN NUMBER 1398 00:57:19,520 --> 00:57:21,720 OF RO1 APPLICATIONS, SUBMITTED 1399 00:57:21,720 --> 00:57:24,320 TO THE NIH AND A MODEST INCREASE 1400 00:57:24,320 --> 00:57:26,520 IN FUNDING RATES FOR 1401 00:57:26,520 --> 00:57:27,760 UNDER-REPRESENTED GROUPS. 1402 00:57:27,760 --> 00:57:29,960 RESEARCHERS FROM 1403 00:57:29,960 --> 00:57:31,120 UNDER-REPRESENTED GROUPS HOWEVER 1404 00:57:31,120 --> 00:57:34,040 HAVE BEEN AND CONTINUE TO BE 1405 00:57:34,040 --> 00:57:35,280 SUBSTANTIALLY UNDER-REPRESENTED 1406 00:57:35,280 --> 00:57:37,960 IN THE BIOMEDICAL RESEARCH WORK 1407 00:57:37,960 --> 00:57:40,480 FORCE AND THE NIH EXTRAMURAL 1408 00:57:40,480 --> 00:57:41,480 RESEARCH PORTFOLIO. 1409 00:57:41,480 --> 00:57:43,040 DISPARITIES REMAIN AND WE STILL 1410 00:57:43,040 --> 00:57:45,440 HAVE A LONG WAY TO GO. 1411 00:57:45,440 --> 00:57:47,320 NIAID HAS LONG BEEN A LEADER IN 1412 00:57:47,320 --> 00:57:49,240 WORK FORCE DIVERSITY FROM OUR 1413 00:57:49,240 --> 00:57:50,720 TECHNICAL ASSISTANCE WORKSHOPS 1414 00:57:50,720 --> 00:57:52,040 TO SUPPORT FOR TRAINEES AND 1415 00:57:52,040 --> 00:57:53,600 EARLY CAREER INVESTIGATORS. 1416 00:57:53,600 --> 00:57:56,760 AND MANY YEARS AGO NIAID PILOTED 1417 00:57:56,760 --> 00:57:59,240 TWO APPROACH TO SUPPORT 1418 00:57:59,240 --> 00:58:00,560 INVESTIGATORS FROM 1419 00:58:00,560 --> 00:58:01,840 UNDER-REPRESENTED GROUPS. 1420 00:58:01,840 --> 00:58:03,160 ENHANCEMENT AWARDS FOR 1421 00:58:03,160 --> 00:58:05,160 UNDER-REPRESENTED MINORITY 1422 00:58:05,160 --> 00:58:07,240 RESEARCHERS IN HIV AIDS AND THE 1423 00:58:07,240 --> 00:58:08,560 ENHANCEMENT AWARDS FROM 1424 00:58:08,560 --> 00:58:09,600 UNDER-REPRESENTED MINORITY 1425 00:58:09,600 --> 00:58:10,200 SCIENTISTS. 1426 00:58:10,200 --> 00:58:14,040 DUE TO LEGAL DECISIONS, 1427 00:58:14,040 --> 00:58:15,240 REGARDING USE OF GENDER RACE 1428 00:58:15,240 --> 00:58:16,840 ETHNICITY IN FUNDING DECISIONS 1429 00:58:16,840 --> 00:58:18,440 THESE PRIOR EFFORTS WERE 1430 00:58:18,440 --> 00:58:19,000 DISCONTINUED. 1431 00:58:19,000 --> 00:58:20,480 WITHIN THE LAST YEAR HOWEVER 1432 00:58:20,480 --> 00:58:24,280 HERE AT THE NIH, SEVERAL OTHER 1433 00:58:24,280 --> 00:58:27,320 NIH INSTITUTES AND WITHIN THE OD 1434 00:58:27,320 --> 00:58:29,360 AND CENTERS HAVE LAUNCHED 1435 00:58:29,360 --> 00:58:31,000 SIMILAR PROGRAMS TO OUR PROPOSED 1436 00:58:31,000 --> 00:58:32,800 INITIATIVE TO ACCELERATE 1437 00:58:32,800 --> 00:58:34,120 ENHANCING DIVERSITY AT THE HO 1 1438 00:58:34,120 --> 00:58:35,520 LEVEL. 1439 00:58:35,520 --> 00:58:37,840 AND AFTER CAREFUL CONSIDERATION 1440 00:58:37,840 --> 00:58:39,400 INTERNALLY WITH OUR LEADERSHIP, 1441 00:58:39,400 --> 00:58:42,160 WE ARE NOW MOVING FORWARD AND 1442 00:58:42,160 --> 00:58:43,600 COMING TO YOU WITH THIS 1443 00:58:43,600 --> 00:58:44,840 DIVERSITY RO1 CONCEPT FOR 1444 00:58:44,840 --> 00:58:46,640 CLEARANCE. 1445 00:58:46,640 --> 00:58:48,160 ENHANCING DIVERSITY REMAINS ONE 1446 00:58:48,160 --> 00:58:50,440 OF THE NIH TOP PRIORITIES AND IT 1447 00:58:50,440 --> 00:58:58,000 IS A PRIORITY FOR ALL OF NIAID 1448 00:58:58,000 --> 00:58:59,320 SO THE OBJECTIVE OF THIS 1449 00:58:59,320 --> 00:59:01,000 DIVERSITY RO1 INITIATIVE IS TO 1450 00:59:01,000 --> 00:59:03,000 SUPPORT RESEARCH FROM NEW EARLY 1451 00:59:03,000 --> 00:59:04,680 STAGE AND AT RISK INVESTIGATORS 1452 00:59:04,680 --> 00:59:06,240 FROM UNDER-REPRESENTED 1453 00:59:06,240 --> 00:59:09,320 BACKGROUNDS AND BIOMEDICAL 1454 00:59:09,320 --> 00:59:10,600 RESEARCH TO ENHANCE DIVERSITY OF 1455 00:59:10,600 --> 00:59:13,320 RO1 FUNDED INVESTIGATORS. 1456 00:59:13,320 --> 00:59:14,960 NIAID WILL SUPPORT APPLICATIONS 1457 00:59:14,960 --> 00:59:17,600 RELATED TO ALL AREAS OF OUR 1458 00:59:17,600 --> 00:59:18,480 INSTITUTE'S MISSION WITH THE 1459 00:59:18,480 --> 00:59:20,760 GOAL OF DEVELOPING A DIVERSE 1460 00:59:20,760 --> 00:59:23,840 HIGHLY IMPACTFUL SCIENTIFIC WORK 1461 00:59:23,840 --> 00:59:25,320 FORCE OF THE FUTURE THAT 1462 00:59:25,320 --> 00:59:27,200 CONDUCTS STATE OF THE ART 1463 00:59:27,200 --> 00:59:28,680 RESEARCH IN INFECTIOUS 1464 00:59:28,680 --> 00:59:30,720 IMMUNOLOGIC ALLERGIC DISEASES. 1465 00:59:30,720 --> 00:59:32,600 WITH THAT, I WILL OPEN THE FLOOR 1466 00:59:32,600 --> 00:59:35,720 FOR DISCUSSION. 1467 00:59:35,720 --> 00:59:39,480 >> THANK YOU, DR. PRICE FOR YOUR 1468 00:59:39,480 --> 00:59:40,840 PRESENTATION. 1469 00:59:40,840 --> 00:59:42,440 ARE THERE QUESTIONS ABOUT THIS 1470 00:59:42,440 --> 00:59:48,600 INITIATIVE? 1471 00:59:48,600 --> 00:59:49,960 >> I HAVE ONE QUESTION. 1472 00:59:49,960 --> 00:59:54,400 THANK YOU SO MUCH FOR THIS 1473 00:59:54,400 --> 00:59:55,400 EFFORT AND LAUNCHING THIS 1474 00:59:55,400 --> 00:59:58,040 PROGRAM. 1475 00:59:58,040 --> 00:59:59,280 INTERESTED IN HOW DO YOU 1476 00:59:59,280 --> 01:00:01,200 DETERMINE WHAT LEVEL OF FUNDING 1477 01:00:01,200 --> 01:00:03,080 TO ALLOCATE FOR SUCH -- BECAUSE 1478 01:00:03,080 --> 01:00:05,760 CLEARLY THE NEED IS LARGE AND 1479 01:00:05,760 --> 01:00:07,440 COULD BE EXPANDED FURTHER. 1480 01:00:07,440 --> 01:00:09,320 IS THIS A PILOT PHASE? 1481 01:00:09,320 --> 01:00:11,120 HOW WILL THIS SORT OF THEN BE 1482 01:00:11,120 --> 01:00:12,200 EXPANDED IF WORKING WELL AND IF 1483 01:00:12,200 --> 01:00:18,280 THERE IS A BIG DEMAND? 1484 01:00:18,280 --> 01:00:19,480 THIS -- FOR THIS TYPE OF 1485 01:00:19,480 --> 01:00:19,920 SUPPORT? 1486 01:00:19,920 --> 01:00:23,480 >> THANK YOU FOR THAT QUESTION. 1487 01:00:23,480 --> 01:00:24,800 THERE'S ALWAYS COMPETING 1488 01:00:24,800 --> 01:00:25,320 PRIORITIES. 1489 01:00:25,320 --> 01:00:27,440 IN THIS FIRST PHASE, THIS FIRST 1490 01:00:27,440 --> 01:00:29,440 FEW YEARS, THIS WILL SET THE 1491 01:00:29,440 --> 01:00:32,120 STAGE AND WILL BE ABLE TO HAVE A 1492 01:00:32,120 --> 01:00:33,240 BETTER IDEA OF HOW MANY 1493 01:00:33,240 --> 01:00:38,240 APPLICANTS WE CAN EXPECT AND 1494 01:00:38,240 --> 01:00:40,080 FROM THERE BE ABLE TO HOPEFULLY 1495 01:00:40,080 --> 01:00:42,720 CROSS MY FINGERS PERSUASIVELY 1496 01:00:42,720 --> 01:00:43,720 ENCOURAGE ADDITIONAL RESOURCES 1497 01:00:43,720 --> 01:00:46,080 TO BE ALLOCATED. 1498 01:00:46,080 --> 01:00:48,560 AT THIS FIRST STAGE WE PROPOSED 1499 01:00:48,560 --> 01:00:51,840 AN INITIAL IDEA FOR WHAT WE 1500 01:00:51,840 --> 01:00:53,320 THOUGHT MIGHT BE A GOOD STARTING 1501 01:00:53,320 --> 01:00:54,920 POINT AND THEN NEGOTIATED WITHIN 1502 01:00:54,920 --> 01:00:58,640 OUR LEADERSHIP AND WORKING WITH 1503 01:00:58,640 --> 01:01:03,480 OUR OFFICE OF BUDGETS OFFICE TO 1504 01:01:03,480 --> 01:01:04,960 COME UP WITH WHAT WE MIGHT BE 1505 01:01:04,960 --> 01:01:05,440 ABLE TO DO. 1506 01:01:05,440 --> 01:01:08,000 SO THIS IS A PILOT PHASE AND WE 1507 01:01:08,000 --> 01:01:10,000 WILL SEE HOW THINGS GO AFTER 1508 01:01:10,000 --> 01:01:11,280 THIS AND WHAT WE ARE ABLE TO DO 1509 01:01:11,280 --> 01:01:13,480 IN THE FUTURE. 1510 01:01:13,480 --> 01:01:15,720 >> THANK YOU, LESHAWNDRA. 1511 01:01:15,720 --> 01:01:17,720 >> I WILL SAY THERE'S BEEN 1512 01:01:17,720 --> 01:01:20,040 TREMENDOUS EFFORTS AT THE T 32 1513 01:01:20,040 --> 01:01:21,640 LEVEL TO EXPAND DIVERSITY AND 1514 01:01:21,640 --> 01:01:24,600 THROUGH THE Ks SO THIS REALLY 1515 01:01:24,600 --> 01:01:28,800 IS A NEXT VERY IMPORTANT LOGICAL 1516 01:01:28,800 --> 01:01:30,880 STEP TO ENCOURAGE AND SUPPORT 1517 01:01:30,880 --> 01:01:31,320 THIS EFFORT. 1518 01:01:31,320 --> 01:01:34,440 THANK YOU. 1519 01:01:34,440 --> 01:01:35,440 ANY OTHER QUESTIONS? 1520 01:01:35,440 --> 01:01:36,880 LET ME REMIND EVERYONE TO OPEN 1521 01:01:36,880 --> 01:01:41,720 THEIR ELECTRONIC COUNCIL BOOKS 1522 01:01:41,720 --> 01:01:46,240 AND GO TO THE DAIDS TAB AND THE 1523 01:01:46,240 --> 01:01:51,160 DOCUMENT VOTING LINK. 1524 01:01:51,160 --> 01:01:52,360 THERE'S SOME NICE COMMENTS IN 1525 01:01:52,360 --> 01:01:54,280 THE CHAT AS WELL WHICH IN THE 1526 01:01:54,280 --> 01:01:56,360 INTEREST OF TIME I WON'T READ 1527 01:01:56,360 --> 01:01:57,280 THROUGH BUT EVERYONE SHOULD TAKE 1528 01:01:57,280 --> 01:02:01,400 A LOOK AT THOSE AS WE GO. 1529 01:02:01,400 --> 01:02:04,640 SO WHY DOESN'T EVERYONE TAKE A 1530 01:02:04,640 --> 01:02:10,680 MOMENT AND VOTE ON THIS 1531 01:02:10,680 --> 01:02:11,080 INITIATIVE. 1532 01:02:11,080 --> 01:02:13,960 THANK YOU AGAIN, DR. PRICE. 1533 01:02:13,960 --> 01:02:15,120 MENT WE APPRECIATE IT. 1534 01:02:15,120 --> 01:02:16,000 >> MY PLEASURE. 1535 01:02:16,000 --> 01:02:17,600 THANK YOU. 1536 01:02:17,600 --> 01:02:22,000 >> WE WILL MOVE ON TO OUR NEXT 1537 01:02:22,000 --> 01:02:26,920 PRESENTATION WHICH WILL BE BY 1538 01:02:26,920 --> 01:02:31,720 DR. GERARD LACOURCIERE, HIV 1539 01:02:31,720 --> 01:02:33,960 INDUCED INFLAMMATION AND IMMUNE 1540 01:02:33,960 --> 01:02:39,560 ACTIVATION DURING SUPPRESSIVE 1541 01:02:39,560 --> 01:02:40,280 DR. LACOURCIERE. 1542 01:02:40,280 --> 01:02:41,440 >> THANK YOU, KEN. 1543 01:02:41,440 --> 01:02:43,040 DO I HAVE THE NEXT SLIDE PLEASE. 1544 01:02:43,040 --> 01:02:45,080 THE OBJECTIVE OF THIS INITIATIVE 1545 01:02:45,080 --> 01:02:47,080 IS GO CUSSED ON DEFINING 1546 01:02:47,080 --> 01:02:49,640 MOLECULAR MECHANISMS ON HIV 1547 01:02:49,640 --> 01:02:51,040 PROIGNS AND NUCLEIC ACIDS 1548 01:02:51,040 --> 01:02:53,120 INCLUDE IMMUNE ACTIVATION DURING 1549 01:02:53,120 --> 01:02:54,000 VIRAL SUPPRESSION. 1550 01:02:54,000 --> 01:02:58,120 THE MECHANISM IS PROPOSED IN THE 1551 01:02:58,120 --> 01:03:01,560 RFA BY PHASIC R 33 MECHANISM, IT 1552 01:03:01,560 --> 01:03:02,760 IS NEW WE ARE REQUESTING A 1553 01:03:02,760 --> 01:03:04,520 DURATION OF FIVE YEARS. 1554 01:03:04,520 --> 01:03:06,600 BUDGET OF $3 MILLION, AND WE 1555 01:03:06,600 --> 01:03:10,920 ESTIMATE TO AWARD BETWEEN 4 TO 5 1556 01:03:10,920 --> 01:03:11,440 GRANTS. 1557 01:03:11,440 --> 01:03:12,800 NEXT SLIDE. 1558 01:03:12,800 --> 01:03:14,280 ANTI-RETROVIRAL THERAPEUTICS 1559 01:03:14,280 --> 01:03:15,840 MAKE VIRAL SUPPRESSION 1560 01:03:15,840 --> 01:03:16,680 ACHIEVABLE SUSTAINABLE GOAL AND 1561 01:03:16,680 --> 01:03:19,200 MOST PEOPLE LIVING WITH HIV 1562 01:03:19,200 --> 01:03:20,080 ADHERE TO THAT TREATMENT. 1563 01:03:20,080 --> 01:03:22,120 PEOPLE LIVING WITH HIV ARE ARE 1564 01:03:22,120 --> 01:03:23,960 LIVING LONGER YET THEY CONTINUE 1565 01:03:23,960 --> 01:03:26,120 TO EXPERIENCE ELEVATED RISK OF 1566 01:03:26,120 --> 01:03:27,760 CHRONIC HEALTH COMPLICATIONS 1567 01:03:27,760 --> 01:03:29,200 PARTICULARLY CARDIOVASCULAR 1568 01:03:29,200 --> 01:03:30,680 DISEASE, CANCER, COGNITIVE 1569 01:03:30,680 --> 01:03:32,840 IMPAIRMENT, FRAILTY. 1570 01:03:32,840 --> 01:03:34,960 NON-AIDS RELATED CO-MORE BITTIES 1571 01:03:34,960 --> 01:03:37,240 MAYBE DRIVEN AT LEAST IN PART BY 1572 01:03:37,240 --> 01:03:38,440 PERSISTENT LOW GRADE 1573 01:03:38,440 --> 01:03:39,240 IMMUNOACTIVATION AND 1574 01:03:39,240 --> 01:03:42,880 INFLAMMATION DESPITE SUPPRESSIVE 1575 01:03:42,880 --> 01:03:43,240 ART. 1576 01:03:43,240 --> 01:03:44,800 HIV RNA PROTEINS ARE EXPRESSED 1577 01:03:44,800 --> 01:03:46,800 AFTER PROLONGED ANTIVIRAL 1578 01:03:46,800 --> 01:03:47,200 TREATMENT. 1579 01:03:47,200 --> 01:03:48,960 THESE VIRAL PRODUCTS MAY 1580 01:03:48,960 --> 01:03:50,880 CONTRIBUTE TO INFLAMMATION 1581 01:03:50,880 --> 01:03:52,840 IMMUNE ACTIVATION, EXHAUSTION AS 1582 01:03:52,840 --> 01:03:55,280 WELL AS HIV PERSISTENCE. 1583 01:03:55,280 --> 01:03:58,120 HIV ANTIGEN EXPRESSION MAY DRIVE 1584 01:03:58,120 --> 01:04:00,680 INACTIVATION MAY LEAD TO CLONAL 1585 01:04:00,680 --> 01:04:05,800 EXPANSION OF RESERVOIR CELLS. 1586 01:04:05,800 --> 01:04:08,600 THE HIV RESERVOIR ARE VERY 1587 01:04:08,600 --> 01:04:09,920 HETEROGENOUS, WHILE SUPPRESS TO, 1588 01:04:09,920 --> 01:04:11,560 ART SOME CELLS REMAIN TOTALLY 1589 01:04:11,560 --> 01:04:12,120 SILENT. 1590 01:04:12,120 --> 01:04:13,640 THERE IS A SUBPOPULATION OF 1591 01:04:13,640 --> 01:04:16,600 CELLS CAPABLE OF TRANSCRIBING 1592 01:04:16,600 --> 01:04:19,800 VIRAL RNA, THIS ANOTHER 1593 01:04:19,800 --> 01:04:21,080 SUBPOPULATION CAPABLE OF TRANS 1594 01:04:21,080 --> 01:04:22,880 LATING VIRAL PROTEINS, AND THERE 1595 01:04:22,880 --> 01:04:24,760 IS ALSO ANOTHER SUBPOPULATION 1596 01:04:24,760 --> 01:04:28,200 THAT IS REPLICATION COMPETENT 1597 01:04:28,200 --> 01:04:30,840 THAT CAN REPLICATE FULLY IMPACT 1598 01:04:30,840 --> 01:04:31,440 VIRUSES. 1599 01:04:31,440 --> 01:04:33,440 SO UNDERSTANDING THE RESERVOIR 1600 01:04:33,440 --> 01:04:35,320 SINGLE CELL LEVEL, PROVIDE 1601 01:04:35,320 --> 01:04:37,000 ADDITIONAL CRITICAL INFORMATION 1602 01:04:37,000 --> 01:04:38,720 OF HETEROGENEITY. 1603 01:04:38,720 --> 01:04:41,360 THESE PROVIRUSES AND PRODUCTS 1604 01:04:41,360 --> 01:04:42,960 MAY BE STRONG CONTRIBUTORS TO 1605 01:04:42,960 --> 01:04:44,960 ONGOING ISSUE ASSOCIATED WITH 1606 01:04:44,960 --> 01:04:46,840 HIV INDUCED INFLAMMATION AND 1607 01:04:46,840 --> 01:04:52,400 IMMUNE ACTIVATION. 1608 01:04:52,400 --> 01:04:54,520 NIH PROVIRUS IS CAPABLE OF 1609 01:04:54,520 --> 01:04:56,640 TRANSCRIBING NOVEL UNSPLICED HIV 1610 01:04:56,640 --> 01:04:59,400 RNA AND HIV INFECTED INDIVIDUALS 1611 01:04:59,400 --> 01:05:00,240 ON PART. 1612 01:05:00,240 --> 01:05:01,880 THIS PAPER -- ON ART. 1613 01:05:01,880 --> 01:05:04,440 IN THIS PAPER SEVERAL DE FACTO 1614 01:05:04,440 --> 01:05:05,880 PRO VIRUSES WERE ISOLATED FROM 1615 01:05:05,880 --> 01:05:08,120 PATIENTS AND SEQUENCE ANALYSIS 1616 01:05:08,120 --> 01:05:10,600 REVEALED THAT THEY HAVE NOVEL 1617 01:05:10,600 --> 01:05:12,520 UNSPLICE HIV RNA TRANSCRIPTS AND 1618 01:05:12,520 --> 01:05:14,560 THEY REVEALED EXON STRUCTURE 1619 01:05:14,560 --> 01:05:17,480 THAT WERE DIFFERENT FROM THOSE 1620 01:05:17,480 --> 01:05:19,320 KNOWN FROM SLICE HIV mRNA 1621 01:05:19,320 --> 01:05:22,840 VARIANTS AND RANGE IN SIZE FROM 1622 01:05:22,840 --> 01:05:25,800 .5-KILOBASE TO 2.6-KILO BASE. 1623 01:05:25,800 --> 01:05:28,440 THESE TRANSCRIPTS APPROPRIATE 1624 01:05:28,440 --> 01:05:30,840 TRANSCRIPTION START AND STOP 1625 01:05:30,840 --> 01:05:32,960 SIGNALS AND THUS THEY POSSESS 1626 01:05:32,960 --> 01:05:34,160 TRANSLATIONALLY COMPETENT OPEN 1627 01:05:34,160 --> 01:05:36,280 READING FRAMES. 1628 01:05:36,280 --> 01:05:38,160 UNSPLICE HIV RNA TRANSCRIPTS 1629 01:05:38,160 --> 01:05:39,880 LACK ANY CLASSIC SPLICE SITES IN 1630 01:05:39,880 --> 01:05:44,200 THE GENOMES. 1631 01:05:44,200 --> 01:05:47,200 THIS STUDY SHOWED THAT DEFECTIVE 1632 01:05:47,200 --> 01:05:50,360 PRO VIRUS CAPABLE OF EXPRESSING 1633 01:05:50,360 --> 01:05:51,840 HIV PROTEINS THIS DEFECTIVE 1634 01:05:51,840 --> 01:05:55,160 VIRUS WAS FOUND TO HAVE 2.4-KILO 1635 01:05:55,160 --> 01:05:56,960 BASE DELETION IN DNA WHICH 1636 01:05:56,960 --> 01:05:58,400 AFFECTED THE HIV PROTEINS 1637 01:05:58,400 --> 01:06:00,000 HIGHLIGHTED IN RED. 1638 01:06:00,000 --> 01:06:01,960 BUT THERE ARE SOME PROTEINS SUCH 1639 01:06:01,960 --> 01:06:06,600 AS GAG POL AND NAF STILL PRESENT 1640 01:06:06,600 --> 01:06:09,560 IN FORMS AND WHAT THIS STUDY 1641 01:06:09,560 --> 01:06:11,640 SHOWED WAS THE NAF AND GAG 1642 01:06:11,640 --> 01:06:13,480 PROTEINS WERE EXPRESSED BY 1643 01:06:13,480 --> 01:06:17,840 DEFECTIVE PROVIRUS IN THE NORMAL 1644 01:06:17,840 --> 01:06:18,200 SIZE. 1645 01:06:18,200 --> 01:06:21,360 SO PROPOSED DE FACTO PRO VIRUSES 1646 01:06:21,360 --> 01:06:22,520 MAYBE BIOLOGICALLY ACTIVE AND 1647 01:06:22,520 --> 01:06:25,080 PLAY A ROLE IN HIV PATHOGENESIS. 1648 01:06:25,080 --> 01:06:26,840 THE HIV RNA TRANSCRIPTS AND 1649 01:06:26,840 --> 01:06:29,000 RESULTING PROTEINS EXPRESS DE 1650 01:06:29,000 --> 01:06:30,600 FACTO PROVIRUS MAY TRIGGER 1651 01:06:30,600 --> 01:06:33,040 ELEMENTS OF INNATE AND ADAPTIVE 1652 01:06:33,040 --> 01:06:35,200 IMMUNITY LEADING TO A STATE OF 1653 01:06:35,200 --> 01:06:36,640 PERSISTENT IMMUNE ACTIVATION 1654 01:06:36,640 --> 01:06:39,720 WITH LONG TERM CLINICAL 1655 01:06:39,720 --> 01:06:41,280 CONSEQUENCES. 1656 01:06:41,280 --> 01:06:45,360 THIS STUDY SHOWS THE HIV NEF 1657 01:06:45,360 --> 01:06:47,240 PROTEIN IS ASSOCIATED WITH 1658 01:06:47,240 --> 01:06:47,640 INFLAMMATION. 1659 01:06:47,640 --> 01:06:50,120 THE NEF PROTEIN IS CAPABLE OF 1660 01:06:50,120 --> 01:06:51,440 ENTERING BLOOD VESSELS THROUGH 1661 01:06:51,440 --> 01:06:53,520 THE ENDOTHELIAL CELL LINE. 1662 01:06:53,520 --> 01:06:55,600 ONCE ENTERS BLOOD VESSEL IT 1663 01:06:55,600 --> 01:06:58,040 INCREASES EXPRESSION OF 1664 01:06:58,040 --> 01:06:59,360 ENDOTHELIAL CELL ADHESION MARKER 1665 01:06:59,360 --> 01:07:01,960 SUCH AS ICAM 1 WHICH RESULTED IN 1666 01:07:01,960 --> 01:07:05,160 INCREASE T-CELL ADHESION TO 1667 01:07:05,160 --> 01:07:06,760 BLOOD VESSEL ENDOTHELIAL CELLS. 1668 01:07:06,760 --> 01:07:08,440 THE MORE IMPORTANTLY THE NEF 1669 01:07:08,440 --> 01:07:10,760 PROTEIN WAS FOUND TO ACTIVATE 1670 01:07:10,760 --> 01:07:13,000 THE RAP 1 PROTEIN WHICH 1671 01:07:13,000 --> 01:07:15,080 INCREASES REACTIVE OXYGEN 1672 01:07:15,080 --> 01:07:16,480 SPECIES IN THE BLOOD VESSEL. 1673 01:07:16,480 --> 01:07:18,560 THIS RESULTS IN APOPTOSIS OF 1674 01:07:18,560 --> 01:07:19,880 ENDOTHELIAL CELLS AND INCREASES 1675 01:07:19,880 --> 01:07:21,480 INFLAMMATION WHICH RESULTS IN 1676 01:07:21,480 --> 01:07:23,000 CARDIOVASCULAR DYSFUNCTION AND 1677 01:07:23,000 --> 01:07:24,840 INCREASES OF RISK OF 1678 01:07:24,840 --> 01:07:27,880 CARDIOVASCULAR DISEASE. 1679 01:07:27,880 --> 01:07:29,840 SO AS I MENTIONED WE ARE 1680 01:07:29,840 --> 01:07:33,040 PROPOSING THIS TO BE A TWO PHASE 1681 01:07:33,040 --> 01:07:35,880 MECHANISM R 65 PHASE IS INITIAL 1682 01:07:35,880 --> 01:07:38,280 PHASE, THREE YEARS IN LENGTH AND 1683 01:07:38,280 --> 01:07:39,560 WILL BE BASIC RESEARCH AND 1684 01:07:39,560 --> 01:07:39,920 SCOPE. 1685 01:07:39,920 --> 01:07:43,120 THE FOCUS WILL BE TO DETERMINE 1686 01:07:43,120 --> 01:07:45,120 THE HIV RNA PROTEIN LANDSCAPE IN 1687 01:07:45,120 --> 01:07:47,600 DIFFERENT CELLULAR 1688 01:07:47,600 --> 01:07:48,800 SUBPOPULATIONS, OFFERING INTACT 1689 01:07:48,800 --> 01:07:50,720 AND DEFECTIVE PROVIRUS IN 1690 01:07:50,720 --> 01:07:52,600 CONTEXT OF ART AND MECHANISMS 1691 01:07:52,600 --> 01:07:54,400 HIV RNA PROTEINS EXPRESS INTO 1692 01:07:54,400 --> 01:07:56,280 ART MIGHT LEAD TO INFLAMMATION 1693 01:07:56,280 --> 01:07:58,040 IMMUNE ACTIVATION AND IMMUNE 1694 01:07:58,040 --> 01:07:59,480 EXHAUSTION. 1695 01:07:59,480 --> 01:08:02,360 THE R 33 PHASE WILL BE TWO YEARS 1696 01:08:02,360 --> 01:08:04,760 IN RANGE AND WILL BE APPLIED 1697 01:08:04,760 --> 01:08:05,680 RESEARCH AND SCOPE. 1698 01:08:05,680 --> 01:08:07,200 THIS PHASE WILL BE USED TO 1699 01:08:07,200 --> 01:08:09,360 DEVELOP NOVEL THERAPEUTIC 1700 01:08:09,360 --> 01:08:10,240 STRATEGIES INTENDED TO BE USED 1701 01:08:10,240 --> 01:08:13,440 IN THE CONTEXT OF ART TO INHIBIT 1702 01:08:13,440 --> 01:08:15,680 HIV EXPRESSION FOR ALTERED 1703 01:08:15,680 --> 01:08:17,360 PATHWAYS HIV INEXCUSED 1704 01:08:17,360 --> 01:08:21,480 ACTIVATION AND IMMUNE ACTIVATION 1705 01:08:21,480 --> 01:08:23,120 AND IMMUNE EXHAUSTION AND 1706 01:08:23,120 --> 01:08:24,240 EVALUATING THESE STRATEGIES IN 1707 01:08:24,240 --> 01:08:27,040 SMALL ANIMAL MODELS. 1708 01:08:27,040 --> 01:08:28,400 INCLUDING DEVELOPMENT OF NOVEL 1709 01:08:28,400 --> 01:08:29,880 DRUGS THAT BLOCK HIV 1710 01:08:29,880 --> 01:08:32,560 TRANSCRIPTION, TAP MEDIATED 1711 01:08:32,560 --> 01:08:33,640 TRANSCRIPTIONAL ELONGATION 1712 01:08:33,640 --> 01:08:35,960 PATHWAYS THAT IDENTIFY R 61 1713 01:08:35,960 --> 01:08:37,000 PHASE. 1714 01:08:37,000 --> 01:08:41,120 ANIMAL MODEL PROOF OF CONCEPT IS 1715 01:08:41,120 --> 01:08:42,080 OPTIONAL GIVEN KNIFE YEAR TIME 1716 01:08:42,080 --> 01:08:42,920 FRAME OF THE GRANTS. 1717 01:08:42,920 --> 01:08:44,240 APPLICATION PROPOSED IN THE 1718 01:08:44,240 --> 01:08:45,600 FOLLOWING RESEARCH TOPICS WON'T 1719 01:08:45,600 --> 01:08:47,280 BE SUPPORTED. 1720 01:08:47,280 --> 01:08:49,040 IDENTIFICATION OF CELLULAR 1721 01:08:49,040 --> 01:08:51,040 BIOMARKERS WHICH ARE ELEVATED 1722 01:08:51,040 --> 01:08:54,360 DURING HIV INDUCE INFLAMMATION, 1723 01:08:54,360 --> 01:08:55,840 ANIMAL MODEL IS THE DIS USING 1724 01:08:55,840 --> 01:08:57,280 NON-HUMAN PRIMATES AND 1725 01:08:57,280 --> 01:08:58,280 THERAPEUTIC STRATEGIES WITH 1726 01:08:58,280 --> 01:09:03,160 TARGET CELLULAR BIOMARKERS. 1727 01:09:03,160 --> 01:09:05,320 SO WHERE DOES THIS MECHANISM 1728 01:09:05,320 --> 01:09:08,480 INITIATIVE FIT IN THE DAIDS 1729 01:09:08,480 --> 01:09:09,440 PORTFOLIO? 1730 01:09:09,440 --> 01:09:10,400 SONCES BIPHASIC MECHANISM FIRST 1731 01:09:10,400 --> 01:09:12,560 PHASE BASIC VERGE AND SECOND 1732 01:09:12,560 --> 01:09:17,000 PHASE IS APPLIED Z SCIENCE AT 1733 01:09:17,000 --> 01:09:18,760 INTERSECTION OF BASIC RESEARCH 1734 01:09:18,760 --> 01:09:21,480 AND TRANSLATIONAL RESEARCH, INTO 1735 01:09:21,480 --> 01:09:25,120 MENTION THAT THERE WAS AN RFA 1736 01:09:25,120 --> 01:09:27,040 APPROVED BACK IN 2012 WHICH 1737 01:09:27,040 --> 01:09:29,200 FOCUSED ON TARGETED INFLAMMATION 1738 01:09:29,200 --> 01:09:31,520 IMMUNE ACTIVATION HIV DISEASE 1739 01:09:31,520 --> 01:09:33,240 AND THERE WERE TWO AWARDS THAT 1740 01:09:33,240 --> 01:09:35,720 CAME OUT OF THIS RFA. 1741 01:09:35,720 --> 01:09:37,360 BOTH TARGETED CELLULAR 1742 01:09:37,360 --> 01:09:40,720 BIOMARKERS WHICH ARE ELEVATED 1743 01:09:40,720 --> 01:09:43,160 DURING HIV INDUCED INFLAMMATION 1744 01:09:43,160 --> 01:09:46,040 AND THERE WAS NO REAL IMPACT OF 1745 01:09:46,040 --> 01:09:48,600 TARGETING THESE BIOMARKERS ON 1746 01:09:48,600 --> 01:09:54,360 HIV INDUCE INFLAMMATION. 1747 01:09:54,360 --> 01:09:56,880 SO OUR ARAC MEMBERS REVIEWED 1748 01:09:56,880 --> 01:10:01,280 THIS PROPOSED INITIATIVE DR. 1749 01:10:01,280 --> 01:10:03,000 (INAUDIBLE) AND DR. JEROME AT 1750 01:10:03,000 --> 01:10:06,200 THE PRE-ARAC MEETING THEY BOTH 1751 01:10:06,200 --> 01:10:07,840 RECOMMEND THIS INITIATIVE FOR 1752 01:10:07,840 --> 01:10:08,200 APPROVAL. 1753 01:10:08,200 --> 01:10:10,160 I WILL HIGHLIGHT SOME OF THE 1754 01:10:10,160 --> 01:10:12,320 COMMENTS AND OUR RESPONSES. 1755 01:10:12,320 --> 01:10:15,080 CLARIFYING THE ANIMAL MODEL NOT 1756 01:10:15,080 --> 01:10:17,080 NECESSARILY REQUIRE R 33 PHASE, 1757 01:10:17,080 --> 01:10:18,320 SEEMS IMPORTANT. 1758 01:10:18,320 --> 01:10:20,400 MIGHT ALSO CONSIDER SPECIFYING 1759 01:10:20,400 --> 01:10:24,200 THAT SMALL ANIMAL MODELS, ARE 1760 01:10:24,200 --> 01:10:25,400 ANTICIPATED GIVEN BUDGET AND 1761 01:10:25,400 --> 01:10:27,000 TIME CONSTRAINTS. 1762 01:10:27,000 --> 01:10:28,880 SO WE WILL WRITE THE RFA WILL BE 1763 01:10:28,880 --> 01:10:30,760 WRITTEN TO CLARIFY ANIMAL MODEL 1764 01:10:30,760 --> 01:10:33,280 WORK IN THE R 33 PHASE. 1765 01:10:33,280 --> 01:10:35,080 ANIMAL STUDIES BE NOTE AS 1766 01:10:35,080 --> 01:10:36,520 OPTIONAL AND LIMITED USE OF 1767 01:10:36,520 --> 01:10:39,240 SMALL ANIMAL MODEL FOR PROOF OF 1768 01:10:39,240 --> 01:10:40,360 CONCEPT STUDIES. 1769 01:10:40,360 --> 01:10:41,480 IT MIGHT BE USEFUL TO 1770 01:10:41,480 --> 01:10:42,480 ACKNOWLEDGE IN THE RFA THAT THE 1771 01:10:42,480 --> 01:10:44,320 ISSUE OF CHRONIC INFLAMMATION 1772 01:10:44,320 --> 01:10:46,520 IMMUNE ACTIVATION IS ALSO LIKELY 1773 01:10:46,520 --> 01:10:49,240 TO BE RELEVANT IN CONTEXT OF 1774 01:10:49,240 --> 01:10:50,440 CURE STRATEGIES IN ADDITION TO 1775 01:10:50,440 --> 01:10:52,560 THE SETTING OF SUPPRESSIVE ART. 1776 01:10:52,560 --> 01:10:54,520 CALLING THIS OUT MAY INCREASE 1777 01:10:54,520 --> 01:10:55,800 INTEREST IN RESPONSE TO THE RFA. 1778 01:10:55,800 --> 01:10:57,800 WE AGREE WITH THAT COMMENT AND 1779 01:10:57,800 --> 01:11:00,240 WHEN THE RFA WILL BE WRITTEN IT 1780 01:11:00,240 --> 01:11:01,840 WILL INCLUDE CURE RESEARCH 1781 01:11:01,840 --> 01:11:09,240 STRATEGIES AS WELL. 1782 01:11:09,240 --> 01:11:10,800 POSSIBILITIES FOR CERTAIN NEWLY 1783 01:11:10,800 --> 01:11:12,480 DISCOVERED IMMUNE ACTIVATION MAY 1784 01:11:12,480 --> 01:11:14,120 LEAD TO NEW BIOMARKERS SOME 1785 01:11:14,120 --> 01:11:15,480 WHICH MIGHT BE RELEVANT 1786 01:11:15,480 --> 01:11:19,200 POTENTIAL THERAPEUTIC TARGETS AS 1787 01:11:19,200 --> 01:11:20,920 SUCH THERE MAYBE SOME AMBIGUITY 1788 01:11:20,920 --> 01:11:22,760 GRAY AREAS IN TERMS OF HOW 1789 01:11:22,760 --> 01:11:26,840 UPSTREAM AND SIGNALING THE 1790 01:11:26,840 --> 01:11:28,320 PATHWAYS TARGET MUST BE 1791 01:11:28,320 --> 01:11:31,160 CONSIDERED NEW RESPONSIVE. 1792 01:11:31,160 --> 01:11:33,280 RESPONSE TO ART 65 PHASE OF RFA 1793 01:11:33,280 --> 01:11:35,040 WILL FOCUS ON DETERMINING HIV 1794 01:11:35,040 --> 01:11:36,760 DERIVED PROTEINS AND NUCLEIC 1795 01:11:36,760 --> 01:11:38,640 ACIDS AND HOW THEY INDUCE 1796 01:11:38,640 --> 01:11:40,680 INFLAMMATION IMMUNE ACTIVATION. 1797 01:11:40,680 --> 01:11:42,560 THOUGH NEW MECHANISMS MAYBE 1798 01:11:42,560 --> 01:11:43,920 DISCOVERED ALONG WITH NEW 1799 01:11:43,920 --> 01:11:46,360 BIOMARKERS THE PROPOSED FOCUS OF 1800 01:11:46,360 --> 01:11:48,440 THIS RFA WILL REMAIN ON 1801 01:11:48,440 --> 01:11:49,560 TARGETING VIRAL COMPONENTS TO 1802 01:11:49,560 --> 01:11:51,560 INDUCE INFLAMMATION AND IMMUNE 1803 01:11:51,560 --> 01:11:52,040 ACTIVATION. 1804 01:11:52,040 --> 01:11:54,120 SO RFA WILL BE WRITTEN TO 1805 01:11:54,120 --> 01:11:55,280 EMPHASIZE THIS THERAPEUTIC 1806 01:11:55,280 --> 01:11:58,360 PRIORITY. 1807 01:11:58,360 --> 01:12:02,560 THIS IS JUST THE OVERVIEW OF THE 1808 01:12:02,560 --> 01:12:03,520 PROPOSED INITIATIVE, THAT 1809 01:12:03,520 --> 01:12:06,280 CONCLUDES MY PRESENTATION. 1810 01:12:06,280 --> 01:12:12,240 >> THANK YOU VERY MUCH. 1811 01:12:12,240 --> 01:12:13,440 QUESTIONS FOR DR. LACOURCIERE 1812 01:12:13,440 --> 01:12:23,840 ABOUT THIS INITIATIVE? 1813 01:12:26,960 --> 01:12:32,920 QUESTIONS OR COMMENTS? 1814 01:12:32,920 --> 01:12:34,520 IT SPEAKS TO CLARITY OF YOUR 1815 01:12:34,520 --> 01:12:37,880 PRESENTATION. 1816 01:12:37,880 --> 01:12:38,440 THANK YOU. 1817 01:12:38,440 --> 01:12:41,240 LET ME AGAIN ASK EVERYONE TO GO 1818 01:12:41,240 --> 01:12:46,440 TO THEIR ECB AND VOTE UNDER 1819 01:12:46,440 --> 01:12:48,560 VOTING DOCUMENTS TAB IF YOU ARE 1820 01:12:48,560 --> 01:12:52,320 VOTING ON THESE. 1821 01:12:52,320 --> 01:12:54,760 WHILE WE DO THAT WE WILL 1822 01:12:54,760 --> 01:12:59,120 TRANSITION TO THE NEXT 1823 01:12:59,120 --> 01:13:01,360 PRESENTATION WHICH WILL BE DR. 1824 01:13:01,360 --> 01:13:03,560 ERIC REFSLAND ON THE CENTER -- 1825 01:13:03,560 --> 01:13:05,160 CENTERS FOR AIDS RESEARCH 1826 01:13:05,160 --> 01:13:07,360 DEVELOPMENTAL CENTERS, FOR AIDS 1827 01:13:07,360 --> 01:13:10,200 RESEARCH OR THE DC FAR. 1828 01:13:10,200 --> 01:13:12,480 DR. REFSLAND. 1829 01:13:12,480 --> 01:13:13,920 >> THANK YOU, KEN, GOOD 1830 01:13:13,920 --> 01:13:14,480 AFTERNOON OR GOOD MORNING, 1831 01:13:14,480 --> 01:13:16,160 EVERYONE. 1832 01:13:16,160 --> 01:13:18,440 I AM PROGRAM OFFICER PATHOYENSIS 1833 01:13:18,440 --> 01:13:20,160 BASIC RESEARCH BRANCH BASIC 1834 01:13:20,160 --> 01:13:20,640 SCIENCE PROGRAM. 1835 01:13:20,640 --> 01:13:23,680 I'M EXCITED TO BE PRESENTING TWO 1836 01:13:23,680 --> 01:13:25,880 CONCEPTS FOR REISSUE. 1837 01:13:25,880 --> 01:13:27,600 NIH CENTERS FOR AIDS RESEARCH 1838 01:13:27,600 --> 01:13:30,480 FOR CFAR AND RELATED COMPANION 1839 01:13:30,480 --> 01:13:32,200 CONCEPT DEVELOPMENTAL CENTER FOR 1840 01:13:32,200 --> 01:13:34,880 AIDS RESEARCH OR DCFAR. 1841 01:13:34,880 --> 01:13:36,960 PURPOSE OF CFAR PROGRAM IS 1842 01:13:36,960 --> 01:13:38,440 POSTER HIGH QUALITY HIV RESEARCH 1843 01:13:38,440 --> 01:13:40,160 BY INCREASING COLLABORATIONS IN 1844 01:13:40,160 --> 01:13:42,200 RESEARCH ACROSS DISCIPLINES AT 1845 01:13:42,200 --> 01:13:43,120 AN INSTITUTION OR BETWEEN 1846 01:13:43,120 --> 01:13:45,160 INSTITUTIONS. 1847 01:13:45,160 --> 01:13:48,640 AND ENTRANSLATION OF BASIC 1848 01:13:48,640 --> 01:13:51,080 RESEARCH FINDINGSINGS IN VACCINE 1849 01:13:51,080 --> 01:13:54,120 THERAPEUTIC HIV PREVENTION CURE 1850 01:13:54,120 --> 01:13:55,560 CONCEPTS MACKMIZEING EFFICIENCY 1851 01:13:55,560 --> 01:13:56,480 AND COST EFFECTIVENESS. 1852 01:13:56,480 --> 01:13:58,880 THIS IS ACCOMPLISHED WITH CENTER 1853 01:13:58,880 --> 01:14:00,440 CORE P 30 GRANT MECHANISM AND 1854 01:14:00,440 --> 01:14:02,760 TODAY I'M SEEKING APPROVAL FOR 1855 01:14:02,760 --> 01:14:06,880 REISSUE OF THE CFAR AND D CFAR 1856 01:14:06,880 --> 01:14:07,240 PROGRAMS. 1857 01:14:07,240 --> 01:14:09,840 EACH GRANT IS FIVE YEARS AND WE 1858 01:14:09,840 --> 01:14:11,200 ANTICIPATE ONE TO SIX AWARDS PER 1859 01:14:11,200 --> 01:14:11,560 YEAR. 1860 01:14:11,560 --> 01:14:13,080 THE NIAID PORTION OF THE FIRST 1861 01:14:13,080 --> 01:14:17,400 YEAR TOTAL COST IS 1.5 MILLION. 1862 01:14:17,400 --> 01:14:20,720 THE CFAR PROGRAM WAS ESTABLISHED 1863 01:14:20,720 --> 01:14:22,040 IN 1988 TO INCREASE 1864 01:14:22,040 --> 01:14:23,480 COLLABORATIVE SCIENCE AND 1865 01:14:23,480 --> 01:14:24,280 PROVIDE INFRASTRUCTURE SUPPORT 1866 01:14:24,280 --> 01:14:26,840 TO INSTITUTIONS WITH AT LEAST 1867 01:14:26,840 --> 01:14:29,920 $10 MILLION IN ONGOING NIH HIV 1868 01:14:29,920 --> 01:14:31,680 RELATED RESEARCH ACTIVITIES. 1869 01:14:31,680 --> 01:14:33,440 CURRENTLY WE HAVE TWO SEPARATE 1870 01:14:33,440 --> 01:14:35,480 FUNDING OPPORTUNITIES. 1871 01:14:35,480 --> 01:14:38,240 CFAR AND D CFAR, BOTH PROGRAMS 1872 01:14:38,240 --> 01:14:39,240 PROVIDE SHARED INFRASTRUCTURE 1873 01:14:39,240 --> 01:14:41,720 SUPPORT THAT IS NOT AVAILABLE 1874 01:14:41,720 --> 01:14:43,240 THROUGH OTHER GRANT MECHANISMS 1875 01:14:43,240 --> 01:14:45,360 AND BRINGS TOGETHER DISCIPLINES 1876 01:14:45,360 --> 01:14:46,080 GIVING INSTITUTION SCIENTIFIC 1877 01:14:46,080 --> 01:14:47,840 AND FISCAL FLEXIBILITY TO 1878 01:14:47,840 --> 01:14:50,320 RESPOND TO NEEDS OF OUR 1879 01:14:50,320 --> 01:14:50,920 INVESTIGATORS. 1880 01:14:50,920 --> 01:14:53,400 A D CFAR PROGRAM IS THOSE 1881 01:14:53,400 --> 01:14:54,760 INSTITUTIONS THAT HAVE THE 1882 01:14:54,760 --> 01:14:57,000 CRITICAL MASS OF HIV RESEARCHERS 1883 01:14:57,000 --> 01:15:00,760 BUT HAVE GAPS TO FILL. 1884 01:15:00,760 --> 01:15:01,880 DCFAR PROGRAM PROVIDES FIVE 1885 01:15:01,880 --> 01:15:03,280 YEARS OF FUNDING TO ADDRESS GAPS 1886 01:15:03,280 --> 01:15:04,680 AND STRENGTHEN PROGRAM TO BECOME 1887 01:15:04,680 --> 01:15:08,520 COMPETITIVE FOR A FULL CFAR. 1888 01:15:08,520 --> 01:15:10,920 DCFARS CANNOT BE RENEWED. 1889 01:15:10,920 --> 01:15:12,480 SINCE LAUNCH FOUR OUT OF FIVE 1890 01:15:12,480 --> 01:15:13,840 SUCCESSFULLY COMPLETED AND 1891 01:15:13,840 --> 01:15:15,400 TRANSITIONED TO CFAR PROGRAM. 1892 01:15:15,400 --> 01:15:17,600 THERE IS A FOUR TIERED STRUCTURE 1893 01:15:17,600 --> 01:15:20,240 SO TOTAL FUND OF THESE PROGRAMS, 1894 01:15:20,240 --> 01:15:22,160 D CFARS ARE CAPPED $1 MILLION 1895 01:15:22,160 --> 01:15:24,840 TOTAL, COST PER YEAR. 1896 01:15:24,840 --> 01:15:26,720 TIER 1 CFARS ARE NOSE PROGRAMS 1897 01:15:26,720 --> 01:15:37,200 AND INSTITUTIONS WITHIN HIV 1898 01:15:56,240 --> 01:16:02,960 NEXT SLIDE PLEASE. 1899 01:16:02,960 --> 01:16:03,560 THE C AT LEAST FAR PROGRAM IS 1900 01:16:03,560 --> 01:16:04,720 CO-FUNDED BY 11 INSTITUTES. 1901 01:16:04,720 --> 01:16:05,960 EACH INSTITUTE YEARLY 1902 01:16:05,960 --> 01:16:06,840 CONTRIBUTION IS LISTED IN THIS 1903 01:16:06,840 --> 01:16:08,040 TABLE. 1904 01:16:08,040 --> 01:16:09,480 THE PROGRAM IS MANAGED BY 1905 01:16:09,480 --> 01:16:11,120 REPRESENTATIVES FROM EACH OF 1906 01:16:11,120 --> 01:16:12,480 THESE INSTITUTES AND THE NIH 1907 01:16:12,480 --> 01:16:14,360 OFFICE OF AIDS RESEARCH AND THE 1908 01:16:14,360 --> 01:16:16,920 FOGARTY INTERNATIONAL CENTER. 1909 01:16:16,920 --> 01:16:18,320 NIAID IS THE LARGEST SINGLE 1910 01:16:18,320 --> 01:16:19,920 CONTRIBUTOR WITH JUST OVER $27 1911 01:16:19,920 --> 01:16:22,040 MILLION CONTRIBUTED YEARLY. 1912 01:16:22,040 --> 01:16:25,040 THE TOTAL YEARLY BUDGET FOR THE 1913 01:16:25,040 --> 01:16:27,000 ENTIRE PROGRAM IS $45.8 MILLION 1914 01:16:27,000 --> 01:16:28,840 AND THIS IS NOT INCLUDING THE 1915 01:16:28,840 --> 01:16:31,200 EHE APPROPRIATIONS WE WILL SAY 1916 01:16:31,200 --> 01:16:34,320 MORE ON IN A MOMENT. 1917 01:16:34,320 --> 01:16:37,840 THE CFAR PROGRAM IS HIGHLY 1918 01:16:37,840 --> 01:16:39,160 MULTI-DISCIPLINARY, AROUND 1919 01:16:39,160 --> 01:16:40,840 ONE-THIRD OF THE TOTAL NIH HIV 1920 01:16:40,840 --> 01:16:43,000 AIDS BUDGET IS AWARDED TO 1921 01:16:43,000 --> 01:16:45,840 INSTITUTIONS WITH A C FAR OR D C 1922 01:16:45,840 --> 01:16:48,480 FAR PROGRAM T. GRANTS MADE BY 11 1923 01:16:48,480 --> 01:16:49,800 CO-FUNDING NIH INSTITUTES IN 1924 01:16:49,800 --> 01:16:51,360 PROPORTIONS SHOWN HERE. 1925 01:16:51,360 --> 01:16:52,480 WITH OVER HALF COMING FROM 1926 01:16:52,480 --> 01:16:54,880 NIAID. 1927 01:16:54,880 --> 01:16:56,320 REPRESENTING THE PRIORITIES OF 1928 01:16:56,320 --> 01:16:57,680 EACH INSTITUTES, THESE GRANTS 1929 01:16:57,680 --> 01:16:59,960 AND THEIR ASSOCIATED 1930 01:16:59,960 --> 01:17:02,200 INVESTIGATORS RECEIVE 1931 01:17:02,200 --> 01:17:03,440 INFRASTRUCTURE SUPPORT AND CORE 1932 01:17:03,440 --> 01:17:08,720 SERVICES FROM THEIR RESPECTIVE 1933 01:17:08,720 --> 01:17:09,240 CFAR PROGRAMS. 1934 01:17:09,240 --> 01:17:11,880 THERE ARE CURRENTLY 19 FUNDED 1935 01:17:11,880 --> 01:17:14,080 CENTERS, 18 C FAR AND ONE D C 1936 01:17:14,080 --> 01:17:14,720 FAR. 1937 01:17:14,720 --> 01:17:16,160 HAPPY TO SUPPORT SINCE LAST 1938 01:17:16,160 --> 01:17:17,880 REISSUE THE PROGRAM ADDED THE 1939 01:17:17,880 --> 01:17:19,640 TEXAS D C FAR BAILOR COLLEGE OF 1940 01:17:19,640 --> 01:17:21,160 MEDICINE UNIVERSITY OF TEXAS 1941 01:17:21,160 --> 01:17:22,600 HEALTH SCIENCE CENTER AND TEXAS 1942 01:17:22,600 --> 01:17:24,520 BIOMEDICAL RESEARCH INSTITUTE IN 1943 01:17:24,520 --> 01:17:25,200 SAN ANTONIO. 1944 01:17:25,200 --> 01:17:28,960 IN ADDITION RECENTLY, UCLA AND 1945 01:17:28,960 --> 01:17:30,560 CHARLES UNIVERSITY OF MEDICINE 1946 01:17:30,560 --> 01:17:31,680 SCIENCE,INGS HAVE SUCCESSFULLY 1947 01:17:31,680 --> 01:17:32,840 COMPETED FOR A C FAR. 1948 01:17:32,840 --> 01:17:34,720 AND THE UNIVERSITY OF PITTSBURGH 1949 01:17:34,720 --> 01:17:36,800 JOINED WITH CASE WESTERN RESERVE 1950 01:17:36,800 --> 01:17:38,840 UNIVERSITY TO FORM THE RUST BELT 1951 01:17:38,840 --> 01:17:46,840 C FAR. 1952 01:17:46,840 --> 01:17:48,840 THE P 30 GRANT IS STRUCTURED OF 1953 01:17:48,840 --> 01:17:50,440 FOUR COURTS AND ONE SCIENTIFIC 1954 01:17:50,440 --> 01:17:51,360 WORKING GROUP. 1955 01:17:51,360 --> 01:17:53,000 THESE CORES PROVIDE SERVICES TO 1956 01:17:53,000 --> 01:17:54,360 INVESTIGATORS AT THEIR 1957 01:17:54,360 --> 01:17:55,040 INSTITUTIONS, EVERYTHING FROM 1958 01:17:55,040 --> 01:17:56,600 COMMUNICATION AND PLANNING 1959 01:17:56,600 --> 01:17:58,160 ADMINISTRATIVE CORE TO HUMAN 1960 01:17:58,160 --> 01:17:59,400 SUBJECT RESOURCE SUPPORT IN 1961 01:17:59,400 --> 01:18:00,840 CLINICAL COURSE TO DEVELOPMENTAL 1962 01:18:00,840 --> 01:18:02,000 CORE WHICH PROVIDES SUPPORT AND 1963 01:18:02,000 --> 01:18:03,160 MENTORING TO EARLY CAREER 1964 01:18:03,160 --> 01:18:07,760 INVESTIGATORS. 1965 01:18:07,760 --> 01:18:09,200 SUPPORT FOR EARLY CAREER 1966 01:18:09,200 --> 01:18:10,320 INVESTIGATORS CAN CORM IN THE 1967 01:18:10,320 --> 01:18:11,440 FORM OF FINANCIAL SUPPORT FOR 1968 01:18:11,440 --> 01:18:13,200 PILOT STUDIES WHICH ENABLE 1969 01:18:13,200 --> 01:18:15,440 INVESTIGATOR TO GATHER 1970 01:18:15,440 --> 01:18:17,240 PRELIMINARY DATA FOR NIH K OR R 1971 01:18:17,240 --> 01:18:19,720 SERIES APPLICATION. 1972 01:18:19,720 --> 01:18:23,280 FROM 2009 TO 2021, CFARS AWARDED 1973 01:18:23,280 --> 01:18:24,480 1,836 PILOT AWARDS TO EARLY 1974 01:18:24,480 --> 01:18:26,280 CAREER INVESTIGATORS. 1975 01:18:26,280 --> 01:18:28,360 DEFINED AS THOSE WHO NEVER 1976 01:18:28,360 --> 01:18:29,920 RECEIVED INDEPENDENT NIH AWARD. 1977 01:18:29,920 --> 01:18:32,600 OF THOSE NEARLY A THIRD LED TO 1978 01:18:32,600 --> 01:18:36,440 SUBSEQUENT GRANT, 29% RO1 1979 01:18:36,440 --> 01:18:38,120 EQUIVALENT, 27% K MENTORED AWARD 1980 01:18:38,120 --> 01:18:41,800 AND ANOTHER 20% RO 3 OR R21. 1981 01:18:41,800 --> 01:18:45,480 THE RETURN ON INVESTMENT IS 1982 01:18:45,480 --> 01:18:47,560 $6.76 FOR DOLLAR SPENT BY CFAR 1983 01:18:47,560 --> 01:18:50,840 ON PILOT PROJECTS THIS INCREASE 1984 01:18:50,840 --> 01:18:52,840 5.65 IN 2019 MEASURED FROM THE 1985 01:18:52,840 --> 01:18:58,720 LAST ISSUE OF CFAR PROGRAM. 1986 01:18:58,720 --> 01:19:02,120 ANOTHER AREA WHICH CARL AND 1987 01:19:02,120 --> 01:19:04,480 MAUREEN SET ME UP NICELY WERE 1988 01:19:04,480 --> 01:19:06,560 CFAR INVESTIGATORS PLAYED ROLES 1989 01:19:06,560 --> 01:19:08,680 IN ENDING THE NIH EPIDEMIC 1990 01:19:08,680 --> 01:19:11,160 INITIATIVE THAT AIMS TO REDUCE 1991 01:19:11,160 --> 01:19:13,600 HIV INFECTION BY 75% IN THE U.S. 1992 01:19:13,600 --> 01:19:15,880 BY 2025 AND 90% BY 2030. 1993 01:19:15,880 --> 01:19:18,760 48 COUNTIES SAN JUAN, PUERTO 1994 01:19:18,760 --> 01:19:20,280 RICO AND SEVEN STATES HIV 1995 01:19:20,280 --> 01:19:22,040 PRIORITY JURISDICTIONS AND ON 1996 01:19:22,040 --> 01:19:23,400 THIS MAP THEY ARE REPRESENTED BY 1997 01:19:23,400 --> 01:19:24,960 BLUE DOTS OR BLUE STATES, ALSO 1998 01:19:24,960 --> 01:19:27,040 SHOWN HERE ARE THE LOCATIONS OF 1999 01:19:27,040 --> 01:19:29,800 THE 19TH CFAR SITES RED RIBBONS 2000 01:19:29,800 --> 01:19:31,800 AND SEVEN NIMH AIDS RESEARCH 2001 01:19:31,800 --> 01:19:33,600 CENTERS, THE YELLOW STARS, THOSE 2002 01:19:33,600 --> 01:19:36,440 ARE THE AHRQs, BOTH 2003 01:19:36,440 --> 01:19:39,320 WELL-POSITIONED TO COORDINATE 2004 01:19:39,320 --> 01:19:42,480 RESPONSE. 2005 01:19:42,480 --> 01:19:43,760 EHE IS AN HHS INITIATIVE. 2006 01:19:43,760 --> 01:19:45,560 SHOWN HERE FUNDING TO FIVE 2007 01:19:45,560 --> 01:19:46,920 AGENCIES. 2008 01:19:46,920 --> 01:19:48,160 APPROPRIATED FUNDING BEGAN IN 2009 01:19:48,160 --> 01:19:50,600 2020 AND AMOUNT OF NIH RECEIVED 2010 01:19:50,600 --> 01:19:55,520 HAS INCREASED IN 2021 AND 2022 2011 01:19:55,520 --> 01:19:56,280 WITH $26 MILLION TOTAL. 2012 01:19:56,280 --> 01:19:58,200 ALL THE NIH FUNDING SO FAR IS 2013 01:19:58,200 --> 01:20:01,280 ALLOCATED TO THE NIH CFARS AND 2014 01:20:01,280 --> 01:20:05,480 NIMH RESEARCH CENTERS. 2015 01:20:05,480 --> 01:20:09,960 SO THE WORK IN EHE IS FOCUSED ON 2016 01:20:09,960 --> 01:20:10,520 IMPLEMENTATION SCIENCE AND 2017 01:20:10,520 --> 01:20:12,680 STRETCHING PARTNERSHIPS BEYOND 2018 01:20:12,680 --> 01:20:13,760 COORDINATING EFFORTS BETWEEN 2019 01:20:13,760 --> 01:20:14,440 INVESTIGATORS COMMUNITY 2020 01:20:14,440 --> 01:20:15,800 IMPLEMENTING PARTNERS AND LOCAL 2021 01:20:15,800 --> 01:20:16,800 HEALTH DEPARTMENTS BUT ALSO 2022 01:20:16,800 --> 01:20:18,360 HELPS SYNERGIZE OUR WORK AND 2023 01:20:18,360 --> 01:20:20,280 DEEPEN COLLABORATIONS. 2024 01:20:20,280 --> 01:20:22,400 IN PARTICULAR THE COOPERATION 2025 01:20:22,400 --> 01:20:24,000 COLLABORATION BETWEEN NIH AND 2026 01:20:24,000 --> 01:20:27,240 OTHER HHS AGENCIES ESPECIALLY 2027 01:20:27,240 --> 01:20:29,440 CDC AND HRSA IS CRITICAL TO 2028 01:20:29,440 --> 01:20:30,800 SUCCESS SO FAR. 2029 01:20:30,800 --> 01:20:33,880 THE NIH SPECIFIC ROLE IN THE EHE 2030 01:20:33,880 --> 01:20:35,560 HAS LEVERAGED FLEXIBILITY AND 2031 01:20:35,560 --> 01:20:37,560 ORGANIZATION AT THE CFAR AND 2032 01:20:37,560 --> 01:20:39,480 NIMH AHRQ, THE CENTERS FOCUS ON 2033 01:20:39,480 --> 01:20:41,880 O ENHANCING THE IMPLEMENTATION 2034 01:20:41,880 --> 01:20:43,400 KNOWLEDGE RESEARCH BASE HAIRING 2035 01:20:43,400 --> 01:20:45,280 BEST PRACTICES ON RESEARCH 2036 01:20:45,280 --> 01:20:46,160 FINDINGS AND COLLECTING 2037 01:20:46,160 --> 01:20:47,880 DISSEMINATING DATA ON THE 2038 01:20:47,880 --> 01:20:49,080 EFFECTIVENESS OF APPROACHES USED 2039 01:20:49,080 --> 01:20:50,720 IN THIS INITIATIVE. 2040 01:20:50,720 --> 01:20:53,880 NEXT SLIDE PLEASE. 2041 01:20:53,880 --> 01:20:56,560 SO HERE IS AGAIN SNAP SHOT OF 2042 01:20:56,560 --> 01:20:58,440 THE RESEARCH FUNDED BY -- 2043 01:20:58,440 --> 01:20:59,920 THROUGH THE NIH PROJECT THE LAST 2044 01:20:59,920 --> 01:21:01,560 THREE YEARS OF EHE. 2045 01:21:01,560 --> 01:21:02,640 INCLUDED AGAIN ARE TOTAL NUMBER 2046 01:21:02,640 --> 01:21:05,160 OF THE PROJECTS FOR EACH YEAR 2047 01:21:05,160 --> 01:21:06,760 FOCUS AREA WHICH OF THE FOUR 2048 01:21:06,760 --> 01:21:08,200 PILLARS DIAGNOSE PREVENT TREAT 2049 01:21:08,200 --> 01:21:10,080 AND RESPOND OF THE EHE 2050 01:21:10,080 --> 01:21:11,680 INITIATIVE THE PROJECTS ADDRESS, 2051 01:21:11,680 --> 01:21:13,280 SHOULDN'T NOTED SOME PROJECTS 2052 01:21:13,280 --> 01:21:15,040 ADDRESS MORE THAN ONE PILLAR. 2053 01:21:15,040 --> 01:21:16,520 135 PROJECTS FUNDED TO DATE AND 2054 01:21:16,520 --> 01:21:18,520 THEY RANGE FROM PLANNING 2055 01:21:18,520 --> 01:21:20,720 PROJECTS TO FOCUS ON 2056 01:21:20,720 --> 01:21:23,280 DISPROPORTIONATELY AFFECTED 2057 01:21:23,280 --> 01:21:23,640 GROUP. 2058 01:21:23,640 --> 01:21:25,960 TO TEAM INITIATED PROJECTS THE 2059 01:21:25,960 --> 01:21:27,160 INVESTIGATOR COMMUNITY AND 2060 01:21:27,160 --> 01:21:28,800 IMPLEMENTING PARTNERS IDENTIFY 2061 01:21:28,800 --> 01:21:31,320 PROPOSE A PROJECT IN A PRIORITY 2062 01:21:31,320 --> 01:21:32,800 JURISDICTION AND AS CARL 2063 01:21:32,800 --> 01:21:34,480 MENTIONED BEFORE THE PROJECTS 2064 01:21:34,480 --> 01:21:38,120 FOR FISCAL YEAR 2022 CURRENTLY 2065 01:21:38,120 --> 01:21:38,840 UNDER CONSIDERATION. 2066 01:21:38,840 --> 01:21:43,520 FOR FUNDING LATER THIS SUMMER. 2067 01:21:43,520 --> 01:21:45,720 I WOULD LIKE TO NOW DETAIL 2068 01:21:45,720 --> 01:21:47,800 PROPOSED CHANGES TO CFAR AND D 2069 01:21:47,800 --> 01:21:48,640 CFAR PROGRAMS. 2070 01:21:48,640 --> 01:21:50,200 FIRST CHANGE TO TIER FUNDING 2071 01:21:50,200 --> 01:21:50,840 LEVELS. 2072 01:21:50,840 --> 01:21:52,520 THE CURRENT TIER SYSTEM I 2073 01:21:52,520 --> 01:21:53,920 MENTIONED BEFORE WAS FIRST 2074 01:21:53,920 --> 01:21:55,720 INTRODUCED IN 2003 AND IS NOT 2075 01:21:55,720 --> 01:21:57,560 CHANGED IN NEARLY 20 YEARS 2076 01:21:57,560 --> 01:21:58,640 SINCE. 2077 01:21:58,640 --> 01:22:01,480 THE CURRENT BASE FUNDING OF THE 2078 01:22:01,480 --> 01:22:03,160 CFAR PROGRAM SUPPORTS THE 2079 01:22:03,160 --> 01:22:04,920 EXISTING CENTERS BUT ALSO ALLOWS 2080 01:22:04,920 --> 01:22:07,200 FUNDING OF NEW MERITORIOUS CFAR 2081 01:22:07,200 --> 01:22:09,200 AND DC FARES AND ADMINISTRATIVE 2082 01:22:09,200 --> 01:22:09,760 SUPPLEMENTS. 2083 01:22:09,760 --> 01:22:11,560 WE ARE PROPOSING TO INCREASE THE 2084 01:22:11,560 --> 01:22:13,960 FUNDING OF EACH TIER BY $250,000 2085 01:22:13,960 --> 01:22:15,320 PER YEAR. 2086 01:22:15,320 --> 01:22:17,080 THE RATIONALE FOR THIS CHANGE IS 2087 01:22:17,080 --> 01:22:18,400 COUNTER INFLATION AND INCREASE 2088 01:22:18,400 --> 01:22:20,840 THE LOCAL CONTROL OF CFAR TO 2089 01:22:20,840 --> 01:22:22,480 ADDRESS SPECIFIC NEEDS. 2090 01:22:22,480 --> 01:22:24,040 THIS CHANGE WOULD RESULT IN 2091 01:22:24,040 --> 01:22:25,960 INCREASE FUNDING TO THE EXISTING 2092 01:22:25,960 --> 01:22:28,080 CENTERS BY TOTAL OF 2093 01:22:28,080 --> 01:22:28,800 $4.5 MILLION, THESE FUNDS COME 2094 01:22:28,800 --> 01:22:31,080 FROM OUR EXISTING BASE, NOT NEW 2095 01:22:31,080 --> 01:22:32,560 MONEY AND MADE POSSIBLE WITH 2096 01:22:32,560 --> 01:22:34,080 ADDITION OF NEW CO-FUNDING 2097 01:22:34,080 --> 01:22:35,440 INSTITUTES AND THE INCREASE IN 2098 01:22:35,440 --> 01:22:36,880 MINIMUM CO-FUNDING AMOUNT OF 1 2099 01:22:36,880 --> 01:22:37,600 MILLION-DOLLAR. 2100 01:22:37,600 --> 01:22:39,600 THIS IS A FEASIBLE CHANGE AND WE 2101 01:22:39,600 --> 01:22:41,160 WILL STILL RETAIN OUR 2102 01:22:41,160 --> 01:22:42,440 FLEXIBILITY TO FUND NEW CENTERS 2103 01:22:42,440 --> 01:22:45,240 AND TO MAKE SUPPLEMENTAL AWARDS 2104 01:22:45,240 --> 01:22:46,240 WITH ANY REMAINING FUNDS IN OUR 2105 01:22:46,240 --> 01:22:47,800 BASE. 2106 01:22:47,800 --> 01:22:50,680 NEXT SLIDE PLEASE. 2107 01:22:50,680 --> 01:22:53,120 THE NEXT PROPOSED CHANGE FOCUS 2108 01:22:53,120 --> 01:22:54,840 ON ENHANCING DIVERSITY EQUITY 2109 01:22:54,840 --> 01:22:56,760 INCLUSION IN THE CFAR PROGRAM, 2110 01:22:56,760 --> 01:22:57,560 WITH YOU HEARD ABOUT THAT TODAY 2111 01:22:57,560 --> 01:22:58,960 IN THE PRESENTATIONS. 2112 01:22:58,960 --> 01:23:02,160 THE CFARS ARE ENGAGED IN 2113 01:23:02,160 --> 01:23:03,880 DIVERSITY EQUITY INCLUSION 2114 01:23:03,880 --> 01:23:05,160 ACTIVITIES ON THE INDIVIDUAL 2115 01:23:05,160 --> 01:23:07,120 CFAR LEVEL AS WELL AS PROGRAM 2116 01:23:07,120 --> 01:23:10,680 WIDE EFFORTS TO EXAMPLES OF 2117 01:23:10,680 --> 01:23:14,120 WIDER EFFORTS CFARADELANTE WHICH 2118 01:23:14,120 --> 01:23:17,640 ENGAGES THE HISTOMA PANIC LATIN 2119 01:23:17,640 --> 01:23:19,560 COMMUNITIES MENTORS DECREASING 2120 01:23:19,560 --> 01:23:22,800 ON HIV RELATED HEALTH DISPARITY 2121 01:23:22,800 --> 01:23:23,880 ACE AMONG HISPANIC AND LATINX 2122 01:23:23,880 --> 01:23:24,920 PEOPLE. 2123 01:23:24,920 --> 01:23:26,840 THE GOAL OF THE CFAR PIPELINE 2124 01:23:26,840 --> 01:23:30,160 INITIATIVE IS INCREASE NUMBER OF 2125 01:23:30,160 --> 01:23:32,720 UNDER-REPRESENTED MINORS BLACK 2126 01:23:32,720 --> 01:23:35,800 PEOPLE INDIGENOUS, HIGH SCHOOL 2127 01:23:35,800 --> 01:23:38,160 GRADUATE POST GRADUATE AND 2128 01:23:38,160 --> 01:23:40,160 POST-DOCTORAL LEVELS AN LAUNCH 2129 01:23:40,160 --> 01:23:41,400 CAREERS IN SCIENCE AND MEDICINE. 2130 01:23:41,400 --> 01:23:42,640 THIS INCREASES COLLABORATION 2131 01:23:42,640 --> 01:23:47,040 WITH HBCUs AND OTHER MINORITY 2132 01:23:47,040 --> 01:23:48,160 SERVING INSTITUTIONS. 2133 01:23:48,160 --> 01:23:49,400 MORE THAN 25 SO FAR. 2134 01:23:49,400 --> 01:23:52,040 AND THIS IS ALSO COORDINATING 2135 01:23:52,040 --> 01:23:54,480 OUTREACH TO PLACES WE HAVEN'T 2136 01:23:54,480 --> 01:23:58,120 PREVIOUSLY ENGAGED. 2137 01:23:58,120 --> 01:24:01,800 SO FOR THIS ISSUE WE ISSUE I AM 2138 01:24:01,800 --> 01:24:02,920 PROPOSING ADDING A NEW COMPONENT 2139 01:24:02,920 --> 01:24:05,720 TO THE APPLICATION, DISCUSSED 2140 01:24:05,720 --> 01:24:07,040 PREVIOUSLY A ONE PAGE SCORABLE 2141 01:24:07,040 --> 01:24:09,720 PLAN FOR ENHANCING DIVERSE 2142 01:24:09,720 --> 01:24:10,680 PERSPECTIVES, THIS INITIALLY WAS 2143 01:24:10,680 --> 01:24:13,160 LAUNCHED BY THE BRAIN INITIATIVE 2144 01:24:13,160 --> 01:24:14,480 NATIONAL INSTITUTE NEUROLOGICAL 2145 01:24:14,480 --> 01:24:15,200 DISORDERS AND STROKE. 2146 01:24:15,200 --> 01:24:16,960 THIS COMPONENT IS NOW 2147 01:24:16,960 --> 01:24:18,800 REQUIREMENT IN 19 FUNDING 2148 01:24:18,800 --> 01:24:20,840 OPPORTUNITIES ACROSS 8 NIH 2149 01:24:20,840 --> 01:24:22,280 INSTITUTES, AND THE PLANS 2150 01:24:22,280 --> 01:24:24,040 RECOGNIZE DIVERSE TEAM WORKING 2151 01:24:24,040 --> 01:24:25,360 TOGETHER ON A PROBLEM 2152 01:24:25,360 --> 01:24:27,240 CAPITALIZING ON INNOVATIVE IDEAS 2153 01:24:27,240 --> 01:24:29,400 AND DISTINCT PERSPECTIVES 2154 01:24:29,400 --> 01:24:30,800 PERFORMS HOMOGENOUS TEAMS. 2155 01:24:30,800 --> 01:24:35,200 THE KEY ELEMENTS OF THE PDDP 2156 01:24:35,200 --> 01:24:37,680 INCLUDE RATIONALES AND TECHNICAL 2157 01:24:37,680 --> 01:24:39,000 MERIT OF PROGRAM THROUGH 2158 01:24:39,000 --> 01:24:40,480 EXPANDED ENINCLUSIVITY, THE TIME 2159 01:24:40,480 --> 01:24:42,040 LINE AND MILESTONES FOR THE PLAN 2160 01:24:42,040 --> 01:24:45,560 AND EVALUATIVE APPROACHES TO 2161 01:24:45,560 --> 01:24:46,880 MEASURE PROGRESS AND SUCCESS. 2162 01:24:46,880 --> 01:24:49,000 ADDING THIS COMPONENT TO THE D 2163 01:24:49,000 --> 01:24:52,080 CFAR AMPLYCATION WILL PROVIDE AM 2164 01:24:52,080 --> 01:24:53,080 APPLICATION WILL PROVIDE CLEAR 2165 01:24:53,080 --> 01:24:54,120 INSTRUCTIONS CRITERIA AND 2166 01:24:54,120 --> 01:24:56,160 INSTRUCTIONS FOR DEI EFFORTS 2167 01:24:56,160 --> 01:24:58,520 WITHIN INDIVIDUAL PROGRAM. 2168 01:24:58,520 --> 01:24:59,960 THE LONG TERM GOALS IN THIS 2169 01:24:59,960 --> 01:25:02,160 APPLICATION ELEMENT INCLUDE 2170 01:25:02,160 --> 01:25:03,840 INCREASE RECRUITMENT RETENTION 2171 01:25:03,840 --> 01:25:05,720 WITH FACULTY CFAR INSTITUTIONS 2172 01:25:05,720 --> 01:25:07,600 GREATER DIVERSITY IN COHORT 2173 01:25:07,600 --> 01:25:08,720 LEADERSHIP, MORE HIV APPLICATION 2174 01:25:08,720 --> 01:25:10,400 AND I WARD UNDER-REPRESENTED 2175 01:25:10,400 --> 01:25:12,320 INVESTIGATOR, AND EXPANSION 2176 01:25:12,320 --> 01:25:14,280 OFFER CREATION OF PROGRAMS 2177 01:25:14,280 --> 01:25:16,800 TARGETING HIV WORK FORCE 2178 01:25:16,800 --> 01:25:17,920 DIVERSITY. 2179 01:25:17,920 --> 01:25:20,040 TODAY I AM PROPOSING TWO CHANGES 2180 01:25:20,040 --> 01:25:22,600 TO CFAR CORES ONE CHANGE WILL 2181 01:25:22,600 --> 01:25:24,000 REPLACE CURRENT REQUIRED BASIC 2182 01:25:24,000 --> 01:25:25,400 SCIENCE WITH ADVANCED TECHNOLOGY 2183 01:25:25,400 --> 01:25:25,760 CORE. 2184 01:25:25,760 --> 01:25:27,320 THE CFAR WILL CONTINUE TO OFFER 2185 01:25:27,320 --> 01:25:31,240 HIGHLY UTILIZED BASIC SERVICES 2186 01:25:31,240 --> 01:25:32,760 BUT OFTEN SERVICES ARE HANDLED 2187 01:25:32,760 --> 01:25:34,080 BY INDIVIDUAL LABS OR 2188 01:25:34,080 --> 01:25:34,800 DEPARTMENTS. 2189 01:25:34,800 --> 01:25:35,880 WITH THIS CHANGE EMPHASIS WILL 2190 01:25:35,880 --> 01:25:37,920 BE ON INNOVATION AND ADVANCE 2191 01:25:37,920 --> 01:25:40,000 TECHNOLOGY SUCH AS SPECIALIZED 2192 01:25:40,000 --> 01:25:42,320 IMMUNOLOGY IMAGING MICROSCOPY 2193 01:25:42,320 --> 01:25:43,520 AND STRUCTURAL BIOLOGY. 2194 01:25:43,520 --> 01:25:46,120 TEN OF THE 19 CFARS HAVE THE 2195 01:25:46,120 --> 01:25:47,880 TYPE OF SPECIALIZED TECHNOLOGY 2196 01:25:47,880 --> 01:25:49,120 CORE ALREADY. 2197 01:25:49,120 --> 01:25:51,000 AS MENTIONED PREVIOUSLY THEY 2198 01:25:51,000 --> 01:25:52,040 INCREASINGLY ENGAGE IN 2199 01:25:52,040 --> 01:25:53,320 IMPLEMENTATION SCIENCE RESEARCH 2200 01:25:53,320 --> 01:25:55,280 AND CFAR INVESTIGATORS HAVE 2201 01:25:55,280 --> 01:25:57,000 GROWING NEED TO ACCESS EXPERTISE 2202 01:25:57,000 --> 01:25:58,520 AND CONSULTING SERVICES IN THIS 2203 01:25:58,520 --> 01:25:58,960 AREA. 2204 01:25:58,960 --> 01:26:00,280 WE ARE PROPOSING ADDING LANGUAGE 2205 01:26:00,280 --> 01:26:03,240 TO THIS REISSUE TO ENCOURAGE 2206 01:26:03,240 --> 01:26:04,720 APPLICANT TO ADD IMPLEMENTATION 2207 01:26:04,720 --> 01:26:06,720 SCIENCE CORE OR COMPONENT TO 2208 01:26:06,720 --> 01:26:07,440 EXISTING CORE SCIENTIFIC WORKING 2209 01:26:07,440 --> 01:26:09,120 GROUP. 2210 01:26:09,120 --> 01:26:10,800 AT THIS TIME FIVE CFARS HAVE 2211 01:26:10,800 --> 01:26:11,840 IMPLEMENTATION SCIENCE CORES AND 2212 01:26:11,840 --> 01:26:14,360 SIX HAVE EHE SCIENTIFIC WORKING 2213 01:26:14,360 --> 01:26:15,480 GROUPS WITH IMPLEMENTATION 2214 01:26:15,480 --> 01:26:18,080 SCIENCE COMPONENTS. 2215 01:26:18,080 --> 01:26:19,920 WE STOP SHORT OF REQUIREMENT AS 2216 01:26:19,920 --> 01:26:21,920 CFARS NEEDS TIME TO GATHER 2217 01:26:21,920 --> 01:26:23,360 EXPERTISE AT INSTITUTIONS. 2218 01:26:23,360 --> 01:26:25,160 WE FEEL IT IS AN IMPORTANT TO 2219 01:26:25,160 --> 01:26:26,240 SIGNAL INTEREST IN CFARS 2220 01:26:26,240 --> 01:26:28,200 PROVIDING A PLACE FOR THEIR 2221 01:26:28,200 --> 01:26:29,200 INVESTIGATORS CAN GET THIS KIND 2222 01:26:29,200 --> 01:26:32,320 OF SUPPORT FOR THEIR RESEARCH 2223 01:26:32,320 --> 01:26:35,640 PROJECTS. 2224 01:26:35,640 --> 01:26:37,040 CHANGE FOR THIS REISSUE U IN 2225 01:26:37,040 --> 01:26:38,160 RESPONSE TO RAPIDLY CHANGING 2226 01:26:38,160 --> 01:26:39,440 LANDSCAPE OF COLLABORATIVE 2227 01:26:39,440 --> 01:26:40,440 SCIENCE ESPECIALLY THE LAST TWO 2228 01:26:40,440 --> 01:26:41,080 AND A HALF YEARS. 2229 01:26:41,080 --> 01:26:42,880 WE ARE PROPOSING THAT 2230 01:26:42,880 --> 01:26:44,640 APPLICATIONS FROM GEOGRAPHICALLY 2231 01:26:44,640 --> 01:26:46,040 DISTANT MULTI-INSTITUTIONAL 2232 01:26:46,040 --> 01:26:47,680 CFARS BE CONSIDERED CFARS ARE 2233 01:26:47,680 --> 01:26:49,040 CENTERS AND HISTORICALLY HAVE 2234 01:26:49,040 --> 01:26:51,800 BEEN SUCCESSFUL IN SINGLE 2235 01:26:51,800 --> 01:26:52,480 INSTITUTION OR INSTITUTION IN 2236 01:26:52,480 --> 01:26:54,360 THE SAME CITY OR VERY CLOSE 2237 01:26:54,360 --> 01:26:54,760 NEIGHBOR. 2238 01:26:54,760 --> 01:26:56,440 RECENT WILL I THE TOOLS 2239 01:26:56,440 --> 01:26:57,160 COLLABORATION HAVE MADE IT 2240 01:26:57,160 --> 01:27:00,640 EASIER TO WORK TOGETHER AND 2241 01:27:00,640 --> 01:27:02,120 INTEGRATE EFFORTS AND TWO GROUPS 2242 01:27:02,120 --> 01:27:04,200 TEXAS D CFAR AND RUST BELT HAVE 2243 01:27:04,200 --> 01:27:05,840 SUCCESSFULLY COMPETED FOR 2244 01:27:05,840 --> 01:27:07,400 PROGRAM WITH 100 PLUS MILES 2245 01:27:07,400 --> 01:27:09,040 BETWEEN THEIR PARTNER 2246 01:27:09,040 --> 01:27:09,920 INSTITUTIONS. 2247 01:27:09,920 --> 01:27:11,120 THIS CHANGE CAN HELP ADDRESS THE 2248 01:27:11,120 --> 01:27:13,480 NEED FOR NEW CFAR PROGRAMS AND 2249 01:27:13,480 --> 01:27:14,720 CENTER OF THE COUNTRY AND AREAS 2250 01:27:14,720 --> 01:27:19,200 OF HIGH TRANSMISSION BURDEN. 2251 01:27:19,200 --> 01:27:24,520 I WANT TO THANK DR. AGARWAL AND 2252 01:27:24,520 --> 01:27:25,720 PETIFOR FOR REVIEWING THE 2253 01:27:25,720 --> 01:27:26,440 CONCEPTS. 2254 01:27:26,440 --> 01:27:27,800 EXPRESS SUPPORT FOR REISSUE OF 2255 01:27:27,800 --> 01:27:29,040 PROGRAMS HIGHLIGHTED A FEW OF 2256 01:27:29,040 --> 01:27:29,600 THEIR COMMENTS AND QUESTIONS 2257 01:27:29,600 --> 01:27:30,680 HERE. 2258 01:27:30,680 --> 01:27:32,960 ONE QUESTION WAS ABOUT COMPARING 2259 01:27:32,960 --> 01:27:35,120 THESE PROGRAMS TO OTHERS 2260 01:27:35,120 --> 01:27:36,440 REGARDING RETURN ON INVESTMENT 2261 01:27:36,440 --> 01:27:38,320 AND WHILE PILOT AWARDS ARE NOT 2262 01:27:38,320 --> 01:27:41,640 TRACKED WE BELIEVE THE CFAR ROI 2263 01:27:41,640 --> 01:27:43,360 IS COMPARABLE TO OTHER SIMILAR 2264 01:27:43,360 --> 01:27:43,640 PROGRAMS. 2265 01:27:43,640 --> 01:27:47,000 BOTH REVIEWERS WERE SUPPORTED OF 2266 01:27:47,000 --> 01:27:49,360 THE EDITION OF THE PDEP 2267 01:27:49,360 --> 01:27:50,680 REQUIREMENT BUT INDICATED 2268 01:27:50,680 --> 01:27:53,440 HELPFUL TO PROVIDE EXAMPLES TO 2269 01:27:53,440 --> 01:27:54,600 EMPHASIZE DIVERSITY SHOULD BE 2270 01:27:54,600 --> 01:27:55,840 INTERPRETED BROADLY AND WE 2271 01:27:55,840 --> 01:27:57,920 SHOULD STRIVE FOR FINDING THE 2272 01:27:57,920 --> 01:27:59,840 BALANCE BETWEEN TOO PRESCRIPTIVE 2273 01:27:59,840 --> 01:28:00,720 VERSUS NO SHARED UNDERSTANDING 2274 01:28:00,720 --> 01:28:01,520 BETWEEN APPLICANTS AND 2275 01:28:01,520 --> 01:28:02,800 REVIEWERS. 2276 01:28:02,800 --> 01:28:05,360 WE AGREE AND WE WILL PROVIDE 2277 01:28:05,360 --> 01:28:06,800 WHERE WE CAN WITHIN THE NIH WIDE 2278 01:28:06,800 --> 01:28:11,560 CONSTRAINTS ON THE USE OF PDPP 2279 01:28:11,560 --> 01:28:12,560 ELEMENT. 2280 01:28:12,560 --> 01:28:13,720 REGARDING THE CORE CHANGES ONE 2281 01:28:13,720 --> 01:28:15,400 QUESTION WAS WHETHER WE CONSIDER 2282 01:28:15,400 --> 01:28:16,560 REQUIRING THE IMPLEMENTATION 2283 01:28:16,560 --> 01:28:19,640 SCIENCE CORE AND AS I MENTIONED 2284 01:28:19,640 --> 01:28:20,480 WE PREFER AT THIS TIME TO START 2285 01:28:20,480 --> 01:28:21,960 WITH ENCOURAGING THIS TYPE OF 2286 01:28:21,960 --> 01:28:23,200 CORE RECOGNIZING THAT SOME 2287 01:28:23,200 --> 01:28:25,320 CENTERS ARE GOING TO NEED SOME 2288 01:28:25,320 --> 01:28:27,560 TIME TO DEVELOP CAPACITY TO DO 2289 01:28:27,560 --> 01:28:28,040 THIS. 2290 01:28:28,040 --> 01:28:30,720 THE FINAL COMMENT WAS GIVEN NIH 2291 01:28:30,720 --> 01:28:32,880 WITH NIH EMPHASIS ON BIG DATA, 2292 01:28:32,880 --> 01:28:34,320 DATA SCIENCE AND ARTIFICIAL 2293 01:28:34,320 --> 01:28:35,800 INTELLIGENCE, THE DATA SCIENCE 2294 01:28:35,800 --> 01:28:38,240 CORE COMPONENT COULD BE GOOD 2295 01:28:38,240 --> 01:28:38,760 ADDITION. 2296 01:28:38,760 --> 01:28:40,560 WE ENCOURAGE THESE TOPICS IN THE 2297 01:28:40,560 --> 01:28:44,320 PAR AS WELL. 2298 01:28:44,320 --> 01:28:46,800 THIS BRINGS ME BACK TO MY 2299 01:28:46,800 --> 01:28:47,440 SUMMARY SLIDE. 2300 01:28:47,440 --> 01:28:48,600 THANK YOU VERY MUCH FOR YOUR 2301 01:28:48,600 --> 01:28:50,920 ATTENTION TODAY AND I'M HAPPY TO 2302 01:28:50,920 --> 01:28:57,200 ANSWER ANY QUESTIONS YOU HAVE. 2303 01:28:57,200 --> 01:28:58,240 THANK YOU VERY MUCH. 2304 01:28:58,240 --> 01:29:00,040 WE ARE FAMILIAR WITH THE WORK IN 2305 01:29:00,040 --> 01:29:02,040 THE CFARS AND IMPRESSED FOR 2306 01:29:02,040 --> 01:29:03,320 MANY, MANY YEARS. 2307 01:29:03,320 --> 01:29:05,840 WE HAVE TIME FOR A FEW 2308 01:29:05,840 --> 01:29:06,320 QUESTIONS. 2309 01:29:06,320 --> 01:29:07,920 I SEE DR. WALLACE HAS A QUESTION 2310 01:29:07,920 --> 01:29:09,160 AND I KNOW THERE ARE AT LEAST A 2311 01:29:09,160 --> 01:29:12,720 COUPLE OF PEOPLE ON ARAC WHO ARE 2312 01:29:12,720 --> 01:29:14,560 CONFLICTED WITH THE CFARS SO I 2313 01:29:14,560 --> 01:29:17,000 WILL ASK YOU OF COURSE TO NOT 2314 01:29:17,000 --> 01:29:17,600 VOTE. 2315 01:29:17,600 --> 01:29:19,680 I THINK IT IS FINE FOR YOU TO BE 2316 01:29:19,680 --> 01:29:21,240 HERE BUT WITHOUT A VOTE ON THIS 2317 01:29:21,240 --> 01:29:22,400 ONE TO BE SURE. 2318 01:29:22,400 --> 01:29:24,520 DR. WALLACE. 2319 01:29:24,520 --> 01:29:25,600 >> THANK YOU. 2320 01:29:25,600 --> 01:29:29,760 I WON'T BE VOTING BUT WANT TO 2321 01:29:29,760 --> 01:29:32,880 ASK AND TO SAY THANK YOU, ERIC 2322 01:29:32,880 --> 01:29:33,480 FOR THIS. 2323 01:29:33,480 --> 01:29:35,280 I'M FAMILIAR WITH THE CFAR, WE 2324 01:29:35,280 --> 01:29:38,480 ARE OBVIOUSLY BEING WITH THE 2325 01:29:38,480 --> 01:29:41,480 CFAR BUT I'M SORT OF WONDERING 2326 01:29:41,480 --> 01:29:44,160 HAVE THERE BEEN ANY 2327 01:29:44,160 --> 01:29:45,760 CONVERSATIONS AT YOUR TEAM LEVEL 2328 01:29:45,760 --> 01:29:47,240 ABOUT THE CHALLENGES THAT SOME 2329 01:29:47,240 --> 01:29:48,720 HAVE HAD WITH MAINTAINING 2330 01:29:48,720 --> 01:29:51,400 COMMUNITY ENGAGEMENT MECHANISMS? 2331 01:29:51,400 --> 01:29:53,600 RECOGNIZING THAT SOME CFARS HAVE 2332 01:29:53,600 --> 01:29:56,920 HAD SIGNIFICANT CHALLENGES 2333 01:29:56,920 --> 01:29:58,040 MAINTAINING CABS AND WHAT 2334 01:29:58,040 --> 01:29:59,160 SUPPORT YOUR TEAM OR OFFICE 2335 01:29:59,160 --> 01:30:02,680 MIGHT BE ABLE TO PROVIDE TO THEM 2336 01:30:02,680 --> 01:30:03,560 REGARDING THAT. 2337 01:30:03,560 --> 01:30:07,320 >> THANK YOU FOR THAT QUESTION. 2338 01:30:07,320 --> 01:30:11,120 THAT HAS COME UP AND WE HAVE 2339 01:30:11,120 --> 01:30:13,800 BEEN DISCUSSING AROUND THAT 2340 01:30:13,800 --> 01:30:16,160 ISSUE AND HOW BEST TO WORK ON 2341 01:30:16,160 --> 01:30:18,240 COMMUNITY ENGAGEMENT WITHIN THE 2342 01:30:18,240 --> 01:30:20,080 CFAR. 2343 01:30:20,080 --> 01:30:23,240 THERE IS THE NCCC ORGANIZATION 2344 01:30:23,240 --> 01:30:26,680 THAT WORKS IN THE CFAR COMMUNITY 2345 01:30:26,680 --> 01:30:27,080 ENGAGEMENT. 2346 01:30:27,080 --> 01:30:29,280 BUT I THINK IF THERE ARE ISSUES 2347 01:30:29,280 --> 01:30:30,520 I THINK THAT THAT IS SOMETHING 2348 01:30:30,520 --> 01:30:33,320 THAT WE DEFINITELY NEED TO VISIT 2349 01:30:33,320 --> 01:30:38,720 AND FIGURE OUT IF THERE ARE 2350 01:30:38,720 --> 01:30:39,760 CFARS BEING VERY SUCCESSFUL WHAT 2351 01:30:39,760 --> 01:30:43,600 THEY ARE DOING AT THEIR 2352 01:30:43,600 --> 01:30:44,800 INSTITUTIONS TO ACCOMPLISH IT. 2353 01:30:44,800 --> 01:30:46,440 IT IS A VERY IMPORTANT ISSUE 2354 01:30:46,440 --> 01:30:48,360 BROUGHT UP AND WILL CERTAINLY 2355 01:30:48,360 --> 01:30:50,120 TRY TO FIGURE OUT HOW BEST TO DO 2356 01:30:50,120 --> 01:31:00,200 THAT. 2357 01:31:05,120 --> 01:31:06,640 >> OTHER QUESTIONS? 2358 01:31:06,640 --> 01:31:08,240 ERIC QUICK QUESTION. 2359 01:31:08,240 --> 01:31:11,040 IN TERMS OF EVALUATION OF THE 2360 01:31:11,040 --> 01:31:12,800 PEDP EFFORTS, I THINK ONE OF 2361 01:31:12,800 --> 01:31:17,560 YOUR SLIDES HAS A BULLET ABOUT 2362 01:31:17,560 --> 01:31:18,760 MEASURABLE END POINTS OR 2363 01:31:18,760 --> 01:31:19,040 OUTCOMES. 2364 01:31:19,040 --> 01:31:23,680 DO YOU HAVE A SENSE OF HOW WE 2365 01:31:23,680 --> 01:31:25,800 KNOW WE HAVE NOT HAD GREAT 2366 01:31:25,800 --> 01:31:28,760 SUCCESS AS ORGANIZATIONS OR CARL 2367 01:31:28,760 --> 01:31:33,040 REFERRED EARLIER I THINK ABYSMAL 2368 01:31:33,040 --> 01:31:35,320 WAS USED. 2369 01:31:35,320 --> 01:31:38,720 HOW WILL THOSE GOAL POSTS BE 2370 01:31:38,720 --> 01:31:41,640 ESTABLISHED FOR THESE PROGRAMS. 2371 01:31:41,640 --> 01:31:44,080 >> THAT IS A GREAT QUESTION. 2372 01:31:44,080 --> 01:31:46,000 WE ARE FORTUNATE IN THAT THESE 2373 01:31:46,000 --> 01:31:47,840 OTHER ICs ARE STARTING TO 2374 01:31:47,840 --> 01:31:49,320 ALREADY DO THIS IN THEIR 2375 01:31:49,320 --> 01:31:52,520 APPLICATIONS ARE BEING REVIEWED 2376 01:31:52,520 --> 01:31:54,440 AND APPLICANTS ARE PUTTING 2377 01:31:54,440 --> 01:31:57,880 TOGETHER THEIR PLANS, NONE WILL 2378 01:31:57,880 --> 01:31:59,600 BE EXACTLY ALIKE SO BY THE TIME 2379 01:31:59,600 --> 01:32:02,800 THIS IS INCORPORATED INTO THE 2380 01:32:02,800 --> 01:32:05,360 CFAR PROGRAM AND PAR WE WILL 2381 01:32:05,360 --> 01:32:07,240 HAVE QUITE A BIT OF INFORMATION 2382 01:32:07,240 --> 01:32:10,040 ON HOW TO DO THAT AND WE ARE IN 2383 01:32:10,040 --> 01:32:11,680 CLOSE CONTACT WITH THOSE 2384 01:32:11,680 --> 01:32:14,880 INSTITUTES THAT ARE ROLLING IT 2385 01:32:14,880 --> 01:32:16,680 OUT ALREADY AND I THINK THAT WE 2386 01:32:16,680 --> 01:32:18,160 HAVE A LOT TO LEARN ABOUT THAT. 2387 01:32:18,160 --> 01:32:20,360 IT IS A LEARNING PROCESS FOR 2388 01:32:20,360 --> 01:32:22,480 EVERYBODY INVOLVED. 2389 01:32:22,480 --> 01:32:24,320 BECAUSE AS CARL MENTIONED YOU 2390 01:32:24,320 --> 01:32:29,120 MENTIONED I THINK THERE IS A LOT 2391 01:32:29,120 --> 01:32:30,400 OF NEED TO IMPROVE IN THIS AREA. 2392 01:32:30,400 --> 01:32:32,640 THAT IS OUR APPROACH, TO JUST 2393 01:32:32,640 --> 01:32:36,040 LEAN HEAVILY AND REACH OUT AND 2394 01:32:36,040 --> 01:32:38,960 TALK TO OUR COLLEAGUES ACROSS 2395 01:32:38,960 --> 01:32:40,280 DIFFERENT ICs TO COME UP WITH 2396 01:32:40,280 --> 01:32:44,240 OUR PLAN FOR THAT. 2397 01:32:44,240 --> 01:32:45,880 >> THANK YOU. 2398 01:32:45,880 --> 01:32:48,000 OTHER COMMENTS OR QUESTIONS? 2399 01:32:48,000 --> 01:32:49,880 LET ME REMIND PEOPLE THERE ARE 2400 01:32:49,880 --> 01:32:50,800 TWO VOTES HERE. 2401 01:32:50,800 --> 01:32:52,880 NUMBER THREE IS FOR THE CFARS 2402 01:32:52,880 --> 01:32:54,880 AND NUMBER 4 IS FOR THE D CFARS 2403 01:32:54,880 --> 01:32:58,880 SO MAKE SURE TO MARK BOTH ON 2404 01:32:58,880 --> 01:33:04,560 YOUR BALLOTS PLEASE. 2405 01:33:04,560 --> 01:33:08,080 ALL RIGHT. 2406 01:33:08,080 --> 01:33:09,200 I DON'T SEE ADDITIONAL 2407 01:33:09,200 --> 01:33:09,600 QUESTIONS. 2408 01:33:09,600 --> 01:33:11,640 THANK YOU, DR. REFSLAND. 2409 01:33:11,640 --> 01:33:12,880 WE ARE FOR THE FIRST TIME 2410 01:33:12,880 --> 01:33:15,560 CERTAINLY IN MY TENURE I THINK 2411 01:33:15,560 --> 01:33:19,040 TEN MINUTES AHEAD OF SCHEDULE IS 2412 01:33:19,040 --> 01:33:19,360 THAT RIGHT? 2413 01:33:19,360 --> 01:33:20,920 20 MINUTES AHEAD OF SCHEDULE? 2414 01:33:20,920 --> 01:33:24,760 DID WE FORGET AN ENTIRE 2415 01:33:24,760 --> 01:33:26,200 PRESENTATION? 2416 01:33:26,200 --> 01:33:26,920 THAT WOULD BE MOST LIKELY FOR 2417 01:33:26,920 --> 01:33:28,080 ME. 2418 01:33:28,080 --> 01:33:31,360 BUT I DON'T BELIEVE WE DID. 2419 01:33:31,360 --> 01:33:31,840 SO ALL RIGHT. 2420 01:33:31,840 --> 01:33:34,920 WHY DON'T WE TAKE A BREAK FOR 2421 01:33:34,920 --> 01:33:39,360 SHOULD WE JUST TAKE TEN MINUTES? 2422 01:33:39,360 --> 01:33:41,920 >> TEN MINUTES. 2423 01:33:41,920 --> 01:33:44,080 >> WE'LL COME BACK AT 2:45. 2424 01:33:44,080 --> 01:33:46,080 SO REVISE YOUR SCHEDULE TO MOVE 2425 01:33:46,080 --> 01:33:46,840 UP 20 MINUTES EVERYONE. 2426 01:33:46,840 --> 01:33:50,680 THANK YOU. 2427 01:33:50,680 --> 01:33:51,280 WELCOME. 2428 01:33:51,280 --> 01:33:54,080 PEOPLE MANAGE TO STAND UP AT 2429 01:33:54,080 --> 01:33:56,120 LEAST IF NOT MOVE AROUND A 2430 01:33:56,120 --> 01:33:56,640 LITTLE BIT. 2431 01:33:56,640 --> 01:33:59,760 AND SO WE WILL CONTINUE. 2432 01:33:59,760 --> 01:34:04,600 WE HAVE GAINED 18 MINUTES ON OUR 2433 01:34:04,600 --> 01:34:06,360 SCHEDULE, IT LOOKS PER CHAT LIKE 2434 01:34:06,360 --> 01:34:08,640 ALL THE PEOPLE WHO WILL BE 2435 01:34:08,640 --> 01:34:10,200 PRESENTING ARE AVAILABLE. 2436 01:34:10,200 --> 01:34:12,840 SO IF YOU ARE ABLE TO DO THE 2437 01:34:12,840 --> 01:34:15,200 MATH, IT IS A LITTLE 2438 01:34:15,200 --> 01:34:17,440 COMPLICATED, TO MOVE AHEAD TO 2439 01:34:17,440 --> 01:34:21,200 STARTING WITH OUR NEXT 2440 01:34:21,200 --> 01:34:21,560 PRESENTATION. 2441 01:34:21,560 --> 01:34:24,760 WHICH WILL BE THE THERAPEUTICS 2442 01:34:24,760 --> 01:34:26,960 RESEARCH PROGRAM AND BOB MAHON 2443 01:34:26,960 --> 01:34:30,720 WILL BE PRESENTING ON ANALYZING 2444 01:34:30,720 --> 01:34:33,400 EARLY EVENTS IN TUBERCULOSIS AND 2445 01:34:33,400 --> 01:34:36,480 TB HIV INFECTION TO IDENTIFY 2446 01:34:36,480 --> 01:34:37,640 INTERVENTIONAL TARGETS RO1. 2447 01:34:37,640 --> 01:34:43,520 THANK YOU, DR. MAHON. 2448 01:34:43,520 --> 01:34:44,560 >> THANK YOU. 2449 01:34:44,560 --> 01:34:46,200 TB CLINICAL RESEARCH BRANCH 2450 01:34:46,200 --> 01:34:51,840 WITHIN TRP AND TODAY I WILL BE 2451 01:34:51,840 --> 01:34:53,240 PRESENTING OUR POTENTIAL 2452 01:34:53,240 --> 01:34:54,600 INITIATIVES SO THE OBJECTIVE OF 2453 01:34:54,600 --> 01:34:57,240 THIS INITIATIVE IS TO IDENTIFY 2454 01:34:57,240 --> 01:34:59,880 ESSENTIAL IMMUNOPATHOGENESIS 2455 01:34:59,880 --> 01:35:02,720 MECHANISMS IN EARLY NTB AND TB 2456 01:35:02,720 --> 01:35:04,920 HIV INFECTION TO IDENTIFY NOVEL 2457 01:35:04,920 --> 01:35:06,520 TARGETS FOR HOST DIRECTED 2458 01:35:06,520 --> 01:35:06,920 INTERVENTION. 2459 01:35:06,920 --> 01:35:08,640 THIS WOULD BE A NEW RO1 2460 01:35:08,640 --> 01:35:09,760 MECHANISM WITH ANTICIPATED 2461 01:35:09,760 --> 01:35:12,640 NUMBER OF APPLICATIONS BEING 8 2462 01:35:12,640 --> 01:35:14,640 TO 11 AND AWARD -- NUMBER OF 2463 01:35:14,640 --> 01:35:15,880 AWARDS BEING 3 TO 4. 2464 01:35:15,880 --> 01:35:18,680 WE HAVE POTENTIAL PARTNERS IN 2465 01:35:18,680 --> 01:35:20,320 DMID DEPENDING ON TYPE OF 2466 01:35:20,320 --> 01:35:27,560 APPLICATIONS WE RECEIVE. 2467 01:35:27,560 --> 01:35:29,320 SO AS WE ALWAYS WANT TO STATE 2468 01:35:29,320 --> 01:35:31,440 WHEN WE ARE TALKING TB IN HIV 2469 01:35:31,440 --> 01:35:33,200 AUDIENCE, PEOPLE LIVING WITH HIV 2470 01:35:33,200 --> 01:35:35,840 ARE INCREASE RISK OF TB DISEASE 2471 01:35:35,840 --> 01:35:37,800 AND RECURRENCE REINFECTION AND 2472 01:35:37,800 --> 01:35:39,600 TREATMENT OUTCOMES AND WE NEED 2473 01:35:39,600 --> 01:35:41,360 NEW THERAPEUTICS AND PREVENTIVE 2474 01:35:41,360 --> 01:35:43,120 STRATEGIES TO PREVENT IMPROVE 2475 01:35:43,120 --> 01:35:44,360 PREVENTION TREATMENT OUTCOMES, 2476 01:35:44,360 --> 01:35:45,920 WE NEED TO KNOW THAT THEY ARE 2477 01:35:45,920 --> 01:35:48,320 GOING TO BE INFECTIVE IN TB AS 2478 01:35:48,320 --> 01:35:50,120 WITH TB AND HIV. 2479 01:35:50,120 --> 01:35:51,800 WITH THIS SPECIFIC INITIATIVE 2480 01:35:51,800 --> 01:35:54,240 SINCE TB INFECTED INDIVIDUALS 2481 01:35:54,240 --> 01:35:56,800 ARE OBSERVED OR ONLY SEEN WELL 2482 01:35:56,800 --> 01:36:00,000 INTO THEIR INFECTION WITH 2483 01:36:00,000 --> 01:36:03,200 LATENCY OR LEE ACTIVATED 2484 01:36:03,200 --> 01:36:06,920 DISEASE, THE EARLY TB INFECTION 2485 01:36:06,920 --> 01:36:11,920 ARE NOT WELL THERAPY OF HTB HOST 2486 01:36:11,920 --> 01:36:13,720 DIRECTED THERAPEUTIC STUDY. 2487 01:36:13,720 --> 01:36:15,840 THE FIRST FEW WEEKS ARE CRUCIAL 2488 01:36:15,840 --> 01:36:17,560 DETERMINING EFFECTIVENESS OF THE 2489 01:36:17,560 --> 01:36:20,360 IMMUNOLOGICAL RESPONSE TO 2490 01:36:20,360 --> 01:36:22,880 MYCOBACTERIUM TUBERCULOSIS IN TB 2491 01:36:22,880 --> 01:36:26,080 AND THE CLINICAL OUTCOME, 2492 01:36:26,080 --> 01:36:29,600 CONTAINS CLINICALLY LATENT 2493 01:36:29,600 --> 01:36:29,840 DISEASE. 2494 01:36:29,840 --> 01:36:33,440 TWO AREAS WE SEE ARE GAP IN 2495 01:36:33,440 --> 01:36:35,440 OPPORTUNITIES DISTINCT MYELOID 2496 01:36:35,440 --> 01:36:36,760 LYMPHOID CELLS THAT PLAY CENTRAL 2497 01:36:36,760 --> 01:36:38,320 ROLES IN THE OUTCOME BEFORE THE 2498 01:36:38,320 --> 01:36:40,520 DEVELOPMENT OF ADAPTIVE IMMUNE 2499 01:36:40,520 --> 01:36:43,920 RESPONSES, AND THE HOW MTB IS 2500 01:36:43,920 --> 01:36:44,880 SUPPRESSING THE FUNCTION DURING 2501 01:36:44,880 --> 01:36:46,720 THIS PERIOD FOR SURVIVAL. 2502 01:36:46,720 --> 01:36:47,840 FURTHER ELUCIDATION OF THESE 2503 01:36:47,840 --> 01:36:55,520 EVANS WILL IDENTIFY TARGETS WHY 2504 01:36:55,520 --> 01:36:57,200 WE THINK NOW IS THE TIME FOR 2505 01:36:57,200 --> 01:36:59,040 THIS TYPE OF INITIATIVE. 2506 01:36:59,040 --> 01:37:02,040 SO SIV AND HIV INNATE IMMUNITY 2507 01:37:02,040 --> 01:37:03,720 INVOLVED IN MANY EARLY MTB 2508 01:37:03,720 --> 01:37:04,840 INFECTION WITHIN THE LUNG. 2509 01:37:04,840 --> 01:37:08,520 THE FIRST IMMUNE CELLS MTB COMES 2510 01:37:08,520 --> 01:37:10,640 IN CONTACT WITH DURING INFECTION 2511 01:37:10,640 --> 01:37:11,920 ARE MAY CASH FLOW PHAGOS THAT 2512 01:37:11,920 --> 01:37:15,880 SURVEY THE AIRWAY AND PROTECT 2513 01:37:15,880 --> 01:37:17,120 AGAINST FOREIGN PARTICLES 2514 01:37:17,120 --> 01:37:19,480 ANTIGENS AND PATHOGENS AND 2515 01:37:19,480 --> 01:37:22,320 REMOVE THESE ENTITIES THROUGH 2516 01:37:22,320 --> 01:37:24,000 PHAGOCYTOSIS WE LIMBNATING 2517 01:37:24,000 --> 01:37:25,160 INFLAMMATORY RESPONSE SO 2518 01:37:25,160 --> 01:37:26,280 PROTECTS AGAINST TISSUE DAMAGE 2519 01:37:26,280 --> 01:37:29,080 FOR THE LUNG AND AIRWAY. 2520 01:37:29,080 --> 01:37:30,200 OBVIOUSLY YOU CAN IMAGINE 2521 01:37:30,200 --> 01:37:32,640 PATHOGENS EXPLOIT THESE CELLS 2522 01:37:32,640 --> 01:37:35,400 MTB AND HIV ARE NO EXEMPTION AND 2523 01:37:35,400 --> 01:37:38,000 -- EXCEPTION AND FOR THEIR OWN 2524 01:37:38,000 --> 01:37:41,320 SURVIVAL AND HIV ANDSIVE IMPACTS 2525 01:37:41,320 --> 01:37:43,320 MACROPHAGE AND IN ADDITION CAN 2526 01:37:43,320 --> 01:37:45,040 INCREASE MTB REPLICATION. 2527 01:37:45,040 --> 01:37:47,320 IT DOES THIS THROUGH SEVERAL 2528 01:37:47,320 --> 01:37:48,680 MECHANISMS OUTLINE MISDEMEANOR 2529 01:37:48,680 --> 01:37:49,920 THE FIGURE INCLUDING THE 2530 01:37:49,920 --> 01:37:52,760 SUPPRESSION OF RECEPTORS ON THE 2531 01:37:52,760 --> 01:37:55,120 MACROPHAGE THAT RECOGNIZE MTB 2532 01:37:55,120 --> 01:37:58,280 INHADN'TING PHAGOCYTOSIS AND 2533 01:37:58,280 --> 01:37:59,880 PHAGOLYSOSOMAL FUSION AS WELL AS 2534 01:37:59,880 --> 01:38:01,000 INHEIGHTING T-CELL ACTIVATION 2535 01:38:01,000 --> 01:38:04,600 THROUGH SUPPRESSION OF ANTIGEN 2536 01:38:04,600 --> 01:38:07,200 PRESENTATION AND FACTORS ON 2537 01:38:07,200 --> 01:38:09,560 T-CELLS AND FURTHERMORE IMPAIRS 2538 01:38:09,560 --> 01:38:11,120 ANTIOXIDANT DEFENSES INCREASING 2539 01:38:11,120 --> 01:38:12,600 OXIDATIVE STRESS AND INHIBITS 2540 01:38:12,600 --> 01:38:14,040 APOPTOSIS. 2541 01:38:14,040 --> 01:38:16,800 IN ADDITION TO MACROPHAGES AND 2542 01:38:16,800 --> 01:38:19,600 HIV ALSO INHIBITS THE ANTIGEN 2543 01:38:19,600 --> 01:38:21,320 PRESENTING CELL FUNCTIONS OF 2544 01:38:21,320 --> 01:38:23,680 ANOTHER APC DENDRITIC CELLS 2545 01:38:23,680 --> 01:38:25,200 WHICH CAN FURTHER EXACERBATE 2546 01:38:25,200 --> 01:38:28,200 DELAY AND MTB INDUCED T-CELL 2547 01:38:28,200 --> 01:38:28,680 RESPONSES. 2548 01:38:28,680 --> 01:38:32,520 THIS HAS NOT BEEN WELL OR EVEN 2549 01:38:32,520 --> 01:38:35,040 PERFECTIVELY STUDIED IN CONTEXT 2550 01:38:35,040 --> 01:38:37,240 OF NATURAL HIV ESTABLISHED HIV 2551 01:38:37,240 --> 01:38:39,880 INFECTION IN NEW NTB INFECTION 2552 01:38:39,880 --> 01:38:41,800 BUT THERE ARE THEORETICAL MODELS 2553 01:38:41,800 --> 01:38:43,040 SUGGESTING THESE DEFECTS CAN 2554 01:38:43,040 --> 01:38:45,240 LEAD TO HIGHER MTB BURDENS 2555 01:38:45,240 --> 01:38:48,160 WITHIN FIRST FEW WEEKS OF 2556 01:38:48,160 --> 01:38:49,640 INFECTION BEFORE T-CELL RESPONSE 2557 01:38:49,640 --> 01:38:52,520 REALLY IS KICKED INTO GEAR. 2558 01:38:52,520 --> 01:38:55,280 THE DEPLETED T-CELLS WITHIN HIV 2559 01:38:55,280 --> 01:38:57,080 INDIVIDUAL INCREASES THE RISK OF 2560 01:38:57,080 --> 01:38:58,360 ACTIVE DISEASE. 2561 01:38:58,360 --> 01:39:00,120 SO WE ARE WITH THIS INITIATIVE 2562 01:39:00,120 --> 01:39:02,960 WE WANT TO SIMULATE AREAS THIS 2563 01:39:02,960 --> 01:39:06,160 AREA OF RESEARCH NEW TB 2564 01:39:06,160 --> 01:39:07,400 INFECTIONS IN ESTABLISHED HIV 2565 01:39:07,400 --> 01:39:08,520 COHORT. 2566 01:39:08,520 --> 01:39:14,440 OR ANIMALS. 2567 01:39:14,440 --> 01:39:16,600 SO THE MOST EXCITING INTERESTING 2568 01:39:16,600 --> 01:39:20,400 MTB RESEARCH CURRENTLY IS IN THE 2569 01:39:20,400 --> 01:39:23,240 WORK ON ENHANCING THE ACTIVITY 2570 01:39:23,240 --> 01:39:26,160 OF EFFECTIVENESS OF ONLY 2571 01:39:26,160 --> 01:39:28,480 APPROVED VACCINE FOR MTB KNOWN 2572 01:39:28,480 --> 01:39:33,920 AS MYCOBACTERIUM AS A RESULT 2573 01:39:33,920 --> 01:39:36,520 VIES BCG, GIVEN IN NEWBORN AND 2574 01:39:36,520 --> 01:39:39,880 INFANTS, PROTECTIVE AGAINST 2575 01:39:39,880 --> 01:39:42,560 EXTRA PULMONARY DISEASE BUT ONCE 2576 01:39:42,560 --> 01:39:44,240 REACHES ADOLESCENTS INTO 2577 01:39:44,240 --> 01:39:45,240 ADULTHOOD IT LOSES 2578 01:39:45,240 --> 01:39:45,600 EFFECTIVENESS. 2579 01:39:45,600 --> 01:39:48,000 SO THERE'S STRATEGIES, ONES THAT 2580 01:39:48,000 --> 01:39:50,000 RESEARCHERS ARE USING TO ENHANCE 2581 01:39:50,000 --> 01:39:51,440 THE ACTIVITY, I WANT TO 2582 01:39:51,440 --> 01:39:53,120 HIGHLIGHT ONE IN PARTICULAR 2583 01:39:53,120 --> 01:39:55,320 TODAY AND HOW IT TIES TO WHAT 2584 01:39:55,320 --> 01:39:57,320 INITIATIVE IS FOCUSED ON AND 2585 01:39:57,320 --> 01:39:59,880 THAT IS WHERE DR. STEVE AND 2586 01:39:59,880 --> 01:40:01,240 CARTER WHICH ARE TRYING TO 2587 01:40:01,240 --> 01:40:03,800 ADDRESS THE BOTTLENECK OBSERVED 2588 01:40:03,800 --> 01:40:05,600 WITH THE INABILITY TO ACTIVATE 2589 01:40:05,600 --> 01:40:08,640 T-CELLS IN A TIMELY FASHION BY 2590 01:40:08,640 --> 01:40:11,480 PULSING ECG VACCINATED MICE WITH 2591 01:40:11,480 --> 01:40:14,240 DENDRITIC CELLS THAT CONTAIN MTB 2592 01:40:14,240 --> 01:40:16,040 ANTIGEN PRIOR TO AND SOON AFTER 2593 01:40:16,040 --> 01:40:19,560 THE NTB CHALLENGE AND TO GET A 2594 01:40:19,560 --> 01:40:20,680 BETTER IMMUNE RESPONSE. 2595 01:40:20,680 --> 01:40:23,240 SO PREVIOUS THIS IS NEW 2596 01:40:23,240 --> 01:40:28,640 PUBLISHED IN 2021, PRIOR TO THIS 2597 01:40:28,640 --> 01:40:29,440 RESEARCH PULSE DENDRITIC CELLS 2598 01:40:29,440 --> 01:40:32,520 SHOW INDUCE THAT STRONGER FASTER 2599 01:40:32,520 --> 01:40:33,880 T-CELL RESPONSE RELATED TO 2600 01:40:33,880 --> 01:40:35,880 ALMOST COMPLETE CONTROL OF MTB 2601 01:40:35,880 --> 01:40:38,920 EARLY AFTER INFECTION IN THESE 2602 01:40:38,920 --> 01:40:40,480 PULSE MICE. 2603 01:40:40,480 --> 01:40:41,720 INCREASE WHAT THEY FOUND 2604 01:40:41,720 --> 01:40:43,320 SUBSEQUENTLY NOW, IS THAT THERE 2605 01:40:43,320 --> 01:40:45,400 IS INCREASE IN ALVEOLAR 2606 01:40:45,400 --> 01:40:47,560 MACROPHAGE ACCUMULATION IN EARLY 2607 01:40:47,560 --> 01:40:49,640 CD4 T-CELL LOCALIZATION IN THE 2608 01:40:49,640 --> 01:40:52,000 PARENCHYMA AIRWAYS. 2609 01:40:52,000 --> 01:40:54,720 FOR OUR SAKE NF KAPPA B 2610 01:40:54,720 --> 01:40:58,040 SIGNALING BY TYPE 2 ALVEOLAR 2611 01:40:58,040 --> 01:41:00,960 EPITHELIAL CELLS IS REQUIRED FOR 2612 01:41:00,960 --> 01:41:03,040 PULSE DENDRITIC CELL CONTROL 2613 01:41:03,040 --> 01:41:03,960 MTB. 2614 01:41:03,960 --> 01:41:06,080 MECHANISM IS NOT EXACTLY CLEAR 2615 01:41:06,080 --> 01:41:07,520 ONLY SHOWN IN KNOCK OUT STUDIES 2616 01:41:07,520 --> 01:41:09,880 SO THIS IS THE TYPE OF STUDY HOW 2617 01:41:09,880 --> 01:41:12,520 EXACTLY ARE INTERACTIONS WITH 2618 01:41:12,520 --> 01:41:15,120 DENDRITIC CELLS IN EPITHELIA 2619 01:41:15,120 --> 01:41:17,520 CELLS PRODUCING STRONGER T-CELL 2620 01:41:17,520 --> 01:41:19,560 RESPONSE OUR INITIATIVE WOULD BE 2621 01:41:19,560 --> 01:41:21,320 WANTING TO SUPPORT. 2622 01:41:21,320 --> 01:41:24,600 SO IN ADDITION TO THE WORK WITH 2623 01:41:24,600 --> 01:41:25,800 VACCINATIONS WE ARE ALSO 2624 01:41:25,800 --> 01:41:28,800 LEARNING THE PAST FEW YEARS THAT 2625 01:41:28,800 --> 01:41:30,720 PREVIOUSLY UNTHOUGHT OF IMMUNE 2626 01:41:30,720 --> 01:41:33,080 CELLS AND HAVING A ROLE IN NTB 2627 01:41:33,080 --> 01:41:35,040 HAVE A PROFOUND EFFECT AND 2628 01:41:35,040 --> 01:41:36,920 SIGNIFICANT ROLE IN CONTROLLING 2629 01:41:36,920 --> 01:41:37,520 TB. 2630 01:41:37,520 --> 01:41:39,400 SO THE TWO I WANT TO HIGHLIGHT 2631 01:41:39,400 --> 01:41:41,960 MOST RECENT NOTE ARE EOSINOPHILS 2632 01:41:41,960 --> 01:41:46,040 AND INNATE LYMPHOID CELLS SO 2633 01:41:46,040 --> 01:41:48,120 EOSINOPHILS FROM GROUP HERE IN 2634 01:41:48,120 --> 01:41:50,120 NIAID SHOWN IN ABSENCE OF 2635 01:41:50,120 --> 01:41:51,960 EOSINOPHILS THERE IS INCREASE 2636 01:41:51,960 --> 01:41:55,720 CFU COUNTS AND AS SHOWN HERE 2637 01:41:55,720 --> 01:41:57,600 SIGNIFICANTLY VALID COMPARED TO 2638 01:41:57,600 --> 01:42:00,280 WILD TYPE AND THERE INDUCTION IN 2639 01:42:00,280 --> 01:42:01,400 EOSINOPHIL WITNESS THE FIRST 2640 01:42:01,400 --> 01:42:02,840 FIVE DAYS OF THE INFECTION 2641 01:42:02,840 --> 01:42:04,440 COMPARED TO NEUTROPHILS WHICH 2642 01:42:04,440 --> 01:42:06,640 COME OUT AND IS NOT HERE IN THIS 2643 01:42:06,640 --> 01:42:09,040 FIGURE BUT 15 TO 20 DAYS LATER. 2644 01:42:09,040 --> 01:42:10,880 INNATE LYMPHOID CELLS 2645 01:42:10,880 --> 01:42:12,800 SPECIFICALLY ILC 3s SIMILAR 2646 01:42:12,800 --> 01:42:23,560 EFFECTS WHETHER INCREASE WITH TE 2647 01:42:59,720 --> 01:43:02,160 WHAT WE ARE ULTIMATELY WANTING 2648 01:43:02,160 --> 01:43:04,160 TO DO IS REFOCUS OUR ATTENTION 2649 01:43:04,160 --> 01:43:07,040 TO THE EARLY NTB INFECTION FROM 2650 01:43:07,040 --> 01:43:08,440 WHERE HOST DIRECTED THERAPEUTIC 2651 01:43:08,440 --> 01:43:10,200 RESEARCH IS PRIMARILY BEEN 2652 01:43:10,200 --> 01:43:12,520 FOCUSED ON THAT BEING THE 2653 01:43:12,520 --> 01:43:14,040 GRANULOMA IN ACTIVE TB. 2654 01:43:14,040 --> 01:43:16,800 WE THINK THAT WHILE THIS IS 2655 01:43:16,800 --> 01:43:19,520 IMPORTANT, THESE EARLIER EVENTS, 2656 01:43:19,520 --> 01:43:21,640 THERE'S ACTIVE INCREDIBLY ACTIVE 2657 01:43:21,640 --> 01:43:23,040 IMMUNOLOGICAL PERIOD WITH 2658 01:43:23,040 --> 01:43:24,640 MYELOID LYMPHOID CELLS PLAYING A 2659 01:43:24,640 --> 01:43:26,440 CENTRAL ROLE IN CONTROLLING THE 2660 01:43:26,440 --> 01:43:28,640 INFECTION WHILE NTB IS 2661 01:43:28,640 --> 01:43:30,440 SUPPRESSING KEY IMMUNE FOR 2662 01:43:30,440 --> 01:43:32,400 SURVIVAL AND THIS IS AN 2663 01:43:32,400 --> 01:43:34,040 UNEXPLORED AND IMPORTANT AREA OF 2664 01:43:34,040 --> 01:43:38,960 FOCUS WE SHOULD LOOK AT WITH HDT 2665 01:43:38,960 --> 01:43:39,400 RESEARCH. 2666 01:43:39,400 --> 01:43:41,880 SO THE SCOPE OF THIS INITIATIVE 2667 01:43:41,880 --> 01:43:44,200 WITH MECHANISTIC STUDIES OF NTB 2668 01:43:44,200 --> 01:43:47,400 OR NTB HIV OR NTB ALONE 2669 01:43:47,400 --> 01:43:48,840 INFECTION BEFORE FOLDED IN 2670 01:43:48,840 --> 01:43:50,160 ADAPTIVE IMMUNE FUNCTIONS 2671 01:43:50,160 --> 01:43:51,640 TYPICALLY BEFORE FOUR WEEKS. 2672 01:43:51,640 --> 01:43:54,160 IN THE ALVEOLAR PULMONARY TISSUE 2673 01:43:54,160 --> 01:43:55,920 SETTING FOCUSED ON THE 2674 01:43:55,920 --> 01:43:57,440 INTERACTION MYELOID LYMPHOID 2675 01:43:57,440 --> 01:44:00,320 CELLS WITHIN THE ALVEOLAR AND 2676 01:44:00,320 --> 01:44:01,720 ADJACENT LONG EFFECTS ON 2677 01:44:01,720 --> 01:44:03,400 DEVELOPMENT AND TIMING OF KEY 2678 01:44:03,400 --> 01:44:06,080 T-CELL FUNCTIONS, MTB IMMUNE 2679 01:44:06,080 --> 01:44:07,960 EVASION DISRUPTION OF IMMUNE 2680 01:44:07,960 --> 01:44:10,760 CELL FUNCTIONS, STUDIES OF HOW 2681 01:44:10,760 --> 01:44:13,920 HIV SIV AND SHIV MODULATE EARLY 2682 01:44:13,920 --> 01:44:15,920 MTB EVENTS, IMMUNITY EVENTS SO 2683 01:44:15,920 --> 01:44:18,120 THIS WILL BE BASIC PRE-CLINICAL 2684 01:44:18,120 --> 01:44:20,120 IMMUNOLOGICAL RESEARCH 2685 01:44:20,120 --> 01:44:22,240 IDENTIFYING VACCINE ADJUVANT IN 2686 01:44:22,240 --> 01:44:23,840 NEOMODULATORY THERAPEUTIC AND 2687 01:44:23,840 --> 01:44:25,440 VACCINE COMPONENTS FOR FURTHER 2688 01:44:25,440 --> 01:44:26,080 STUDY. 2689 01:44:26,080 --> 01:44:28,280 WHILE THIS WOULD PRIMARILY BE 2690 01:44:28,280 --> 01:44:30,800 STUDIES UTILIZED IN SMALL ANIMAL 2691 01:44:30,800 --> 01:44:34,560 MODELS AND NHPs THE USE OF 2692 01:44:34,560 --> 01:44:36,640 HUMAN SAMPLES WOULD BE ALLOWED. 2693 01:44:36,640 --> 01:44:38,440 SO OUT OF SCOPE WOULD INCLUDE 2694 01:44:38,440 --> 01:44:41,280 RESEARCH PRIMARILY IN LATENCY 2695 01:44:41,280 --> 01:44:42,920 CHRONIC DISEASE REACTIVATION 2696 01:44:42,920 --> 01:44:44,640 ESTABLISHED MTB INFECTION, 2697 01:44:44,640 --> 01:44:46,480 STUDIES FOCUS ON ONE SINGLE 2698 01:44:46,480 --> 01:44:48,280 IMMUNE CELL AND SPECIFIC TO 2699 01:44:48,280 --> 01:44:51,080 T-CELL OR JUST WANTING TO LOOK 2700 01:44:51,080 --> 01:44:52,280 MACROPHAGE, RESEARCH THAT ONLY 2701 01:44:52,280 --> 01:44:54,080 TESTS EFFECTIVENESS OF 2702 01:44:54,080 --> 01:44:55,440 INTERVENTION, IF YOU HAVE AN 2703 01:44:55,440 --> 01:44:56,520 INTERVENTION THIS NOT THE 2704 01:44:56,520 --> 01:44:58,400 INITIATIVE FOR YOU. 2705 01:44:58,400 --> 01:45:00,960 AND STUDIES FOCUSED ON 2706 01:45:00,960 --> 01:45:03,000 TRANSMISSION MODEL DEVELOPMENT 2707 01:45:03,000 --> 01:45:05,600 WOULD ALSO BE OUT OF SCOPE. 2708 01:45:05,600 --> 01:45:08,000 SO THERE FOR THIS DOCTORS GUPTA 2709 01:45:08,000 --> 01:45:09,600 AND REUBEN HARRIS, THANK THEM 2710 01:45:09,600 --> 01:45:11,120 FOR TIME AND EFFORT, THEY WERE 2711 01:45:11,120 --> 01:45:13,160 RESPONSIVE AND SUPPORTIVE AND 2712 01:45:13,160 --> 01:45:14,480 THOUGHT IT WAS IMPORTANT. 2713 01:45:14,480 --> 01:45:15,680 SOME OF THE KEY QUESTIONS AND 2714 01:45:15,680 --> 01:45:17,400 COMMENTS THEY HAD WAS SHOULD WE 2715 01:45:17,400 --> 01:45:18,960 DEFINE EARLY AS TWO TO FOUR 2716 01:45:18,960 --> 01:45:20,120 WEEKS, WHEN DIFFERENT ANIMAL 2717 01:45:20,120 --> 01:45:21,560 MODELS HAVE DIFFERENT TIME 2718 01:45:21,560 --> 01:45:22,080 COURSES. 2719 01:45:22,080 --> 01:45:25,400 WE AGREE ARBITRARY TIME FRAME 2720 01:45:25,400 --> 01:45:27,400 ISN'T NECESSARY, SO FOR THE RFA 2721 01:45:27,400 --> 01:45:30,360 WE REPHRASE TO EITHER GRANULOMA 2722 01:45:30,360 --> 01:45:31,880 FORMATION OR LIKELY THE FULL 2723 01:45:31,880 --> 01:45:33,680 DEVELOPMENT OF ADAPTIVE IMMUNE 2724 01:45:33,680 --> 01:45:34,240 RESPONSE. 2725 01:45:34,240 --> 01:45:35,520 AND WE SEE THAT AS BEING 2726 01:45:35,520 --> 01:45:37,160 BENEFICIAL AND MAKE THOSE 2727 01:45:37,160 --> 01:45:37,880 CHANGES. 2728 01:45:37,880 --> 01:45:40,080 THERE WAS CONCERN ABOUT 2729 01:45:40,080 --> 01:45:42,120 INTERACTION BETWEEN HIV AND CB 2730 01:45:42,120 --> 01:45:44,080 WILL BE COMPLEX TO MODEL OUTSIDE 2731 01:45:44,080 --> 01:45:46,080 OF HUMANS WE APPRECIATE THE 2732 01:45:46,080 --> 01:45:46,680 CONCERN. 2733 01:45:46,680 --> 01:45:50,200 AND BELIEVE THE SIV NHV MODELS 2734 01:45:50,200 --> 01:45:52,160 USED TO MODEL HIV TB 2735 01:45:52,160 --> 01:45:53,280 CO-INFECTION FOR OTHER STAGES OF 2736 01:45:53,280 --> 01:45:54,400 INFECTION WILL ALLOW FOR 2737 01:45:54,400 --> 01:45:56,400 MODELING OF EARLY EVENTS. 2738 01:45:56,400 --> 01:45:58,120 DOES THE STAGE OF HIV 2739 01:45:58,120 --> 01:45:59,120 PROGRESSION MATTER WHEN ONE 2740 01:45:59,120 --> 01:46:02,360 FIRST BECOMES INFECTED WITH MTB, 2741 01:46:02,360 --> 01:46:04,640 CONSIDERING T-CELL COUNTS? 2742 01:46:04,640 --> 01:46:06,280 WE BELIEVE THE STAGE OF HIV 2743 01:46:06,280 --> 01:46:07,920 PROGRESSION AT TIME OF MTB 2744 01:46:07,920 --> 01:46:10,680 INFECTION IS IMPORTANT BUT 2745 01:46:10,680 --> 01:46:11,760 IMPACT IS NOT -- WE HOPE TO 2746 01:46:11,760 --> 01:46:13,680 ADDRESS IT WITH THIS INITIATIVE. 2747 01:46:13,680 --> 01:46:15,200 FURTHERMORE IF PATHOLOGICAL 2748 01:46:15,200 --> 01:46:17,520 INTERACTIONS ARE STILL POSSIBLE 2749 01:46:17,520 --> 01:46:18,760 DESPITE SUPPRESSION FOR THIS 2750 01:46:18,760 --> 01:46:20,280 INCLUDED IN CONCEPT WE ARE 2751 01:46:20,280 --> 01:46:21,360 THANKFUL FOR THIS COMMENT WE 2752 01:46:21,360 --> 01:46:24,000 AGREE AND WE WILL INCLUDE BEING 2753 01:46:24,000 --> 01:46:26,320 VIRALLY SUPPRESSED DOES 2754 01:46:26,320 --> 01:46:27,160 SIGNIFICANTLY CONTRIBUTE TO 2755 01:46:27,160 --> 01:46:30,640 BETTER OUTCOMES WITH MTB BUT 2756 01:46:30,640 --> 01:46:33,720 DOESN'T EQUAL THOSE NEGATIVE, DO 2757 01:46:33,720 --> 01:46:36,720 NOT HAVE HIV SO THEY ARE STILL 2758 01:46:36,720 --> 01:46:37,680 PATHOLOGICAL INTERACTIONS 2759 01:46:37,680 --> 01:46:39,480 OCCURRING AND WE DEFINITELY 2760 01:46:39,480 --> 01:46:41,000 AGREE THAT THIS IS AN AREA OF 2761 01:46:41,000 --> 01:46:43,480 NEEDED STUDY. 2762 01:46:43,480 --> 01:46:45,160 SO FINAL, IT WILL BE USEFUL AND 2763 01:46:45,160 --> 01:46:46,920 IMPORTANT TO ASSESS AGE OF 2764 01:46:46,920 --> 01:46:48,760 ANIMAL SEX DIFFERENCES, WE 2765 01:46:48,760 --> 01:46:50,760 AGREE. 2766 01:46:50,760 --> 01:46:51,760 SO DOES THE NIH SEX AS 2767 01:46:51,760 --> 01:46:53,560 BIOLOGICAL VARIABLE IS NOW NIH 2768 01:46:53,560 --> 01:46:56,720 POLICY AND WE WILL ALSO MAKE A 2769 01:46:56,720 --> 01:46:57,320 NOTE OF AGE. 2770 01:46:57,320 --> 01:47:00,160 WILL BE USED IN VIVO IMAGING TO 2771 01:47:00,160 --> 01:47:01,320 STUDY EARLY RESPONSES IN 2772 01:47:01,320 --> 01:47:03,280 PRE-CLINICAL MODELS BECAUSE 2773 01:47:03,280 --> 01:47:04,200 EITHER ARE ALLOWED. 2774 01:47:04,200 --> 01:47:07,880 T IT IS ALLOWED AND NIBBING 2775 01:47:07,880 --> 01:47:08,440 LIKELY NECESSARY TO ACHIEVE 2776 01:47:08,440 --> 01:47:09,040 GOALS OF THE INITIATIVE SO 2777 01:47:09,040 --> 01:47:09,680 CERTAINLY BE DESIRED. 2778 01:47:09,680 --> 01:47:11,160 FINALLY SPECIFYING HOW THE STUDY 2779 01:47:11,160 --> 01:47:13,480 OF TB PREVENTATIVE THERAPY WILL 2780 01:47:13,480 --> 01:47:15,080 BE INCLUDED, WHETHER IT OPTIONAL 2781 01:47:15,080 --> 01:47:15,640 OR MUST. 2782 01:47:15,640 --> 01:47:17,720 THE RESEARCH DESIGN UTILIZE 2783 01:47:17,720 --> 01:47:20,640 METHODS OF PREVENTIVE THERAPY TO 2784 01:47:20,640 --> 01:47:22,280 ELUCIDATE EARLY INFECTION EVENTS 2785 01:47:22,280 --> 01:47:22,840 WILL BE OPTIONAL. 2786 01:47:22,840 --> 01:47:24,560 MOST OF THESE WILL BE VACCINE 2787 01:47:24,560 --> 01:47:26,840 BASED AND MAKE SURE THAT IS 2788 01:47:26,840 --> 01:47:28,160 CLEARING OUT AND WHEN TALKING 2789 01:47:28,160 --> 01:47:29,400 PREVENTIVE THERAPY WE ARE 2790 01:47:29,400 --> 01:47:30,640 PRIMARILY TALKING ABOUT VACCINE 2791 01:47:30,640 --> 01:47:32,920 RESEARCH. 2792 01:47:32,920 --> 01:47:35,600 FOR THAT, THAT CONCLUDES MY 2793 01:47:35,600 --> 01:47:36,600 PRESENTATION. 2794 01:47:36,600 --> 01:47:39,000 I PAM THANKFUL ONCE AGAIN FOR 2795 01:47:39,000 --> 01:47:40,240 THE COMMENTS AND QUESTIONS AND 2796 01:47:40,240 --> 01:47:43,840 LOOK FORWARD TO ADDITIONAL ONES 2797 01:47:43,840 --> 01:47:54,320 FROM COMMITTEE THANK YOU DR. 2798 01:47:54,320 --> 01:47:55,200 MAHON. 2799 01:47:55,200 --> 01:47:57,920 ANY QUESTIONS IN TB INFECTION 2800 01:47:57,920 --> 01:47:59,520 AND TB HIV INFECTION. 2801 01:47:59,520 --> 01:48:09,960 QUESTIONS PEOPLE MAY HAVE? 2802 01:48:18,600 --> 01:48:22,560 I DO NOT SEE ANY QUESTIONS. 2803 01:48:22,560 --> 01:48:23,400 THANK YOU AGAIN. 2804 01:48:23,400 --> 01:48:27,160 LET ME ASK PEOPLE TO REOPEN 2805 01:48:27,160 --> 01:48:29,560 THEIR ELECTRONIC COUNCIL BOOKS 2806 01:48:29,560 --> 01:48:30,720 IF THEY HAVE SHUT AUTOMATICALLY 2807 01:48:30,720 --> 01:48:32,840 WHICH THEY DO OVER TIME. 2808 01:48:32,840 --> 01:48:33,960 PLEASE VOTE ON THIS. 2809 01:48:33,960 --> 01:48:36,280 PROPOSAL. 2810 01:48:36,280 --> 01:48:41,000 THANKS, EVERYONE. 2811 01:48:41,000 --> 01:48:43,200 WE WILL MOVE TO OUR NEXT 2812 01:48:43,200 --> 01:48:45,240 PRESENTATION WHICH WILL BE BY 2813 01:48:45,240 --> 01:48:48,840 DANIELLA LIVNAT, AGAIN TB 2814 01:48:48,840 --> 01:48:50,040 MYCOBACTERIUM TUBERCULOSIS 2815 01:48:50,040 --> 01:48:55,320 QUALITY ASSESSMENT TBQA PROGRAM. 2816 01:48:55,320 --> 01:48:58,600 >> THANK YOU, EVERYONE FOR THE 2817 01:48:58,600 --> 01:48:59,640 OPPORTUNITY TO PRESENT THIS 2818 01:48:59,640 --> 01:49:00,600 INITIATIVE. 2819 01:49:00,600 --> 01:49:02,400 I'LL DANIELLA LIVNAT, 2820 01:49:02,400 --> 01:49:04,160 THERAPEUTIC RESEARCH PROGRAM 2821 01:49:04,160 --> 01:49:08,000 DIVISION OF AIDS. 2822 01:49:08,000 --> 01:49:10,440 N SLIDE PLEASE. 2823 01:49:10,440 --> 01:49:12,800 THIS OBJECTIVE OF THIS 2824 01:49:12,800 --> 01:49:15,560 INITIATIVE IS PROVIDE RESOURCE 2825 01:49:15,560 --> 01:49:16,920 TO SUPPORT ABILITY OF 2826 01:49:16,920 --> 01:49:19,040 LABORATORIES TO RELIABLY PERFORM 2827 01:49:19,040 --> 01:49:21,320 STUDY SPECIFIED MTB TESTS, 2828 01:49:21,320 --> 01:49:23,880 EVALUATE MTB TECHNOLOGIES AND 2829 01:49:23,880 --> 01:49:30,000 SPECIMEN PROCESSES FOR USING 2830 01:49:30,000 --> 01:49:33,600 CLINICAL INVESTIGATIONS, PERFORM 2831 01:49:33,600 --> 01:49:35,720 LATE STAGE VALIDATION OR AS A 2832 01:49:35,720 --> 01:49:37,800 TESTING OF CLINICAL SAMPLES IN A 2833 01:49:37,800 --> 01:49:39,800 CLEAR CERTIFIED LABORATORY. 2834 01:49:39,800 --> 01:49:41,920 THIS ONE IS AN OPTION. 2835 01:49:41,920 --> 01:49:44,520 THIS IS A CONCEPT MECHANISM 2836 01:49:44,520 --> 01:49:47,120 FITTED FOR RENEWAL IN FY 24, 2837 01:49:47,120 --> 01:49:49,520 THIS IS FOR SEVEN YEARS, WE 2838 01:49:49,520 --> 01:49:51,640 EXPECT ONE AWARD, AT THIS POINTE 2839 01:49:51,640 --> 01:49:52,920 DON'T HAVE POTENTIAL PARTNERS. 2840 01:49:52,920 --> 01:49:55,920 NEXT SLIDE PLEASE. 2841 01:49:55,920 --> 01:49:59,120 SO WHAT IS IMPORTANCE OF TBQA? 2842 01:49:59,120 --> 01:50:00,320 MTB CONTINUES TO BE SIGNIFICANT 2843 01:50:00,320 --> 01:50:02,760 PUBLIC HEALTH BURDEN AND GLOBAL 2844 01:50:02,760 --> 01:50:06,520 HEALTH ESPECIALLY AMONG PEOPLE 2845 01:50:06,520 --> 01:50:08,480 LIVING WITH HIV. 2846 01:50:08,480 --> 01:50:10,080 THOSE CONTINUED NEED FOR RAPID 2847 01:50:10,080 --> 01:50:12,520 ACCURATE AND EARLY DIAGNOSIS OF 2848 01:50:12,520 --> 01:50:14,760 MTB INFECTION TO FACILITATE 2849 01:50:14,760 --> 01:50:18,040 SCREENING AND TRIAGE, IMPROVE 2850 01:50:18,040 --> 01:50:20,480 CASE DETECTION, INITIATE 2851 01:50:20,480 --> 01:50:21,840 EFFECTIVE TREATMENT REGIMENS AND 2852 01:50:21,840 --> 01:50:24,480 DIAGNOSIS OF TB OF PEOPLE LIVING 2853 01:50:24,480 --> 01:50:25,920 WITH HIV IS MORE DIFFICULT THAN 2854 01:50:25,920 --> 01:50:26,840 AMONG THOSE WITHOUT HIV 2855 01:50:26,840 --> 01:50:29,560 INFECTION. 2856 01:50:29,560 --> 01:50:31,640 CONTINUED SUPPORT FROM THE TBQA 2857 01:50:31,640 --> 01:50:33,720 CONTRACT IS NEEDED TO ENABLE 2858 01:50:33,720 --> 01:50:35,880 FACILITATE ONGOING RESEARCH 2859 01:50:35,880 --> 01:50:38,160 EFFORTS TO DEVELOPMENT OF NEW 2860 01:50:38,160 --> 01:50:40,200 DRUGS VACCINES AND DIAGNOSTICS. 2861 01:50:40,200 --> 01:50:43,480 BY DEVELOPMENT OF NEW BIOMARKERS 2862 01:50:43,480 --> 01:50:45,800 AND FOR USING CLINICAL RESEARCH 2863 01:50:45,800 --> 01:50:48,760 AND SUPPORT OF TAB LAB RELATED 2864 01:50:48,760 --> 01:50:49,760 QUALITY ASSURANCE AND CLINICAL 2865 01:50:49,760 --> 01:50:52,280 RESEARCH. 2866 01:50:52,280 --> 01:50:53,800 TBQA IS A CRITICAL 2867 01:50:53,800 --> 01:50:56,040 INFRASTRUCTURE RESOURCE AND A 2868 01:50:56,040 --> 01:50:57,600 COMPONENT OF THE DAIDS TOTAL 2869 01:50:57,600 --> 01:50:59,040 QUALITY MANAGEMENT SYSTEM. 2870 01:50:59,040 --> 01:51:03,640 THE USE OF APPROPRIATE 2871 01:51:03,640 --> 01:51:04,640 METHODOLOGIES RELIABLE 2872 01:51:04,640 --> 01:51:06,160 HARMONIZED TESTING AMONG LABS 2873 01:51:06,160 --> 01:51:08,280 ALLOWS FOR BETWEEN STUDY 2874 01:51:08,280 --> 01:51:10,920 COMPARABILITY OF RESULTS AND 2875 01:51:10,920 --> 01:51:11,920 HENCE ABILITY TO SUSTAIN 2876 01:51:11,920 --> 01:51:14,000 LABORATORY END POINTS. THIS 2877 01:51:14,000 --> 01:51:15,320 SUPPORTS DECISION MAKING FOR 2878 01:51:15,320 --> 01:51:17,200 PRODUCT ADVANCEMENT AND APPROVAL 2879 01:51:17,200 --> 01:51:20,080 BY US AND NON-U.S. REGULATORY 2880 01:51:20,080 --> 01:51:23,240 ENTITIES. 2881 01:51:23,240 --> 01:51:25,920 SO WHAT DO WE EXPECT FROM TBQA 2882 01:51:25,920 --> 01:51:26,600 RESOURCE? 2883 01:51:26,600 --> 01:51:30,120 ACCESS TO ALLOW BSL 3 CLINICAL 2884 01:51:30,120 --> 01:51:32,240 LABORATORY, ACCESS TO CURRENT TB 2885 01:51:32,240 --> 01:51:36,120 INSTRUMENTS AND METHODOLOGIES. 2886 01:51:36,120 --> 01:51:39,360 ACCESS TO TB DRUGS SUCH AS 2887 01:51:39,360 --> 01:51:40,760 (INAUDIBLE). 2888 01:51:40,760 --> 01:51:42,480 DYNAMIC REPLENISHABLE REPOSITORY 2889 01:51:42,480 --> 01:51:45,840 OF TB ISOLATES DERIVED FROM HIV 2890 01:51:45,840 --> 01:51:48,120 POSITIVE NEGATIVE INDIVIDUALS, 2891 01:51:48,120 --> 01:51:49,200 CHARACTERIZED FOR SENSITIVITY 2892 01:51:49,200 --> 01:51:52,400 AND RESISTANCE TO ANTI-TB DRUGS 2893 01:51:52,400 --> 01:51:55,800 BY VIRUS METHODOLOGIES. 2894 01:51:55,800 --> 01:51:58,640 WE EXPECT ACCESS TO SPEW THEM 2895 01:51:58,640 --> 01:52:01,080 MATERIALS INCLUDING WHOLE BLOOD 2896 01:52:01,080 --> 01:52:04,800 PLASMA PBMC, SALIVA FROM 2897 01:52:04,800 --> 01:52:07,520 INFECTED UNINFECTED PEDIATRIC 2898 01:52:07,520 --> 01:52:09,760 INDIVIDUALS WITH OR WITHOUT HIV 2899 01:52:09,760 --> 01:52:12,760 INFECTION VACCINATED 2900 01:52:12,760 --> 01:52:14,320 NON-VACCINATED, AND INDIVIDUALS 2901 01:52:14,320 --> 01:52:22,520 NOT NTB RESPIRATORY DISEASE. 2902 01:52:22,520 --> 01:52:23,840 WE AIM FOR EFFICIENT 2903 01:52:23,840 --> 01:52:25,000 INTERACTIONS WITH INVESTIGATORS 2904 01:52:25,000 --> 01:52:26,720 AND PROTOCOL TOMES TO 2905 01:52:26,720 --> 01:52:28,400 PROACTIVELY ASSESS AND ADDRESS 2906 01:52:28,400 --> 01:52:29,560 LABORATORY RELATED NEEDS. 2907 01:52:29,560 --> 01:52:31,960 AND WE EXPECT COLLABORATION WITH 2908 01:52:31,960 --> 01:52:35,280 OTHER DAIDS LABORATORY CURE 2909 01:52:35,280 --> 01:52:38,600 RESOURCES SUCH AS THE P SMILE 2910 01:52:38,600 --> 01:52:38,840 CONTRACT. 2911 01:52:38,840 --> 01:52:41,520 SO LET'S TALK ABOUT SPECIFIC 2912 01:52:41,520 --> 01:52:42,040 TASKS. 2913 01:52:42,040 --> 01:52:43,800 SO THE KEY TASK HERE IS TO 2914 01:52:43,800 --> 01:52:46,360 SUPPORT ABILITY OF LABS TO 2915 01:52:46,360 --> 01:52:49,600 RELIABLY PERFORM STUDY SPECIFIED 2916 01:52:49,600 --> 01:52:51,720 NTB TEST, THIS INCLUDES EXTERNAL 2917 01:52:51,720 --> 01:52:54,200 QUALITY ASSURANCE EQA FOR SHORT, 2918 01:52:54,200 --> 01:52:55,640 THE CONTRACTOR WILL BE REQUIRED 2919 01:52:55,640 --> 01:52:59,160 TO ACQUIRE OR CREATE PANELS OF 2920 01:52:59,160 --> 01:53:00,720 SAMPLES AND PERIODICALLY SENT TO 2921 01:53:00,720 --> 01:53:02,600 LABS FOR TESTING. 2922 01:53:02,600 --> 01:53:04,520 CAPTURE RESULTS AND REVIEW 2923 01:53:04,520 --> 01:53:06,320 PERFORMANCE AND THEN PROVIDE 2924 01:53:06,320 --> 01:53:07,880 FOLLOW-UP TRAINING GUIDANCE FOR 2925 01:53:07,880 --> 01:53:10,800 IMPROVEMENT INCLUDING SITE 2926 01:53:10,800 --> 01:53:11,600 VISITS AS NEEDED. 2927 01:53:11,600 --> 01:53:15,440 THE FOCUS WILL BE ON CUSTOMIZE 2928 01:53:15,440 --> 01:53:17,480 EQA BECAUSE IF YOU STANDARDIZED 2929 01:53:17,480 --> 01:53:20,080 TEST LIKE AAB IS PROVIDED BY THE 2930 01:53:20,080 --> 01:53:22,360 P SMILE CONTRACT. 2931 01:53:22,360 --> 01:53:24,200 ANOTHER ELEMENT IS ACID 2932 01:53:24,200 --> 01:53:26,520 VALIDATION AT PARTICIPATING 2933 01:53:26,520 --> 01:53:27,440 LABS. THE CONTRACTOR WILL BE 2934 01:53:27,440 --> 01:53:32,000 EXPECTED TO PROVIDE LABS WITH 2935 01:53:32,000 --> 01:53:32,760 GUIDANCE AND MATERIALS SUCH AS 2936 01:53:32,760 --> 01:53:40,200 DRUGS, RESISTANCE STRAINS, 2937 01:53:40,200 --> 01:53:41,800 NON-SPEW THEM MA TRY SEIZE AND 2938 01:53:41,800 --> 01:53:44,120 REVIEW VALIDATION DATA. 2939 01:53:44,120 --> 01:53:45,000 MATRIXES. 2940 01:53:45,000 --> 01:53:46,280 THE CONTRACTOR WILL BE EXPECTED 2941 01:53:46,280 --> 01:53:50,520 TO CREATE AND DISTRIBUTE 2942 01:53:50,520 --> 01:53:53,600 DOCUMENTS VIDEOS, CONDUCT 2943 01:53:53,600 --> 01:53:55,480 WEBINARS, VISIT LABS AND TRAIN 2944 01:53:55,480 --> 01:53:56,680 LAB STAFF CONTRACTORS 2945 01:53:56,680 --> 01:53:57,960 FACILITIES. 2946 01:53:57,960 --> 01:54:00,000 THERE WILL BE EXPECTED TO 2947 01:54:00,000 --> 01:54:03,080 SUPPORT CAPACITY BUILDING OF NEW 2948 01:54:03,080 --> 01:54:03,960 LABORATORIES. 2949 01:54:03,960 --> 01:54:06,080 AND REVIEW THE IDENTIFY 2950 01:54:06,080 --> 01:54:07,920 LONGITUDINAL STUDY DATA PROVIDED 2951 01:54:07,920 --> 01:54:10,360 BY DATA CENTERS ACROSS ALL 2952 01:54:10,360 --> 01:54:11,720 ENROLLING SITES TO ASSESS 2953 01:54:11,720 --> 01:54:15,800 QUALITY INDICATORS AND INFORM 2954 01:54:15,800 --> 01:54:19,360 TRAINING NEEDS. 2955 01:54:19,360 --> 01:54:21,360 SUPPORT WILL BE EXTENDED TO 2956 01:54:21,360 --> 01:54:23,760 DAIDS SUPPORTED AND 2957 01:54:23,760 --> 01:54:25,400 COLLABORATIVE NETWORKS COHORT 2958 01:54:25,400 --> 01:54:30,480 AND INDIVIDUAL INVESTIGATORS. 2959 01:54:30,480 --> 01:54:31,800 NEXT TASK EVALUATE METHODS AND 2960 01:54:31,800 --> 01:54:34,160 SAMPLE PROCESSES, IT COULD BE IN 2961 01:54:34,160 --> 01:54:38,520 HOUSE BY CONTRACTORS LAB OR 2962 01:54:38,520 --> 01:54:39,480 FACILITATED BY MULTIPLE 2963 01:54:39,480 --> 01:54:39,920 LABORATORIES. 2964 01:54:39,920 --> 01:54:43,320 THE PURPOSE HERE IS TO 2965 01:54:43,320 --> 01:54:45,640 FACILITATE OPTIMIZATION AND 2966 01:54:45,640 --> 01:54:48,720 VALIDATION OF MTB ESTIMATED 2967 01:54:48,720 --> 01:54:50,160 METHODOLOGIES FOR IMPLEMENTATION 2968 01:54:50,160 --> 01:54:51,720 IN SUPPORTED OR COLLABORATIVE 2969 01:54:51,720 --> 01:54:52,400 STUDIES. 2970 01:54:52,400 --> 01:54:56,720 SO FOR MTB METHODOLOGY IT WOULD 2971 01:54:56,720 --> 01:54:59,880 BE EVALUATE COMPARE EXISTING OR 2972 01:54:59,880 --> 01:55:02,680 NEWLY DEVELOPED NTB ASSAYS, FOR 2973 01:55:02,680 --> 01:55:07,760 INSTANCE IF GENE SCHOLAR 2974 01:55:07,760 --> 01:55:08,600 (INDISCERNIBLE) ASSAY THAT 2975 01:55:08,600 --> 01:55:10,280 DETECTS MUTATIONS TO PREDICT 2976 01:55:10,280 --> 01:55:12,760 RESISTANCE TO PZA. 2977 01:55:12,760 --> 01:55:15,280 ASSAY KITS OR REAGENTS SUCH AS 2978 01:55:15,280 --> 01:55:18,520 UPGRADES TO THE GENEXPER 2979 01:55:18,520 --> 01:55:22,320 CARTRIDGES. ASSAYS IN 2980 01:55:22,320 --> 01:55:27,480 NON-SPUTUM MATRICES FUJI FILM 2981 01:55:27,480 --> 01:55:33,240 POC TB LAM RAPID TEST IN URINE. 2982 01:55:33,240 --> 01:55:34,480 SPECIMEN COLLECTION PROCESSES 2983 01:55:34,480 --> 01:55:39,640 SPORED SHIPPING CONDITION Z SUCH 2984 01:55:39,640 --> 01:55:44,160 AS THE (INDISCERNIBLE). 2985 01:55:44,160 --> 01:55:45,680 ANOTHER TASK IS TO VALIDATE 2986 01:55:45,680 --> 01:55:47,720 SCIENTIFIC DATA, WE EXPECT THE 2987 01:55:47,720 --> 01:55:49,160 CONTRACTOR TOO MAKE AVAILABLE A 2988 01:55:49,160 --> 01:55:51,560 CENTRALIZED RESOURCE TO TRIAL 2989 01:55:51,560 --> 01:55:54,640 GROUPS, INVESTIGATORS, AND 2990 01:55:54,640 --> 01:55:56,960 PUBLIC FOR RESULTS OF TBQA 2991 01:55:56,960 --> 01:55:58,600 EVALUATION OR COMPARATIVE 2992 01:55:58,600 --> 01:56:01,560 STUDIES, BEST PRACTICES, 2993 01:56:01,560 --> 01:56:02,520 GUIDANCE FOR PERFORMING ASSAYS 2994 01:56:02,520 --> 01:56:04,960 AND PROCESSING SAMPLES, GUIDANCE 2995 01:56:04,960 --> 01:56:09,080 AND TRAINING MATERIALS, WE USE 2996 01:56:09,080 --> 01:56:12,120 NEW TECHNOLOGIES AND TB RELATED 2997 01:56:12,120 --> 01:56:13,520 TESTING AND TREATMENT GUIDELINES 2998 01:56:13,520 --> 01:56:15,040 SUCH AS THOSE ISSUED BY THE 2999 01:56:15,040 --> 01:56:19,040 WORLD HEALTH ORGANIZATION. 3000 01:56:19,040 --> 01:56:19,960 PRESENTATIONS AT SCIENTIFIC 3001 01:56:19,960 --> 01:56:21,480 INVESTIGATOR MEETINGS AND 3002 01:56:21,480 --> 01:56:26,560 PUBLICATIONS IN PEER REVIEW 3003 01:56:26,560 --> 01:56:31,280 JOURNALS. 3004 01:56:31,280 --> 01:56:32,600 PERFORM LATE STAGE ASSAY 3005 01:56:32,600 --> 01:56:33,520 VALIDATION OR TESTING OF 3006 01:56:33,520 --> 01:56:35,560 CLINICAL SAMPLES IN THE COLLIEIA 3007 01:56:35,560 --> 01:56:36,240 CERTIFIED LABORATORY. 3008 01:56:36,240 --> 01:56:38,360 LET ME EXPLAIN THE OPTION IS 3009 01:56:38,360 --> 01:56:40,320 ADDITIONAL WORK THAT IF NEEDED, 3010 01:56:40,320 --> 01:56:43,400 MAY REQUIRE ADDITIONAL FUNDS. 3011 01:56:43,400 --> 01:56:44,680 DURING THE COURSE OF THE 3012 01:56:44,680 --> 01:56:47,000 CONTRACT IT MAY BECOME NECESSARY 3013 01:56:47,000 --> 01:56:49,720 TO USE NOVEL MTB ASSAYS IN 3014 01:56:49,720 --> 01:56:50,520 CLINICAL TRIALS WHERE RESULTS 3015 01:56:50,520 --> 01:56:52,000 WILL BE USED FOR CLINICAL 3016 01:56:52,000 --> 01:56:54,280 DECISIONS WITHIN THE TRIAL. 3017 01:56:54,280 --> 01:56:56,360 THIS WILL NECESSITATE ASSAY 3018 01:56:56,360 --> 01:56:59,280 VALIDATION IN A CLIA CERTIFIED 3019 01:56:59,280 --> 01:57:00,600 LABORATORY. 3020 01:57:00,600 --> 01:57:02,600 SIMILARLY IT MAY BECOME 3021 01:57:02,600 --> 01:57:03,840 NECESSARY OR MORE EFFICIENT FOR 3022 01:57:03,840 --> 01:57:07,040 THE TBQA TO PERFORM PROTOCOL 3023 01:57:07,040 --> 01:57:09,320 SPECIFIED MTB TESTING SUCH AS 3024 01:57:09,320 --> 01:57:09,880 SEQUENCING. 3025 01:57:09,880 --> 01:57:11,800 IF THE TESTING IS USED FOR 3026 01:57:11,800 --> 01:57:14,720 PARTICIPANT MANAGEMENT DECISION, 3027 01:57:14,720 --> 01:57:18,480 OR FOR PRIMARY IND STUDY, CLIA 3028 01:57:18,480 --> 01:57:19,480 CERTIFIED LABORATORY WILL BE 3029 01:57:19,480 --> 01:57:21,880 NEEDED. 3030 01:57:21,880 --> 01:57:25,360 SO A FEW WORDS ABOUT CURRENT 3031 01:57:25,360 --> 01:57:27,320 TBQA ACCOMPLISHMENTS. 3032 01:57:27,320 --> 01:57:33,000 I ORGANIZE IT ALONG SAME AREAS 3033 01:57:33,000 --> 01:57:35,600 OF TBQA. 3034 01:57:35,600 --> 01:57:36,960 SO TO SUPPORT ASSET VALIDATION 3035 01:57:36,960 --> 01:57:43,680 AT LABORATORIES, TBQA ALLOWED IN 3036 01:57:43,680 --> 01:57:45,480 GHESKIO IN HAITI TO VALIDATE TO 3037 01:57:45,480 --> 01:57:49,400 ASSAYS TO PARTICIPATE IN THE 3038 01:57:49,400 --> 01:57:51,880 ACPG TRIAL WHICH IS AN EBA 3039 01:57:51,880 --> 01:57:53,920 PROTOCOL. 3040 01:57:53,920 --> 01:57:55,400 REGARDING QUALITY CONTROL MERLES 3041 01:57:55,400 --> 01:57:56,600 THE ESTABLISHED REPOSITORY OF TB 3042 01:57:56,600 --> 01:58:00,360 ISOLATES THAT HAVE UNDERGONE 3043 01:58:00,360 --> 01:58:01,480 WHOLE GENOME TARGETED SEQUENCING 3044 01:58:01,480 --> 01:58:03,000 AS WELL AS CHARACTERIZED FOR 3045 01:58:03,000 --> 01:58:04,840 RESISTANCE TO CURRENTLY 3046 01:58:04,840 --> 01:58:07,120 AVAILABLE DRUGS BY VARIOUS 3047 01:58:07,120 --> 01:58:15,880 METHODS LIKE MIC MGIT HAIN 3048 01:58:15,880 --> 01:58:17,480 GENEXPERT AND ULTRA PLATFORM. 3049 01:58:17,480 --> 01:58:20,080 THEY REVIEWED DEIDENTIFIED STUDY 3050 01:58:20,080 --> 01:58:20,640 DATA. 3051 01:58:20,640 --> 01:58:23,120 THE DATA CENTER MONITORING THE 3052 01:58:23,120 --> 01:58:24,920 EXPERT ULTRA POSITIVE TRACE 3053 01:58:24,920 --> 01:58:31,120 CALLS ACROSS SITES THAT IS 3054 01:58:31,120 --> 01:58:33,160 POSITIVE AND REAL SOON CULTURE 3055 01:58:33,160 --> 01:58:36,800 POSITIVITY AND CONTAMINATION AS 3056 01:58:36,800 --> 01:58:39,240 WELL AS DRUG SUSCEPTIBILITY 3057 01:58:39,240 --> 01:58:39,800 TESTING RESULTS. 3058 01:58:39,800 --> 01:58:41,760 NEXT SLIDE PLEASE. 3059 01:58:41,760 --> 01:58:47,040 REGARDING IN HOUSE EVALUATION, 3060 01:58:47,040 --> 01:58:48,760 EVALUATED TRUE ARRAY NBR TB 3061 01:58:48,760 --> 01:58:51,600 ASSAY A PORTABLE BENCH TOP ASSAY 3062 01:58:51,600 --> 01:58:54,720 THAT DETECTS MYCOBACTERIAL 3063 01:58:54,720 --> 01:58:58,120 SUSCEPTIBILITY TO INH. 3064 01:58:58,120 --> 01:59:02,000 EVALUATED THE GENUS DEEPLEX NEXT 3065 01:59:02,000 --> 01:59:03,320 GENERATION SEQUENCING WITH 3066 01:59:03,320 --> 01:59:04,480 TARGETED AMPLIFICATION KIT THAT 3067 01:59:04,480 --> 01:59:06,640 CAN BE USED ON CLINICAL SAMPLES 3068 01:59:06,640 --> 01:59:09,440 AND NO NEED FOR RESULTS -- HAVE 3069 01:59:09,440 --> 01:59:12,560 RESULTS IN LESS THAN 48 HOURS. 3070 01:59:12,560 --> 01:59:15,680 EVALUATED CSF ON THE GENEXPERT 3071 01:59:15,680 --> 01:59:16,880 ULTRA PLATFORM INCLUDING 3072 01:59:16,880 --> 01:59:18,800 VARIABLES RELATEMENTED TO SAMPLE 3073 01:59:18,800 --> 01:59:19,840 VOLUME STORAGE CONDITIONS AND 3074 01:59:19,840 --> 01:59:21,920 LENGTH OF STORAGE AND THEY VALUE 3075 01:59:21,920 --> 01:59:25,280 WAITED METHODS TO PROCESS 3076 01:59:25,280 --> 01:59:29,160 GASTRIC ASPIRATES NEEDED FOR THE 3077 01:59:29,160 --> 01:59:32,360 PHOENIX TRIAL AND ADDRESS 3078 01:59:32,360 --> 01:59:34,520 VARIABLES FOR SAMPLE PROCESSING 3079 01:59:34,520 --> 01:59:35,520 NEUTRALIZATION AND SAMPLE 3080 01:59:35,520 --> 01:59:36,000 TRANSPORT. 3081 01:59:36,000 --> 01:59:37,240 IN ADDITION THEY PROVIDED 3082 01:59:37,240 --> 01:59:40,240 OVERVIEW AND TRAINING OF THE 3083 01:59:40,240 --> 01:59:42,560 HAIN GENOTYPE ASSAYS INTO IMPACT 3084 01:59:42,560 --> 01:59:43,480 ANNUAL MEETING. 3085 01:59:43,480 --> 01:59:46,560 NEXT SLIDE. 3086 01:59:46,560 --> 01:59:48,640 THIS WAS THE END OF MY 3087 01:59:48,640 --> 01:59:49,120 PRESENTATION. 3088 01:59:49,120 --> 01:59:50,280 NOT QUITE. 3089 01:59:50,280 --> 01:59:53,240 WE DID HAVE A PRE-ARAC REVIEW 3090 01:59:53,240 --> 01:59:58,440 WITH DR. ABRAMS AND GUPTA WHICH 3091 01:59:58,440 --> 01:59:58,800 WAS EXCELLENT. 3092 01:59:58,800 --> 01:59:59,680 THANK YOU VERY MUCH, BOTH 3093 01:59:59,680 --> 02:00:01,960 REVIEWERS BOTH SUPPORT FOR THE 3094 02:00:01,960 --> 02:00:04,880 RENEWAL OF TBQA CONTRACT. 3095 02:00:04,880 --> 02:00:08,000 ONE COMMON WAS IT WAS CRITICAL 3096 02:00:08,000 --> 02:00:10,360 TO EMPHASIZE THE ROLE OF TBQA 3097 02:00:10,360 --> 02:00:11,920 ENSURING HIGH QUALITY HARMONIZE 3098 02:00:11,920 --> 02:00:13,680 NTB TESTING TO SUPPORT 3099 02:00:13,680 --> 02:00:16,160 ASCERTAINMENT OF STUDY END 3100 02:00:16,160 --> 02:00:21,600 POINTS AND DEFINITELY AGREE 3101 02:00:21,600 --> 02:00:22,720 ANOTHER COMMENT MUST PROVIDE 3102 02:00:22,720 --> 02:00:24,200 CENTRALIZED RESOURCE OF GUIDANCE 3103 02:00:24,200 --> 02:00:26,280 MATERIALS AND BEST PRACTICES TO 3104 02:00:26,280 --> 02:00:29,160 STUDY TEAMS AND ALSO THE TBQA 3105 02:00:29,160 --> 02:00:34,520 ABILITY SHOULD BE ENHANCED AND 3106 02:00:34,520 --> 02:00:35,880 SO THIS IS THE END OF MY 3107 02:00:35,880 --> 02:00:37,880 PRESENTATION AND I WILL BE HAPPY 3108 02:00:37,880 --> 02:00:38,640 TO ANSWER ANY QUESTIONS YOU MAY 3109 02:00:38,640 --> 02:00:41,720 HAVE. 3110 02:00:41,720 --> 02:00:43,120 NEXT SLIDE IS REPEAT OF THE 3111 02:00:43,120 --> 02:00:45,480 FIRST SLIDE. 3112 02:00:45,480 --> 02:00:46,520 >> GREAT. 3113 02:00:46,520 --> 02:00:51,680 THANK YOU, THANK YOU FOR YOUR 3114 02:00:51,680 --> 02:00:53,320 PRESENTATION. 3115 02:00:53,320 --> 02:00:58,880 QUESTIONS OR COMMENTS ABOUT THE 3116 02:00:58,880 --> 02:01:03,320 TBQA? 3117 02:01:03,320 --> 02:01:05,760 LOT OF EXCITING AND OTHER 3118 02:01:05,760 --> 02:01:16,240 LABORATORY VALUATIONS IN TB. 3119 02:01:17,240 --> 02:01:20,080 I'M MOST EXCITED ABOUT FUJI LAND 3120 02:01:20,080 --> 02:01:21,960 POINT OF CARE. 3121 02:01:21,960 --> 02:01:26,520 QUESTIONS? 3122 02:01:26,520 --> 02:01:26,960 ALL RIGHT. 3123 02:01:26,960 --> 02:01:32,400 THANK YOU, DANIELLA, APPRECIATE 3124 02:01:32,400 --> 02:01:32,840 YOUR PRESENTATION. 3125 02:01:32,840 --> 02:01:38,240 WE ARE MOVING ALONG AND WE WILL 3126 02:01:38,240 --> 02:01:43,000 GO TO DR. QUE DANG, VACCINE 3127 02:01:43,000 --> 02:01:44,320 RESEARCH PROGRAM TO PRESENT 3128 02:01:44,320 --> 02:01:45,280 CELLULAR IMMUNOLOGY CORE 3129 02:01:45,280 --> 02:01:48,360 LABORATORY. 3130 02:01:48,360 --> 02:01:51,320 >> THANK YOU, DR. FREEBURG. 3131 02:01:51,320 --> 02:01:53,560 GOOD AFTERNOON, MY NAME IS QUE 3132 02:01:53,560 --> 02:01:54,360 TANK AND I WILL BE PRESENTING 3133 02:01:54,360 --> 02:01:56,360 THE CELLULAR IMMUNOLOGY CORE 3134 02:01:56,360 --> 02:01:58,320 LABORATORY INITIATIVE CONCEPT 3135 02:01:58,320 --> 02:02:01,880 FOR COUNCIL APPROVAL. 3136 02:02:01,880 --> 02:02:04,040 BEFORE I START TALKING ABOUT THE 3137 02:02:04,040 --> 02:02:05,200 CELLULAR IMMUNOLOGY CORE 3138 02:02:05,200 --> 02:02:08,280 LABORATORY INITIATIVE, I NEED TO 3139 02:02:08,280 --> 02:02:11,000 PROVIDE CONTEXT WHICH CELLULAR 3140 02:02:11,000 --> 02:02:12,040 IMMUNOLOGY FUNCTIONS IN THE 3141 02:02:12,040 --> 02:02:15,080 DIVISION OF AIDS, THE VACCINE 3142 02:02:15,080 --> 02:02:17,360 RESEARCH PROGRAM HAS THE ABILITY 3143 02:02:17,360 --> 02:02:19,360 TO EVALUATE IMMUNOGENICITY AND 3144 02:02:19,360 --> 02:02:21,240 EFFICACY OF CANDIDATE AIDS 3145 02:02:21,240 --> 02:02:23,200 VACCINES IN NON-HUMAN PRIMATES. 3146 02:02:23,200 --> 02:02:25,200 THIS IS POSSIBLE DURING 3147 02:02:25,200 --> 02:02:27,600 COORDINATED SET OF CONTRACTS 3148 02:02:27,600 --> 02:02:29,680 THAT CONSIST OF THE SIMIAN 3149 02:02:29,680 --> 02:02:31,840 VACCINE EVALUATION UNITS IN FOUR 3150 02:02:31,840 --> 02:02:35,400 CENTRALIZE CORE LABORATORIES. 3151 02:02:35,400 --> 02:02:40,600 THE SIMIAN VACCINE EVALUATION 3152 02:02:40,600 --> 02:02:42,200 UNITS IS A CONTRACT WE USED TO 3153 02:02:42,200 --> 02:02:44,000 CONDUCT THE PRE-CLINICAL 3154 02:02:44,000 --> 02:02:44,560 STUDIES. 3155 02:02:44,560 --> 02:02:46,960 THERE ARE THREE SVU SITES TO DO 3156 02:02:46,960 --> 02:02:49,200 THIS WORK. 3157 02:02:49,200 --> 02:02:53,120 THEY ARE BIOQUAL IN MARYLAND, 3158 02:02:53,120 --> 02:02:54,760 TULANE UNIVERSITY AND UNIVERSITY 3159 02:02:54,760 --> 02:02:56,720 OF LOUISIANA LAFAYETTE, BOTH IN 3160 02:02:56,720 --> 02:03:00,360 LOUISIANA. 3161 02:03:00,360 --> 02:03:03,360 TO CONDUCT THE STUDY THE SVU 3162 02:03:03,360 --> 02:03:05,360 SITES ACQUIRE IN AND HOUSE THE 3163 02:03:05,360 --> 02:03:07,800 ANIMALS DEVELOP THE PROTOCOLS, 3164 02:03:07,800 --> 02:03:09,280 ADMINISTER THE VACCINE AND 3165 02:03:09,280 --> 02:03:10,760 CHALLENGE VIRUS IF IT IS IN 3166 02:03:10,760 --> 02:03:14,640 EFFICACY STUDY AND COLLECT THE 3167 02:03:14,640 --> 02:03:15,760 SAMPLES THIS VALUABLE RESOURCE 3168 02:03:15,760 --> 02:03:17,720 IS AVAILABLE TO ALL AIDS VACCINE 3169 02:03:17,720 --> 02:03:19,600 RESEARCHERS AND CAN SUPPORT ALL 3170 02:03:19,600 --> 02:03:22,800 STAGES OF AIDS VACCINE RESEARCH 3171 02:03:22,800 --> 02:03:24,120 FROM PILOT STUDY PROOF OF 3172 02:03:24,120 --> 02:03:27,480 CONCEPT UP TO AND INCLUDING 3173 02:03:27,480 --> 02:03:29,760 EFFICACY STUDIES I WILL HAVE A 3174 02:03:29,760 --> 02:03:30,960 SLIDE TO GIVE YOU THE TYPES OF 3175 02:03:30,960 --> 02:03:32,760 IDEAS OF TYPES OF STUDIES BEING 3176 02:03:32,760 --> 02:03:32,960 DONE. 3177 02:03:32,960 --> 02:03:34,520 AND ALSO FOR THE SAKE OF TIME, 3178 02:03:34,520 --> 02:03:36,760 AS THIS IS NOT THE FOCUS OF 3179 02:03:36,760 --> 02:03:38,200 TODAY'S INITIATIVE, I INCLUDE 3180 02:03:38,200 --> 02:03:39,880 THE WEBSITE ADDRESS AT THE 3181 02:03:39,880 --> 02:03:42,000 BOTTOM OF THIS SLIDE FOR FURTHER 3182 02:03:42,000 --> 02:03:44,280 INFORMATION ON THE SBEU 3183 02:03:44,280 --> 02:03:45,600 REGARDING HOW TO ACCESS THIS 3184 02:03:45,600 --> 02:03:50,080 VALUABLE RESOURCE. 3185 02:03:50,080 --> 02:03:52,520 NEXT IN COORDINATION WITH THE 3186 02:03:52,520 --> 02:03:54,280 SVU, WE HAVE FOUR CENTRALIZED 3187 02:03:54,280 --> 02:03:56,320 CORE LABORATORIES THAT CONDUCT 3188 02:03:56,320 --> 02:03:59,080 STANDARDIZE ASSAYS BY SAMPLES 3189 02:03:59,080 --> 02:04:00,760 FROM THESE STUDIES AND CORE 3190 02:04:00,760 --> 02:04:04,320 LABORATORIES PROVIDE ABILITY TO 3191 02:04:04,320 --> 02:04:07,000 COMPREHENSIVELY EVALUATE IMMUNE 3192 02:04:07,000 --> 02:04:08,360 RESPONSES AND EFFICACY GENERATED 3193 02:04:08,360 --> 02:04:12,680 BY AIDS VACCINE CANDIDATES. 3194 02:04:12,680 --> 02:04:17,640 THE FOUR CORE LABORATORY ARE 3195 02:04:17,640 --> 02:04:18,120 NEXT. 3196 02:04:18,120 --> 02:04:21,040 DAVID MONTEKURY DUKE UNIVERSITY 3197 02:04:21,040 --> 02:04:23,480 IS PI FOR HUMORAL IMMUNOLOGY 3198 02:04:23,480 --> 02:04:25,640 CORE LABORATORY CONTRACT. 3199 02:04:25,640 --> 02:04:27,400 HUMORAL KNEWNOLOGY LAB CONDUCTS 3200 02:04:27,400 --> 02:04:29,880 ASSAY TO DETECT NEUTRALIZING 3201 02:04:29,880 --> 02:04:32,520 ANTIBODY RESPONSES THAT BREADTH 3202 02:04:32,520 --> 02:04:34,840 AND SPECIFICITY, MUCOSAL A IGA 3203 02:04:34,840 --> 02:04:38,040 AND IGG ANTIBODY AND DIFFERENT 3204 02:04:38,040 --> 02:04:40,920 ANTIBODY FUNCTIONS. 3205 02:04:40,920 --> 02:04:42,160 MICHAEL GAIL AT UNIVERSITY OF 3206 02:04:42,160 --> 02:04:44,080 WASHINGTON IS THE PI FOR THE 3207 02:04:44,080 --> 02:04:46,400 FUNCTIONAL GENOMICS CORE 3208 02:04:46,400 --> 02:04:47,160 LABORATORY CONTRACT. 3209 02:04:47,160 --> 02:04:48,800 WITH THE OVERALL GOAL OF 3210 02:04:48,800 --> 02:04:50,400 IDENTIFYING HOST RESPONSES THAT 3211 02:04:50,400 --> 02:04:55,240 PREDICT VACCINE EFFICACY THIS 3212 02:04:55,240 --> 02:04:56,440 APPLIES FUNCTIONAL GENOMIC 3213 02:04:56,440 --> 02:05:00,480 APPROACHES TO EVALUATE ADAPTIVE 3214 02:05:00,480 --> 02:05:05,080 IMNEIGHBOR IMMUNE RESPONSES. 3215 02:05:05,080 --> 02:05:06,360 TOM JENNINGS AT DUKE UNIVERSITY 3216 02:05:06,360 --> 02:05:08,760 IS PI FOR THE VIROLOGY MAP. 3217 02:05:08,760 --> 02:05:10,280 THE VIROLOGY LAB PRIMARILY 3218 02:05:10,280 --> 02:05:12,480 CONDUCTS ASSAYS THAT ARE USED TO 3219 02:05:12,480 --> 02:05:14,480 DETECT AND MEASURE LEVELS OF 3220 02:05:14,480 --> 02:05:25,000 VIRAL RNA TO DETERMINE WHETHER 3221 02:05:25,960 --> 02:05:27,280 LASTLY WE HAVE THE CELLULAR 3222 02:05:27,280 --> 02:05:28,240 IMMUNOLOGY LAB, THE FOCUS OF 3223 02:05:28,240 --> 02:05:28,840 TODAY'S INITIATIVE. 3224 02:05:28,840 --> 02:05:31,480 THE PI FOR THE CELLULAR 3225 02:05:31,480 --> 02:05:32,400 IMMUNOLOGY LAB IS (INAUDIBLE) AT 3226 02:05:32,400 --> 02:05:34,200 THE PRIMATE CENTER AT TULANE 3227 02:05:34,200 --> 02:05:36,760 UNIVERSITY. 3228 02:05:36,760 --> 02:05:39,320 TOGETHER THESE FOUR CORE 3229 02:05:39,320 --> 02:05:42,800 LABORATORIES ARE RESPONSIBLE FOR 3230 02:05:42,800 --> 02:05:46,240 STATE OF ART ASSAYS TO EVALUATE 3231 02:05:46,240 --> 02:05:47,720 IMMUNOGENICITY AND/OR EFFICACY 3232 02:05:47,720 --> 02:05:50,760 OF CANDIDATE AIDS VACCINES. 3233 02:05:50,760 --> 02:05:52,120 I HOPE THIS HELPS YOU TO BETTER 3234 02:05:52,120 --> 02:05:53,800 UNDERSTAND THE CONTEXT IN WHICH 3235 02:05:53,800 --> 02:05:59,640 THE CELLULAR IMMUNOLOGY LIBRATES 3236 02:05:59,640 --> 02:06:00,920 AND E WILL NOW PRESENT THE 3237 02:06:00,920 --> 02:06:04,000 INITIATIVE CONCEPT. 3238 02:06:04,000 --> 02:06:05,960 THE OBJECTIVE IS TO HAVE A 3239 02:06:05,960 --> 02:06:07,480 CELLULAR IMMUNOLOGY LABORATORY 3240 02:06:07,480 --> 02:06:08,840 TO PROVIDE A CENTRALIZED SERVICE 3241 02:06:08,840 --> 02:06:12,280 TO CONDUCT ASSAYS MEASURING 3242 02:06:12,280 --> 02:06:13,480 CELLULAR IMMUNE RESPONSES IN 3243 02:06:13,480 --> 02:06:14,840 SUPPORT OF PRE-CLINICAL AIDS 3244 02:06:14,840 --> 02:06:15,400 VACCINE STUDIES. 3245 02:06:15,400 --> 02:06:19,040 THIS ENSURES STANDARDSIZATION 3246 02:06:19,040 --> 02:06:20,320 AND COMPARABILITY OF DATA ACROSS 3247 02:06:20,320 --> 02:06:20,840 STUDIES. 3248 02:06:20,840 --> 02:06:23,240 THE ASSAYS ARE ESSENTIAL FOR THE 3249 02:06:23,240 --> 02:06:28,600 EVALUATION OF THE IMMUNE 3250 02:06:28,600 --> 02:06:29,160 GENICITY OF CANDIDATE AIDS 3251 02:06:29,160 --> 02:06:30,160 VACCINES FOR POTENTIAL 3252 02:06:30,160 --> 02:06:31,240 IDENTIFICATION OF PROTECTIVE 3253 02:06:31,240 --> 02:06:32,720 IMMUNE RESPONSES IN EFFICACY 3254 02:06:32,720 --> 02:06:33,800 STUDIES. 3255 02:06:33,800 --> 02:06:35,880 IF APPROVED, THIS WILL BE A 3256 02:06:35,880 --> 02:06:37,520 REISSUE OF THE CURRENT CONTRACT 3257 02:06:37,520 --> 02:06:40,640 USING REQUEST FOR PROPOSAL FOR 3258 02:06:40,640 --> 02:06:42,040 RFP SOLICITATION. 3259 02:06:42,040 --> 02:06:44,200 THE CONTRACT WILL BE AWARDED FOR 3260 02:06:44,200 --> 02:06:46,240 SEVEN YEARS AND WE ANTICIPATE 3261 02:06:46,240 --> 02:06:49,760 MAKING ONE AWARD. 3262 02:06:49,760 --> 02:06:51,800 SO WHY IS THIS INITIATIVE 3263 02:06:51,800 --> 02:06:52,160 IMPORTANT? 3264 02:06:52,160 --> 02:06:54,480 WHY DO WE NEED TO DO THIS NOW? 3265 02:06:54,480 --> 02:06:56,760 THE DEVELOPMENT OF EFFECTIVE HIV 3266 02:06:56,760 --> 02:06:59,000 VACCINE IS A HIGH PRIORITY FOR 3267 02:06:59,000 --> 02:06:59,920 THE NIH. 3268 02:06:59,920 --> 02:07:01,480 PRE-CLINICAL STUDIES NON-HUMAN 3269 02:07:01,480 --> 02:07:04,240 PRIMATES ARE SMALL ANIMALS KEY 3270 02:07:04,240 --> 02:07:06,840 TO EVALUATE THE IMMUNOGENICITY, 3271 02:07:06,840 --> 02:07:10,920 EFFICACY AND TOXICITY OF THAT 3272 02:07:10,920 --> 02:07:12,280 VACCINE CANDIDATE, PRE-CLINICAL 3273 02:07:12,280 --> 02:07:14,760 STUDIES ARE IMPORTANT TO DERISK 3274 02:07:14,760 --> 02:07:16,880 THE PRODUCT IN PLATFORM IN 3275 02:07:16,880 --> 02:07:18,280 COSTLY GMP MANUFACTURING AND 3276 02:07:18,280 --> 02:07:20,880 THEY CAN HELP TO INFORM GUIDE 3277 02:07:20,880 --> 02:07:26,760 PHASE 1 CLINICAL TRIALS STUDIES. 3278 02:07:26,760 --> 02:07:28,040 THE CELLULAR IMMUNOLOGY 3279 02:07:28,040 --> 02:07:31,760 LABORATORY AND ALL THE LAB 3280 02:07:31,760 --> 02:07:33,600 CATEGORIES ARE CRITICAL FOR 3281 02:07:33,600 --> 02:07:34,840 EVALUATION OF THESE POTENTIAL 3282 02:07:34,840 --> 02:07:36,920 VACCINES SO THIS TABLE SHOWS YOU 3283 02:07:36,920 --> 02:07:39,640 THE SBU STUDIES THE CELLULAR 3284 02:07:39,640 --> 02:07:40,520 IMMUNOLOGY LAB SUPPORTED OVER 3285 02:07:40,520 --> 02:07:45,520 THE LAST FEW YEARS. 3286 02:07:45,520 --> 02:07:46,640 THEY WERE SELECTED TO EXPLORE 3287 02:07:46,640 --> 02:07:47,280 VARIOUS QUESTIONS. 3288 02:07:47,280 --> 02:07:52,280 FOR EXAMPLE IN P 209 DR. CROTTY 3289 02:07:52,280 --> 02:07:53,920 ASKED WHETHER SLOW DELIVERY 3290 02:07:53,920 --> 02:07:54,920 IMMUNIZATION ENHANCE 3291 02:07:54,920 --> 02:07:56,000 NEUTRALIZING ANTIBODY IN 3292 02:07:56,000 --> 02:07:58,320 GERMINAL CENTER REACTIONS OVER 3293 02:07:58,320 --> 02:07:59,920 CONVENTIONAL STRATEGIES AND THE 3294 02:07:59,920 --> 02:08:03,680 ANSWER WAS YES. 3295 02:08:03,680 --> 02:08:06,920 IN P 213 WE REPEAT TO CONFIRM 3296 02:08:06,920 --> 02:08:08,200 PRE-CLINICAL STUDY BY DR. 3297 02:08:08,200 --> 02:08:11,000 HUNTERS AND AMARA VACCINE INDUCE 3298 02:08:11,000 --> 02:08:12,600 CELLULAR IMMUNE RESPONSE REDUCE 3299 02:08:12,600 --> 02:08:14,720 THRESHOLD OF NEUTRALIZING 3300 02:08:14,720 --> 02:08:16,480 ANTIBODIES REQUIRED TO CONFER 3301 02:08:16,480 --> 02:08:20,840 SUPERIOR AND DURABLE PROTECTION. 3302 02:08:20,840 --> 02:08:22,880 I WOULD LIKE TO ALSO POINT OUT 3303 02:08:22,880 --> 02:08:24,560 AS MENTIONED ON THE PREVIOUS 3304 02:08:24,560 --> 02:08:26,240 SLIDE THESE PRE-CLINICAL STUDIES 3305 02:08:26,240 --> 02:08:29,720 MAY ALSO HELP TO GUIDE INFORM 3306 02:08:29,720 --> 02:08:30,080 PHASE 1 TRIALS. 3307 02:08:30,080 --> 02:08:33,160 SUCH AS WAS THE CASE WITH P 192 3308 02:08:33,160 --> 02:08:35,200 WITH DR. ROBINSON WHERE PRODUCTS 3309 02:08:35,200 --> 02:08:38,040 PLATFORM WENT ON TO BE TESTED IN 3310 02:08:38,040 --> 02:08:41,000 THREE CLINICAL TRIALS. 3311 02:08:41,000 --> 02:08:44,760 HBTN 094, 114 AND 205. 3312 02:08:44,760 --> 02:08:48,040 NEXT. 3313 02:08:48,040 --> 02:08:49,840 IN P 210A THIS PRE-CLINICAL 3314 02:08:49,840 --> 02:08:51,440 STUDY IS CONDUCTED IN PARALLEL 3315 02:08:51,440 --> 02:08:54,160 WITH THE CLINICAL TRIAL HBTN 137 3316 02:08:54,160 --> 02:08:57,640 TO COMPARE THE IMMUNOGENICITY OF 3317 02:08:57,640 --> 02:08:58,720 DIFFERENT ADJUVANTS. 3318 02:08:58,720 --> 02:09:00,480 THUS IN ITS CAPACITY THE 3319 02:09:00,480 --> 02:09:02,160 CELLULAR IMMUNOLOGY LAB SUPPORTS 3320 02:09:02,160 --> 02:09:04,160 AND CONTRIBUTES TO THE 3321 02:09:04,160 --> 02:09:08,040 EVALUATION OF ALL THESE VACCINE 3322 02:09:08,040 --> 02:09:09,880 CANDIDATES. 3323 02:09:09,880 --> 02:09:11,840 THE CURRENT ACTIVITIES OF THE 3324 02:09:11,840 --> 02:09:13,960 CELLULAR LAB ARE TO DEVELOP 3325 02:09:13,960 --> 02:09:16,000 OPTIMIZE AND VALIDATE CELLULAR 3326 02:09:16,000 --> 02:09:16,920 ASSAYS. 3327 02:09:16,920 --> 02:09:20,880 EXAMPLES OF SUCH ASSAYS ARE THE 3328 02:09:20,880 --> 02:09:22,840 ELISPOT FLOW BASE ASSAY Z SUCH 3329 02:09:22,840 --> 02:09:24,640 AS INTRACELLULAR CYTOKINE 3330 02:09:24,640 --> 02:09:26,480 STAINING ACTIVATION IMMUNE 3331 02:09:26,480 --> 02:09:28,480 MARKER OR ASSAYS AND CELL 3332 02:09:28,480 --> 02:09:28,920 SORTING. 3333 02:09:28,920 --> 02:09:31,320 IN ADDITION THE LAB GENERATES 3334 02:09:31,320 --> 02:09:33,800 STANDARDIZED SOPs FOR 3335 02:09:33,800 --> 02:09:35,440 EQUIPMENT OPERATION AND VARIOUS 3336 02:09:35,440 --> 02:09:37,120 PROCESSES SUCH AS ANTIBODY 3337 02:09:37,120 --> 02:09:39,280 TITRATION AND HOW TO PROCESS 3338 02:09:39,280 --> 02:09:41,520 MUCOSAL SAMPLES. 3339 02:09:41,520 --> 02:09:42,600 IMPORTANTLY, ALL THE WORK DONE 3340 02:09:42,600 --> 02:09:45,480 BY THE LABORATORY FOLLOWS GOOD 3341 02:09:45,480 --> 02:09:47,720 LABORATORY PRACTICE OR GLP. 3342 02:09:47,720 --> 02:09:50,520 THE CELLULAR LAB IS ABLE TO 3343 02:09:50,520 --> 02:09:52,400 CONDUCT ASSAYS ON FRESH AND 3344 02:09:52,400 --> 02:09:55,160 FROZEN PBMCs WHOLE BLOOD 3345 02:09:55,160 --> 02:09:56,640 MUCOSAL TISSUE AS WELL AS 3346 02:09:56,640 --> 02:09:57,840 LYMPHOID TISSUES. 3347 02:09:57,840 --> 02:09:59,440 AND THE DATA GENERATED FROM 3348 02:09:59,440 --> 02:10:03,520 THESE ASSAYS ARE ANALYZED USING 3349 02:10:03,520 --> 02:10:04,280 DIFFERENT ANALYTICAL SOFTWARE 3350 02:10:04,280 --> 02:10:09,680 SUCH AS FLOW JOE, PRISM, UMAP 3351 02:10:09,680 --> 02:10:11,120 AND R AND PUBLICATION QUALITY 3352 02:10:11,120 --> 02:10:13,920 FIGURES CAN BE GENERATED. 3353 02:10:13,920 --> 02:10:16,280 LASTLY FROM START TO FINISH, ALL 3354 02:10:16,280 --> 02:10:19,000 THESE ACTIVITIES ARE REVIEWED BY 3355 02:10:19,000 --> 02:10:22,480 INDEPENDENT QUALITY ASSURANCE 3356 02:10:22,480 --> 02:10:26,840 UNIT. 3357 02:10:26,840 --> 02:10:28,760 THE CURRENT CONTRACT IS ABOUT 28 3358 02:10:28,760 --> 02:10:30,440 VALIDATED ASSAY SOPs. 3359 02:10:30,440 --> 02:10:33,120 FOR THE SAKE OF TIME, I WON'T GO 3360 02:10:33,120 --> 02:10:34,480 THROUGH THE LIST BUT I WILL 3361 02:10:34,480 --> 02:10:37,120 BRIEFLY GO OVER AWE THE ASSAYS 3362 02:10:37,120 --> 02:10:40,720 ARE VALIDATED LATER IN THE 3363 02:10:40,720 --> 02:10:41,520 PRESENTATION. 3364 02:10:41,520 --> 02:10:44,480 IN ADDITION TO THE ASSAYS, THE 3365 02:10:44,480 --> 02:10:45,840 CURRENT CONTRACT HAS DEVELOPED 3366 02:10:45,840 --> 02:10:47,960 20 VALIDATED EQUIPMENT SOPs. 3367 02:10:47,960 --> 02:10:50,040 I THINK IT IS EASY TO UNDERSTAND 3368 02:10:50,040 --> 02:10:51,720 WHY THE ASSAYS ARE VALIDATED. 3369 02:10:51,720 --> 02:10:53,440 BUT YOU MAY WONDER WHY IT IS 3370 02:10:53,440 --> 02:10:55,720 IMPORTANT TO HAVE A VALIDATED 3371 02:10:55,720 --> 02:10:57,360 PROTOCOL FOR EQUIPMENT SUCH AS 3372 02:10:57,360 --> 02:10:59,360 FREEZERS AS AN EXAMPLE. 3373 02:10:59,360 --> 02:11:00,840 SO AS YOU CAN IMAGINE WE DO NOT 3374 02:11:00,840 --> 02:11:03,920 WANT TO RISK LOSING THOUSANDS OF 3375 02:11:03,920 --> 02:11:07,320 SAMPLES SO WE HAVE AN AUTOMATED 3376 02:11:07,320 --> 02:11:08,560 MONITORING SYSTEM AS WELL AS 3377 02:11:08,560 --> 02:11:10,640 MANUAL CHECKS TO ENSURE THE 3378 02:11:10,640 --> 02:11:11,520 PROPER TEMPERATURE AND STORES OF 3379 02:11:11,520 --> 02:11:14,360 THE SAMPLES. 3380 02:11:14,360 --> 02:11:15,960 AND BECAUSE CELLULAR IMMUNOLOGY 3381 02:11:15,960 --> 02:11:18,200 LAB WORKS UNDER GLP LIKE 3382 02:11:18,200 --> 02:11:20,360 PRACTICES THESE SOPs ARE 3383 02:11:20,360 --> 02:11:21,960 IMPORTANT FOR DOCUMENTATION 3384 02:11:21,960 --> 02:11:24,200 WHICH ARE REVIEWED BY THE 3385 02:11:24,200 --> 02:11:27,560 INDEPENDENT QUALITY ASSURANCE 3386 02:11:27,560 --> 02:11:29,360 PROGRAM. 3387 02:11:29,360 --> 02:11:30,880 TO GIVE YOU A SENSE OF WHAT WE 3388 02:11:30,880 --> 02:11:33,880 ARE ABLE TO DO THE LAB HAS THE 3389 02:11:33,880 --> 02:11:35,720 CAPABILITY TO CONDUCT COMPLEX 3390 02:11:35,720 --> 02:11:38,400 SORTING TO ISOLATE RARE ANTIGEN 3391 02:11:38,400 --> 02:11:39,800 SPECIFIC B CELLS FROM LYMPH 3392 02:11:39,800 --> 02:11:40,200 NODES. 3393 02:11:40,200 --> 02:11:42,000 THIS IS QUITE LABORIOUS AND 3394 02:11:42,000 --> 02:11:43,680 THESE SORTS CAN TAKE THE WHOLE 3395 02:11:43,680 --> 02:11:44,320 DATA RUN. 3396 02:11:44,320 --> 02:11:47,000 IN CONTRAST TO THIS TYPE OF CELL 3397 02:11:47,000 --> 02:11:49,120 SORT THE LAB CAN CONDUCT HIGH 3398 02:11:49,120 --> 02:11:51,120 THROUGH PUT SORTING WITH UP TO 3399 02:11:51,120 --> 02:11:53,280 18 HIGH PURITY SORTS. 3400 02:11:53,280 --> 02:11:56,680 AS AN EXAMPLE WE CAN CONINE 3401 02:11:56,680 --> 02:11:58,120 ANIMALS WITH TWO SAMPLES A DAY. 3402 02:11:58,120 --> 02:12:00,200 IN EITHER CASE THE SORTED CELLS 3403 02:12:00,200 --> 02:12:01,320 ARE USED FOR OTHER COULDN'T 3404 02:12:01,320 --> 02:12:04,800 STREAM APPLICATIONS SUCH AS 10X 3405 02:12:04,800 --> 02:12:09,240 GENOMICS OR CELL SPECIFIC RNA 3406 02:12:09,240 --> 02:12:09,640 SEQ. 3407 02:12:09,640 --> 02:12:10,000 NEXT. 3408 02:12:10,000 --> 02:12:12,200 THE LAB ALSO HAS THE CAPABILITY 3409 02:12:12,200 --> 02:12:14,320 TO CONDUCT FLOW BASE ASSAYS, 3410 02:12:14,320 --> 02:12:16,840 THEY CAN DESIGN AND OPTIMIZE UP 3411 02:12:16,840 --> 02:12:18,680 TO 20 PARAMETER PANELS. 3412 02:12:18,680 --> 02:12:20,880 THEY CAN ALSO CONDUCT ABSOLUTE 3413 02:12:20,880 --> 02:12:23,040 COUNTS, HAVE HIGH THROUGH PUT 3414 02:12:23,040 --> 02:12:24,800 ACQUISITION AND HAVE EXPERTISE 3415 02:12:24,800 --> 02:12:26,960 IN CELL PROLIFERATION AND CELL 3416 02:12:26,960 --> 02:12:30,000 OF CYCLE ASSAYS SUCH AS THE BRDU 3417 02:12:30,000 --> 02:12:32,680 AND CFSE ASSAYS. 3418 02:12:32,680 --> 02:12:34,480 LASTLY THEY ALSO HAVE THE 3419 02:12:34,480 --> 02:12:36,720 EXPERTISE TO CONDUCT ASSAYS TO 3420 02:12:36,720 --> 02:12:40,760 EXAMINE PHAGOCYTOSIS. 3421 02:12:40,760 --> 02:12:45,240 AN EXAMPLE OF HIGH THROUGH PUT 3422 02:12:45,240 --> 02:12:46,280 ACQUISITION SINCE THE START OF 3423 02:12:46,280 --> 02:12:48,280 THE CONTRACT THEY HAVE RUN 3424 02:12:48,280 --> 02:12:50,200 20,000 FAX TUBES FOR FLOW SIGH 3425 02:12:50,200 --> 02:12:54,000 FOE ME TRUCK ASSAYS ALONE. 3426 02:12:54,000 --> 02:12:57,240 THE CONDUCT OF ASSAYS IS 3427 02:12:57,240 --> 02:12:58,600 OBVIOUSLY INTEGRAL TO CONTRACT 3428 02:12:58,600 --> 02:12:59,520 ACTIVITIES. 3429 02:12:59,520 --> 02:13:00,960 HOWEVER, THE DATA ANALYSIS IS 3430 02:13:00,960 --> 02:13:03,440 NOT USUALLY EMPHASIZED AS MUCH. 3431 02:13:03,440 --> 02:13:05,120 HERE IN THE NEXT FEW SLIDES I 3432 02:13:05,120 --> 02:13:07,480 WANT TO DEMONSTRATE THAT NOT 3433 02:13:07,480 --> 02:13:08,920 ONLY DATA -- NOT ONLY ARE THE 3434 02:13:08,920 --> 02:13:10,880 DATA ANALYSES EQUALLY AS 3435 02:13:10,880 --> 02:13:13,400 IMPORTANT AS ASSAYS THEMSELVES. 3436 02:13:13,400 --> 02:13:15,600 BUT THE CURRENT CONTRACT ALSO 3437 02:13:15,600 --> 02:13:17,000 UTILIZES STATES OF THE ART 3438 02:13:17,000 --> 02:13:19,480 METHODS FOR DATA ANALYSIS. 3439 02:13:19,480 --> 02:13:22,280 AS JUST MENTIONED, THE CELLULAR 3440 02:13:22,280 --> 02:13:24,480 IMMUNOLOGY LAB IS ABLE TO DESIGN 3441 02:13:24,480 --> 02:13:27,080 A FLOW PANEL UP TO 28 PARAMETERS 3442 02:13:27,080 --> 02:13:29,560 OR CELL MARKERS TO PHENOTYPE 3443 02:13:29,560 --> 02:13:33,160 IMMUNE CELL POPULATIONS. 3444 02:13:33,160 --> 02:13:34,920 THE DATA OBTAINED ARE THEN 3445 02:13:34,920 --> 02:13:37,960 COMMONLY VISUALIZED USING 3446 02:13:37,960 --> 02:13:38,520 SCATTER PLOTS. 3447 02:13:38,520 --> 02:13:40,200 YOU CAN DRAW GATES AROUND THE 3448 02:13:40,200 --> 02:13:43,480 POPULATION OF INTEREST TO 3449 02:13:43,480 --> 02:13:44,640 FURTHER DRILL DOWN TO SPECIFIC 3450 02:13:44,640 --> 02:13:47,480 MARKER YOU ARE ANALYZING. 3451 02:13:47,480 --> 02:13:50,720 DRAW BACK IS THIS IS ONLY DONE 3452 02:13:50,720 --> 02:13:52,200 WITH TWO PARAMETERS OR MARKER AT 3453 02:13:52,200 --> 02:13:52,640 A TIME. 3454 02:13:52,640 --> 02:13:55,520 ONE MARKER ON THE Y AXIS AND ONE 3455 02:13:55,520 --> 02:13:58,360 ON X AXIS. 3456 02:13:58,360 --> 02:14:00,320 YOU HAVE 28 MARKERS NEED TO BE 3457 02:14:00,320 --> 02:14:01,120 ANALYZED IN DIFFERENT 3458 02:14:01,120 --> 02:14:03,920 COMBINATIONS. 3459 02:14:03,920 --> 02:14:04,720 AS YOU CAN IMAGINE YOU CAN END 3460 02:14:04,720 --> 02:14:06,160 UP WITH LOTS OF LITTLE GRAPHS 3461 02:14:06,160 --> 02:14:11,720 THAT LOOK LIKE THIS. 3462 02:14:11,720 --> 02:14:13,280 YOU HAVE HUNDREDS OF LOW GRAPHS 3463 02:14:13,280 --> 02:14:15,320 BUT WHAT IF YOU HAVE MULTIPLE 3464 02:14:15,320 --> 02:14:16,560 TISSUES TO ANALYZE? 3465 02:14:16,560 --> 02:14:18,560 HERE WE HAVE DATA ON CELLS TAKEN 3466 02:14:18,560 --> 02:14:20,920 FROM THE BLOOD PBMCs AND ALSO 3467 02:14:20,920 --> 02:14:25,680 CELLS FROM THE COLON. 3468 02:14:25,680 --> 02:14:27,280 SO NOT ONLY DO YOU HAVE TO 3469 02:14:27,280 --> 02:14:29,280 ANALYZE DATA FROM THE SAME 3470 02:14:29,280 --> 02:14:32,440 ANIMAL, WITH DIFFERENT TISSUES 3471 02:14:32,440 --> 02:14:33,000 NOW YOU HAVE MULTIPLE TIME 3472 02:14:33,000 --> 02:14:37,640 POINTS. YOU DON'T DO A STUDY 3473 02:14:37,640 --> 02:14:39,200 WITH ONE ANIMAL, U YOU DO THE 3474 02:14:39,200 --> 02:14:40,960 SAME ANALYSIS FOR MULTIPLE 3475 02:14:40,960 --> 02:14:41,560 ANIMALS. 3476 02:14:41,560 --> 02:14:44,720 SOME OF THESE SBU STUDIES CAN 3477 02:14:44,720 --> 02:14:46,840 HAVE UP TO 20 TO 30 ANIMALS. 3478 02:14:46,840 --> 02:14:49,800 DEPENDING ON THE STUDY, WE HAVE 3479 02:14:49,800 --> 02:14:51,400 DIFFERENT -- SEVERAL DIFFERENT 3480 02:14:51,400 --> 02:14:53,320 PHENOTYPE PANELS TO ANALYZE. 3481 02:14:53,320 --> 02:14:55,160 SO EACH PRE-CLINICAL STUDY CAN 3482 02:14:55,160 --> 02:14:57,240 GENERATE HUNDREDS AND HUNDREDS 3483 02:14:57,240 --> 02:15:00,320 OF THESE LITTLE GRAPHS. 3484 02:15:00,320 --> 02:15:00,880 WHILE THERE IS NOTHING WRONG 3485 02:15:00,880 --> 02:15:03,080 WITH THIS ANALYSIS AND DOES HAVE 3486 02:15:03,080 --> 02:15:04,880 ITS PLACE, TO TRY TO GET A 3487 02:15:04,880 --> 02:15:06,800 GLOBAL PERSPECTIVE OF WHAT IS 3488 02:15:06,800 --> 02:15:08,320 HAPPENING AFTER VACCINATION 3489 02:15:08,320 --> 02:15:09,480 AND/OR INFECTION IS VERY 3490 02:15:09,480 --> 02:15:14,120 DIFFICULT. 3491 02:15:14,120 --> 02:15:15,680 A DIFFERENT METHOD OF ANALYSIS 3492 02:15:15,680 --> 02:15:17,200 MUST BE DONE IF YOU WANT TO GET 3493 02:15:17,200 --> 02:15:20,600 A GLOBAL SENSE OF THE IMMUNE 3494 02:15:20,600 --> 02:15:21,000 RESPONSE. 3495 02:15:21,000 --> 02:15:22,480 IN THE PREVIOUS SLIDES WE ARE 3496 02:15:22,480 --> 02:15:24,080 ONLY ANALYZING TWO VARIABLES AT 3497 02:15:24,080 --> 02:15:24,600 A TIME. 3498 02:15:24,600 --> 02:15:27,440 BUT IF YOU WANT TO LOOK AT ALL 3499 02:15:27,440 --> 02:15:30,360 28 VARIABLES YOU NEED WAY TO 3500 02:15:30,360 --> 02:15:32,520 PERFORM A MULTI-DIMENSIONALITY 3501 02:15:32,520 --> 02:15:34,400 ANALYSIS AND GRAPH IT ON A 2D 3502 02:15:34,400 --> 02:15:38,680 PLOT TO VISUALIZE THE DATA. 3503 02:15:38,680 --> 02:15:40,240 ONE METHOD IS THE PRINCIPLE 3504 02:15:40,240 --> 02:15:41,920 COMPONENT ANALYSIS. 3505 02:15:41,920 --> 02:15:44,160 WHICH YOU MAY BE LIKELY FAMILIAR 3506 02:15:44,160 --> 02:15:45,480 WITH OR AT LEAST HEARD OF. 3507 02:15:45,480 --> 02:15:48,760 PCA IS A LINEAR PAIR WISE TYPE 3508 02:15:48,760 --> 02:15:50,320 ANALYSIS BUT IN THE RESULTING 3509 02:15:50,320 --> 02:15:52,120 DATA, IT IS HARD TO TEASE OUT 3510 02:15:52,120 --> 02:15:58,640 THE INDIVIDUAL POPULATION. 3511 02:15:58,640 --> 02:16:00,160 THEN IN 2008 THE STOCHASTIC 3512 02:16:00,160 --> 02:16:03,040 NEIGHBORHOOD EMBEDDING ANALYSIS 3513 02:16:03,040 --> 02:16:04,120 WAS DEVELOPED. 3514 02:16:04,120 --> 02:16:06,440 THIS METHOD UTILIZES A 3515 02:16:06,440 --> 02:16:08,640 NON-LINEAR DIMENSIONALITY 3516 02:16:08,640 --> 02:16:09,760 REDUCTION ALGORITHM. 3517 02:16:09,760 --> 02:16:12,040 YOU BEGIN TO SEE INDIVIDUAL 3518 02:16:12,040 --> 02:16:13,200 POPULATIONS BUT THEY STILL ARE 3519 02:16:13,200 --> 02:16:19,440 NOT SEPARATED WELL. 3520 02:16:19,440 --> 02:16:21,320 THE UNIFORMMAN FOLD 3521 02:16:21,320 --> 02:16:24,360 APPROXIMATION AND PROJECTION 3522 02:16:24,360 --> 02:16:25,160 AREN'T YOU GLAD OF THESE 3523 02:16:25,160 --> 02:16:28,640 ACRONYM? 3524 02:16:28,640 --> 02:16:30,840 NON-LINEAR DIMENSIONALITY 3525 02:16:30,840 --> 02:16:32,280 REDUCTION ALGORITHM WHEN THAT 3526 02:16:32,280 --> 02:16:35,000 WAS RECENTLY DEVELOPED IN 2018. 3527 02:16:35,000 --> 02:16:37,480 THIS METHOD PRESERVES LOCAL 3528 02:16:37,480 --> 02:16:38,880 GLOBAL STRUCTURE INCLUDING 3529 02:16:38,880 --> 02:16:40,480 CLUSTER DISTANCE AND WHAT THAT 3530 02:16:40,480 --> 02:16:41,880 BOILS DOWN TO IS THAT YOU NOW 3531 02:16:41,880 --> 02:16:44,200 GET MORE DEFINED AND SEPARATED 3532 02:16:44,200 --> 02:16:49,120 CELL POPULATION. 3533 02:16:49,120 --> 02:16:52,840 SO SURE THAT WAS A BIT MIND 3534 02:16:52,840 --> 02:16:54,680 NUMBING BUT WHAT DOES THIS DATA 3535 02:16:54,680 --> 02:16:57,040 REALLY LOOK LIKE ONCE EMPLOY 3536 02:16:57,040 --> 02:16:58,360 THESE DIMENSIONALITY REDUCTION 3537 02:16:58,360 --> 02:16:59,760 METHODS? 3538 02:16:59,760 --> 02:17:01,520 SO AS A REMINDER THIS IS WHAT WE 3539 02:17:01,520 --> 02:17:02,400 STARTED WITH. 3540 02:17:02,400 --> 02:17:05,160 HUNDREDS OF THESE LITTLE GRAPHS. 3541 02:17:05,160 --> 02:17:06,640 WE WANT TO RECUSE NUMBER OF 3542 02:17:06,640 --> 02:17:08,040 GRAPHS TO LOOK -- REDUCE NUMBER 3543 02:17:08,040 --> 02:17:09,400 OF GRAPHS TO LOOK AT VARIABLES 3544 02:17:09,400 --> 02:17:12,240 AT ONCE. 3545 02:17:12,240 --> 02:17:14,880 SO USING THE TISNE METHOD YOU 3546 02:17:14,880 --> 02:17:16,320 CAN TRANSFORM THE DATA TO GET 3547 02:17:16,320 --> 02:17:19,480 ONE GLOBAL PICTURE. 3548 02:17:19,480 --> 02:17:21,800 FROM THIS GLOBAL PICTURE YOU CAN 3549 02:17:21,800 --> 02:17:24,280 THEN DRILL DOWN IDENTIFY AND 3550 02:17:24,280 --> 02:17:26,280 CHARACTERIZE CELL POPULATION OF 3551 02:17:26,280 --> 02:17:28,280 INTEREST BASED ON GROUPS FORMED 3552 02:17:28,280 --> 02:17:31,160 AS DEPICTED BY THE REGION 3553 02:17:31,160 --> 02:17:32,960 OUTLINED IN BLUE. 3554 02:17:32,960 --> 02:17:34,440 EARLIER I SAID WE CAN ALSO 3555 02:17:34,440 --> 02:17:36,800 CONDUCT ASSAYS ON MULTIPLE 3556 02:17:36,800 --> 02:17:37,040 TISSUES. 3557 02:17:37,040 --> 02:17:38,800 HERE HAVING THE ABILITY TO 3558 02:17:38,800 --> 02:17:41,800 QUICKLY COMPARE BETWEEN TWO 3559 02:17:41,800 --> 02:17:43,360 TISSUES IS HELPFUL. 3560 02:17:43,360 --> 02:17:46,640 AND IN THIS CASE THE DECIDUA, A 3561 02:17:46,640 --> 02:17:49,800 SPECIALIZED LAYER OF THE 3562 02:17:49,800 --> 02:17:51,640 ENDOMETRIUM IN UTERUS THAT FORMS 3563 02:17:51,640 --> 02:17:53,760 IN PREGNANCY IS IS IN THE TOP 3564 02:17:53,760 --> 02:17:55,720 MIDDLE PANEL AND PBMCs ARE 3565 02:17:55,720 --> 02:17:57,480 BOTTOM MIDDLE PANEL. 3566 02:17:57,480 --> 02:17:59,400 WITH JUST A GLANCE ONE CAN 3567 02:17:59,400 --> 02:18:01,040 READILY SEE GLOBAL DIFFERENCES 3568 02:18:01,040 --> 02:18:02,560 BETWEEN THE TWO SAMPLES WITHOUT 3569 02:18:02,560 --> 02:18:04,080 HAVING TO LOOK AT A BUNCH OF 3570 02:18:04,080 --> 02:18:08,880 LITTLE GRAPHS. 3571 02:18:08,880 --> 02:18:10,360 FINALLY, WE GET TO WHAT THE DATA 3572 02:18:10,360 --> 02:18:11,840 WOULD LOOK LIKE WHEN YOU 3573 02:18:11,840 --> 02:18:14,120 TRANSITION FROM TSNE TO U MAP 3574 02:18:14,120 --> 02:18:14,680 ANALYSIS. 3575 02:18:14,680 --> 02:18:17,360 HERE YOU CAN CLEARLY SEE THAT 3576 02:18:17,360 --> 02:18:18,360 THE DIFFERENT CELL POPULATIONS 3577 02:18:18,360 --> 02:18:19,480 ARE NOW WELL DEFINED AND 3578 02:18:19,480 --> 02:18:22,920 SEPARATED. 3579 02:18:22,920 --> 02:18:25,040 SO THE OVERALL POINT I'M TRYING 3580 02:18:25,040 --> 02:18:27,240 TO MAKE, OVER THE LIFE SPAN OF 3581 02:18:27,240 --> 02:18:30,320 THE CONTRACT, AS THE FIELD 3582 02:18:30,320 --> 02:18:31,840 CHANGES, NOT ONLY DO TYPES OF 3583 02:18:31,840 --> 02:18:33,760 ASSAYS NEED TO ADAPT AND EVOLVE 3584 02:18:33,760 --> 02:18:35,920 JUST AS IMPORTANTLY, SO DO THE 3585 02:18:35,920 --> 02:18:38,360 METHODS FOR DATA ANALYSES. 3586 02:18:38,360 --> 02:18:41,120 MAINTAINING STATE OF THE ART 3587 02:18:41,120 --> 02:18:41,800 CAPABILITIES IS REQUIREMENT 3588 02:18:41,800 --> 02:18:43,600 WRITTEN INTO THE STATEMENT OF 3589 02:18:43,600 --> 02:18:51,040 WORK IN THE CONTRACT. 3590 02:18:51,040 --> 02:18:54,280 CONDUCTED BY CELLULAR IMMUNOLOGY 3591 02:18:54,280 --> 02:18:55,480 LABORATORY ALLOW COMPARISON 3592 02:18:55,480 --> 02:18:56,680 ACROSS MULTIPLE STUDY. 3593 02:18:56,680 --> 02:18:58,240 WE HAVE PROCEDURES IN PLACE WITH 3594 02:18:58,240 --> 02:19:02,120 INTERNALLY AND EXTERNALLY TO 3595 02:19:02,120 --> 02:19:04,080 ENSURE RIGOR AND REPRODUCIBLE. 3596 02:19:04,080 --> 02:19:08,160 INTERNAL MEASURES INCLUDE USE OF 3597 02:19:08,160 --> 02:19:08,960 REFERENCE CONTROLS SASS INTERNAL 3598 02:19:08,960 --> 02:19:11,080 QC QUALITY CONTROL AND ASSAYS, 3599 02:19:11,080 --> 02:19:13,280 AND WHEN NEW ASSAYS ARE 3600 02:19:13,280 --> 02:19:14,920 VALIDATED WE HAVE A LARGE 3601 02:19:14,920 --> 02:19:16,400 REFERENCE PANEL USED AS 3602 02:19:16,400 --> 02:19:20,120 REFERENCE CONTROL SAMPLES. 3603 02:19:20,120 --> 02:19:22,760 WE VALIDATE ASSAYS USING THE 3604 02:19:22,760 --> 02:19:24,040 RULE 3 SUCH AS TESTING TWO OR 3605 02:19:24,040 --> 02:19:26,080 THREE OPERATORS, THAT DEPENDS ON 3606 02:19:26,080 --> 02:19:27,400 NUMBER OF PERSONNEL STAFF WE 3607 02:19:27,400 --> 02:19:27,880 HAVE. 3608 02:19:27,880 --> 02:19:30,760 EACH CONDITION TESTED IS DONE 3609 02:19:30,760 --> 02:19:32,320 TRIPLICAT AND TESTING IS DONE ON 3610 02:19:32,320 --> 02:19:34,240 THREE DIFFERENT DAYS. 3611 02:19:34,240 --> 02:19:37,160 THIS ALLOWS US US TO EVALUATE 3612 02:19:37,160 --> 02:19:40,520 THE INTRAAND INTERASSAY AND THE 3613 02:19:40,520 --> 02:19:42,600 ENTER AND INTEROPERATOR 3614 02:19:42,600 --> 02:19:44,320 VARIABILITY MEASURED USING THE 3615 02:19:44,320 --> 02:19:45,800 MIEN STANDARD DEVIATION AND 3616 02:19:45,800 --> 02:19:46,760 COEFFICIENT OF VARIATION AS 3617 02:19:46,760 --> 02:19:50,400 PARAMETERS. 3618 02:19:50,400 --> 02:19:51,760 LASTLY, CROSS TRAINING OF STAFF 3619 02:19:51,760 --> 02:19:53,840 ASSAYS ARE DONE TO ENSURE 3620 02:19:53,840 --> 02:19:55,160 SEAMLESS COVERAGE AND THIS 3621 02:19:55,160 --> 02:19:57,200 ALLOWS US TO MINIMIZE 3622 02:19:57,200 --> 02:20:00,720 INTEROPERATOR VARIABILITY. 3623 02:20:00,720 --> 02:20:02,640 OUR EXTERNAL PROCEDURES TO 3624 02:20:02,640 --> 02:20:05,280 ENSURE RIGOR AND REPRODUCIBILITY 3625 02:20:05,280 --> 02:20:07,320 INCLUDE REGULAR INSPECTIONS BY 3626 02:20:07,320 --> 02:20:08,960 INDEPENDENT QUALITY ASSURANCE 3627 02:20:08,960 --> 02:20:11,520 UNIT OF ALL SOPs, ALL 3628 02:20:11,520 --> 02:20:12,200 DOCUMENTATIONS, EQUIPMENT AND 3629 02:20:12,200 --> 02:20:13,200 TRAINING. 3630 02:20:13,200 --> 02:20:15,960 IN ADDITION, THIS UNIT ATTENDS 3631 02:20:15,960 --> 02:20:18,960 ALL BIWEEKLY CALLS. 3632 02:20:18,960 --> 02:20:21,600 THE LABORATORY ALSO PARTICIPATE 3633 02:20:21,600 --> 02:20:24,000 IN THE EXTERNAL QUALITY 3634 02:20:24,000 --> 02:20:29,600 ASSURANCE PROGRAM OR EQUIPAL. 3635 02:20:29,600 --> 02:20:31,800 ELISPOT AND FLOW CYTOMETRY 3636 02:20:31,800 --> 02:20:33,600 ASSAYS ACT CANNED THROUGH EQAPOL 3637 02:20:33,600 --> 02:20:34,680 AND THIS IS DONE ANNUALLY. 3638 02:20:34,680 --> 02:20:40,520 YOU WILL HERE MORE ABOUT THE 3639 02:20:40,520 --> 02:20:42,120 EQAPOL BY MY COLLEAGUE MILTON 3640 02:20:42,120 --> 02:20:43,440 MACIEL RIGHT AFTER THIS 3641 02:20:43,440 --> 02:20:44,080 PRESENTATION. 3642 02:20:44,080 --> 02:20:47,160 SO FOR THE REISSUANCE OF THIS 3643 02:20:47,160 --> 02:20:48,320 CONTRACT THE CONTRACT WILL BE 3644 02:20:48,320 --> 02:20:49,840 EXPECTED TO MAINTAIN STATE OF 3645 02:20:49,840 --> 02:20:51,760 THE ART CAPABILITY FOR THE 3646 02:20:51,760 --> 02:20:54,840 CONDUCT OF CELLULAR IMMUNE SAYS 3647 02:20:54,840 --> 02:20:56,600 IN SUPPORT OF PRE-CLINICAL SAW 3648 02:20:56,600 --> 02:20:57,440 STUDIES. 3649 02:20:57,440 --> 02:20:58,640 ADDITIONALLY WE PROPOSE TO 3650 02:20:58,640 --> 02:21:00,000 EXPAND ACTIVITIES TO CONDUCT 3651 02:21:00,000 --> 02:21:02,840 ASSAYS ON SMALL ANIMALS. 3652 02:21:02,840 --> 02:21:04,280 NOT EVERY PRE-CLINICAL STUDY 3653 02:21:04,280 --> 02:21:05,840 NEEDS TO BE DONE ON NON-HUMAN 3654 02:21:05,840 --> 02:21:06,520 PRIMATES. 3655 02:21:06,520 --> 02:21:08,520 AND WITH THE LIMITED NUMBER OF 3656 02:21:08,520 --> 02:21:11,800 NHPs AVAILABLE, EXPERIMENTS 3657 02:21:11,800 --> 02:21:12,720 USING DIFFERENT MOUSE MODELS 3658 02:21:12,720 --> 02:21:14,720 MAYBE APPROPRIATE AND WE WOULD 3659 02:21:14,720 --> 02:21:16,480 LIKE TO BE ABLE TO SUPPORT THESE 3660 02:21:16,480 --> 02:21:18,120 STUDIES. 3661 02:21:18,120 --> 02:21:20,320 WE WOULD ALSO LIKE TO BROADEN 3662 02:21:20,320 --> 02:21:22,560 THE SCOPE OF THE CONTRACT FROM 3663 02:21:22,560 --> 02:21:25,040 JUST HIV TO OTHER PATHOGENS. 3664 02:21:25,040 --> 02:21:26,280 IN PARTICULAR WE WERE THINKING 3665 02:21:26,280 --> 02:21:28,800 ABOUT BEING ABLE TO SUPPORT TB 3666 02:21:28,800 --> 02:21:30,920 VACCINE STUDIES IN THE CONTEXT 3667 02:21:30,920 --> 02:21:33,120 OF MYCOBACTERIUM TUBERCULOSIS 3668 02:21:33,120 --> 02:21:37,120 AND SIV HIV CO-INFECTION. 3669 02:21:37,120 --> 02:21:38,800 MOREOVER THE BROADER SCOPE WOULD 3670 02:21:38,800 --> 02:21:40,680 ALLOW US TO HAVE GREATER 3671 02:21:40,680 --> 02:21:42,280 FLEXIBILITY AS PART OF THE 3672 02:21:42,280 --> 02:21:43,760 EFFORTS FOR PANDEMIC 3673 02:21:43,760 --> 02:21:44,360 PREPAREDNESS SHOULD THE NEED 3674 02:21:44,360 --> 02:21:47,120 ARISE. 3675 02:21:47,120 --> 02:21:48,720 LASTLY, WE WILL REQUIRE THAT ALL 3676 02:21:48,720 --> 02:21:50,920 DATA BE DEPOSITED INTO A MORE 3677 02:21:50,920 --> 02:21:55,320 CENTRALIZED DATABASE. 3678 02:21:55,320 --> 02:21:58,960 THE REVIEWERS FOR THIS 3679 02:21:58,960 --> 02:22:00,960 INITIATIVE WERE DR.S FREEBURG 3680 02:22:00,960 --> 02:22:02,640 AND JEROME, THEY WERE SUPPORTIVE 3681 02:22:02,640 --> 02:22:03,520 OF THE CONCEPT. 3682 02:22:03,520 --> 02:22:04,640 THEY WROTE I'M ENTHUSIASTIC 3683 02:22:04,640 --> 02:22:06,200 ABOUT THE CELLULAR IMMUNOLOGY 3684 02:22:06,200 --> 02:22:06,800 CORE LAB. 3685 02:22:06,800 --> 02:22:10,120 AND THIS IS AN IMPORTANT RFA. 3686 02:22:10,120 --> 02:22:12,240 THERE IS A CLEAR NEED FOR WELL 3687 02:22:12,240 --> 02:22:13,760 STANDARDIZED ASSAYS ESPECIALLY 3688 02:22:13,760 --> 02:22:16,040 IN THE PRE-CLINICAL AND CLINICAL 3689 02:22:16,040 --> 02:22:16,720 STUDY SPACE. 3690 02:22:16,720 --> 02:22:20,440 WITH THAT WELL STANDARDIZED 3691 02:22:20,440 --> 02:22:22,240 ASSAYS WORK IS NOT EASILY 3692 02:22:22,240 --> 02:22:23,960 COMPARED BETWEEN STUDIES 3693 02:22:23,960 --> 02:22:25,640 HAMPERING PRIORITIZATION OF 3694 02:22:25,640 --> 02:22:27,360 VACCINES AND SLOWING THE ENTIRE 3695 02:22:27,360 --> 02:22:27,920 ENTERPRISE. 3696 02:22:27,920 --> 02:22:29,480 SO THANK YOU, VERY MUCH, DR. 3697 02:22:29,480 --> 02:22:37,240 FREEBURG AND JEROME. 3698 02:22:37,240 --> 02:22:38,760 DR. FREEDBERG HAD COMMENTS 3699 02:22:38,760 --> 02:22:39,560 REGARDING THE PRESENTATION. 3700 02:22:39,560 --> 02:22:41,320 ONE TO CLARIFY THE RELATIONSHIP 3701 02:22:41,320 --> 02:22:43,080 AND STRUCTURE BETWEEN THE SVU 3702 02:22:43,080 --> 02:22:44,640 SITES, AND THE DIFFERENT CORE 3703 02:22:44,640 --> 02:22:46,520 LABS ALONG WITH AN EXPLANATION 3704 02:22:46,520 --> 02:22:50,520 OF HOW PROJECTS ARE CHOSEN FOR 3705 02:22:50,520 --> 02:22:50,920 SUPPORT. 3706 02:22:50,920 --> 02:22:53,720 HIGHLIGHTING THE RANGE OF ASSAY 3707 02:22:53,720 --> 02:22:55,560 SOPs AND EQUIPMENT SOPs IS 3708 02:22:55,560 --> 02:22:58,600 KEY TO UNDERSTANDING THE LAB 3709 02:22:58,600 --> 02:22:59,200 VALUE. 3710 02:22:59,200 --> 02:23:01,480 THREE, EXPANDING THE DESCRIPTION 3711 02:23:01,480 --> 02:23:03,720 OF THE U MAP APPROACH BRIEFLY, 3712 02:23:03,720 --> 02:23:05,520 WOULD BE HELPFUL FOR THE 3713 02:23:05,520 --> 02:23:07,480 NON-BASIC SCIENTIST ON ARAC AND 3714 02:23:07,480 --> 02:23:08,800 AT THE MEETING. 3715 02:23:08,800 --> 02:23:11,240 SOME LISTENERS MAYBE MORE 3716 02:23:11,240 --> 02:23:12,680 FAMILIAR WITH PRINCIPLE 3717 02:23:12,680 --> 02:23:15,080 COMPONENT ANALYSIS AS A STARTING 3718 02:23:15,080 --> 02:23:16,720 POINT FOR EXPLAINING THE CUTTING 3719 02:23:16,720 --> 02:23:18,800 EDGE WORK THIS GROUP HAS DONE 3720 02:23:18,800 --> 02:23:23,080 TRANSITIONING FROM TSNE TO MAP 3721 02:23:23,080 --> 02:23:24,080 UMAP. 3722 02:23:24,080 --> 02:23:24,920 KNEW THANK YOU FOR YOUR 3723 02:23:24,920 --> 02:23:25,880 SUGGESTIONS TO MAKE THE 3724 02:23:25,880 --> 02:23:27,400 PRESENTATION CLEAR. 3725 02:23:27,400 --> 02:23:28,520 YOUR COMMENTS HAVE BEEN 3726 02:23:28,520 --> 02:23:32,760 INCORPORATED TO THIS REVISED 3727 02:23:32,760 --> 02:23:34,120 PRESENTATION. 3728 02:23:34,120 --> 02:23:36,160 LASTLY, THEY SAID CLOSE 3729 02:23:36,160 --> 02:23:38,160 COORDINATION WITH THE ANALOGOUS 3730 02:23:38,160 --> 02:23:40,520 HUMAN CORE LAB IS IMPORTANT. 3731 02:23:40,520 --> 02:23:43,080 THERE ARE PEERS WHO CAN BENEFIT 3732 02:23:43,080 --> 02:23:44,320 FROM ADVANCES IN EACH AND 3733 02:23:44,320 --> 02:23:47,040 COORDINATION BETWEEN THE TWO IS 3734 02:23:47,040 --> 02:23:48,320 TRANSITION TO CLINICAL TRIALS. 3735 02:23:48,320 --> 02:23:49,520 YOU MIGHT CONSIDER CALLING OUT 3736 02:23:49,520 --> 02:23:51,640 THE DESIRE FOR SUCH CONTACT 3737 02:23:51,640 --> 02:23:54,680 CLEARLY IN THE RFA. 3738 02:23:54,680 --> 02:23:55,240 THANK YOU. 3739 02:23:55,240 --> 02:23:57,880 WE AGREE WHERE APPLICABLE HAIR 3740 02:23:57,880 --> 02:23:59,680 MNIZATION OF PROTOCOLS WITH OUR 3741 02:23:59,680 --> 02:24:01,200 CLINICAL PEERS IS IMPORTANT AND 3742 02:24:01,200 --> 02:24:03,040 WE WILL ENCOURAGE AND FACILITATE 3743 02:24:03,040 --> 02:24:07,560 SUCH INTERACTIONS. 3744 02:24:07,560 --> 02:24:08,800 IN CONCLUSION WHICH ARE ASKING 3745 02:24:08,800 --> 02:24:10,760 FOR APPROVAL TO REISSUE A 3746 02:24:10,760 --> 02:24:14,000 CONTRACT THAT WILL PROVIDE A 3747 02:24:14,000 --> 02:24:15,760 CENTRALIZED SERVICE TO CONDUCT 3748 02:24:15,760 --> 02:24:17,040 MEASURE CELLULAR IMMUNE RESPONSE 3749 02:24:17,040 --> 02:24:18,240 IN SUPPORT OF PRE-CLINICAL 3750 02:24:18,240 --> 02:24:19,200 STUDIES. 3751 02:24:19,200 --> 02:24:21,080 THANK YOU FOR YOUR ATTENTION. 3752 02:24:21,080 --> 02:24:22,160 I WOULD BE HAPPY TO ANSWER ANY 3753 02:24:22,160 --> 02:24:26,080 QUESTIONS. 3754 02:24:26,080 --> 02:24:29,280 >> THANK YOU, DR. DANG, 3755 02:24:29,280 --> 02:24:32,360 APPRECIATE YOUR PRESENTATION. 3756 02:24:32,360 --> 02:24:36,120 QUESTIONS FROM THE COMMITTEE? 3757 02:24:36,120 --> 02:24:42,000 OR OTHERS? 3758 02:24:42,000 --> 02:24:43,720 >> THANK YOU -- CAN YOU HEAR ME? 3759 02:24:43,720 --> 02:24:45,240 >> GO AHEAD PAUL. 3760 02:24:45,240 --> 02:24:48,400 >> APPRECIATE THE PRESENTATION 3761 02:24:48,400 --> 02:24:48,960 I'M FULLY SUPPORTIVE. 3762 02:24:48,960 --> 02:24:50,680 I WANT TO KNOW, I THINK IT WAS 3763 02:24:50,680 --> 02:24:54,160 MENTIONED BY THE REVIEWERS SO 3764 02:24:54,160 --> 02:24:58,400 HOW ARE PROTOCOLS CHOSEN AND DO 3765 02:24:58,400 --> 02:25:00,040 THEY -- HOW IS EVERYTHING 3766 02:25:00,040 --> 02:25:01,000 COORDINATED? 3767 02:25:01,000 --> 02:25:08,520 SEEMS LIKE THERE IS A LARGE PART 3768 02:25:08,520 --> 02:25:09,680 LARGE COORDINATION EFFORT THAT 3769 02:25:09,680 --> 02:25:12,320 IS DONE. 3770 02:25:12,320 --> 02:25:17,160 FINALLY, ARE THERE AREAS WHERE 3771 02:25:17,160 --> 02:25:20,600 THINGS CAN BE SHARED SUCH AS 3772 02:25:20,600 --> 02:25:21,400 BIOINFORMATICS THAT YOU WERE 3773 02:25:21,400 --> 02:25:22,600 DESCRIBING? 3774 02:25:22,600 --> 02:25:25,360 EACH HAS ITS OWN SPECIFICS BUT 3775 02:25:25,360 --> 02:25:28,800 CAN THAT BE SHARED? 3776 02:25:28,800 --> 02:25:29,640 >> YES. 3777 02:25:29,640 --> 02:25:32,720 THE STUDIES ARE CHOSEN ON 3778 02:25:32,720 --> 02:25:33,440 PROGRAMMATIC PRIORITY. 3779 02:25:33,440 --> 02:25:34,800 WE ARE LOOKING TO ANSWER 3780 02:25:34,800 --> 02:25:37,240 SPECIFIC QUESTIONS. 3781 02:25:37,240 --> 02:25:39,320 SOMETIMES IT IS A PLATFORM 3782 02:25:39,320 --> 02:25:42,520 QUESTION, SOME OF THE EXAMPLES I 3783 02:25:42,520 --> 02:25:47,880 GAVE ONE WAS TO SEE IF SLOW 3784 02:25:47,880 --> 02:25:51,720 DELIVERY OF WILL BE SUPERIOR TO 3785 02:25:51,720 --> 02:25:53,560 WHAT IS CONVENTIONALLY GIVEN 3786 02:25:53,560 --> 02:25:56,320 WHICH IS A LARGE WHOLE LIST OF 3787 02:25:56,320 --> 02:25:57,920 THE IMMUNOGEN AND AS AN EXAMPLE 3788 02:25:57,920 --> 02:26:01,240 OF THE OTHER STUDY WE ARE DOING 3789 02:26:01,240 --> 02:26:04,840 CURRENTLY WHICH WAS P 213 IS TO 3790 02:26:04,840 --> 02:26:06,800 CONFIRM REPEAT AND CONFIRM WHAT 3791 02:26:06,800 --> 02:26:09,880 THEY OBSERVED IN THEIR STUDY 3792 02:26:09,880 --> 02:26:12,000 WHICH WAS THAT CELLULAR IMMUNE 3793 02:26:12,000 --> 02:26:14,680 RESPONSES WERE ABLE TO LOWER THE 3794 02:26:14,680 --> 02:26:16,200 THRESHOLD OF NEUTRALIZING 3795 02:26:16,200 --> 02:26:17,320 ANTIBODIES SHOWN TO BE 3796 02:26:17,320 --> 02:26:20,000 PROTECTIVE IN THEIR STUDY. 3797 02:26:20,000 --> 02:26:22,240 SO THAT IS HOW STUDIES ARE 3798 02:26:22,240 --> 02:26:22,600 CHOSEN. 3799 02:26:22,600 --> 02:26:25,600 THE BIOINFORMATICS, THE ANSWER 3800 02:26:25,600 --> 02:26:28,400 TO YOUR QUESTION IS COMPLICATED 3801 02:26:28,400 --> 02:26:29,840 BECAUSE SOME OF THESE PLATFORMS 3802 02:26:29,840 --> 02:26:32,520 ARE PROPRIETARY. 3803 02:26:32,520 --> 02:26:34,480 WE HAVE INDUSTRY THAT WE 3804 02:26:34,480 --> 02:26:36,280 SOMETIMES SUPPORT STUDIES FOR 3805 02:26:36,280 --> 02:26:37,720 WHERE WE HAVE INVESTIGATORS WHO 3806 02:26:37,720 --> 02:26:42,840 ARE NOT QUITE YET READY TO 3807 02:26:42,840 --> 02:26:46,520 ADVANCE PRODUCT AND EXPLORATORY. 3808 02:26:46,520 --> 02:26:52,520 SO WHERE AND WHEN POSSIBLE WE 3809 02:26:52,520 --> 02:26:55,960 CERTAINLY TO MAKE AVAILABLE THE 3810 02:26:55,960 --> 02:26:57,160 INFORMATION. 3811 02:26:57,160 --> 02:26:58,840 THAT IS WHAT IN PART WE WANT TO 3812 02:26:58,840 --> 02:27:01,720 HAVE A CENTRALIZED DATABASE SO 3813 02:27:01,720 --> 02:27:05,600 THAT WHEN THE DATA IS ABLE TO BE 3814 02:27:05,600 --> 02:27:08,640 SHARED THEN WE CAN INVITE THE 3815 02:27:08,640 --> 02:27:11,160 FIELD TO LOOK AT THE DATA MORE 3816 02:27:11,160 --> 02:27:12,840 CLOSELY. 3817 02:27:12,840 --> 02:27:16,680 THANK YOU FOR YOUR QUESTION. 3818 02:27:16,680 --> 02:27:19,680 >> WE HAVE A QUESTION FROM DR. 3819 02:27:19,680 --> 02:27:20,240 GANDHI. 3820 02:27:20,240 --> 02:27:21,840 >> THANK YOU SO MUCH, REALLY 3821 02:27:21,840 --> 02:27:23,560 IMPORTANT CELLULAR IMMUNITY IS 3822 02:27:23,560 --> 02:27:24,640 SO IMPORTANT FOR ALL SORTS OF 3823 02:27:24,640 --> 02:27:25,040 INFECTIONS. 3824 02:27:25,040 --> 02:27:27,960 I GUESS THE QUESTION IS, IS THIS 3825 02:27:27,960 --> 02:27:31,160 A RESOURCE AND THEN PEOPLE WOULD 3826 02:27:31,160 --> 02:27:36,200 APPLY TO HEY IN THIS INFECTION, 3827 02:27:36,200 --> 02:27:37,600 DUETTING MORE FUNDING WE NEED TO 3828 02:27:37,600 --> 02:27:41,440 LOOK MORE DEEPLY DIFFERENT 3829 02:27:41,440 --> 02:27:42,440 IMMUNE RESPONSE? 3830 02:27:42,440 --> 02:27:43,640 WOULDN'T BE FOR SPECIFIC 3831 02:27:43,640 --> 02:27:45,600 INFECTIONS. 3832 02:27:45,600 --> 02:27:46,720 IT WOULD BE JUST WHATEVER WAS 3833 02:27:46,720 --> 02:27:47,480 HAPPENING AT THE TIME. 3834 02:27:47,480 --> 02:27:49,480 THAT IS WHAT -- I GUESS THAT'S 3835 02:27:49,480 --> 02:27:50,680 WHAT I'M TRYING TO UNDERSTAND 3836 02:27:50,680 --> 02:27:53,080 BECOME A CORE RESOURCE LAB 3837 02:27:53,080 --> 02:27:54,960 MULTIPLE GRANTS TO FEEDS INTO. 3838 02:27:54,960 --> 02:27:59,720 TO USE THIS LAB THIS RESOURCE TO 3839 02:27:59,720 --> 02:28:02,320 ENHANCE EVALUATION IMMUNITY TO 3840 02:28:02,320 --> 02:28:03,400 INFECTIOUS DISEASES. 3841 02:28:03,400 --> 02:28:05,280 >> THANK YOU FOR THAT GREAT 3842 02:28:05,280 --> 02:28:05,800 QUESTION. 3843 02:28:05,800 --> 02:28:07,640 THE CONTRACT IS CURRENTLY SET UP 3844 02:28:07,640 --> 02:28:09,440 TO SUPPORT PRIMARILY OUR 3845 02:28:09,440 --> 02:28:10,600 PRE-CLINICAL STUDIES CONDUCTED 3846 02:28:10,600 --> 02:28:13,480 THROUGH THE SBU. 3847 02:28:13,480 --> 02:28:15,840 UNFORTUNATELY OUR BUDGET AT THIS 3848 02:28:15,840 --> 02:28:19,520 TIME IS NOT ENOUGH TO SUPPORT 3849 02:28:19,520 --> 02:28:22,680 OTHER INVESTIGATORS ON THEIR 3850 02:28:22,680 --> 02:28:25,280 GRANTS BUT OCCASIONALLY WE NOT 3851 02:28:25,280 --> 02:28:28,800 SO MUCH FOR THIS CORE CONTRACT 3852 02:28:28,800 --> 02:28:31,680 BUT OTHER CORE CONTRACTS WE DID 3853 02:28:31,680 --> 02:28:33,120 HAVE SOME AVAILABILITY IN 3854 02:28:33,120 --> 02:28:34,360 FUNDING WHERE WE ARE ABLE TO 3855 02:28:34,360 --> 02:28:37,760 SUPPORT OTHER INVESTIGATORS FOR 3856 02:28:37,760 --> 02:28:46,880 THEIR RESEARCH AND THEIR GRANTS. 3857 02:28:46,880 --> 02:28:54,040 >> OTHER QUESTIONS? 3858 02:28:54,040 --> 02:28:59,680 WE ARE IN THE HOME STRETCH HERE. 3859 02:28:59,680 --> 02:29:00,400 FAS EVERYONE COULD REMEMBER TO 3860 02:29:00,400 --> 02:29:04,920 VOTE. 3861 02:29:04,920 --> 02:29:06,640 EARLY AND OFTEN OR AS OFTEN AS 3862 02:29:06,640 --> 02:29:13,800 APPROPRIATE WOULD BE GREAT. 3863 02:29:13,800 --> 02:29:14,560 THANK YOU. 3864 02:29:14,560 --> 02:29:16,600 LAST PRESENTATION IS BY DR. 3865 02:29:16,600 --> 02:29:18,640 MILTON MACIEL, EXTRA QUALITY 3866 02:29:18,640 --> 02:29:21,560 ASSURANCE PROGRAM OVERSIGHT 3867 02:29:21,560 --> 02:29:25,960 LABORATORY OR EQAPOL. 3868 02:29:25,960 --> 02:29:26,640 DR. MACIEL. 3869 02:29:26,640 --> 02:29:28,600 >> THANK YOU SO MUCH. 3870 02:29:28,600 --> 02:29:31,400 GOOD AFTERNOON, MY NAME IS MIL 3871 02:29:31,400 --> 02:29:35,800 MACIEL, PROGRAM OFFICER WITH 3872 02:29:35,800 --> 02:29:36,920 DIVISION OF (INAUDIBLE) EXTERNAL 3873 02:29:36,920 --> 02:29:38,240 QUALITY ASSURANCE PROGRAM 3874 02:29:38,240 --> 02:29:42,600 OVERSIGHT EQAPOL FOR SHORT. 3875 02:29:42,600 --> 02:29:45,040 EQAPOL OVERARCHING OBJECTIVE IS 3876 02:29:45,040 --> 02:29:47,160 MAINTAIN FACILITY SUPPORT THE 3877 02:29:47,160 --> 02:29:49,000 DEVELOPMENT IMPLEMENTATION AND 3878 02:29:49,000 --> 02:29:50,800 OVER SIGHT OF EXTERNAL QUALITY 3879 02:29:50,800 --> 02:29:53,080 ISSUE PROGRAMS TO MONITOR 3880 02:29:53,080 --> 02:29:55,040 LABORATORIES PERFORMING HIV AIDS 3881 02:29:55,040 --> 02:29:58,840 RESEARCH AND VACCINE TRIALS. 3882 02:29:58,840 --> 02:30:02,560 EQAPOL IS A CONTRACT AND SECOND 3883 02:30:02,560 --> 02:30:04,600 RENEWAL SINCE INCEPTION 2010 3884 02:30:04,600 --> 02:30:06,760 WITH ITERATION OF 7 YEARS AND IF 3885 02:30:06,760 --> 02:30:09,080 APPROVED WE EXPECT TO MAKE ONE 3886 02:30:09,080 --> 02:30:13,160 AWARD. 3887 02:30:13,160 --> 02:30:15,760 TO MAKE CLEAR THIS EQAPOL, I'M 3888 02:30:15,760 --> 02:30:17,120 SHOWING THE PORTFOLIO OF 3889 02:30:17,120 --> 02:30:19,400 CONTRACTS THAT ASSIST DAIDS AND 3890 02:30:19,400 --> 02:30:21,160 OVERSEEN QUALITY OF LABORATORY 3891 02:30:21,160 --> 02:30:26,680 TESTS FOR DIVISION ACTIVITY TBQA 3892 02:30:26,680 --> 02:30:30,600 AND I WILL GIVE AN EXAMPLE OF 3893 02:30:30,600 --> 02:30:32,400 KNOWLEDGE PROGRAM FOCUS ON 3894 02:30:32,400 --> 02:30:35,280 PROVIDING EFFICIENCY TESTS AND 3895 02:30:35,280 --> 02:30:37,680 MEASUREMENTS AND 3896 02:30:37,680 --> 02:30:38,400 CRYOPRESERVATION. 3897 02:30:38,400 --> 02:30:40,040 NEXT SLIDE. 3898 02:30:40,040 --> 02:30:43,200 NOW, EQAPOL MISSION ARE FOCUS ON 3899 02:30:43,200 --> 02:30:45,040 SPECIALIZED ASSAY WITH 3900 02:30:45,040 --> 02:30:49,960 PROFICIENCY PROGRAMS THAT ENSURE 3901 02:30:49,960 --> 02:30:51,160 COMPARABILITY AMONG MULTIPLE 3902 02:30:51,160 --> 02:30:52,680 LABORATORIES TESTING MULTIPLE 3903 02:30:52,680 --> 02:30:55,120 VACCINE CANDIDATES, AS WELL AS 3904 02:30:55,120 --> 02:30:59,000 CROSS POPULATION COMPARISON. 3905 02:30:59,000 --> 02:31:01,440 WITH THAT, EQAPOL SERVES AS 3906 02:31:01,440 --> 02:31:04,000 MECHANISM TO PROVIDE RESPONSIVE 3907 02:31:04,000 --> 02:31:07,160 REGULATORY AGENCIES THE FDA 3908 02:31:07,160 --> 02:31:07,840 RAISE CONFIDENCE INDIVIDUAL 3909 02:31:07,840 --> 02:31:10,080 LABORATORIES ARE GENERATING DATA 3910 02:31:10,080 --> 02:31:12,480 WITH RIGOR TO SUPPORT NEW 3911 02:31:12,480 --> 02:31:14,720 VACCINE FORMULATION ADVANCEMENT. 3912 02:31:14,720 --> 02:31:16,520 THESE ACTIVITIES ASSURE DECISION 3913 02:31:16,520 --> 02:31:19,240 MAKERS THAT RESULT RELIABLE AND 3914 02:31:19,240 --> 02:31:20,600 ACCURATE AND ENABLE DATA 3915 02:31:20,600 --> 02:31:22,760 COMPARISON AND PRIORITIZATION OF 3916 02:31:22,760 --> 02:31:27,920 THE BEST IMMUNOGENS. 3917 02:31:27,920 --> 02:31:29,640 EQAPOL CONTRACTED ACTIVITIES CAN 3918 02:31:29,640 --> 02:31:31,680 BE DIVIDED IN QUALITY ASSURANCE 3919 02:31:31,680 --> 02:31:33,800 AND OPERATION OF ACTIVITIES. 3920 02:31:33,800 --> 02:31:35,880 WITHIN THE QUALITY ASSURANCE 3921 02:31:35,880 --> 02:31:37,800 ACTIVITIES WE FIND THAT 3922 02:31:37,800 --> 02:31:39,840 PROFICIENCY TASKS AND PROGRAMS 3923 02:31:39,840 --> 02:31:44,440 SUCH AS ELISPOT FLOW CYTOMETRY, 3924 02:31:44,440 --> 02:31:47,480 MENTIONED, LUMINX, NEUTRALIZING 3925 02:31:47,480 --> 02:31:49,760 ANTIBODIES AND THE HIV INCIDENCE 3926 02:31:49,760 --> 02:31:50,240 ASSAY. 3927 02:31:50,240 --> 02:31:51,720 I WILL GIVE MORE DETAIL ABOUT 3928 02:31:51,720 --> 02:31:52,720 SOME OF THE PROGRAMS IN THE NEXT 3929 02:31:52,720 --> 02:31:57,760 SLIDE. 3930 02:31:57,760 --> 02:31:58,560 ANOTHER IMPORTANT PRESUMPTION IS 3931 02:31:58,560 --> 02:32:02,520 BIODIVERSITY WHICH PROCURES HIV 3932 02:32:02,520 --> 02:32:03,760 PANELS WHICH WILL SHOW MORE 3933 02:32:03,760 --> 02:32:06,480 ABOUT LATER ON. 3934 02:32:06,480 --> 02:32:09,480 EQAPOL HOLDS REPOSITORY OF 3935 02:32:09,480 --> 02:32:11,600 PBMCs WHICH CAP ACCREDITED. 3936 02:32:11,600 --> 02:32:13,360 THOSE ARE AVAILABLE UPON REQUEST 3937 02:32:13,360 --> 02:32:15,400 FOR DIFFERENT PURPOSES SUCH AS 3938 02:32:15,400 --> 02:32:17,600 ASSAY DEVELOPMENT. 3939 02:32:17,600 --> 02:32:21,520 FOR ALL PROBLEMS EQAPOL 3940 02:32:21,520 --> 02:32:24,560 MAINTAINS A DATABASE ACCESSIBLE 3941 02:32:24,560 --> 02:32:26,360 BY PARTICIPANTS. 3942 02:32:26,360 --> 02:32:28,160 OTHER OPERATIONAL ACTIVITIES 3943 02:32:28,160 --> 02:32:33,200 EQAPOL OFFERS A DEVICE ASSAY 3944 02:32:33,200 --> 02:32:34,800 VALIDATION REGULATORY COMPLIANCE 3945 02:32:34,800 --> 02:32:36,120 STATISTIC ISSUES. 3946 02:32:36,120 --> 02:32:38,920 ADDITIONALLY EQAPOL WORKS ON THE 3947 02:32:38,920 --> 02:32:40,200 OPTIMIZATION OF TRANSFERENCE OF 3948 02:32:40,200 --> 02:32:42,080 METHODOLOGIES BETWEEN 3949 02:32:42,080 --> 02:32:44,520 LABORATORY, AS WELL AS 3950 02:32:44,520 --> 02:32:45,480 DEVELOPMENT OF VALIDATION 3951 02:32:45,480 --> 02:32:48,480 PROGRAMS FOR NOVEL ASSAYS. 3952 02:32:48,480 --> 02:32:51,920 I JUST LEAVE YOU WITH THIS LINK 3953 02:32:51,920 --> 02:32:53,320 SO YOU CAN LOOK FOR ALL THIS 3954 02:32:53,320 --> 02:32:58,000 INFORMATION. 3955 02:32:58,000 --> 02:33:00,520 WORLDWIDE EQAPOL SERVES 78 3956 02:33:00,520 --> 02:33:02,160 UNIQUE SITES THAT PARTICIPATE ON 3957 02:33:02,160 --> 02:33:05,280 ONE OR MORE OF THE PROFICIENCY 3958 02:33:05,280 --> 02:33:08,040 PROGRAMS AS CAN BE SEEN OVER ON 3959 02:33:08,040 --> 02:33:09,000 THE TABLE ON THE LEFT. 3960 02:33:09,000 --> 02:33:10,640 THE MAP ON THE RIGHT GIVES A 3961 02:33:10,640 --> 02:33:13,920 PERSPECTIVE EQAPOL PRESENCE OF 3962 02:33:13,920 --> 02:33:14,840 NOTABLE INSTITUTION THAT 3963 02:33:14,840 --> 02:33:16,440 PARTICIPATE IN PROFICIENCY 3964 02:33:16,440 --> 02:33:18,600 PROGRAMS. 3965 02:33:18,600 --> 02:33:20,720 FOR EXAMPLE, BETWEEN SITES 3966 02:33:20,720 --> 02:33:23,240 SEATTLE AND CAPE TOWN OR U.S. 3967 02:33:23,240 --> 02:33:25,880 MILITARY PROGRAMS IN SILVER 3968 02:33:25,880 --> 02:33:31,080 SPRING AND THAILAND. 3969 02:33:31,080 --> 02:33:33,920 EACH OF THE FIVE PROFICIENCY 3970 02:33:33,920 --> 02:33:35,160 PROGRAMS WHICH CAN BE SEEN ON 3971 02:33:35,160 --> 02:33:39,920 THE LEFT ARE GOING UNDER EQAPOL 3972 02:33:39,920 --> 02:33:40,800 OFFERS PARTICIPANTS TWO SEND 3973 02:33:40,800 --> 02:33:43,120 OUTS PER YEAR WHICH INCLUDE MILY 3974 02:33:43,120 --> 02:33:46,440 CHARACTERIZED SPECIMENS IN ASSAY 3975 02:33:46,440 --> 02:33:48,440 REAGENTS, COMPLETION OF THE 3976 02:33:48,440 --> 02:33:50,240 TESTING ROUND EACH SITE RECEIVES 3977 02:33:50,240 --> 02:33:52,440 A REPORT THAT INCLUDES A SCORE 3978 02:33:52,440 --> 02:33:55,680 AND PERFORMANCE RATING. 3979 02:33:55,680 --> 02:33:57,800 THIS CORE CAN BE FROM POOR TO 3980 02:33:57,800 --> 02:33:58,640 EXCELLENT AS YOU CAN SEE IN THE 3981 02:33:58,640 --> 02:34:01,920 FIGURE BELOW. 3982 02:34:01,920 --> 02:34:06,400 WHEN NECESSARY SCORES FAIR 3983 02:34:06,400 --> 02:34:09,960 REAGENT SERVICES TO IMPROVE 3984 02:34:09,960 --> 02:34:10,720 ASSAY PERFORMANCE AND 3985 02:34:10,720 --> 02:34:11,880 OPPORTUNITY TO REPEAT 3986 02:34:11,880 --> 02:34:12,880 PROFICIENCY TESTS. 3987 02:34:12,880 --> 02:34:16,720 NEXT SLIDE. 3988 02:34:16,720 --> 02:34:19,000 THE VIRAL DIVERSE PROGRAM IS 3989 02:34:19,000 --> 02:34:20,920 FOCUS ON ESTABLISHING A SET OF 3990 02:34:20,920 --> 02:34:22,680 -- FULLY CHARACTERIZED VIRUS 3991 02:34:22,680 --> 02:34:25,840 FROM EARLY ACUTE HIV INFECTION 3992 02:34:25,840 --> 02:34:28,600 CONSISTENT WITH DEGREE OF 3993 02:34:28,600 --> 02:34:29,680 VARIABLE SOLUTION. 3994 02:34:29,680 --> 02:34:31,520 THIS HAS SEVERAL APPLICATIONS 3995 02:34:31,520 --> 02:34:34,160 SUCH AS DEVELOPMENT OF NEW 3996 02:34:34,160 --> 02:34:36,600 ASSAYS, VALIDATION OF ASSAY 3997 02:34:36,600 --> 02:34:39,560 PLATFORMS, ASSIST REGULATORS ON 3998 02:34:39,560 --> 02:34:41,560 EVALUATION OF THE TASK KITS. 3999 02:34:41,560 --> 02:34:44,680 MORE PERFORMANCE OF HIV DRUG 4000 02:34:44,680 --> 02:34:46,120 RESISTANCE, INFORM VACCINE 4001 02:34:46,120 --> 02:34:48,320 DEVELOPMENT AND MONOCLONAL 4002 02:34:48,320 --> 02:34:49,360 ANTIVIRAL TRIALS. 4003 02:34:49,360 --> 02:34:53,800 AND PARTICIPATE IN CBER EMERGING 4004 02:34:53,800 --> 02:34:57,280 VIRAL PANEL, WHICH IS DIVERSE 4005 02:34:57,280 --> 02:35:00,360 RANGE OF UNIQUE CIRCULATING 4006 02:35:00,360 --> 02:35:02,480 FORMS. 4007 02:35:02,480 --> 02:35:04,760 NEXT. 4008 02:35:04,760 --> 02:35:07,920 OF NOTE, EQAPOL PROVE TO BE 4009 02:35:07,920 --> 02:35:10,760 EXTREMELY FLEXIBLE IN RESPONSE 4010 02:35:10,760 --> 02:35:12,160 WITH UNFORESEEN SECRETIONS SUCH 4011 02:35:12,160 --> 02:35:15,160 AS SARS COV-2 PANDEMIC. 4012 02:35:15,160 --> 02:35:17,960 HERE I WANTED TO HIGHLIGHT SARS 4013 02:35:17,960 --> 02:35:19,640 COV-2 ANTIBODY ASSAY MONITORING 4014 02:35:19,640 --> 02:35:21,040 OR SAM FOR SHORT. 4015 02:35:21,040 --> 02:35:23,520 IN RESPONSE TO THE URGENT NEED 4016 02:35:23,520 --> 02:35:25,400 TO DEVELOP SAFE EFFECTIVE 4017 02:35:25,400 --> 02:35:26,800 VACCINES IMMUNOTHERAPEUTICS 4018 02:35:26,800 --> 02:35:28,720 AGAINST COVID-19. 4019 02:35:28,720 --> 02:35:36,280 THE SAAM PROGRAM SUPPORT R 4020 02:35:36,280 --> 02:35:37,160 RELIABLE TRANSFERENCE OF 4021 02:35:37,160 --> 02:35:38,080 METHODOLOGIES METHOD DOLL GISTS 4022 02:35:38,080 --> 02:35:40,360 FROM INNOVATOR AWARDS TO 4023 02:35:40,360 --> 02:35:43,640 CONTRACT RESEARCHER TO ASSESS 4024 02:35:43,640 --> 02:35:45,640 VACCINE RESPONSE WHICH GUARANTEE 4025 02:35:45,640 --> 02:35:47,200 RESULTS COULD BE USED FOR SUN 4026 02:35:47,200 --> 02:35:50,280 MISSION TO THE FDA AND TO 4027 02:35:50,280 --> 02:35:52,440 INVESTIGATE CORRELATES OF 4028 02:35:52,440 --> 02:35:53,040 PROTECTION. 4029 02:35:53,040 --> 02:35:55,040 THESE PROGRAMS HAPPENS BIMONTHLY 4030 02:35:55,040 --> 02:35:56,680 AS YOU CAN SEE IN THE TABLE 4031 02:35:56,680 --> 02:35:58,600 BELOW AND ALSO YOU SEE NUMBER OF 4032 02:35:58,600 --> 02:36:00,600 PARTICIPANTS AND THE SPORES 4033 02:36:00,600 --> 02:36:04,120 RETAINED. 4034 02:36:04,120 --> 02:36:05,440 THE OTHER PROBLEM THAT WAS ALSO 4035 02:36:05,440 --> 02:36:08,080 SUPPLEMENTED BY EQAPOL WAS THE 4036 02:36:08,080 --> 02:36:12,000 SARS COV-2 NEUTRALIZING ASSAY 4037 02:36:12,000 --> 02:36:15,000 COMPONENTS ASSAY. 4038 02:36:15,000 --> 02:36:16,680 WHICH EVALUATES PERFORMANCE AND 4039 02:36:16,680 --> 02:36:19,480 CONCORDANCE OF LARGE NUMBER OF 4040 02:36:19,480 --> 02:36:21,760 LIVE VIRUS AND AUTHORIZATION 4041 02:36:21,760 --> 02:36:27,160 ASSAYS H 2 INHIBITION ASSAY AND 4042 02:36:27,160 --> 02:36:29,800 LABORATORIES IN CONTRACT 4043 02:36:29,800 --> 02:36:33,720 RESEARCHER IMMUNIZATIONS. 4044 02:36:33,720 --> 02:36:35,040 THROUGH THE CONTRACT MAINTAINED 4045 02:36:35,040 --> 02:36:37,120 TO USE EQAP OXL AS RESOURCE TO 4046 02:36:37,120 --> 02:36:41,560 RESPOND TO THE EVOLVEK SITES, 4047 02:36:41,560 --> 02:36:44,960 CREATING AS GENETIC AS POSSIBLE 4048 02:36:44,960 --> 02:36:47,160 WITH THE LANGUAGE EQAPOL CAN BE 4049 02:36:47,160 --> 02:36:49,000 RESPONSIVE TO THE DEVELOPMENT OF 4050 02:36:49,000 --> 02:36:50,840 NEW STATE OF THE ART ASSAYS, 4051 02:36:50,840 --> 02:36:55,000 THAT PROVIDE ASSISTANCE BASED ON 4052 02:36:55,000 --> 02:36:55,880 UTILIZATION VALIDATION AND 4053 02:36:55,880 --> 02:36:58,480 DEVELOPMENT OF PROFICIENCY 4054 02:36:58,480 --> 02:36:59,080 PROGRAMS. 4055 02:36:59,080 --> 02:37:00,040 THE NEW PROJECTS COULD BE 4056 02:37:00,040 --> 02:37:02,520 CONSIDERED FOR THE CONTRACT 4057 02:37:02,520 --> 02:37:06,360 RENEW ARE TWO FULLY HELPER CELLS 4058 02:37:06,360 --> 02:37:08,040 WHICH IS IMPACT IS ONGOING AND 4059 02:37:08,040 --> 02:37:10,920 FOCUSED ON DEVELOPING A 4060 02:37:10,920 --> 02:37:13,240 CONSENSUS STAINING PROTOCOL 4061 02:37:13,240 --> 02:37:15,040 PHENOTYPIC FUNCTIONAL MARKERS TO 4062 02:37:15,040 --> 02:37:18,480 IDENTIFY CELLS IN HUMAN 4063 02:37:18,480 --> 02:37:20,320 PROLIFERATIVE CONSEQUENTLY 4064 02:37:20,320 --> 02:37:23,200 ASSEMBLY PANEL OF REAGENTS 4065 02:37:23,200 --> 02:37:24,600 SAMPLES FOR THE DISTRIBUTION 4066 02:37:24,600 --> 02:37:29,000 LABORATORIES STUDYING TFH. 4067 02:37:29,000 --> 02:37:33,760 ALSO CONSIDER EXPANSION INCLUDE 4068 02:37:33,760 --> 02:37:36,360 OPTIMIZATION AND STANDARDIZATION 4069 02:37:36,360 --> 02:37:39,400 AND UPDATED ANALYSIS. 4070 02:37:39,400 --> 02:37:40,280 OMICS RELATED TO VACCINE 4071 02:37:40,280 --> 02:37:41,400 RESPONSE, WHICH SHOULD INCLUDE 4072 02:37:41,400 --> 02:37:44,640 DEVELOPMENT OF THE AGENT AND 4073 02:37:44,640 --> 02:37:46,760 POTENTIALLY EVOLVE TO NEW EQA 4074 02:37:46,760 --> 02:37:49,080 PROGRAM AS IT IS CLEAR 4075 02:37:49,080 --> 02:37:51,480 CORRELATES OF HIV VACCINE WILL 4076 02:37:51,480 --> 02:37:53,280 INCLUDE MANY PARAMETERS. 4077 02:37:53,280 --> 02:37:56,520 FINALLY, DATA CURATION ANALYSIS 4078 02:37:56,520 --> 02:37:59,680 WHICH IMPROVE TO BE TIMELY 4079 02:37:59,680 --> 02:38:01,200 GIVING NEW NIH DATA MANAGEMENT 4080 02:38:01,200 --> 02:38:04,760 AND SHARING POLICIES. 4081 02:38:04,760 --> 02:38:06,960 WHICH WILL HAVE ASSAY 4082 02:38:06,960 --> 02:38:10,360 UTILIZATION DATA FORMTY AND 4083 02:38:10,360 --> 02:38:13,120 METADATA AND COMBINE DATA 4084 02:38:13,120 --> 02:38:17,800 SUPPORT DATA SHARING. 4085 02:38:17,800 --> 02:38:21,800 AMONG E QAPOL OVERSIGHT 4086 02:38:21,800 --> 02:38:24,080 LABORATORY, DEDICATED PROGRAM OF 4087 02:38:24,080 --> 02:38:26,680 -- WITH MANAGEMENT STAFF, WEB 4088 02:38:26,680 --> 02:38:29,120 BASE APPLICATION TO SUPPORT ALL 4089 02:38:29,120 --> 02:38:31,160 ACTIVITIES, THE REMEDIATION 4090 02:38:31,160 --> 02:38:33,200 SERVICES REFERRED TO BEFORE AND 4091 02:38:33,200 --> 02:38:36,200 OF COURSE AS DEMONSTRATED IN 4092 02:38:36,200 --> 02:38:38,760 SARS COV-2 PANDEMIC THE 4093 02:38:38,760 --> 02:38:44,560 FLEXIBILITY ON THAT PROGRAM. 4094 02:38:44,560 --> 02:38:47,200 THIS INITIATIVE WAS REVIEWED BY 4095 02:38:47,200 --> 02:38:49,040 PROFESSORS GOLDBURG AND FRANK 4096 02:38:49,040 --> 02:38:50,440 AND BOTH WERE SUPPORTIVE FROM 4097 02:38:50,440 --> 02:38:52,280 THEIR COMMENTS NOT ONLY THE 4098 02:38:52,280 --> 02:38:54,880 PROGRAM IS ESSENTIAL FOR VACCINE 4099 02:38:54,880 --> 02:38:58,080 DEVELOPMENT BUT ALSO KEY FOR THE 4100 02:38:58,080 --> 02:38:59,360 ADVANCEMENT OF COVID-19 4101 02:38:59,360 --> 02:39:00,080 VACCINES. 4102 02:39:00,080 --> 02:39:02,920 WE ALSO RECEIVED SOME COMMENTS 4103 02:39:02,920 --> 02:39:04,880 WHICH I WANT TO ADDRESS, THAT 4104 02:39:04,880 --> 02:39:06,920 THE PROGRAM SHOULD PLAN FOR 4105 02:39:06,920 --> 02:39:08,360 MAINTAINING IMPLEMENTATION 4106 02:39:08,360 --> 02:39:11,360 WITHSTANDING GLOBAL PROFICIENCY 4107 02:39:11,360 --> 02:39:12,360 TESTING, WHICH SHOULD BE 4108 02:39:12,360 --> 02:39:13,240 REQUIREMENT FOR APPLICATION. 4109 02:39:13,240 --> 02:39:15,520 WE AGREE WITH THAT. 4110 02:39:15,520 --> 02:39:18,440 AND ALL SITES PARTICIPATING 4111 02:39:18,440 --> 02:39:21,080 NIAID DAIDS HIV OR AIDS CLINICAL 4112 02:39:21,080 --> 02:39:28,280 TRIALS,S MUST ENROLL EQAPOL IN 4113 02:39:28,280 --> 02:39:29,280 RELATED DAIDS WHICH SNAILLY 4114 02:39:29,280 --> 02:39:34,600 LCONDUCTED INCLINICAL TRIALS. 4115 02:39:34,600 --> 02:39:37,720 WE HAVE SEEN UPWARD TREND IN 4116 02:39:37,720 --> 02:39:38,680 ENROLLMENT IN COMMERCIAL 4117 02:39:38,680 --> 02:39:40,280 LABORATORIES. 4118 02:39:40,280 --> 02:39:42,360 THE OTHER COMMENT WAS 4119 02:39:42,360 --> 02:39:44,960 CHARACTERIZE VIRUS OF THE VIRAL 4120 02:39:44,960 --> 02:39:46,600 DIVERSE PROGRAM IN ANTICIPATION 4121 02:39:46,600 --> 02:39:47,920 INTERNATIONAL LOCATION TO OTHER 4122 02:39:47,920 --> 02:39:49,600 HIV PREVENTION STUDIES. 4123 02:39:49,600 --> 02:39:53,400 LIKELY TO BE PLANNED THUS 4124 02:39:53,400 --> 02:39:55,360 CREATING A TESTING AGENT SUCH AS 4125 02:39:55,360 --> 02:39:58,240 NEUTRALIZING ANTIBODIES AGAINST 4126 02:39:58,240 --> 02:39:59,600 THE LEAD CAUSE SPECIES PRIOR TO 4127 02:39:59,600 --> 02:40:01,040 STUDY ONSET AND WE AGREE WITH 4128 02:40:01,040 --> 02:40:09,760 THAT AND IN FACT EQAPOL THROUGH 4129 02:40:09,760 --> 02:40:10,560 ITS WORLD PRESENCE WHERE 4130 02:40:10,560 --> 02:40:13,600 CLINICAL TRIALS TAKE PLACE AND 4131 02:40:13,600 --> 02:40:15,400 GOAL PROVIDE VIRUS PANELS FOR 4132 02:40:15,400 --> 02:40:18,480 TESTING OF PROPHYLACTIC MEASURES 4133 02:40:18,480 --> 02:40:19,880 IN VACCINES IN MONOCLONAL 4134 02:40:19,880 --> 02:40:20,400 DEVICE. 4135 02:40:20,400 --> 02:40:23,560 ANOTHER EXAMPLE IS EQAPOL IS 4136 02:40:23,560 --> 02:40:25,160 MAKING PANELS OF VIRUSES FROM 4137 02:40:25,160 --> 02:40:29,520 THE AMP PLACEBO EFFECTIVE 4138 02:40:29,520 --> 02:40:32,600 SUBJECTS. 4139 02:40:32,600 --> 02:40:36,880 WITH THAT, IS MY FINAL SLIDE, 4140 02:40:36,880 --> 02:40:38,400 APPROVED FOR THIS NEW WHICH HAS 4141 02:40:38,400 --> 02:40:39,960 DURATION OF SEVEN YEARS AND WE 4142 02:40:39,960 --> 02:40:41,400 EXPECT TO MAKE ONE AWARD. 4143 02:40:41,400 --> 02:40:42,240 THANK YOU SO MUCH. 4144 02:40:42,240 --> 02:40:44,560 THANK YOU FOR THE REVIEWERS FOR 4145 02:40:44,560 --> 02:40:45,920 HELPFUL COMMENTS. 4146 02:40:45,920 --> 02:40:49,960 GLAD TO ANSWER ANY QUESTIONS. 4147 02:40:49,960 --> 02:40:56,240 >> THANK YOU, DR. MACIEL. 4148 02:40:56,240 --> 02:40:59,200 COMMENTS OR QUESTIONS ON THE 4149 02:40:59,200 --> 02:41:05,760 EQAPOL EFFORT AND PROGRAM? 4150 02:41:05,760 --> 02:41:14,040 ANY QUESTIONS? 4151 02:41:14,040 --> 02:41:16,240 LET ME ASK PEOPLE AGAIN TO GO TO 4152 02:41:16,240 --> 02:41:17,800 YOUR ELECTRONIC COUNCIL BOOKS 4153 02:41:17,800 --> 02:41:18,880 AND PLEASE VOTE. 4154 02:41:18,880 --> 02:41:19,960 REOPEN THEM IF THEY HAVE CLOSED 4155 02:41:19,960 --> 02:41:24,760 AN VOTE. 4156 02:41:24,760 --> 02:41:29,200 I THINK MAYBE ONE MORE ISSUE 4157 02:41:29,200 --> 02:41:30,000 CARL THAT YOU WANTED TO DEAL 4158 02:41:30,000 --> 02:41:31,360 WITH, BEFORE WE DO THAT I WILL 4159 02:41:31,360 --> 02:41:33,200 NOTE WE ARE AHEAD OF SCHEDULE SO 4160 02:41:33,200 --> 02:41:35,640 IF WE WERE IN THE NATCHER CENTER 4161 02:41:35,640 --> 02:41:37,040 WHICH WE AREN'T WE COULD USE 4162 02:41:37,040 --> 02:41:40,320 THAT TIME AND ALL GO DOWN TO THE 4163 02:41:40,320 --> 02:41:41,200 CAFETERIA WHERE THEY SUBSCRIBE 4164 02:41:41,200 --> 02:41:44,640 TO THE SOP FOR FREEZERS THAT DR. 4165 02:41:44,640 --> 02:41:46,680 TANK TOLD US ABOUT AND HAVE ICE 4166 02:41:46,680 --> 02:41:47,880 CREAM TO CELEBRATE THE BEGINNING 4167 02:41:47,880 --> 02:41:49,560 OF SUMMER BUT WE ARE NOT THERE. 4168 02:41:49,560 --> 02:41:52,040 SO YOU WILL HAVE TO GET ICE 4169 02:41:52,040 --> 02:41:53,840 CREAM WHERE YOU ARE AND MAYBE 4170 02:41:53,840 --> 02:41:56,280 SEPTEMBER 12 WE WILL PLAN THAT. 4171 02:41:56,280 --> 02:42:01,160 THAT WOULD BE MY VOTE. 4172 02:42:01,160 --> 02:42:02,160 DR. DIEFFENBACH, THERE WAS ONE 4173 02:42:02,160 --> 02:42:03,120 OTHER ISSUE. 4174 02:42:03,120 --> 02:42:05,160 LET ME ALSO BEFORE I HAND BACK 4175 02:42:05,160 --> 02:42:07,680 TO YOU, THANK EVERYONE FOR THEIR 4176 02:42:07,680 --> 02:42:08,720 PRESENTATION. 4177 02:42:08,720 --> 02:42:10,040 TREMENDOUS WORK THAT GOES INTO 4178 02:42:10,040 --> 02:42:12,640 THESE AS EVERYONE KNOWS AND 4179 02:42:12,640 --> 02:42:14,560 REALLY WELL THOUGHT OUT, WELL 4180 02:42:14,560 --> 02:42:16,040 PRESENTED, AND WE APPRECIATE 4181 02:42:16,040 --> 02:42:17,840 ALSO THE FEEDBACK FROM EVERYONE 4182 02:42:17,840 --> 02:42:21,760 ON ARAC AS PEOPLE KNOW DONE 4183 02:42:21,760 --> 02:42:24,320 USUALLY FOUR TO SIX WEEKS BEFORE 4184 02:42:24,320 --> 02:42:27,000 AND WE CAN SEE THE CHANGES THAT 4185 02:42:27,000 --> 02:42:29,200 HAVE BEEN MADE AND YOU SEE THE 4186 02:42:29,200 --> 02:42:31,480 COMMENTS MADE BY LOT OF 4187 02:42:31,480 --> 02:42:32,520 PRESENTATIONS I THINK ARE SO 4188 02:42:32,520 --> 02:42:33,360 CLEAR AND SO WELL DONE. 4189 02:42:33,360 --> 02:42:36,840 SO THANKS TO EVERYONE FOR THAT. 4190 02:42:36,840 --> 02:42:39,600 I WILL TURN IT OVER TO YOU, DR. 4191 02:42:39,600 --> 02:42:42,880 DIEFFENBACH. 4192 02:42:42,880 --> 02:42:47,160 >> THANK YOU DR. FREEBURG, 4193 02:42:47,160 --> 02:42:49,160 PLEASURE TO SIT AND LISTEN TO 4194 02:42:49,160 --> 02:42:51,680 TODAY'S MEETINGS. 4195 02:42:51,680 --> 02:42:54,520 THE LEVEL OF ENGAGEMENT WITH THE 4196 02:42:54,520 --> 02:42:55,960 COMMITTEE LIKE YOU WERE SAYING 4197 02:42:55,960 --> 02:43:02,160 BEFORE WE GET TO THIS POINT IS 4198 02:43:02,160 --> 02:43:02,960 SO CRITICAL. 4199 02:43:02,960 --> 02:43:05,160 IT GIVES THE COUNCIL A CHANCE TO 4200 02:43:05,160 --> 02:43:09,120 SEE SOMETHING AS IT IS BEING 4201 02:43:09,120 --> 02:43:13,640 GERMINATED AND HAVE A INPUT TO 4202 02:43:13,640 --> 02:43:14,120 IT. 4203 02:43:14,120 --> 02:43:15,760 THE WHOLE POINT OF CONSULTATION 4204 02:43:15,760 --> 02:43:17,120 IS IMPROVEMENT. 4205 02:43:17,120 --> 02:43:18,400 SO THANK YOU FOR THE COMMITTEE 4206 02:43:18,400 --> 02:43:20,440 FOR YOUR PERSISTENCE AND 4207 02:43:20,440 --> 02:43:22,480 PARTICIPATION IN OUR ACTIVITIES 4208 02:43:22,480 --> 02:43:25,400 AND MAKING THE PRODUCTS DAIDS 4209 02:43:25,400 --> 02:43:26,880 PRODUCES BETTER AND THANK YOU TO 4210 02:43:26,880 --> 02:43:28,520 THE STAFF THAT JUST DID 4211 02:43:28,520 --> 02:43:30,080 INCREDIBLE JOB TODAY. 4212 02:43:30,080 --> 02:43:33,920 WE DO HAVE ONE LAST PROCEDURAL 4213 02:43:33,920 --> 02:43:36,000 STEP WE NEED TO TAKE INTO 4214 02:43:36,000 --> 02:43:36,520 ACCOUNT. 4215 02:43:36,520 --> 02:43:40,560 WE HAVE TO TAKE AN ENBLOCK 4216 02:43:40,560 --> 02:43:43,600 ACTION AND ACCEPT THE 4217 02:43:43,600 --> 02:43:46,080 RECOMMENDATIONS FOR THE ENTIRE 4218 02:43:46,080 --> 02:43:47,360 PROCEEDINGS WITH VOICE VOTE. 4219 02:43:47,360 --> 02:43:51,920 DO I HAVE A MOTION TO APPROVE 4220 02:43:51,920 --> 02:43:53,520 ALL OF WHAT WAS DISCUSSED TODAY 4221 02:43:53,520 --> 02:43:59,520 AND ALREADY VOTED ON? 4222 02:43:59,520 --> 02:44:00,000 YES. 4223 02:44:00,000 --> 02:44:02,640 >> THANK YOU. 4224 02:44:02,640 --> 02:44:07,320 >> THEN DO I HAVE A SECOND? 4225 02:44:07,320 --> 02:44:07,720 >> SECOND. 4226 02:44:07,720 --> 02:44:12,280 >> THANK YOU. 4227 02:44:12,280 --> 02:44:16,200 CAN I HAVE THE -- EVERYBODY WHO 4228 02:44:16,200 --> 02:44:18,200 SAY YEAH FOR POSITIVES AND NAY 4229 02:44:18,200 --> 02:44:22,000 AND THEN TAKE IT FROM THERE. 4230 02:44:22,000 --> 02:44:22,880 IS EVERYBODY YEAH? 4231 02:44:22,880 --> 02:44:24,240 >> ANY NAYS? 4232 02:44:24,240 --> 02:44:26,720 AT ALL? 4233 02:44:26,720 --> 02:44:29,320 NOT HEARING ANY, WE HAVE NOW 4234 02:44:29,320 --> 02:44:32,480 ACCOMPLISHED THE ENBLOCK ACTION. 4235 02:44:32,480 --> 02:44:36,120 I WANT TO THANK YOU FOR YOUR 4236 02:44:36,120 --> 02:44:36,440 PARTICIPATION. 4237 02:44:36,440 --> 02:44:40,440 AND WITH ANY LUCK AT ALL, PAM 4238 02:44:40,440 --> 02:44:41,760 SENDS A NOTE TO EVERYONE PLEASE 4239 02:44:41,760 --> 02:44:43,200 MAKE SURE ALL YOUR FINAL VOTES 4240 02:44:43,200 --> 02:44:45,760 ARE IN THE ECB SO WE DON'T HAVE 4241 02:44:45,760 --> 02:44:47,920 TO COME AND HASSLE YOU. 4242 02:44:47,920 --> 02:44:51,360 THANK YOU ALL. 4243 02:44:51,360 --> 02:44:52,640 I HOPE YOUR WEATHER WHERE YOU 4244 02:44:52,640 --> 02:44:55,240 ARE IS AS NICE AS THE WEATHER IS 4245 02:44:55,240 --> 02:44:56,200 IN WASHINGTON TODAY. 4246 02:44:56,200 --> 02:44:59,360 TAKE CARE. 4247 02:44:59,360 --> 02:45:00,000 >> THANKS, EVERYBODY. 4248 02:45:00,000 --> 02:45:01,960 >> HAVE A GOOD SUMMER. 4249 02:45:01,960 --> 02:45:13,320 >> THANK YOU, BYE-BYE.